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ABSTRACT 
Jennifer E. Jahn:  Identification of Synaptotagmin XIII as a Liver Tumor Suppressor Gene 
(Under the direction of William B. Coleman, Ph.D.) 
 
The molecular pathogenesis of hepatocellular carcinoma is well-studied but not 
completely understood.  We utilized a microcell-hybrid model approach to facilitate the 
identification of novel liver tumor suppressor genes located on human chromosome 11.  
These investigations confirmed a liver tumor suppressor locus at human chromosome 
11p11.2, and subsequently identified SYT13 as the gene responsible for the suppression of 
tumorigenicity in rat liver tumor cell lines.  Complementary approaches involving both 
silencing SYT13 in suppressed microcell-hybrid cell lines and expressing SYT13 in tumor 
cell lines showed that this gene is both required and sufficient for 11p11.2-mediated 
suppression of tumorigenicity in the GN6TF rat liver tumor cell line.  Furthermore, the 
results strongly suggest that the dimerized form of the SYT13 protein is necessary for tumor 
suppressor function and that tumor suppression may be affected through pathways implicated 
in epithelial to mesenchymal transition.  These observations also suggest that the deficit in 
GN6TF that leads to the tumorigenic phenotype involves loss of the ability of the 
endogenous Syt13 to dimerize, perhaps through protein misfolding or loss of post-
translational processing.   
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INTRODUCTION 
HEPATOCELLULAR CARCINOMA 
Hepatocellular carcinoma (HCC) is a vicious neoplasm with a global incidence that 
ranks fifth among all cancers and a poor prognosis that results in a survival rate of 3-5% (1).  
Eighty-five percent of cases worldwide occur in Asia and Africa, with high concentrations of 
affected individuals in Southeast Asia and sub-Saharan Africa (1).  The incidence of HCC is 
much lower in developed countries, such as the United States.  The geographic disparity in 
HCC incidence reflects varying exposures to different environmental factors that promote 
chronic liver disease (including hepatitis and cirrhosis), which represents a precursor of 
HCC.  Important etiological factors in hepatocarcinogenesis include hepatitis B virus (HBV) 
and hepatitis C virus (HCV) infection and/or exposure to aflatoxin B1 (2).  HBV is the 
primary risk factor in many areas, especially in Asia and Africa (3).  Mechanisms involved in 
HBV-related hepatocarcinogenesis include chronic viral-associated inflammation and 
cellular proliferation as well as HBV-DNA integration into the host genome and interactions 
of HBV-specific proteins with liver genes (4).  The molecular mechanisms of HCV-
associated hepatocarcinogenesis are less well understood although it is not considered a 
directly cytotoxic virus (5).  Hepatitis associated with HCV occurs as a result of the reaction 
of the host immune system against virus-infected cells, and it is thought that the core protein 
of HCV is a likely candidate oncogene (6).  Aflatoxin B1 is a highly mutagenic toxin 
produced by fungus that grows on improperly stored grains.  Not only is it a potent direct-
acting liver carcinogen, but it can also cause p53 mutations leading to HCC and may have a 
synergistic interaction with HBV in hepatocarcinogenesis (2, 7).  Other factors contributing 
to HCC development include various metabolic/genetic abnormalities (i.e. hemochromatosis, 
tyrosinemia, Wilson’s disease, α-1 antitrypsin deficiency, and others), excessive alcohol 
consumption, non-alcoholic fatty liver disease, radiation, some therapeutic drugs, and certain 
chemicals in the workplace or environment (2).  All of these agents cause damage to 
hepatocytes, promote proliferative regeneration, and give rise to the preneoplastic liver 
pathologies which provide settings from which HCC commonly arises. 
MOLECULAR PATHOGENESIS OF HUMAN HEPATOCELLULAR CARCINOMA 
The majority of human hepatocellular carcinomas arise from the preneoplastic 
conditions of either chronic hepatitis or cirrhosis.  Because the liver has great regenerative 
capacity in response to cellular damage, the persistent proliferation of surviving hepatocytes 
provides the setting for the acquisition of genomic alterations (DNA damage, chromosomal 
alterations, gene mutations).  Molecular characterization of the tissue lesions that precede 
HCC, phenotypically altered and dysplastic hepatocytes of chronic hepatitis and cirrhosis, 
provide some evidence of the temporal genomic events involved in hepatocarcinogenesis.  
Commonly documented genetic events involve alterations in gene expression (proto-
oncogenes, growth factors, growth factor receptors), epigenetic modification of DNA 
(aberrant DNA methylation), mutations (in tumor suppressor genes and oncogenes), and 
chromosomal alterations (large-scale deletions, rearrangements) (2).  Interestingly, the 
majority of these molecular lesions have been found in dysplastic hepatocytes of chronic 
hepatitis or cirrhosis.  However, HCC develops in only a subset of patients with chronic liver 
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disease.  This suggests that more frequently recognized genetic lesions may provide a 
selective growth advantage for these hepatocytes, but that these alterations are not sufficient 
to drive neoplastic transformation.  Furthermore, these observations suggest additional 
alterations are required for acquisition of tumorigenic potential of dysplastic hepatocytes in 
preneoplastic lesions.  It is clear that development of HCC requires a number of genomic 
changes, involving both epigenetic and genetic alterations, and that several different 
molecular pathways can lead to development of HCC (8-10).  This possibility is reflected in 
the observation that there is considerable genomic heterogeneity among HCCs, and this 
heterogeneity remains even when consideration is given to size, histological grade, and 
clinical stage of the tumors being studied (10). 
CHROMOSOMAL ABERRATIONS IN HUMAN HEPATOCELLULAR CARCINOMA 
Recurring allelic losses have been documented for 11 chromosome arms affecting 
more than 30% of all HCC examined, including 1p, 1q, 4q, 5q, 6q, 8p, 9p, 13q, 16p, 16q, and 
17p (10).  However, the frequency of LOH involving loci on these chromosome arms is 
rarely observed in >60% of HCCs examined.  Other chromosomal arms demonstrate LOH 
with less frequency, including chromosome 11p (11-14).  The significance of alterations 
involving chromosome 11 in HCC depends upon the specific study evaluated.  Some 
investigators have implicated chromosome 11 as a frequent alteration in human HCC (12), 
while other investigators noted these changes less frequently (15-17), at very low levels (18), 
or not at all (19).  These studies combine to suggest a possible role for genetic loci carried on 
chromosome 11 in the molecular pathogenesis of some subsets of HCC.  In theory, deleted 
chromosomal regions may harbor genes with tumor suppressor-like activity.  In fact, several 
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well known tumor suppressor genes reside on chromosome arms that are frequently affected 
by regional chromosomal deletion, such as p53 at 17p and Rb1 at 13q (11, 13, 14).  These 
observations suggest that chromosomal losses can be effectively exploited to infer the 
location of important tumor suppressor genes that are subject to inactivation through this 
molecular mechanism.  Furthermore, the diversity of chromosomal aberrations among HCCs 
supports the suggestion that several molecular pathways contribute to the development of 
HCC, and that these pathways may involve any of several chromosomal regions and/or genes 
(8-10).  
COMPARATIVE MAPPING OF CHROMOSOMAL ALTERATIONS IN HUMANS AND RODENTS 
Comparative mapping studies of human and rodent genomes suggest that common 
loci may be involved in hepatocellular carcinogenesis in these species.  Rat chromosomes 1, 
4, 7, and 10 are often observed to be structurally abnormal in rat liver tumor cells, as are 
chromosomes 2, 3, 6, 8, and 11 less frequently (20-33).  Various karyotypic analyses of 
murine liver tumors have revealed LOH in chromosomes 1, 2, 4, 5, 6, 7, 8,  9, 12, 13, 14, and 
18 (34, 35).  These studies predict that alterations in orthologous regions of synteny in the 
human, rat, and murine genomes may be relevant in the development of a subset of HCC in 
each species.  One conserved gene cluster is a 27-Mbp syntenic region located on 
chromosome 11 (11q11-11p14.2), rat chromosome 3 (3q24-3q33), and mouse chromosome 2 
(2E1-2E3) (FIGURE 1.1).  Some studies have found frequent, nonrandom aberrations on 
human 11 and rat 3 in HCC (12, 36, 37), while mouse 2 has not been as widely implicated 
(38).   The observation that deletions in these orthologous regions may be causally related to 
liver tumor formation in each species strongly suggests that a subset of neoplasms may 
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 Wt1 WT1 Wt1
2E3
2E2
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CAT Cat
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Cd44
CD44 Cd44
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Ga17
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Hipk3
Cd59
Giap1
pter qterqter
 
FIGURE 1.1.  Comparative mapping of 27-Mb regions of mouse chromosome 2, human 
chromosome 11, and rat chromosome 3.  The relative locations of several gene contained 
within mouse 2E1-E3, human 11p11.2-p13, and rat 3q24-q32 are shown.  These regions 
contain a cluster of syntenic genes including Syt13, Kai1, Cd44, Cat, and Wt1. 
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involve common genetic mechanisms, possibly involving the same gene(s) (34).  
MICROCELL HYBRID MODEL OF TUMOR SUPPRESSION 
Microcell-mediated chromosome transfer (MMCT) is a commonly utilized technique 
in which a microcell, containing single or small numbers of chromosomes, is fused with a 
whole cell. Generally, the genetic information contained in the microcell is expected to 
complement a defect in the recipient cell line, and the resulting microcell hybrid (MCH), 
displaying an altered phenotype, is then characterized.  This system has been successfully 
used to identify and characterize several genes involved in normal cellular activities such as 
the regulation of telomerase activity, genomic stability, chromatin modification, genomic 
methylation, X-inactivation, mitochondrial function, and cellular proliferation (39).  Using 
this method, tumor suppressor genes or loci have been identified on human chromosomes 1, 
3-13, 17-19, 22, and X (39).  Based upon the observation that several chromosomal regions 
altered in neoplasms of humans, rats, and other mammals contain syntenic clusters of genes 
that may harbor common loci involved in carcinogenesis, it was proposed that chromosome 
transfer studies utilizing human chromosomes and rat liver cell lines may facilitate the 
identification and localization of human genes responsible for liver tumor suppression (40). 
A model has been established and characterized for the functional identification of 
human tumor suppressor genes which employs microcell-mediated transfer of human 
chromosomes into rat liver tumor cell lines (FIGURE 1.2).  Because human chromosome 11 
has been implicated in the pathogenesis of several human tumors and is orthologous to 
commonly implicated regions in the rat and mouse genomes, MMCT was employed to 
transfer an intact copy of human chromosome 11 into a highly aggressive rat liver tumor cell 
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 DONOR CELL
Mouse A9 (neo 11)
Colcemid
Cytochalasin B
Centrifugation
MICROCELLS
RECIPIENT CELL
Rat liver tumor
Fusion in polyethylene glycol
Selection with Antibiotic
Normalized
Microcell Hybrid Clone
Containing Human
Chromosome 11neo
 
FIGURE 1.2.  Microcell hybrid model of tumor suppression.  The general methodology 
for production of MCH cell lines is shown.  Donor cells containing a NeoR-tagged 
human chromosome 11 (shown in red) are used to produce microcells, which are fused 
to recipient rat liver tumor cells. Neomycin-resistant MCH cell lines are then selected 
and characterized. 
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line (GN6TF) and to examine the possibility that this chromosome may contain a liver tumor 
suppressor locus (40).  This study demonstrated that human chromosome 11 suppresses the 
tumorigenic potential of some rat liver tumor cell lines (40).   Suppressed MCH cell lines 
exhibit normalized cellular morphology (FIGURE 1.3), reexpression of contact inhibition, 
complete loss of anchorage-independent growth potential, and decreased tumorigenic 
potential in vivo and/or significantly elongated latency for tumor formation following 
transplantation into syngeneic hosts (TABLE 1.1).  Subsequent studies demonstrated 
suppression of tumorigenicity in other rat liver epithelial tumor cell lines after MMCT of 
human chromosome 11 (TABLE 1.1), providing additional evidence for the presence of a liver 
tumor suppressor gene on this human chromosome (41). 
MOLECULAR MAPPING OF THE 11P11.2 TUMOR SUPPRESSOR LOCUS IN SUPPRESSED 
MICROCELL HYBRID CELL LINES 
Several suppressed and non-suppressed MCH cell lines were derived from GN6TF, 
GP10TA, and GN3TG tumor cell lines (TABLE 1.1) (40, 41).  Because human chromosomes 
are unstable on the rodent genomic backgrounds, spontaneous deletions occurred in the 
introduced chromosome in some of these MCH cell lines.  Molecular mapping (by PCR with 
template MCH cell line DNA), using human chromosome 11-positioned markers, was 
employed to discern which region(s) of the introduced chromosome remained intact among 
suppressed and non-suppressed MCH cell lines.  The minimal inclusive liver tumor 
suppressor region was defined by correlating molecular mapping data with information on 
the phenotypic characteristics of each MCH cell line.  Through the screening of >200 human 
markers localized to chromosome 11 by early investigations of the Human Genome Project, 
the minimal inclusive tumor suppressor region was reduced to a <1-Mbp region (D11S1344-
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 TABLE 1.1.  Phenotypic characteristics of GN6TF-11neo neo, GN3TG-11  and GP10TA-11neo 
microcell hybrid cell lines*  
Saturation
Density
(Cells/cm2) 
Soft Agar
Growth
(%CFE)
Tumorigenicity
(%)
Latency
(Days)Cell Line
GN3TG-11neoC3 3.1 x 104 0 8/9 (89%) 45 + 1 
15/15 (100%)GN3TG 1.75 x 105 6.8 + 0.6 18 + 2 
GN3TG-11neoC5 7.9 x 104 3.1 + 0.3 ND NA
GP10TA-11neoC6** 1.3 x 105 12.8 +
 
0.5 9/9 (100%) 99 + 6 
GP10TA-11neoC12 5.1 x 104 3.6 + 0.5 ND NA
GN3TG-11neoC7 4.1 x 104 0 7/8 (88%) 46 +
 
2 
GP10TA 1.69 x 105 13.3 + 1.1 13/13 (100%) 75 + 5 
GP10TA-11neoC7 7.1 x 104 3.6 + 0.3 5/12 (100%) 182 + 5 
GP10TA-11neoC11 5.0 x 104 3.9 + 0.3 ND NA
GN3TG-11neoC4 5.1 x 104 3.5 +
 
0.1 6/6 (100%) 46 + 2 
GN6TF-11neo CX4 1.44 x 104 0 7/7 (100%) 145 + 18
GN6TF-11neo CX2 3.36 x 104 0 9/9 (100%) 164 + 19 
GN6TF-11neo C1 3.00 x 104 0 8/10 (80%) 152 + 16 
GN6TF 2.83 x 105 13.1 + 1.4 21/21 (100%) 21 + 1 
* Derived from Coleman et al. Molecular Carcinogenesis. 1995. 13:220 and Mahon et al. International 
Journal of Oncology. 1999. 14:337.
** non-suppressed MCH cell line.  
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D11S436) centered at 11p11.2 (41, 42) (FIGURE 1.4).  These studies, in addition to efforts by 
the Human Genome Project, provided the foundation, biological reagents, and bioinformatic 
tools to identify and characterize the tumor suppressor gene(s) from this region of human 
chromosome 11p11.2. 
A PUTATIVE ROLE FOR WT1 IN LIVER TUMOR SUPPRESSION 
Having identified and mapped a locus within human chromosome 11p11.2 that 
suppresses the tumorigenic potential of some rat liver tumor cell lines, possible molecular 
mechanisms of tumor suppression were examined by examining gene expression patterns in 
suppressed MCH cell lines (43).  The parental GN6TF rat liver tumor cells express moderate 
levels of p53 mRNA and protein, overexpress mRNAs for c-H-ras, c-myc, and TGFα, and 
does not express detectable levels of Wt1 mRNA or protein.  Suppression of tumorigenicity 
by human chromosome 11p11.2 was not accompanied by significant alterations in the levels 
of expression of p53, c-myc, or TGFα.  Expression of c-H-ras was decreased significantly in 
both suppressed and nonsuppressed MCH cell lines, suggesting that down-regulation of c-H-
ras is not directly responsible for tumor suppression.  In contrast, the level of expression of 
Wt1 correlated precisely with tumor suppression in this model system (43).  All suppressed 
MCH cell lines expressed Wt1 mRNA and protein at levels comparable to that of normal rat 
liver epithelial cells (WB-F344) (FIGURE 1.5).  PCR analysis demonstrated that 2/3 of the 
suppressed MCH cell lines do not carry the human WT1 gene, indicating that Wt1 expression 
in these lines originates from the rat locus.  Reexpression of tumorigenicity by suppressed 
MCH cell lines was accompanied by the coordinate loss of human chromosome 11p11.2 and 
of Wt1 gene expression, suggesting that one or more human 11p11.2 genes 
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FIGURE 1.4.  Molecular mapping of the 11p11.2 tumor suppressor locus among 
suppressed MCH cell lines.  A representative panel of microsatellite/EST markers 
localized to human chromosome 11p is shown (of >200 that were analyzed) and a line 
connects the markers to their relative chromosomal location.  The positive signs (+) in the 
columns indicate the smallest region of overlapped markers contained in each of the 
suppressed GN6TF, GN3TG, and GP10TA-derived MCH cell lines.  The smallest 
common tumor suppressor locus retained in all suppressed MCH cell lines (D11S1344-
D11S436) is shown (adapted from Mahon et al. International Journal of Oncology. 1999. 
14:337). 
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FIGURE 1.5.  Expression of Wt1 in GN6TF-derived MCH Cell Lines.  A representative 
autoradiogram and fluorogram are shown for northern and western analysis of Wt1 mRNA 
and protein among MCH cell lines.  The approximate size of the Wt1 mRNA is 3 Kbp and 
the MCH cell lines (C1, CX2, and CX4) express an approximately 2.8 Kbp Wt1 mRNA.  
The molecular weight of the Wt1 protein is approximately 50 kDa.  GN6TF tumor cells 
are negative for both gene and protein Wt1 products (adapted from Coleman et al. 
International Journal of Oncology. 1999. 14:957) 
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are required for sustained expression of Wt1 in these cell lines.  Together, these results 
suggest that the molecular mechanism governing human chromosome 11p11.2-mediated 
liver tumor suppression may involve induction of rat Wt1 gene expression under the direct or 
indirect transcriptional regulation of a genetic locus (or loci) on human 11p11.2 (43). 
OBJECTIVES OF THIS DISSERTATION RESEARCH 
Strong evidence suggests the presence of a previously unidentified liver tumor 
suppressor gene in a <1-Mbp region on human chromosome 11p11.2.  The overall objectives 
of this research were to (i) identify the gene responsible for suppression of the neoplastic 
phenotype of rat liver tumor cells, (ii) characterize the involvement of this gene in tumor 
suppression, (iii) determine the ability of this gene to individually express tumor suppressor 
activity in vivo, and (iv) identify molecular targets and pathways in liver tumor cell lines that 
are subject to direct or indirect modification in response to the expression of the human 
chromosome 11p11.2 liver tumor suppressor gene.   
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EXPERIMENTAL PROCEDURES 
CELL LINES AND CELL CULTURE 
Rat Liver Epithelial Tumor Cell Lines 
The rat liver epithelial tumor cell lines (44) used in these studies (GN6TF, GN3TG, 
and GP10TA) were derived from a normal rat liver epithelial cell line (WB-F344) that has 
been described (45).  Phenotypically distinct clonal cell lines were established from a 
tumorigenic population of WB-F344 cells transformed in vitro by 11 consecutive brief 
treatments with 5.0 μg/ml N-methyl-N’-nitro-N-nitrosoguanidine (46, 47).  Tumor cell lines 
that expressed altered phenotypic properties and produced subcutaneous tumors in 100% of 
animals after a short latency period were established from tumors that formed in syngeneic 
animals after transplantation of the transformed cell lines (44).  WB-F344 cells and parental 
tumor cell lines were cultured on plastic in Richter’s Improved Minimal Essential Medium 
(prepared by the UNC Lineberger Comprehensive Cancer Center Tissue Culture Facility) 
supplemented with 10% fetal bovine serum (Hyclone, Logan, UT), and Antibiotic-
Antimycotic (Gibco/Invitrogen Life Technologies, Carlsbad, CA) (48).   
Microcell Hybrid Cell Lines 
MCH cell lines were established from GN6TF, GN3TG, and GP10TA liver tumor 
cell lines after the introduction of human chromosome 11 by microcell-mediated 
chromosome transfer (40, 41), using established methods (40).  The derivation of individual 
MCH cell lines and MCH-derived tumor cell lines is outlined in FIGURE 2.1.  The GN6TF-
derived MCH cell lines used included GN6TF-11neoCX2 (designated CX2, which contains an 
intact copy of human chromosome 11), GN6TF-11neoC1 (designated C1, which contains a 
portion of 11p11.2 bounded by, but not including, D11S1361-D11S1357), and GN6TF-
11neoCX4 (designated CX4, which contains the D11S1361-D11S1357 interval) (40).  In 
addition, two MCH-derived tumor cell lines were used (GN6TF-11neoCX2T1 and GN6TF-
11neoCX4T3).  These cell lines were established in culture from tumors that formed at least 
four months after the transplantation of GN6TF-11neo MCH cell lines into syngeneic host rats 
(40).  The GN3TG-derived MCH cell lines included five suppressed MCH cell lines 
(GN3TG-11neoC2, GN3TG-11neoC3, GN3TG-11neoC4, GN3TG-11neoC5, and GN3TG-
11neoC7), and one MCH-derived tumor cell line (GN3TG-11neoC4T3) (41).  The GP10TA-
derived cell lines included a non-suppressed MCH cell line (GP10TA-11neoC6), three 
suppressed MCH cell lines (GP10TA-11neoC7, GP10TA-11neoC11, and GP10TA-11neoC12), 
and one MCH-derived tumor cell line (GP10TA-11neoC7T3) (41).  All MCH cell lines were 
cultured in Richter’s Improved Minimal Essential Medium supplemented as described (48) 
with 800 μg/ml G418 (Gibco) (40).  MCH-derived tumor cell lines were cultured in the same 
growth medium, but without the addition of G418.   
Human Hepatocellular Carcinoma Cell Lines 
The human HCC cell lines used in this study were generously provided by Dr. Snorri 
S. Thorgeirsson (NCI, National Institutes of Health, Bethesda, MD).  This group of cell lines 
included nineteen human hepatoma cell lines (18 HCC and 1 hepatoblastoma) established 
from patients in North America, Japan, China, South Africa, and South Korea (49, 50) 
(TABLE 2.1).  Non-neoplastic control cell lines included Chang and WRL-68 were obtained 
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GP10TA
GP10TA-11neoC6*
GP10TA-11neoC7
GP10TA-11neoC11
GP10TA-11neoC12
GN3TG-11neoC3T1
GP3TG-11neoC3T7
GP3TG-11neoC4T3
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GN3TG
GN3TG-11neoC3
GN3TG-11neoC5
GN3TG-11neoC6
GN3TG-11neoC7
GP10TA-11neoC7T3
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GN6TF
GN6TF-11neoC1
GN6TF-11neoCX2
GN6TF-11neoCX4
GN6TF-11neoCX2T1
GN6TF-11neoCX4T3
GN6
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Multiple sequential carcinogen treatments in vitro
Establishment of clonal populations
Passage through F-344 rats
Establishment of tumor cell lines
Passage through F-344 rats
Establishment of MCH-derived tumor cell lines
Introduction of human chromosome 11
Establishment of clonal populations
Rat Liver Epithelial Cell Lines
 
FIGURE 2.1.  Derivation of rat liver epithelial tumor cell lines and microcell hybrid cell 
lines.  The normal rat liver epithelial cell line WB-F344 was neoplastically transformed by 
11 sequential carcinogen treatments resulting in the growth of clonal cell lines (including 
GN6, GP10, and GN3) with varying tumorigenic potential.  These cloned cell lines were 
passaged through neonatal rats resulting in tumors and tumor cell lines.  MCHs were 
clonally isolated after microcell-mediated chromosome transfer of human chromosome 11 
into tumor cell lines, and MCH-derived tumor cell lines were established after 
transplantation of MCHs into neonatal rats.  * Denotes a non-suppressed MCH cell line.   
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TABLE 2.1.  Human hepatocellular carcinoma cell lines* 
Cell Line Origin HBV-DNA
SNU182 Korea Positive
SNU387 Korea Positive
SNU398 Korea Positive
SNU423 Korea Positive
SNU449 Korea Positive
SNU475 Korea Positive
Hep3B United States Positive
Hep40 China Positive
Focus United States Positive
PRF/PLC/5 South Africa Positive
Huh-1 Japan Positive
HepG2 Argentina Negative
Sk-Hep1 United States Negative
HLE Japan Negative
HLF Japan Negative
7703 China Negative
Huh-6 Japan Negative
Huh-7 Japan Negative
Hep3B-TR United States ND
* Provided by Dr. Snorri S. Thorgeirsson (NCI, National Institutes of Health, Bethesda, MD)  
from American Type Culture Collection (ATCC, Manassas, VA).  Chang (CCL-13), is a 
normal human liver cell line (51), and WRL-68 (CL-48) is a human fetal liver cell line (52).  
All human HCC cell lines and non-neoplastic control cell lines were grown on plastic in 
Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (1:1) mix supplemented with 15 
mM HEPES, 2 mM L-glutamine (Gibco/Invitrogen), 10% fetal bovine serum (Hyclone), and 
Antibiotic-Antimycotic (Gibco/Invitrogen). 
Treatment with 5-aza-2’-deoxycytidine 
To examine the possibility of epigenetic silencing (through promoter 
hypermethylation) of several 11p11.2 candidate tumor suppressor genes in human liver 
tumors, HCC cell lines (FOCUS, SNU475, SNU398, Huh-1, SNU449, Hep3B, PRF/PLC/5, 
and HepG2) were plated at densities between 5x105 and 1.8x106  cells/150 mm culture dish 
in normal growth medium.  The demethylating agent 5-aza-2’-deoxycytidine (5-aza, Sigma, 
St. Louis, MO) was dissolved in DMSO prior to addition to growth medium.  HCC cells lines 
were treated with 5 μM 5-aza for 7 days, with refeeding of fresh culture medium on days 3 
and 5.  Control cultures of HCC cells were grown in culture medium containing DMSO 
vehicle control only.  RNA was isolated on day 7 for gene expression analysis.  
SYT13-targeted and SYT13-transfected Cell Lines 
Transfection:  Plasmid DNA to be transfected into CX4 (for SYT13-targeted cell 
lines) or GN6TF (for SYT13-transfected cell lines) was linearized with the appropriate 
restriction enzymes.  Linearized plasmid DNA (5 μg) and Lipofectamine 2000 (12.5 μl) 
(Invitrogen, Carlsbad, CA) were incubated separately in 1.5 ml Opti-MEM I Reduced Serum 
Medium (Invitrogen), for 5 minutes at room temperature.  The DNA and Lipofectamine were 
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then mixed and incubated at room temperature for 20 minutes.  This mixture was added to 
90-95% confluent cells in a 100 mm tissue culture dish and incubated at 37° overnight.  
Complete growth medium was replaced the next day, and 24 hours after transfection, cells 
were passaged 1:10 into 150 mm tissue culture dishes.  Successfully transfected cells were 
selected with the appropriate antibiotic (G418 or zeocin), and after approximately 2 weeks in 
culture with medium changes 3 times per week, individual clones were identified, isolated 
using cloning rings, and established as individual cell lines. 
Transfected cell lines:  Twelve SYT13-targeted cell lines [CX4SYT13i (designated i1, 
i2, i3…i12)] were established from the suppressed MCH cell line CX4 by transfection with 
the psiRNA-hH1zeo vector (FIGURE 2.2.A; InvivoGen, San Diego, CA) containing a SYT13-
targeted ds-RNA hairpin (shRNA). Eight control cell lines [CX4SYT13s (designated s1, s2, 
s3…s8)] were established by transfecting CX4 cells with the same vector containing a 
scrambled-sequence shRNA.  These cell lines were cultured on plastic and maintained in 
Richter’s Improved Minimal Essential Medium containing 800 μg/ml G418 and 360 μg/ml 
Zeocin (InvivoGen) supplemented as described (48).  GN6TF tumor cells were transfected 
with either SYT13-pReceiver-m11 or a GFP-pReceiver empty vector control (FIGURE 2.2.B.; 
GeneCopoeia, Germantown, MD).  The resulting cell lines, GN6TFneoSYT13- (designated 
B3, C1, C2, E2, F3, J1) and GN6TFneoGFP (designated GFP) were cultured on plastic in 
Dulbecco’s Modified Eagle Medium/Nutrient Mixture F-12 (1:1) mix (Gibco/Invitrogen) 
supplemented with 10% fetal bovine serum (Hyclone), Antibiotic-Antimycotic 
(Gibco/Invitrogen), 3.2 g/L sodium bicarbonate, and 800 μg/ml G418.  
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B.
 
FIGURE 2.2.  Plasmid maps.  (A) The vector used to silence SYT13 (psiRNA-hH1zeo G2) 
contains the Zeocin resistance gene and utilizes an H1 promoter to drive expression of the 
dsRNA hairpin.  (B) SYT13 was cloned into the pReceiver-M11 expression vector which 
contains a neomycin resistance cassette and uses a CMV promoter to drive expression of a 
FLAG-tagged (N-terminus) SYT13 (adapted from www.invivogen.com and 
www.genecopoeia.com).  
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Phenotypic Characterization of SYT13-Targeted and SYT13-Transfected Cell Lines In Vitro 
Morphology:  The morphologies of experimental cell lines were evaluated by phase 
contrast microscopy.  Cells were examined for nuclear/cytoplasmic ratio, shape, and contact 
inhibition during both growth phase and at confluency.  Photographs of cells in culture were 
taken at the UNC Microscopy Services Laboratory with the Olympus IMT2 inverted 
microscope (Center Valley, PA). 
Saturation density:  For determination of saturation density in monolayer cultures, 
cells were plated at a density of 1.25 x 105 cells/60-mm dish (or 6.25 x 104 cells/well in a 6-
well plate) and maintained in culture with medium changes every 3 days.  At the end of 14 
days, cells were harvested, counted using a Model ZM particle counter (Coulter Electronics, 
Hialeah, FL).  Saturation densities for individual cell lines were calculated and expressed as 
total cells/cm2. 
Anchorage-independent growth in soft agar:  Anchorage-independent growth was 
assayed essentially as described (53).  The soft agarose medium consisted of Seaplaque GTG 
low melting point agarose (FMC Bioproducts, Rockville, ME) in Richter's Improved 
Minimal Essential Medium.  Cells suspended in 0.5% agarose were plated (1.0 x 10
4
 
cells/60-mm dish or 5.0 x 103 cells/well in a 6-well plate) between layers of agarose medium 
containing 1% agarose.  Soft agarose cultures were maintained for four weeks with weekly 
feeding of fresh medium.  Viable soft agar colonies were identified by overnight staining 
with 0.05 mg/ml MTT [3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide] 
(Sigma) (54).  MTT-stained colonies were counted for each replicate dish (n=5) in five 
random fields on an inverted microscope (12.6 mm2/field).  Total colonies per plate were 
calculated by averaging the number of colonies/field and extrapolating on to the growth area 
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of the dish.  Colony forming efficiency (CFE) was determined by dividing the total 
colonies/plate by the total number of cells plated.   
Tumorigenicity of Cell Lines In Vivo and Characterization of Tumor Revertants 
Cells intended for transplantation (SYT13-targeted, SYT13-transfected, and 
appropriate controls) were trypsinized, rinsed in PBS (1.54 mM KH2PO4, 155.17 mM NaCl, 
2.71 mM NaH2PO4-7H2O; pH 7.2) (Gibco/Invitrogen), resuspended in PBS at a density of 1 
x 106 cells/0.10 ml, and held on ice until transplanted.  Cell suspensions containing 1 x 106 
cells were injected into the dorsal subcutaneous tissue of 1-day-old Fisher 344 rats (Charles 
River Laboratories, Inc., Wilmington, MA).  Tumor growth was monitored and interim 
tumor measurements were taken with calipers in vivo 10 days after transplantation.  Animals 
were euthanized when tumors reached an approximate diameter of 1 cm, or after 10 months.  
Tumor tissue was harvested aseptically and used for cell culture or histology.  Tissue for 
histology was fixed in 10% formalin, and processed by Histo-Scientific Research 
Laboratories (Woodstock, VA) for paraffin embedding, sectioning, and staining with 
hematoxylin and eosin.  Tumor cell lines were established from freshly harvested tumor 
tissue essentially as described previously (44).  Tissue was washed in Ca2+- and Mg2+- free 
red Hank’s Balanced Salt Solution (Cellgro #21-021-CV, Mediatech Inc., Herndon, VA), 
placed in a tissue culture plate, and minced finely with a scalpel.  The culture was incubated 
in Richter’s Improved Minimal Essential Medium (supplemented as described) overnight at 
37°C.  On the following day, growth medium and solid tissue remnants were removed 
completely to discourage outgrowth of fibroblasts.  After 2 weeks in culture, individual 
clones were isolated with cloning rings and established as tumor revertant cell lines.  
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GENERAL METHODS 
Nucleic Acid Preparation and Quantitation 
DNA isolation from cultured cells:  High molecular weight DNA was isolated from 
cultured cells using the Puragene DNA Purification Kit (Gentra Systems, Minneapolis, MN).  
Briefly, 1-2 million cells were lysed in 300 µl Cell Lysis Solution and incubated overnight 
with 1.2 U Proteinase K (Gentra Systems).  Subsequently, the lysate was treated with 0.12 U 
RNase A (Gentra Systems), 100 µl Protein Precipitation Solution was added, and the 
precipitate was allowed to form for 5 minutes on ice.  After centrifugation at 15,000 x g for 1 
minute, the supernatant containing DNA was transferred to a new microfuge tube containing 
300 µl 100% isopropanol.  Tubes were inverted 50 times and centrifuged at 15,000 x g for 1 
minute.  The DNA pellet was dried briefly and resuspended in DNA Hydration Solution. 
DNA isolation from tissue:  Paraffin-embedded tissue sections were deparaffinized 
with xylene and subsequently rehydrated using a gradient of ethanol solutions (100%, 95%, 
70%).  DNA was then extracted from the tissue using the Puragene DNA Purification Kit 
(Gentra Systems). 
RNA isolation:  Total cellular RNA was isolated from cultured cells using the 
RNeasy® Mini Kit (Qiagen, Valencia, CA).  Cells were lysed in Buffer RLT, homogenized 
by vortexing for 1 minute, and 70% ethanol was added before addition to the RNA binding 
column.  After RNA was absorbed by the membrane, contaminants were removed, and total 
RNA was washed on the column with  Buffers RW1 and RPE.  RNA was eluted with RNase-
Free H2O. 
Nucleic acid quantitation:  Concentrations of isolated DNA and RNA were 
determined by analyzing UV absorbance (OD at 260nm) using the SmartSpec™ 3000 
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spectrophotometer (Bio-Rad, Hercules, CA), and purity was assessed by OD260/OD280 
ratios. 
Nucleic Acid Amplification 
Reverse transcription:  Total RNA (1-2 μg) was reverse-transcribed for 1 hour at 
42°C using MMLV reverse transcriptase (Ambion, Austin, TX) in a buffer consisting of 100 
mM Tris-HCl (pH 8.3), 500 mM KCl, 15 mM MgCl2, 0.25 mM of each dNTP, 1 μM cDNA 
synthesis primer (RETROscript™ First-Strand Synthesis Kit, Ambion, Austin, TX), in a total 
volume of 20 μl.  Newly synthesized cDNA was used as the template for PCR. 
Polymerase chain reaction:  PCR reactions consisted of 50 ng of template DNA or 2 
μl RT-reaction mixture (cDNA) in 50 μl total of a buffer consisting of 50 mM KCl, 20 mM 
Tris-HCl (pH 8.4), 2 mM MgCl2, 200 μM of each dNTP (EasyStart PCR Mix-in-a-Tube, 
Molecular Bio-Products, San Diego, CA), 0.4 μM of each primer, and 2.5 U AmpliTaq 
enzyme (Perkin Elmer, Boston, MA).  Amplifications were carried out in a Perkin Elmer 
Thermocycler using a step-cycle program consisting of 35 cycles of 94°C for denaturing (1 
minute), 55-65°C for annealing (1 minute), and 72°C for extension (2 minutes).  TABLE 2.2 
contains the list of genes and corresponding oligonucleotide primers utilized for deletion and 
transcription mapping of the human 11p11.2 tumor suppressor locus. 
Agarose and polyacrylamide gel electrophoresis:  PCR products were either 
fractionated on a 2% agarose gel containing 40 mM Tris-acetate/1 mM EDTA (pH 8.0), or an 
8% polyacrylamide gel in TBE [89 mM Tris-borate, 89 mM boric acid, 2 mM EDTA (pH 
8.0)] and visualized by ethidium bromide staining. 
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 TABLE 2.2.  Oligonucleotide PCR primers for deletion and transcription mapping of the 
11p11.2 liver tumor suppressor locus  
Gene Forward Primer Reverse Primer Amplicon Size(bp)  
ALX4 CTCTTGTTTGGTTCAACCATTGG TGCTTTACCAGCCTCACTCCC 400 
AP15 TTTCAAAAGCATAAGGGGACA CCCCTTCCCTTTCCTAAGG 152 
BHC80 CCAGTTCTGACACCTTTTTAATAGA CGGGCACTGTTTTTTTATGC 210 
C1QTNF4 GGCGCCTACTTCTTCTCCTT TACTTGCCGTGGTTGCTGTA 231 
ch-TOG CCTGCTGAGGCCATTTTTAA AGAATAAAGAGCAGCCGCAA 105 
DEPC-1 GCGCCTTCCTGACTTACTGC CTGAGCCCCAGTTTTTCCTC 241 
DKFZp779M0652 CACCCTGGAAGGTAGCACAT AAGGAACTCTGGCGAGTCAA 215 
FLJ10450 CTATTTTCTGGCTTACCCCTTGG CCTTTTCTCAGACCTTAGGCACA 337 
FLJ10890 GCACCTGTTATAAGGGGCTG AAACTTCAAAATCAAGTGCCA 234 
FLJ11320 GGATTCTTTATTCAATCACA CTATATAGTGAAAAGCTACCCA 132 
FLJ12827 CTGGCTTCCCTACACTCTCG GCCACACTCAGTGCAAAGAA 173 
FLJ14213 TGTTGTTTATTGAATCCATTTTGG TTTTTCTCTCCTAGATTCATTTTCA 147 
FLJ14576 CAAACAGTCCAGAAAGAAAG TTGGGTTGTAGGTTGGGCTC 90 
FLJ1904 CCTCGTGCTGATAGATGG AGAGTGTCTTGTTGTATTTACTGCC 170 
FLJ20294 AGCAGAAGAGGCAAAAGAGTCA TGAGAGCAACCTTCTTTTGGACT 303 
FLJ23598 TGGGCATGTGGTCAAGATGC GAGCAAACCTGACATACAGC 303 
FLJ25785 CTGCCCAATACGTGGCATGC GGGAGCAGATCCAGGTGTCC 230 
FLJ32675 GTTTCCACGGCAGTTCATTT GACATTGGCAACACAACGAC 202 
FLJ35207 CGTCTGACCTCAAGGTGATC GGGGCAGGAAAGTGACATGC 270 
FLJ41423 CTCTGAGGCCAAGACCTGAC CTGCATTCTCCTTCCTCCTG 172 
HSA249128 CAGGAAGAAGGGTTCTGGTC CCATGTGTTCTGAATTCAGC 78 
HSD17B12 AATGATGCTGATAGCAGATGGCT TGAAATATGCAGCAAGAAGATTGG 193 
HSPC166 GGGAACACTCTGGATGGAC TGGAGGGAATCGGACAGG 95 
KIAA1580 TCTCCTCGCAGAGGACTAGC ATCGCTGGCTCTTCTCATCC 140 
LOC120297 GTGTCTTTTGGTGCCTCACC GCCAAACATACCCCACAACC 162 
LOC399888 AGGAGTGGGCACAGAGCTAA GGGATGCTCAGCACCTAGAG 239 
LOC90139 ATTTCCCTCATTGGTCCTCATTT TGGTTTCTCTTCTGATAGGCAGG 305 
MAPK8IP1 GACTCTGTCAAGTACACGCTGG TCATATTCCTCTCCGATGGC 167 
NDUFS3 TTAAGTCATTGTCTTCTGAAGATGG CCTTAACCATAATGTCTTTTGATGG 102 
NR1H3 GACAGAACAGTCATTCGTGCA ATGCCTACGTCTCCATCCAC 184 
NUP160 GTGCTTGCTGGTGGTGCTAAC TACAACAAGCCAACAACCCT 185 
OASIS GCAATTAAAAAGGCCCAGC AAATCTCCCTCTTCCCTTCG 150 
PEX16 TTCAAGAGATGGGGTGAAGG CACAGAAGGACCGTACGACA 156 
PHACS GTATCTGGCTGTGGATTCGC TTCTGGAGCATTCTCCTTCC 260 
PRDM11 CTTGGGGATGACCTCGTTTA AAAGCTTCCAGCAAGTGGAC 218/729 
RAG1 ACCATGAACCCTCAGGCAAG CCCCATACACAGCAGTAAAG 178 
SPI1 ACCAGTTCCTGTTGGACCTG CTTCACCTTCTTGACCTCGC 218 
SYT13 TTAACAATGTGGACATCTGTTTAGA TTAGTCTATGACATCTGGCTACATG 177 
TBP1 TCAGCCGTGAGACTGG AAGGCATCCTGGAGGTG 88 
TP53I11 TGTGGAACGCTCTCTACACG TTCGGCCGACTTGGTAATAG 204/747 
TRAF6 TTTTTATGTTGCTGATTGTATGTGT TTGTTATGCTATGTAACCCTTTTTG 125 
TYRL AGCCATCTGCGTTTGAGC GGGCATGTTAATGCACTTTG 175 
β-ACTIN AGAGATGGCCACGGCTGCTT ATTTGCGGTGGACGATGGAG 605/810 
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Real-time reverse transcription-polymerase chain reaction:  Oligonucleotides and 
fluorescently labeled probes were designed around intron-exon boundaries using Primer 
Express software (Applied Biosystems, Foster City, CA) (TABLE 2.3).  Additional real-time 
probe/primer sets were purchased directly from Applied Biosystems and supplied in a 20X 
mix containing both primers and the FAM-labeled probe.  These TaqMan assays included 
Cdh1 (Rn00580109_m1), Gapdh (Rn99999916_s1), Pawr/Par4 (Rn00583738_m1), Snail 
(Rn00441533_g1), SYT13 (Hs00951871_m1), and Wt1 (Rn00580566_m1).  Each RT-PCR 
was carried out in triplicate in a 30 μl volume [2X ABsolute™ QPCR ROX Mix (ABgene, 
Rochester, NY), 0.1 μg/μl of each primer, 20 μM TaqMan probe, 5 U Reverse-iT™ Rtase 
Blend (ABgene), 100 ng total RNA] for 30 minutes at 48°C for reverse transcription, 10 
minutes at 95°C for initial denaturing, followed by 40 cycles of 95°C for 15 seconds and 
60°C for 1 minute in the ABI 7700 Prism Sequence Detection System.  Values for expression 
levels (CT) were normalized to the expression of glyceraldehyde-3-phosphate dehydrogenase  
(GAPDH) and relative quantitation of the multiplex reactions was compared to a reference 
sample mRNA using the Comparative (ΔΔCT) Method described in User Bulletin #2: ABI 
Prism 7700 Sequence Detection System.  In this method, the number of PCR cycles is 
recorded when the fluorescence intensity of excited PCR probes exceeds a pre-determined 
threshold (the cycle threshold or CT).  A CT which exceeds the maximum limit of 40 cycles is 
equivalent to zero expression.  It is therefore critical to note that quantitation of a fold-
increase from zero expression to any discernable level is a mathematical impossibility.  
However, to facilitate the analysis of quantitative increases in gene expression, a CT of 40 
was assigned to genes with zero expression.  Thus, the fold-change values for expression of 
these genes correspond to the value that would be expected if expression of the control were 
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detected at a CT of 40.  The ΔCT represents the CT normalized to the endogenous GAPDH 
housekeeping gene [ΔCT = CT (GENE) - CT (GAPDH)].  To calculate expression fold-change 
relative to a reference calibrator, the equation 2-ΔΔCT is used where ΔΔCT = ΔCT (5-aza TREATED) 
- ΔCT (DMSO).   
Protein Analysis 
Whole cell lysate preparation and protein quantitation:  Cells intended for western 
blot analysis were lysed in ice-cold RIPA buffer [50 mM Tris-HCl (pH 8), 150 mM NaCl, 
1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS], and protein concentrations were 
determined with the bicinchoninic acid protein assay (Pierce, Rockford, IL) using bovine 
serum album (BSA) as the protein standard.   
Western analysis:  Lysates (30-80 μg protein) were boiled for five minutes in sample 
buffer (125 mM Tris-HCl, 4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 0.004% 
bromophenol blue) and fractioned by SDS-PAGE on 10% polyacrylamide resolving gels 
[0.375 M Tris-HCl (pH 8.8),  1.6% SDS] and transferred to nitrocellulose membrane [BA85 
(0.45 μm), Schleicher & Schuell, Keene, NH], as previously described (55).  After transfer, 
the gel and blot were stained with Coomassie Blue (0.1% Coomassie Blue R250, 20% 
methanol, and 10% acetic acid) (Sigma) or PonceauS (0.1% in 5% acetic acid) (Sigma), 
respectively, to assess successful transfer and equal loading.  Blots were rinsed briefly with 
TBST [10 mM Tris-HCl (pH 8.0), 0.15 M NaCl, 8 mM sodium azide, 0.05% Tween-20] and 
blocked for 1 hour at room temperature in 5% milk/TBST.  Primary antibodies were used at a 
dilution of 1:500-1:1000 in 5% milk/TBST.  Bound primary antibody was detected using the 
appropriate peroxidase-conjugated secondary antibody and visualized by chemiluminescence 
using the Amersham ECL kit (GE Healthcare, Buckinghamshire, UK) and Kodak BioMax 
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Light Film (Eastman Kodak Company, Rochester, NY).  For quantitation of immunoreactive 
protein bands, exposed films were scanned and analyzed by densitometry using ImageJ 
software (v1.37, http://rsb.info.nih.gov/ij/). 
Development of a polyclonal antibody to SYT13:  A rabbit polyclonal antibody 
directed against human SYT13 was generated by Anaspec (San Jose, CA).  The antibody was 
raised against a 14 amino acid sequence (RDQDPDLEKAKPSL) located in the linker region 
between the transmembrane (TMR) and C2A domains of human SYT13, corresponding to 
amino acids 41-57 (FIGURE 2.3.A).  This peptide target was chosen based on its antigenicity 
and divergence from the rat Syt13 homolog [57% similarity (8/14aa)] (FIGURE 2.3.B).  
Rabbits (n=2) were immunized with 4 mg KLH-conjugated peptide in Complete Freund’s 
Adjuvant, and subsequently immunized at 3, 6, and 10 weeks with the KLH-conjugated 
peptide in incomplete Freund’s Adjuvant.  Serum was collected 7 and 11 weeks after the 
initial immunization.  The serum was used directly without antibody purification at a dilution 
of 1:1000 for western blotting (suggested from ELISA analysis performed by Anaspec). 
Additional antibodies:  Rabbit polyclonal antibody directed against E-cadherin (H-
108) and rabbit polyclonal antibody directed against WT1 (C-19) (Santa Cruz Biotechnology, 
Santa Cruz, CA) were used at a dilution of 1:500 for western blotting.  Goat polyclonal 
antibody directed against the FLAG antigen DDDDK (anti-FLAG, ab1238; 1:1000) and 
rabbit polyclonal directed against GAPDH (ab9385; 1:1000) were both primary antibodies 
conjugated to horseradish peroxidase (Abcam, Cambridge, MA).  A donkey anti-rabbit IgG 
horseradish peroxidase-conjugated secondary antibody was used to detect primary antibodies 
raised in rabbits (NA 934, GE Healthcare; 1:10,000). 
 30
 TMR C2A C2B
7-29 158-282 289-426
A.
Human: 1   MVLSVPVIALGATLGTATSILALCGVTCLCRHMHPKKGLLPRDQDPDLEKAKPSLLGSAQ 60
MVLSVPVIALGATLGTATSILALCGVTCLCRHMHPKKGLLPRD++PD EKA+P +L +AQ
Rat: 1   MVLSVPVIALGATLGTATSILALCGVTCLCRHMHPKKGLLPRDREPDPEKARPGVLQAAQ 60
Human: 61  QFNVKKSTEPVQPRALLKFPDIYGPRPAVTAPEVINYADYSLRSTEEPTAPASPQPPNDS 120
QFNVKKSTEPVQPR LLKFPDIYGPRPAVTAPEVINYADY+L +TEE  APASPQ  +DS
Rat: 61  QFNVKKSTEPVQPRPLLKFPDIYGPRPAVTAPEVINYADYTLGTTEESAAPASPQAQSDS 120
Human: 121 RLKRQVTEELFILPQNGVVEDVCVMETWNPEKAASWNQAPKLHYCLDYDCQKAELFVTRL 180
RLKRQVTEELFILPQNGVVEDVCVMETWNPEKAASWNQAPKLH+ LDYD +KAELFVT L
Rat: 121 RLKRQVTEELFILPQNGVVEDVCVMETWNPEKAASWNQAPKLHFRLDYDQKKAELFVTSL 180
Human: 181 EAVTSNHDGGCDCYVQGSVANRTGSVEAQTALKKRQLHTTWXXXXXXXXXXXXXXXXXXX 240
EAVTS+H+GGCDCY+QGSVA +TGSVEAQTALKKRQLHTTW            
Rat: 181 EAVTSDHEGGCDCYIQGSVAVKTGSVEAQTALKKRQLHTTWEEGLALPLGEEELPTATLT 240
Human: 241 XXXXXCDRFSRHSVAGELRLGLDGTSVPLGAAQWGELKTSAKEPSAGAGEVLLSISYLPA 300
CDRFSRHSV GELRLGL+G SVPLG AQWGELKT+AKEPSAG GEVLLSISYLPA
Rat: 241 LTLRTCDRFSRHSVIGELRLGLNGASVPLGTAQWGELKTTAKEPSAGTGEVLLSISYLPA 300
Human: 301 ANRLLVVLIKAKNLHSNQSKELLGKDVSVKVXXXXXXXXXXXXXXXXXXXXINPVWNEMI 360
ANRLLVVLIKAKNLHSNQSKELLGKDVSVKV                    INPVWNEMI
Rat: 301 ANRLLVVLIKAKNLHSNQSKELLGKDVSVKVTLKHQAQKLKKKQTKRAKHKINPVWNEMI 360
Human: 361 MFELPDDLLQASSVELEVLGQDDSGQSCALGHCSLGLHTSGSERSHWEEMLKNPRRQIAM 420
MFELPDDLLQASSVELEVLGQ + G SC LG CSLGLH SGSERSHWEEMLKNPRRQIAM
Rat: 361 MFELPDDLLQASSVELEVLGQGEEGPSCELGRCSLGLHASGSERSHWEEMLKNPRRQIAM 420
Human: 421 WHQLHL 426
WHQLHL
Rat: 421 WHQLHL 426
B.
 
FIGURE 2.3.  Polyclonal SYT13 antibody peptide selection.  (A) The SYT13 protein 
contains an N-terminal transmembrane region (TMR, in blue) followed by a cytoplasmic 
linker region (in white) and two tandem C2 domains (C2A and C2B, in red).  (B) The 
SYT13 antibody was raised against a 14 amino acid sequence (green) with 57% (8/14) 
homology to the rat Syt13 protein.  Amino acids in blue correspond to the TMR and in red 
correspond to the individual C2 domains. 
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Statistical Analysis 
Data in the text, tables, and figures represent mean values + the standard error of the 
mean.  Statistical analysis of real-time PCR data was accomplished using one-way ANOVA 
(Kaleidagraph, Reading, PA).  The statistical significance of data from densitometry, 
saturation density, and anchorage-independent growth assays was assessed using the 
Student’s t-Test for unpaired data with unequal variance.  Statistical significance associated 
with Kaplan-Meier survival analysis was determined using the Log-Rank test (Lifetest 
Procedure, SAS System, SAS Institute, Cary, NC). 
STUDY-SPECIFIC METHODS 
Methods Specific to Loss of Heterozygosity Study 
Patients and tumor specimens:  Forty-seven hepatocellular carcinomas were selected 
for this study. DNA corresponding to tumor and matched non-tumor tissue were provided by 
Dr. Snorri S. Thorgeirsson (NCI, National Institutes of Health, Bethesda, MD).  All HCC 
tumors were from patients in China.  The majority of patients were male (75%) and HBV+ 
(76%).  These HCCs occurred in the setting of cirrhosis in slightly less than half the patients 
(42%) and in non-cirrhotic patients in the remainder (58%).  HCC stage II disease and stage 
III disease were detected in 33% and 42% of the samples respectively. 
Microsatellite markers:  Deletions involving chromosome 11 were examined by PCR 
utilizing two markers from 11q13 (D11S1777, D11S4076), seven markers from 11p11.2 
(D11S1344, D11S436, D11S4174, D11S1290, D11S1361, D11S554, D11S4103), seven 
markers from 11p12 (D11S4102, D11S4083, D11S4185, D11S935, D11S4203, D11S907, 
D11S4200), two markers from 11p13 (WT1, D11S914), and two markers from 11p15.5 
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FIGURE 2.4.  Experimental design of the SYT13-silencing study.  Annealed 
oligonucleotides are ligated into the psiRNA vector and transformed into competent 
GT116 E. coli.   Plasmids with proper inserts were transfected into suppressed MCH cells, 
and stable production of targeted shRNAs silence SYT13. 
BbsI digested 
psiRNA Annealed 
oligonucleotides
+
Transformation of GT116 E coli.
Selection of white 
recombinant clones Insert Verification
Transfection into 
suppressed MCH cell line
Stable production of 
shRNAs
Reversion to tumorigenic 
phenotype  
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(D11S922, D11S3806).  The majority of these were MapPairs microsatellite markers 
purchased from Invitrogen (formerly Research Genetics).  Others (D11S4203, D11S935, 
D11S4185, D11S4083, D11S4102, D11S907, and D11S4200) were synthesized by the UNC 
Oligonucleotide Core Facility based on sequences obtained from the UniSTS Database on the 
NCBI website (www.ncbi.nlm.nih.gov). 
Methods Specific to RNAi Study 
Stable silencing system:  Stable knock-down of SYT13 was accomplished using a 
system from InvivoGen (San Diego, CA) that is summarized in FIGURE 2.4.  The psiRNA-
hH1zeo expression vector was obtained from InvivoGen (FIGURE 2.2.A).  It utilizes the 
human H1 RNA Pol III promoter.  The message is transcribed into a short dsRNA with a 
hairpin structure (shRNA) which is recognized and cleaved by the endogenous Dicer 
complex into a 21nt double-stranded siRNA that directs the RISC complex toward cleavage 
of target SYT13 mRNA (56-58). 
Design of shRNA oligonucleotides:  Several guidelines for choosing RNAi target 
regions have been published (59-62).  An ideal target region was identified in exon 2 of 
hSYT13 (FIGURE 2.5.A) using the following guidelines suggested by literature and customer 
support from InvivoGen:  (i) the sequence should be 19-21 nucleotides within the coding 
region of the gene of interest; (ii) it should begin with an A and should not contain 3 
repeating nucleotides, especially TTT; (iii) the G/C content should be ≤50%; (iv) 
palendromic sequences should be avoided; and (v) the sequence should not be homologous to 
other genes within the genome.  Additional considerations for target design in this unique 
MCH system were that the selected sequence would not interfere with the expression of other 
human 11p11.2 genes or other genes in the rat genome, including rat SYT13 (FIGURE 2.5.B).  
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333  tcaactatgcagactattcactgaggtctacggaggag 370
||||||| ||||||||  | ||| || | || ||||||    
469  tcaactacgcagactacaccctggggaccacagaggag 506 
AGACTATTCACTGAGGTCTAC
TCTGATAAGTGACTCCAGATG
T
CC
C C
A
T
C
CC
T
5’
AGCAT CAATTC T
GT
GAGGTCTAC
TC AT GTAAG ACTCCAGATG
T
CC
C C
A
T
C
CC
T
5’
A.
B.
C.
human
rat
TTCAATGTTAAAAAGTCCACGGAACCTGTTCAGCCCCGTGCCCTCCTCA
AGTTCCCAGACATCTATGGACCCAGGCCAGCTGTGACGGCTCCAGAGG
TCATCAACTATGCAGACTATTCACTGAGGTCTAC
5’ 3’
GGAGGAGCCCACTGC
ACCTGCCAGCCCCCAACCCCCGAATGACAGTCGCCTCAAGAGGCAGGT
CACAGAGGAGCTGTTCATCCTCCCTCAGAATG
 
FIGURE 2.5.  Design of the SYT13i and SYT13s shRNAs.  (A) The SYT13 gene is 
comprised of 6 exons depicted by blue boxes.  The 21nt SYT13 target (indicated in 
blue/underlined) localizes to the coding sequence of exon 2.  (B) The target sequence has 
71% (15/21) homology to the rat Syt13 gene. (C) Sequence and structure of SYT13i and 
SYT13s shRNAs.  The four scrambled nucleotides of SYT13s are shown in red/underlined. 
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Oligonucleotides (53-mers) were designed that encode a 4 nucleotide BbsI-compatible 
overhang and two complementary 21 nucleotide sequences separated by a 7 nucleotide 
spacer (this targeting sequence is referred to as SYT13i) (FIGURE 2.5.C).     A matched control 
RNAi oligonucleotide was also constructed that encodes siRNA of the same basic design as 
the silencing vector and contains the identical nucleotide composition, but the sequence has 
been scrambled (SYT13s) (FIGURE 2.5.C).  The scrambled-control sequence was confirmed to 
contain low sequence homology to other genes in the rat genome. 
Synthesis, annealing, and ligation of shRNA oligonucleotides:  Two DNA 
oligonucleotide strands (sense and antisense) for both the SYT13i and SYT13s sequences were 
synthesized by the UNC Oligonucleotide Core Facility.  To anneal, the complimentary 
oligonucleotides were dissolved to a concentration of 1.7 μM in 10 mM NaCl and incubated 
at 80°C for 2 minutes.  Power was removed from the heating block and the samples were 
maintained in the block until the temperature reached 35°C.  100 ng of BbsI-linearized 
psiRNA vector (obtained from InvivoGen) and 1 μl of the annealed siRNA insert reaction 
were ligated at 16°C overnight in a reaction containing 1 U T4 DNA Ligase (New England 
BioLabs, Beverly, MA) and T4 DNA Ligase Reaction Buffer (50 mM Tris-HCl, 10 mM 
MgCl2, 10m M DTT, 1 mM ATP, 25 μg/ml BSA, pH 7.5 at 25°C) (New England BioLabs, 
Beverly, MA) (Figure 2.6). 
Preparation of chemically competent GT116 cells:  The E. coli GT116 strain, a 
sbcCD deletion mutant, was provided with the psiRNA-hH1zeo kit (InvivoGen).  Hairpin 
structures are known to be unstable in E. coli due to their elimination by a protein complex 
called SbcCD that recognizes and cleaves hairpins (63).  The sbcCD gene deletion in the 
GT116 strain supports the growth of plasmid DNAs carrying hairpin structures. 
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N(21nt target)A-AAACTN(21nt target) AGTTCTC 5’3’
+
N(21nt target)T-TTCCC-AN(21nt target) TCAAGAG5’ 3’
TCCC-AN(21nt target)
TN(21nt target)
N(21nt target)T-T
N(21nt target)A-AAAC
Sense Loop Inverted
Annealing
EM7-α peptide
H1 prom +1
BbsI
BbsI
Digestion with BbsI
TCTTTCCCAGGTCTTCA
AGAAAGGGTCCAGAAGT
GGAAGACTT
CCTTCTGAAAAAC
TTTGGAAAAGCTT
CTTTTCGAA
psiRNA
AGTTCTC
TCAAGAGTCTT
AGAAAGGG
TCCC -AN(target)
-TN(target)
TTTGGAAAAGCTT
CTTTTCGAA
N(target)T- T
N(target)A- AAAAC
AGTTCTC
TCAAGAG
Ligation
Synthesis of 
Complementary 
Oligonucleotides
 
FIGURE 2.6.  Cloning of the SYT13i and SYT13s shRNAs.  Two complementary 
oligonucleotides were synthesized with overhangs to correspond with the asymmetrical 
overhangs of the BbsI cloning site.  Annealed oligonucleotides were cloned into the BbsI 
cloning site disrupting the EM7-α peptide and allowing blue/white selection after ligation 
and transformation. 
A GT116/LB broth suspension was streaked on an LB agar plate and placed in a 37°C 
incubator overnight.  A single colony was picked from the plate and grown for 2 hours in 5 
ml of LB broth.  This culture was transferred to 100 ml LB broth and shaken until 
OD600=0.5 (approximately 5 hours).  Bacteria were collected by centrifugation at 700 x g 
for 5 minutes, gently resuspended in 25 ml ice cold TFB1 solution (30 mM C2H3KO2, 50 
mM MnCl2, 100 mM KCl, 10 mM CaCl2, pH 5.8), and kept on ice for 1 hour.  After being 
pelleted at 450 x g for 5 minutes, the bacteria were resuspended in 4 ml ice cold TFB2 
solution [10 mM Na-MOPS (pH 7.0), 75 mM CaCl2, 10 mM KCl, 20% glycerol], and 
incubated on ice for 1 hour.  100 μl aliquots were then snap frozen in liquid N2 and stored at  
-80°C. 
Bacterial transformation and culture:  Ten μl ligated psiRNA was transformed into 
100 μl chemically competent GT116 bacteria.  The DNA/bacteria mixture was incubated on 
ice for 30 minutes and heat-shocked at 42°C for 90 seconds.  After a brief cooling on ice, 900 
μl warm LB broth (1% bacto-tryptone, 0.5% bacto-yeast extract, 0.5% NaCl) was added, and 
the transformation mixture was incubated 1 hour at 37°C with gentle agitation.  100 μl of 
transformed cells were spread on Fast-Media Zeo XGal agar plates (InvivoGen) and 
incubated at 37°C overnight.  Fifty ml ImMedia Zeo Liquid (Invitrogen, Carlsbad, CA) 
medium was used to culture white recombinant clones picked from psiRNA-transformed 
bacteria overnight at 37°C.  Overnight cultures were pelleted at 10,000 x g for 10 minutes 
and used for plasmid preparation.   
Plasmid preparation:  Plasmid DNA was extracted from bacterial clones using the 
Wizard® Plus Midipreps DNA Purification System (Promega, Madison, WI).  The cell pellet 
was resuspended in 3 ml Cell Resuspension Solution (50 mM Tris-HCl, pH 7.5; 10 mM 
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EDTA; 100 μg/ml RNase A).  Three ml Cell Lysis Solution (0.2 M NaOH, 1% SDS) was 
added followed by neutralization with 3 ml Neutralization Solution (1.32 M C2H3KO2, pH 
4.8).  Cellular debris was pelleted at 14,000 x g for 30 minutes and the DNA-containing 
supernatant was collected.  Ten ml Wizard® Midiprep DNA Purification Resin was added to 
the supernatant and the mixture was applied to a column.  After the sample passed through 
the column, the resin was washed twice with 15 ml Column Wash Solution (80 mM 
C2H3KO2; 8.3 mM Tris-HCl, pH 7.5; 40 μM EDTA).  The resin was dried briefly by 
centrifugation and eluted with 300 μl Nuclease-Free water. 
Digestion mapping of psiRNA-transformed plasmids and DNA sequencing:  After 
plasmid preparation, successful siRNA insert verification was accomplished by digesting 1 
μg of the psiRNA plasmid with the SpeI restriction enzyme (New England BioLabs, Beverly, 
MA) for 2 h at 37°C  in a reaction consisting of 100 μg/ml BSA, 50 mM NaCl, 10 mM Tris-
HCl (pH 7.9), 10 mM MgCl2, and 1 mM DTT.  Plasmids with siRNA inserts yielded 2 
restriction digestion products of 2208 and 425 base pairs.  Additional insert verification was 
obtained by DNA sequencing.  Purified plasmid DNA was sequenced at the UNC-CH 
Genome Analysis Facility using a 3100 Genetic Analyzer (Applied Biosystems).  Template 
DNA (1.5 μg plasmid) was sequenced using the ABI PRISM BigDye Terminator Cycle 
Sequencing Ready Reaction Kit with AmpliTaq DNA Polymerase FS (Applied Biosystems) 
and 10 pmoles of either the OL381 reverse primer or OL178 forward primer supplied with 
the psiRNA kit (InvivoGen). 
Plasmid restriction digestion:  Prior to transfection into CX4 cells, cloned plasmids 
were linearized to direct insertion into the host genome.  psiRNA-hH1-derived vectors with 
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verified shRNA inserts were linearized by digestion for 1 h at 25°C with SwaI [10 U enzyme, 
100 mM NaCl, 50 mM Tris-HCl (pH 7.9), 10 mM MgCl2, 1 mM DTT, 100 μg/ml BSA].   
Methods Specific to SYT13 Transfection 
The open reading frame of human SYT13 (1281/5108) bp was cloned into the 
pReceiver-M11x vector by GeneCopoeia (FIGURE 2.2.B), and the GFP-pReceiver was 
utilized as an empty vector control (not shown).  Thirty ng of the SYT13-pReceiver-M11 or 
GPF-pReceiver vector control were transformed into 100 μl competent JM109 cells 
(Promega, Madison, WI).  Transformed bacteria were streaked on LB-ampicillin agar plates 
(1.5% bacto-agar, 1% bacto-tryptone, 0.5% bacto-yeast, 0.5% NaCl, and 0.1 mg/ml 
ampicillin) and cultured overnight in 50 ml LB broth with 0.1 mg/ml ampicillin.  Plasmids 
were prepared with the Wizard Plus Midipreps DNA Purification System (Promega) and 
linearized by digestion overnight at 37°C with ScaI [10 U enzyme, 50 mM 100 mM NaCl, 50 
mM Tris-HCl (pH 7.9), 10 mM MgCl2, 1 mM DTT] before transfection into GN6TF tumor 
cells.  
Methods Specific to Large-Scale Gene Expression Analysis 
Affymetrix gene array:  The Affymetrix GeneChip Rat Genome 230 2.0 Array 
(Affymetrix, Santa Clara, CA) was used in this study.  The array chip contains 31,042 probe 
sets that analyze the expression level of >30,000 transcripts and variants from >28,000 genes 
corresponding to the rat genome.  In addition, this microarray contains 100 normalization 
control probe sets and hybridization controls. 
RNA processing for microarray hybridization:  RNA for microarray analysis was 
processed by Expression Analysis (Research Triangle Park, NC) according to the Affymetrix 
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Technical Manual (Affymetrix).  Briefly, total RNA (10 μg) was converted into cDNA using 
Superscript II Reverse Transcriptase (Invitrogen) and a modified oligo(dT)24 primer that 
contains T7 promoter sequences (GenSet, Evry, France).  After first strand synthesis, residual 
RNA was degraded by the addition of RNaseH, and a double-stranded cDNA molecule was 
generated using DNA Polymerase I and DNA Ligase (Invitrogen).  The cDNA was purified 
and concentrated using a standard phenol:chloroform extraction, followed by ethanol 
precipitation.  Labeled cRNA products were generated from the purified cDNAs by 
incubation with T7 RNA Polymerase and biotinylated ribonucleotides using an In Vitro 
Transcription kit (Enzo Diagnostics, Farmingdale, NY).  cRNA products were purified on an 
RNeasy column (Qiagen) and quantified spectrophotometrically. 
Microarray hybridization and analysis:  Microarray hybridization and analysis was 
performed by investigators at Expression Analysis (Durham, NC).  Purified cRNA target (20 
μg) was incubated at 94°C for 35 minutes in fragmentation buffer [200 mM Tris-acetate (pH 
8.1), 500 mM potassium acetate, and 50 mM magnesium acetate], and then diluted into 
hybridization buffer [100 mM 2-(N-morpholino) ethanesulfonic acid, 20 mM EDTA, and 
0.1% Tween 20] containing biotin-labeled OligoB2 and Eukaryotic Hybridization Controls 
(Affymetrix).  The hybridization cocktail was denatured at 99°C for 5 minutes, incubated at 
45°C for 5 minutes, and then injected onto a Rat Genome 230 2.0 Array cartridge 
(Affymetrix).  The Rat Genome 230 2.0 Array was incubated at 42°C for at least 16 hours in 
a rotating oven at 60 rpm.  Subsequently, the hybridized GeneChips were washed under 
nonstringent conditions at 25°C in a buffer consisting of 0.9 M NaCl, 70 mM sodium 
phosphate (pH 7.4), 6 mM EDTA, and 0.01% Tween 20, and stringent conditions at 50°C in 
a buffer consisting of 100 mM 2-(N-morpholino) ethanesulfonic acid, 100 mM NaCl, and 
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0.01% Tween 20.  The microarrays were then stained with Streptavidin Phycoerythrin, and 
the fluorescent signal was amplified using a biotinylated antibody solution.  Fluorescent 
images were detected in an Agilent GeneArray Scanner (Agilent Technologies, Santa Clara, 
CA).  After probe-level data was extracted from the MicroArray Suite-derived CEL files, the 
probes were normalized using quantile probe normalization (64).  Signal was computed using 
the Positional Dependent Nearest Neighbor (PDNN) method (65), and scaled by Expression 
Analysis proprietary methods to mitigate bias in fold change underestimation.  Microarray 
hybridizations were performed in duplicate for each cell line and the final values for (log) 
signal for all graphs are expressed as averages of the duplicates (equivalent to geometric 
averages of signal). 
Gene expression analyses and web-based bioinformatics:  Gene expression profiles 
generated by the microarray analysis were mined and manipulated using Data Desk software 
(Data Descriptions, Ithaca, NY), GenMAPP (v.2, www.genmapp.org) (66), and the DAVID  
and EASE 2006 Bioinformatic Resources (http://david.abcc.ncifcrf.gov/) (67, 68).
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RESULTS 
LOSS OF HETEROZYGOSITY IN HUMAN LIVER TUMORS 
We have identified, using a MCH model system, a tumor suppressor locus on human 
chromosome 11p11.2, and studies from other groups suggest that aberrations of human 11p 
may play a role in the carcinogenesis of a subset of HCC.  While numerous allelotyping 
studies of human HCC have appeared, a detailed allelotype of human 11p11.2 has not been 
reported.  Therefore, we analyzed 47 primary HCCs and their corresponding non-tumor DNA 
for LOH on chromosome arm 11p. 
Loss of Heterozygosity of Chromosome 11 Microsatellite Markers in Human Hepatocellular 
Carcinoma 
A map of the 11p11.2 polymorphic microsatellite markers that were used in this study 
is shown in FIGURE 3.1.  FIGURE 3.2.A shows representative results of this LOH analysis at 
polymorphic loci on human chromosome 11 in our HCC tumor samples, and FIGURE 3.2.B 
summarizes these findings.  15/47 (32%) HCCs showed LOH of >1 marker corresponding to 
chromosome 11.  Furthermore, 10/47 (21%) HCCs exhibited LOH of >1 marker within the 
11p11.2 liver tumor suppressor region (D11S4103-D11S1344).  Other deletions were noted 
in 11p13-pter (4/47, 9%) or involving markers on 11q (1/47, 2%).  The greatest frequency of 
loss involving individual markers was observed with D11S1290 (5/47, 11%) and D11S554 
(4/47, 9%).  These results indicate that chromosomal deletions involving the 11p11.2 liver 
  
 
 
 
 
FIGURE 3.1.  Integrated map of the human chromosome 11p11.2 liver tumor suppressor 
region.  An integrated microsatellite marker/gene map of the region of human 11p11.2-
p12 (corresponding to a 37-49 Mbp interval of human 11p) is shown.  The relative 
location of microsatellite markers is depicted by tick marks above the line.  The location 
of SYT13 and other genes in this region is depicted by dashes parallel to the chromosome. 
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FIGURE 3.2.  Analysis of LOH at polymorphic loci on human chromosome 11 in HCC 
tumor samples. (A) Representative gels demonstrating loss of heterozygosity in HCC 
samples.  The patient on the left retains both alleles of the markers shown in both the 
tumor (T) and non-neoplastic (N) tissue, whereas the patient on the right demonstrates 
LOH in the tumor tissue.  (B) Diagrammatic summary of LOH on chromosome 11 in 15 
HCC tumor samples.  The relative loci of the molecular markers examined are indicated 
on the ideogram of 11p. Closed circles designate LOH, open circles designate no loss, and 
the absence of a circle indicates that the locus was not tested for LOH. 
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tumor suppressor region occur in a subset of human HCCs, suggesting that loss of one or 
more genes in this region may be important in human hepatocarcinogenesis.   
Correlation of LOH with Patient or Clinicopathological Characteristics 
To determine if human 11p11.2 loss tends to correlate with specific patient or clinico-
pathological characteristics, we examined the frequency of 11p11.2 LOH among subsets of 
HCC.  In our HCC sample set, loss of 11p11.2 occurred more frequently among female 
patients (35% show loss) than males patients (15% show loss).  HCC tends to affect men 
much more frequently than women (8), leading to the suggestion that hormonal differences 
may protect from or contribute to development of HCC.  Our observation suggests that 
11p11.2 loss may be more important in hepatocarcinogenesis in females, perhaps by 
contributing to the abrogation of protective factors.  LOH of markers within the 11p11.2 liver 
tumor suppressor region occurred with similar frequency among grade II HCC (26% show 
loss) and grade III HCC (26% show loss).  This observation suggests that 11p11.2 loss may 
be an early alteration (required for tumorigenesis) in the subset of tumors that are affected by 
such loss, rather than a late change associated with progression of the neoplastic phenotype.  
In a similar manner, 11p11.2 loss was documented with similar frequency among patients 
with cirrhosis (21% show loss) and patients without cirrhosis (19% show loss).  This 
observation suggests that 11p11.2 loss may not be a general characteristic of cirrhotic liver, 
but that these deletions may occur in the early lesions that characterize hepatocarcinogenesis, 
such as focal proliferative phenotypically altered hepatocytes, hyperplastic hepatocytes, or 
dysplastic hepatocytes.  In this subset of HCC patients, loss of 11p11.2 markers occurred 
more frequently in HBV-negative samples (30% show loss) than in HBV-positive patients 
(16% show loss), although this trend did not reach statistical significance probably due to 
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small sample size.  Human chromosome 11p11.2 has been suggested as a preferential site for 
HBV insertion (15, 69, 70), possibly causing disruption of genes in that chromosomal region, 
producing a selective growth advantage in affected cells.  Our observation suggests that LOH 
of 11p11.2 might account for disruption of critical target genes in this region in the absence 
of HBV insertional mutagenesis, producing a similar selective growth advantage in affected 
cells. 
IDENTIFICATION OF CANDIDATE LIVER TUMOR SUPPRESSOR GENES FROM HUMAN 
CHROMOSOME 11P11.2 
MCH cell lines were utilized in a candidate gene approach to identify genes from 
human chromosome 11p11.2 that were differentially expressed in the suppressed versus the 
non-suppressed cell lines.  Our criteria for the best candidate(s) for the 11p11.2 tumor 
suppressor gene dictated that the gene(s) be present and expressed in suppressed MCH cell 
lines and absent/silent in non-suppressed MCH cell lines. 
Deletion Analysis of Candidate Tumor Suppressor Genes from Human 11p11.2 in GN6TF-
Derived Microcell Hybrid Cell Lines   
Using DNA samples from an index panel of suppressed MCH cell lines (C1, CX2, 
and CX4) each of 39 genes, ESTs, and predicted genes positioned by the Human Genome 
Project within human 11p11.2 (TABLE 2.2) were analyzed by PCR to determine which 
ESTs/genes map to the human 11p11.2 liver tumor suppressor region.  The suppressed 
GN6TF-11neo MCH cell lines each contain a different, but overlapping, fraction of human 
chromosome 11 (40, 42).  CX2 contains an intact copy of human chromosome 11 based upon 
fluorescence in situ hybridization chromosomal analysis (40), and extensive PCR mapping 
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studies (40, 42, 71).  C1 and CX4 contain only a portion of the short arm of the chromosome, 
including 11p11.2-p12 (40, 42).  Thus, ESTs/genes detected in the DNA from each of these 
cell lines reside in the minimal liver tumor suppressor region of 11p11.2 and are considered 
potential candidate liver tumor suppressor genes.  These selection criteria for identification of 
candidate liver tumor suppressor genes have been described (71).  Seven of the 39 
ESTs/genes evaluated mapped to the human 11p11.2 liver tumor suppressor region defined 
by the index panel of suppressed GN6TF-derived MCH cell lines (FIGURE 3.3 and data not 
shown).  These 7 ESTs/genes include ALX4, FLJ10450, FLJ23598, KIAA1580, LOC399888, 
LOC90139, MAPK8IP1, and SYT13.  The majority of the remaining ESTs/genes (31/32, 
97%) were positive in DNA samples from CX2, indicating a localization to chromosome 11, 
but outside of the minimal liver tumor suppressor region of 11p11.2.  One gene, BHC80, was 
detected in CX2 and CX4, indicating localization to a chromosomal site that is proximal to 
the minimal liver tumor suppressor region, but not contained within it (FIGURE 3.3).  These 
results suggest that ALX4, FLJ10450, FLJ23598, KIAA1580, LOC399888, LOC90139, 
MAPK8IP1, and SYT13 are potential candidates for the human 11p11.2 liver tumor 
suppressor gene based upon their localization to the minimal tumor suppressor region of 
human 11p11.2. 
Transcription Analysis of Candidate Tumor Suppressor Genes from Human 11p11.2 in 
GN6TF-Derived Microcell Hybrid Cell Lines 
The expression levels of ALX4, FLJ10450, FLJ23598, KIAA1580, LOC399888, 
LOC90139, MAPK8IP1, and SYT13 were examined among the index panel of suppressed 
MCH cell lines (C1, CX2, and CX4) using RT-PCR.  FLJ10450, FLJ23598, KIAA1580, 
MAPK8IP1, and SYT13 were absent in GN6TF tumor cells but expressed uniformly among 
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 FIGURE 3.3.  Chromosome 11p11.2 deletion analysis of GN6TF-derived MCH cell lines.  
Representative gels from deletion mapping of 11p11.2 with ESTs/genes that are 
positioned within human 11p11.2 are shown.  ESTs/genes that map to the minimal tumor 
suppressor region are amplified in each MCH cell line (C1, CX2, and CX4). 
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the GN6TF-derived MCH cell lines (FIGURE 3.4). ALX4 was expressed in CX2 and CX4 
only, LOC90139 was found in CX2, and expression of LOC399888 was not detected in any 
of the GN6TF-derived MCHs (data not shown).  Our previously established criteria for 
candidate liver tumor suppressor genes (71) dictate that candidate genes be expressed by 
each of these GN6TF-derived MCH cell lines.  This result suggests that these five 
ESTs/genes represent good candidates for the human 11p11.2 liver tumor suppressor gene.  
Additional expression analyses of these ESTs/genes were conducted using RNA samples 
from GN6TF-derived MCH-derived tumor cell lines (GN6TF-11neoCX2T1 and GN6TF-
11neoCX4T3).  These tumor cell lines were established in cell culture from tumors that 
formed in syngeneic rats following transplantation of the GN6TF-11neo MCH cell lines (40).  
In each case, the MCH-derived tumors developed with long latency compared to the parental 
GN6TF tumor line (40), indicative of tumor suppression.  Molecular characterization of these 
MCH-derived tumor cell lines provided evidence that reexpression of tumorigenicity by 
these cells is accompanied by significant (if not complete) deletion of the introduced 
(suppressive) human chromosome (40).  It is expected that the tumor suppressor gene that is 
active in this model system is lost in conjunction with these chromosomal deletions that 
result in restoration of the tumorigenic phenotype.  In fact, no detectable level of expression 
of FLJ10450, FLJ23598, KIAA1580, and SYT13 was observed in the MCH-derived tumor 
cell lines evaluated (data not shown), consistent with our expectations of a tumor suppressor 
gene.  These results combine to suggest that FLJ10450, FLJ23598, KIAA1580, and SYT13 
are potential candidates for the human 11p11.2 liver tumor suppressor gene based upon their 
expression in GN6TF-derived MCH cell lines and loss of their expression in GN6TF-derived 
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 FIGURE 3.4.  Transcription analysis of GN6TF-derived MCH cell lines. Representative 
gels showing expression patterns of the genes that were amplified in the GN6TF-derived 
cell lines.  β-actin was amplified as a control for quality of the RT template.   
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MCH-derived tumor cell lines. 
Deletion Analysis of Candidate Tumor Suppressor Genes from Human 11p11.2 in GN3TG 
and GP10TA-Derived Microcell Hybrid Cell Lines 
The candidate ESTs/genes identified using GN6TF-derived MCH cell lines were 
further evaluated using two additional panels of MCH cell lines and MCH-derived tumor cell 
lines (41).  Eight suppressed MCH cell lines derived from GN3TG (GN3TG-11neo clones C2, 
C3, C4, C5, and C7) and GP10TA (GP10TA-11neo clones C7, C11, and C12) were utilized, 
as well as four MCH-derived tumor cell lines (GN3TG-11neo C3T1, C3T7, C4T3, and 
GP10TA-11neo C7T3).  Our previous studies implicated the human 11p11.2 liver tumor 
suppressor locus in the suppression of GN3TG-11neo and GP10TA-11neo MCH cell lines (41), 
suggesting that the same tumor suppressor gene(s) will be active (expressed in common) 
between these suppressed MCH cell lines and the suppressed GN6TF-derived MCH cell 
lines.  In addition, GP10TA-11neo C6 was analyzed.  This MCH cell line is not suppressed for 
tumorigenicity and other para-neoplastic phenotypic traits (41).  The lack of suppression in 
this MCH cell line is due to an interstitial deletion of the introduced human chromosome 11 
that involves the 11p11.2 liver tumor suppressor region (41).  Combined, these suppressed 
MCH, nonsuppressed MCH, and MCH-derived tumor cell lines represent excellent reagents 
for examination of candidate liver tumor suppressor genes. 
Using DNA samples from the GN3TG-11neo MCH, GP10TA-11neo MCH, and MCH-
derived tumor cell lines, FLJ10450, FLJ23598, KIAA1580, MAPK8IP1, and SYT13 were 
analyzed by PCR to determine if each of these ESTs/genes is retained by these cells that 
differ in tumorigenic potential. PCR for MAPK8IP1 was uninformative due to its non-
species-specific expression in the parental GN3TG and GP10TA cell lines (data not shown).  
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FLJ10450 and FLJ23598 were detected in DNA samples from 7/8 (88%) suppressed MCH 
cell lines evaluated (FIGURE 3.5), and were lost from each of the MCH-derived tumor cell 
lines analyzed (FIGURE 3.5 and data not shown).  Furthermore, both of these ESTs were 
detected in DNA from the nonsuppressed GP10TA-11neoC6 cell line (FIGURE 3.5).  The loss 
of FLJ10450 and FLJ23598 from the suppressed GN3TG-11neoC5 cell line, combined with 
their retention in the nonsuppressed MCH line, suggest that neither of these genes are 
required/sufficient for suppression of the tumorigenic phenotype in this model system.  
KIAA1580 was detected in each of the 8 suppressed GN3TG-11neo and GP10TA-11neo MCH 
cell lines (FIGURE 3.5), and was lost from each of four MCH-derived tumor cell lines 
(FIGURE 3.5 and data not shown).  These results are consistent with the pattern that we expect 
for a tumor suppressor gene.  However, retention of KIAA1580 in the non-suppressed 
GP10TA-11neoC6 cell line (FIGURE 3.5) argues against this EST being a strong candidate 
tumor suppressor gene.  SYT13 was detected in the DNA of 8/8 (100%) suppressed MCH cell 
lines (FIGURE 3.5), was lost from the DNA of 4/4 (100%) MCH-derived tumor cell lines 
((FIGURE 3.5) and data not shown), and was not found in the DNA of the non-suppressed 
GP10TA-11neoC6 cell line (FIGURE 3.5).  These results combine to suggest that SYT13 is a 
strong candidate for the 11p11.2 liver tumor suppressor gene. 
Transcription Analysis of Candidate Tumor Suppressor Genes from Human 11p11.2 in 
GN3TG and GP10TA-Derived Microcell Hybrid Cell Lines 
The expression of FLJ10450, FLJ23598, KIAA1580, and SYT13 was examined 
among the GN3TG-11neo MCH, GP10TA-11neo MCH, and MCH-derived tumor cell lines 
using RT-PCR to determine patterns of expression of these ESTs/genes for cell lines with 
 53
FLJ10450
FLJ23598
KIAA1580
SYT13
M
ar
ke
r
W
at
er
H
um
an
 D
N
A
C
4
Pa
re
nt
al
Pa
re
nt
al
C
6C
3
C
7
C
2
C
11
C
12
C
7T
3
C
5
C
7
C
4T
3
GN3TG-11neo GP10TA-11neo
 
 
FIGURE 3.5.  Deletion analysis of GN3TG- and GP10TA- derived MCH cell lines. 
Representative gels from PCR analysis of ESTs/genes representing potential 
candidate liver tumor suppressor genes among GN3TG-derived and GP10TA-
derived MCH and MCH-derived tumor cell lines are shown. 
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FIGURE 3.6.  Transcription analysis of GN3TG- and GP10TA- derived MCH cell lines. 
Four of the genes that amplified in GN6TF-derived cell lines were evaluated by RT-PCR 
among the suppressed GN3TG- and GP10TA-derived MCH and MCH-derived tumor cell 
lines.  β-actin was amplified as a control for quality of the RT template (data not shown). 
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known phenotype/genotype.  FLJ10450 and FLJ23598 were expressed at easily detectable 
levels by 6/7 (86%) suppressed MCH cell lines (FIGURE 3.6), and this expression was 
extinguished in the MCH-derived tumor cell lines (FIGURE 3.6 and data not shown).  As 
expected, GN3TG-11neo C5 did not express mRNA for either FLJ10450 or FLJ23598 
(FIGURE 3.6).  KIAA1580 was expressed by each of the suppressed MCH cell lines, although 
the levels of expression varied (FIGURE 3.6).  Expression of KIAA1580 was not detected in 
MCH-derived tumor cell lines (FIGURE 3.6 and data not shown).  FLJ10450, FLJ23598, and 
KIAA1580 were expressed by the nonsuppressed GP10TA-11neoC6 MCH cell line (FIGURE 
3.6).  These results combine to suggest that FLJ10450, FLJ23598, and KIAA1580 are not 
good candidates for the human 11p11.2 liver tumor suppressor gene based upon their lack of 
consistent expression among suppressed MCH cell lines and/or their expression in a non-
suppressed MCH cell line.  In contrast, robust expression of SYT13 was detected in 7/7 
(100%) suppressed MCH cell lines (FIGURE 3.6), and was not detected in 4/4 (100%) of 
MCH-derived tumor cell lines (FIGURE 3.6 and data not shown).  Furthermore, expression of 
SYT13 was not detected in GP10TA-11neo C6 (FIGURE 3.6), as expected.  These results 
suggest that SYT13 is a strong candidate for the human 11p11.2 liver tumor suppressor gene. 
EXPRESSION OF 11P11.2 CANDIDATE TUMOR SUPPRESSOR GENES IN HUMAN 
HEPATOCELLULAR CARCINOMA CELL LINES 
Using specific criteria requiring differential expression of human 11p11.2 candidate 
tumor suppressor genes in a panel of suppressed and nonsuppressed MCHs, we identified 
SYT13 as a strong tumor suppressor candidate.  In parallel studies with identical selection 
criteria, we additionally identified the SYT13-proximal genes TP53I11 and PRDM11 as 
putative 11p11.2 tumor suppressor genes (72).   To investigate if one or more of these genes 
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play a role in the pathogenesis of human HCC we examined the expression of candidate 
genes in a series human hepatocellular carcinoma cell lines.   
Deletion and Transcription Analysis of 11p11.2 Candidate Tumor Suppressor Genes in 
Human Hepatocellular Carcinoma Cell Lines 
The HCC cell lines used in this study (TABLE 2.1) were established from patients in 
North America, Japan, China, South Africa, and South Korea (49).  We expected that 
candidate genes with tumor suppressor function would be down-regulated or extinguished in 
some portion of HCC cell lines, consistent with the elimination of a specific tumor 
suppressor function in these cells.  The expression levels of TP53I11, PRDM11, and SYT13 
varied considerably among these cell lines (FIGURE 3.7.A).  The expression of TP53I11 was 
lost or decreased (<50% relative to mRNA in Chang) in 11/19 (58%) HCC cell lines and 
SYT13 was lost or decreased (<50%) in 7/19 (37%) (FIGURE 3.7.B).  PRDM11 was expressed 
at normal levels in the majority of HCC cell lines, with diminished expression (<50%) noted 
in only 4/19 (21%) (FIGURE 3.7.B).  PCR analysis of template DNA isolated from these cell 
lines show that the candidate tumor suppressor genes are not deleted (FIGURE 3.7.C), which 
suggests that gene deletion does not account for the loss of mRNA expression detected in the 
HCC cell lines.  These results demonstrate that these candidate tumor suppressor genes 
identified in a rat-human MCH model system, are functionally deficient in subsets of human 
HCC cell lines, consistent with the activity of a liver tumor suppressor gene.  Several other 
genes from 11p11.2 were evaluated for expression in this group of HCC cell lines (FIGURE 
3.7.A).  FLJ10450 was expressed in all HCC cell lines, the expression of FLJ23598 was 
decreased in only 5/19 (26%) HCC cell lines, and KIAA1580 was lost or decreased in 8/19 
(42%) HCC cell lines (FIGURE 3.7.A).  These results demonstrate that several of the genes 
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FIGURE 3.7.  Deletion and transcription analysis of candidate 11p11.2 tumor suppressor 
genes in HCC cell lines.  (A) Semi-quantitative RT-PCR of candidate tumor suppressor 
genes in HCC cell lines.  Human fetal brain RNA was used as a positive control.  (B) 
Densitometry of SYT13, PRDM11, and TP53I11 expression from RT-PCR in panel (A) 
using ImageJ software.  Signal strength is expressed relative to the normal liver cell line 
Chang.  (C) PCR of candidate genes using template DNA from HCC cell lines and 
genomic DNA as a positive control. 
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from 11p11.2 that are not considered candidate tumor suppressor genes are expressed at 
normal or near normal levels in HCC cell lines, strengthening the argument for elimination of 
these genes from further consideration.    
Epigenetic Regulation of Candidate Tumor Suppressor Genes in Human Hepatocellular 
Carcinoma Cell Lines 
Because methylation-dependent epigenetic silencing represents a common 
mechanism for inactivation of tumor suppressor genes in several types of tumors (73-76) 
(mechanism reviewed in FIGURE 3.8), and our analysis of candidate gene expression in HCC 
cell lines revealed a loss or reduction of several candidate genes with no clear evidence for 
gene deletion (FIGURE 3.7), we evaluated the possibility that DNA methylation may be 
responsible for inactivation of these genes in a subset of HCC cell lines.  Inspection of 
candidate 11p11.2 tumor suppressor genes TP53I11 and SYT13 reveals a dense CpG 
dinucleotide-rich region at the promoter/exon 1 of these genes (but not in PRDM11) (FIGURE 
3.9), which predicts the potential for methylation-dependent silencing.   
After treatment of HCC cell lines (FOCUS, SNU475, SNU398, Huh-1, SNU449, 
Hep3B, PLC/PRF/5, and HepG2) with 5-aza, TaqMan real-time RT-PCR of treated and 
DMSO control-treated cells was performed targeting SYT13, TP53I11, PRDM11, and WT1.   
WT1 has a CpG dinucleotide-rich region at the promoter/exon 1 (FIGURE 3.9),  has been 
identified as a methylation-target in HCC (77), and has been implicated in 11p11.2-mediated 
tumor suppression (43).  The ΔΔCT method was used to quantitate the fold change in gene 
expression after 5-aza treatment relative to the vehicle control.  Expression of genes in 
several cell lines after treatment with DMSO only was undetectable at the CT maximum of 40 
cycles [denoted (-) in FIGURE 3.10.B and assigned a CT of 40 for calculation of fold-change] 
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FIGURE 3.8.  Mechanism for methylation-dependent silencing of tumor suppressor genes.  
(A) A hypothetical gene containing a promoter CpG island is depicted.  Interaction of the 
transcriptional machinery with the unmethylated promoter results in gene transcription.  
(B) Methylation (or hypermethylation) of the promoter CpG island directly or indirectly 
interferes with the interaction between the transcriptional machinery and the promoter 
sequence, resulting in loss of gene expression.  (C) Treatment of cells with demethylating 
agents (such as 5-aza) results in reexpression of silenced genes in response to promoter 
demethylation. 
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FIGURE 3.10.  Expression of candidate 11p11.2 tumor suppressor genes after treatment of 
HCC cell lines with 5-aza.  (A) Fold-change expression of SYT13, PRDM11, TP53I11, 
and WT1 in 5aza-treated compared to DMSO control-treated HCC cell lines using the 
Comparative ΔΔCT Method.  Average changes determined by assigning a CT of 40 to 
DMSO-treated cells are underlined.  (B) Qualitative analysis of gene expression using 
ΔCT values.  - =ΔCT > 20;  + = ΔCT 15-19;  ++ = ΔCT 12-14;  +++ = ΔCT 8-11;  ++++ = 
ΔCT <8. 
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which suggests that DMSO alone may reduce the basal expression levels of the genes 
depicted in FIGURE 3.7.  Nonetheless, strikingly increased expression for SYT13, TP53I11, 
PRDM11, and WT1 was observed in several HCC cell lines after treatment with 5-aza 
(FIGURE 3.10.A).  Expression of the 11p11.2 candidate tumor suppressor gene SYT13 
increased greater than 5-fold in 4/8 5-aza treated cell lines including SNU398, Hep3B, 
PLC/PRF/5, and HepG2 (FIGURE 3.10.A) and TP53I11 increased >5-fold in 6/8 cell lines, 
including SNU398, Huh-1, SNU449, Hep3B, PLC/PRF/5, and HepG2 (FIGURE 3.10.A).  The 
expression of PRDM11 (with no CpG island) exceeded a 5-fold increase in 3/8 HCC cell 
lines, including SNU475, SNU398, and PLC/PRF/5 (FIGURE 3.10.A).  Surprisingly, WT1 
induction exceeded a 5-fold increase in response to 5-aza treatment in only 2/8 HCC cell 
lines [SNU398 and Huh-1 (FIGURE 3.10.A)].  This may be explained by the robust baseline 
expression of WT1 in several of these cell lines as shown in FIGURE 3.10.B.  These results 
indicate that promoter methylation may be directly or indirectly responsible for silencing of 
the candidate 11p11.2 tumor suppressor genes in a subset of HCC.  Additionally, induction 
of WT1 in response to treatment with 5-aza in these cell lines does not appear to correlate 
with 5-aza-mediated induction of SYT13, TP53I11, or PRDM11 mRNA.  This suggests that 
the previously observed link between 11p11.2 mediated tumor suppression and Wt1 
induction must either involve an indirect pathway or require other mechanisms/modifications 
that are not represented by absolute steady-state levels of tumor suppressor gene mRNA.  
RNAI-MEDIATED SILENCING OF SYT13 IN THE SUPPRESSED CX4 MICROCELL HYBRID 
CELL LINE 
Synaptotagmin XIII (SYT13) is an excellent candidate 11p11.2 tumor suppressor gene 
based on its differential expression in suppressed and non-suppressed MCH cell lines and 
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loss of expression in several human HCC cell lines.  To further characterize a functional role 
for SYT13 in the MCH model system, we employed RNA interference to silence this gene in 
suppressed GN6TF-11neoCX4 MCH cells.   
Molecular Analysis of SYT13i and SYT13s Clones 
SYT13 Expression:  CX4 cells transfected with the SYT13-targeting (designated i1-
i12) and scrambled-control (designated s1-s8) psiRNA vectors were expanded and SYT13 
knockdown was assessed by western blot.  Protein analysis revealed a marked reduction of 
SYT13 protein in several SYT13i cell lines (FIGURE 3.11).  The SYT13 protein is 
approximately 66 kDa in size (78, 79), but synaptotagmin protein family members have been 
shown to form SDS-resistant dimers (80).  We detected both monomer and dimer forms of 
immunoreactive SYT13 protein using the α-SYT13 antibody.  The monomeric and dimeric 
forms of SYT13 were found at similar levels in SYT13-transfected cells relative to the CX4 
cells (FIGURE 3.11).  The antibody, which was designed for human SYT13 specificity 
(FIGURE 2.3), recognizes the rat Syt13 (rSyt13) monomer in GN6TF cells.  However, the 
amount of SYT13 detected in CX4 cells exceeds that of GN6TF cells reflecting the 
contribution of the human allele in the MCH cell line.  SYT13i3, i5, i6, i12, and the 
scrambled control-transfected clone s1 express reduced levels of SYT13 protein (less than 
50% for both monomer and dimer) compared to CX4 (FIGURE 3.11.B), while the SYT13 
monomer in s8 was unaffected.  The apparent protein attenuation in these scrambled control-
transfected cell lines is an unexpected result.  Because the scrambled target differs from the 
SYT13 sequence in only 4 of 21 nucelotides (FIGURE 2.5.C), this observation may be 
explained by inhibition of protein translation which is a poorly-understood mechanism 
identified in microRNA–mediated (miRNA) gene silencing which requires mismatched 
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FIGURE 3.11.  Evidence of shRNA-mediated silencing of SYT13.  (A)  Western analysis of 
SYT13 protein expression in GN6TF, CX4, SYT13i, and SYT13s cell lines.  The migration 
of the monomeric (66 kDa) and dimeric (130 kDa) forms of SYT13 are indicated.  This 
blot shows clear knockdown of both the dimeric and monomeric species of SYT13 among 
SYT13i cell lines.  The level of SYT13 is decreased in the SYT13s cell lines, but not 
eliminated.  (B) Quantitation of protein expression level shown in (A) normalized to 
GAPDH expression in (A) with densitometry. 
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hybridization to the mRNA target (81-83).  Western blot analysis of additional SYT13i- (i2, 
i4, i7, and i9) and SYT13s- (s2 and s3) transfected cell lines did not demonstrate any 
appreciable change in protein levels, therefore providing excellent internal controls for this 
study.  SYT13 mRNA expression was analyzed by both quantitative and semi-quantitative 
RT-PCR.  Neither measure revealed a change in gene expression (FIGURE 3.12.A and data 
not shown).  Thus, there is a clear lack of correspondence between SYT13 mRNA levels and 
SYT13 protein levels in targeted cell lines.  This phenomenon has been noted by other 
investigators using a similar experimental system (84, 85), and these data strongly suggest 
that the knockdown of SYT13 observed in this model system, using the shRNA target 
described, is accomplished through a post-transcriptional mechanism, such as inhibition of 
translation and/or regulation of heterochromatin (81, 86). 
shRNA-mediated interferon response and potential off-target effects:  Transfection of 
cells with shRNA can result in an interferon response (87-89) or off-target effects (86).  In 
studies that have shown an interferon response to shRNA transfection, numerous interferon-
associated genes were found to be induced 2-fold to 5-fold (89).  The gene expression profile 
of both SYT13i and SYT13s cell lines (including SYT13i3, i5, i12, and s1) were evaluated to 
determine the levels of expression of 36 interferon-associated genes (TABLE 3.1).  There was 
minimal change in gene expression for these genes among SYT13i and SYT13s cells when 
compared to CX4 cells; 35/36 interferon-associated genes were expressed at levels similar to 
or less than that observed in CX4 cells (TABLE 3.1 and FIGURE 3.13), and the other (Isg20, 
interferon stimulated exonuclease 20) was modestly induced (2-fold).  These results suggest 
that no interferon-associated gene expression changes accompany the transfection of SYT13i 
or SYT13s shRNA expression vectors in CX4 cells.   
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FIGURE 3.12.  Molecular characterization of SYT13i- and SYT13s-transfected cell lines.  
(A) Semi-quantitative RT-PCR of human 11p11.2 genes in SYT13i and SYT13s clones 
shows no change in mRNA expression of these genes in most shRNA-transfected cell 
lines (a decrease of TP53I11 expression was seen in SYT13i6).  Primers for rSyt13 cross-
react with the human gene (top band), but no significant change in mRNA for either the 
human or the rat gene was detected.  (B) Quantitative real-time RT-PCR analysis of Wt1 
expression in SYT13i and SYT13s cell lines expressed relative to CX4 cells.  *P< 0.05 
compared to CX4 using the one-way ANOVA. 
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siRNAs have also been reported to affect translation of unintended transcripts 
containing partial complementarity to targets (85, 90).  A BLAST search 
(http://www.ncbi.nlm.nih.gov/blast/) of the 21nt sequences of the SYT13i target and SYT13s 
scrambled control identified several potential off-target genes in the rat genome.  The SYT13i 
target matched 31 potential off-target genes with 14/21 (67%) to 18/21 (86%) sequence 
identity (67% n=14, 71% n=8, 76% n=5, 81% n=1, 86% n=3) (TABLE 3.2).  Likewise, the 
SYT13s control matched 25 potential off-targets with 67%-86% sequence identity (67% n=9, 
71% n=5, 76% n=4, 81% n=6, 86% n=1) (TABLE 3.2).  Overall, the SYT13i and SYT13s 
shRNAs match 33 off target genes with >15/21 (71%) sequence identity.  However, 
microarray analysis failed to show significant alterations in mRNA levels of these potential 
off-target genes.  No analysis of the corresponding protein products was performed.   
Gene expression in SYT13i and SYT13s clones:  RNA samples corresponding to 
zeocin-resistant SYT13i and SYT13s clones were analyzed by semi-quantitative and real-time 
RT-PCR to determine RNAi-mediated alterations in the expression of several genes, 
including human genes carried on human 11p11.2 and rat Wt1, which has been implicated in 
11p11.2-mediated tumor suppression in our model system (43).  In addition to SYT13, 
FIGURE 3.12.A shows relative expression levels of the human genes PRDM11 and TP53I11 
which are located within a ~350 Kbp region with SYT13 on human 11p11.2.  The semi-
quantitative RT-PCR results do not show any change in expression of these genes between 
CX4, SYT13i-, and SYT13s-transfected cell clones, suggesting that knockdown of the SYT13 
protein does not result in secondary alterations in the expression of other 11p11.2 genes. 
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 TABLE 3.1.  Expression of interferon-related genes in SYT13i and SYT13s cell lines 
relative to CX4 
UniGene 
Number 
Gene 
Symbol Gene Description 
Log Ratio vs. CX4  
s1           i12           i5 
Rn.10089 Cdkn1a cyclin-dependent kinase inhibitor 1A -0.31 -0.49 -0.30 
Rn.48054 G1p2 similar to interferon-stimulated protein (LOC298693) 0.82 -0.25 -0.70 
Rn.25736 Gbp2 guanylate binding protein 2, interferon-inducible -0.46 -0.73 -0.20 
Rn.3765 Icsbp1 similar to interferon consensus sequence-binding protein (LOC292060) 
-0.21 -0.38 -0.03 
Rn.3867 Ifi27l interferon, alpha-inducible protein 27-like 0.14 -0.78 -0.71 
Rn.44680 Ifi35 similar to Interferon-induced 35 kDa protein homolog (LOC287719) -0.21 -0.06 -0.42 
Rn.22087 Ifitm1 similar to interferon induced transmembrane protein 2 like (LOC293618) 
0.21 0.12 0.06 
Rn.107166 Ifitm3l interferon induced transmembrane protein 3-like -0.04 -2.23 -1.52 
Rn.108174 Ifitm3l interferon induced transmembrane protein 3-like -0.85 -1.89 -1.61 
Rn.105738 Ifnar1 similar to interferon alpha/beta receptor (LOC288264) -0.26 -0.20 -0.32 
Rn.119051 Ifnb1 interferon, beta 1 0.14 0.20 0.10 
Rn.10795 Ifng interferon gamma 0.07 0.10 0.01 
Rn.19927 Ifngr interferon gamma receptor -0.37 -0.43 -0.44 
Rn.23305 Ifngr2 similar to interferon gamma receptor 2 (LOC360697) 0.08 -1.00 -0.62 
Rn.104672 Ifnk similar to interferon kappa precursor (LOC313152) 0.19 0.11 0.16 
Rn.3723 Ifrd1 interferon-related developmental regulator 1 -0.06 -0.26 -0.26 
Rn.20083 Igifbp interferon gamma inducing factor binding protein 0.16 -0.15 -0.16 
Rn.6396 Irf1 interferon regulatory factor 1 -0.40 -0.58 -0.66 
Rn.107887 Irf2 similar to interferon regulatory factor 2 (LOC290749) -0.03 0.26 0.01 
Rn.1499 Irf3 similar to interferon regulatory factor 3 (LOC292892) -0.06 -0.11 -0.15 
Rn.17870 Irf5 similar to interferon regulatory factor 5 (LOC296953) 0.03 0.10 0.15 
Rn.101159 Irf7 similar to interferon regulatory factor 7 (LOC293624) -0.37 -0.54 -0.28 
Rn.16103 Isg20 similar to interferon-stimulated protein; DnaQL protein (LOC293052) 
-0.25 1.01 -0.29 
Rn.35673 Isgf3g similar to interferon stimulated gene factor 3 gamma (LOC305896) 0.01 0.10 -0.23 
Rn.7391 Mig monokine induced by gamma interferon 0.06 0.07 -0.01 
Rn.10373 Mx1 myxovirus (influenza virus) resistance 0.11 -0.07 0.06 
Rn.28882 Ndufv2 24-kDa subunit of mitochondrial NADH dehydrogenase 0.00 -0.03 -0.04 
Rn.10383 Oas1 25 oligoadenylate synthetase 0.01 0.12 0.08 
Rn.10022 Prkr protein kinase, interferon-inducible double stranded RNA dependent -0.06 -0.14 -0.16 
Rn.2742 Psme1 protease (prosome, macropain) 28 subunit, alpha -0.08 0.32 -0.19 
Rn.109376 Psme2 protease (prosome, macropain) 28 subunit, beta -0.07 -0.08 -0.46 
Rn.79620 Pumag interferon-gamma inducible gene, Puma-g 0.04 -0.21 -0.19 
Rn.33229 Stat1 signal transducer and activator of transcription 1 -0.18 -0.16 -0.33 
Rn.2605 Tmsb4x thymosin beta-4 x-linded -0.12 -0.34 -0.23 
Rn.35775 --- ORF homologous to two human interferon-inducible proteins (LOC309526) 
-0.04 -0.04 -0.01 
Rn.101760 --- similar to interferon-inducible GTPase (LOC307414) 0.00 0.00 -0.07 
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FIGURE 3.13.  Interferon response in SYT13i- and SYT13s-transfected cell lines.  Log-
ratios of interferon-associated gene expression compared to CX4 for s1, i5, and i12 cell 
lines.  Lines represent mean values. 
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 Gene % Sequence Identity Location Function 
SYT13i   
Cnga3 86% (18/21) 2041/2231 olfactory transduction 
Cntnap1 86% (18/21) 1055/5379 glial-neuron communication during development 
Kcna3 86% (18/21) 1566/2956 delayed rectifier potassium channel activity 
RGD1306404 81% (17/21) 2762/376 similar to chondroitin synthase 
Camk2d 76% (16/21) 4434/5637 calcium/calmodulin dependent protein kinase 
Cgm3 76% (16/21) 427/2761 cytokinin biosynthesis 
Kdelc1 76% (16/21) 2405/2463 located in ER, function unknown 
LOC686731 76% (16/21) 12020/23862 similar to mucin 17 
RGD1308422 76% (16/21) 12311/25273 similar to ovarian cancer related tumor marker CA125 
Akap13 71% (15/21) 738/9768 scaffolding proteins for Rho signaling pathway, protein kinase A-anchoring protein 
Barhl1 71% (15/21) 1871/2393 DNA-binding transcription regulator 
Ddx26 71% (15/21) 4255/4915 3' end processing of snRNAs 
Gap 71% (15/21) 178/737 inward-rectifier type potassium channel 
Igsf6 71% (15/21) 1742/2244 cell-surface receptor linked signal transduction 
Kcnj6 71% (15/21) 3767/16380 potassium channel activity 
Lama2 71% (15/21) 9153/9715 laminin alpha 2 subunit 
Tra1 71% (15/21) 2328/3215 molecular chaperone protein, histone acetylation 
Centb1 67% (14/21) 466/2503 GTPase regulation 
Falz 67% (14/21) 4318/8151 transcriptional regulation 
Gcn5l2 67% (14/21) 2881/3052 transcriptional activator, histone acetylation  
Hdh 67% (14/21) 8225/10295 Huntington disease gene homolog; neuronal development 
Kcnab1 67% (14/21) 1554/3522 potassium voltage-gated channel subunit 
KIAA0933 67% (14/21) 4965/8940 similar to C21ORF5; unknown function 
Kif15 67% (14/21) 522/4214 kinesin family member 15; neural development and migration 
LOC287274 67% (14/21) 473/866 unknown function 
LOC681610 67% (14/21) 1261/1559 similar to vomeronasal 2 
Lrrc42 67% (14/21) 606/1696 leucine rich repeat containing 42; unknown function 
Nek6 67% (14/21) 188/1314 serine/threonine kinase  
RGD1562451 67% (14/21) 2245/2531 similar to PABPC4; nucleotide metabolism 
Tex2 67% (14/21) 3347/5119 testis expressed sequence 2; unknown function 
Tpp2 67% (14/21) 1195/4566 tripeptidyl peptidase 
SYT13s   
Olr1256 86% (18/21) 670/933 olfactory receptor 
Lep7 81% (17/21) 857/921 unknown function 
LOC294668 81% (17/21) 601/3765 unknown function 
LOC501793 81% (17/21) 84/2619 similar to putative pheromone receptor 
LOC681254 81% (17/21) 1430/2036 unknown function 
LOC683355 81% (17/21) 1274/1773 monoacylglycerol O-acyltransferase 2 
LOC686143 81% (17/21) 767/993 keratinocytes proline-rich protein; unknon function 
StARD9 76% (16/21) 858/11587 microtubule-based movement 
Ifi44 76% (16/21) 793/1686 interferon-induced; HVB-associated microtubular aggregate protein 
RGD1566284 76% (16/21) 1330/1784 similar to heterogeneous nuclear ribonucleoprotein A3; mRNA metabolism and transport 
Xpo4 76% (16/21) 632/4957 transport protein 
Cap1 71% (15/21) 1926/2584 adenyly cyclase-associated protein; cell polarity maintenance 
Dock8 71% (15/21) 3233/7736 guanyl-nucleotide exchange factor activity 
Has3 71% (15/21) 576/2465 synthesis of hyaluronan, an extracellular matrix molecule 
LOC680422 71% (15/21) 188/3593 unknown function 
RGD1304806 71% (15/21) 350/3755 unknown function 
Bpgm 67% (14/21) 528/1609 carbohydrate metabolism 
Cwf19l2 67% (14/21) 2990/4026 unknown function 
Cyb561d1 67% (14/21) 87/686 integral membrane protein; function unknown 
Dnahc11 67% (14/21) 7297/11007 microtubule-based movement 
LOC679442 67% (14/21) 1454/1818 unknown function 
LOC679830 67% (14/21) 1454/1818 unknown function 
Phca 67% (14/21) 838/2390 glycosphingolipid metabolism; protein biosynthesis 
Tex2 67% (14/21) 3347/5119 testis expressed sequence 2; unknown function 
Zfyve9 67% (14/21) 3915/3928 Tgf-β receptor complex assembly 
  
TABLE 3.2.  Rat genes with sequence similarity to the SYT13i and SYT13s targets 
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Our previous studies identified a correlation between human 11p11.2-mediated rat 
liver tumor suppression and induction of rat Wt1 (43).  Based on this observation we 
hypothesized that the molecular mechanism governing rat liver tumor suppression by human 
11p11.2 may directly or indirectly involve this previously identified tumor suppressor gene 
(43).  Thus, if the microcell-mediated introduction of SYT13 into the cells is responsible for 
the induction of Wt1, we expect the expression of Wt1 to be diminished in SYT13-silenced 
cell lines.  The parental GN6TF tumor cells express Wt1 at a significantly lower level than 
the suppressed CX4 cells (FIGURE 3.12.B).  Wt1 was decreased in several SYT13i-transfected 
clones but was unchanged (or higher) in SYT13s-transfected cell lines (FIGURE 3.12.B).  
These data (i) support our previous hypothesis that expression of Wt1 is directly or indirectly 
induced in response to hSYT13 in this model system, and (ii) suggest strongly that Wt1 is an 
important down-stream effecter of SYT13-mediated tumor suppression. 
Phenotypic and Growth Characteristic Analysis of SYT13i and SYT13s Clones In Vitro 
Analysis of morphology, contact inhibition, and anchorage-dependent growth in CX4 
cells, revealed that human 11p11.2 normalizes the aggressive phenotype of the GN6TF cells 
in vitro (41, 43).  After targeting human SYT13 in CX4 cells with shRNAs, we re-examined 
these characteristics to assess the contribution of SYT13 to the suppression of the neoplastic 
cell phenotype of GN6TF cells in vitro.  GN6TF cells are spindle-shaped and grow in 
multiple layers, whereas CX4 cells exhibit a flattened and polygonal cell morphology and 
produce a contact-inhibited growth pattern (FIGURE 3.14.A).  SYT13i cell lines retain some 
polygonal features similar to CX4 cells, but exhibit a multilayer growth pattern after reaching 
confluence in culture (FIGURE 3.14.A).  The morphology of control-transfected cell lines 
(SYT13s) was similar to that of the parental suppressed cell line CX4 (FIGURE 3.14.A).  
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FIGURE 3.14. Phenotypic characterization of SYT13i and SYT13s–transfected cell lines.  
(A) Phase contrast microscopy of GN6TF tumor cells, CX4 MCH cells, and representative 
derived SYT13i and SYT13s transfected cell lines.  (B) Saturation densities of GN6TF 
tumor cells, CX4 MCH cells, and representative derived SYT13i and SYT13s transfected 
cell lines (expressed relative to CX4 cells).  (C) Anchorage-independent growth of 
GN6TF cells, CX4 MCH cells, and representative SYT13i and SYT13s transfected cell 
lines (expressed relative to CX4 cells).  *P< 0.05 and **P<0.001 compared to CX4 using 
Student’s t-Test. 
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Saturation densities of each of the 12 SYT13i- and 8 STY13s-transfected cell lines were 
measured.  FIGURE 3.14.B shows a representative panel of these cell clones (saturation 
densities of cell lines not shown did not significantly differ from CX4).  SYT13i5 and 
SYT13i12 grow to an elevated saturation density that is indistinguishable from GN6TF, 
reflecting multilayer growth.  SYT13i3, i5, i6, and i12 cells efficiently produced colonies in 
soft agarose, indicative of the restoration of anchorage-independent growth potential (FIGURE 
3.14.C).  SYT13s1, s7, and s8 cells formed few or zero colonies in soft agarose (FIGURE 
3.14.C), similar to CX4 cells, and the remainder of the colonies were unable to form any 
colonies in soft agarose.  These results combine to suggest that several cellular features of 
suppressed CX4 MCH cells (including growth pattern, contact inhibition, and anchorage-
dependent growth) may be directly regulated by expression of SYT13. 
Tumorigenicity of SYT13i and SYT13s Clones In Vivo 
Several SYT13-targeted and scrambled control cell lines were selected for analysis of 
tumorigenicity in vivo.  SYT13i5 and i12 cells displayed the greatest tumorigenic potential 
with 86% and 80% of syngeneic animals developing tumors with short latency (TABLE 3.3).  
In contrast, the suppressed parental CX4 cells developed fewer tumors with a much longer 
average latency, consistent with previous studies (40).  The average latency for tumor 
formation for s1 and s8 control cells in the 50% (4/8) of animals which developed tumors 
was 226±31 days, similar to the CX4 cells (TABLE 3.3). The increased aggressiveness of 
SYT13i cell lines was evident from a Kaplan-Meier analysis of survival after transplantation 
of SYT13i (FIGURE 3.15) and SYT13s cell lines.  This analysis revealed a statistically 
significant survival disadvantage for animals transplanted with SYT13i5 cells compared to 
CX4 cells (FIGURE 3.15). 
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TABLE 3.3.  Tumorigenic potential of CX4 and derived SYT13i and SYT13s cell lines 
Cell 
Line 
Tumorigenicity 
(%) 
Latency 
Range (d) 
Average 
Latency (d) 
Latency 
Significance 
(P)* 
Survival 
Significance 
(P)† 
CX4 4/6 (67%) 256 – 293 274 ± 11 -- -- 
i3 1/5 (20%) NA 201 N/A 0.10 (NS) 
i5 6/7 (86%) 110 – 201 144 ± 14 <0.0001 0.04 
i6 1/8 (12%) NA 201 N/A 0.07 (NS) 
i12 8/10 (80%) 87 – 293 164 ± 25 0.002 0.15 (NS) 
s1 1/4 (25%) NA 256 N/A 0.28 (NS) 
s8 3/4 (75%) 153 – 293 216 ± 41 0.28 (NS) 0.48 (NS)  
*Significance of average latency is compared to CX4 cells using the Student’s t-Test 
†Significance of survival is compared to CX4 cells using the Log-Rank test 
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FIGURE 3.16. Characterization of tumor revertants after transplantation into host 
animals.  (A) Representative tissue sections corresponding to tumors generated after 
transplantation of i5, i12, and s8 cells.  All tumors were classified as undifferentiated, 
spindle cell carcinomas regardless of the nature of the transplanted cell line.  (B) PCR 
analysis of tumor cell lines derived from SYT13i and SYT13s cell clones.  The human 
specific repeating element Alu was amplified by PCR in tumor revertants to assess the 
extent of loss of the suppressive human chromosome.  None of the tumor revertants 
retained the human SYT13 allele.  CX4-derived tumor cell lines are designated CX4TR 
(3 and 4).  Likewise, tumor cell lines derived from SYT13i cell lines are designated i5T 
(tumors 1-6), and i12T (tumors 1-8), and tumor cell lines derived from SYT13s8 are 
designated S8T (tumors 1-3).
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Morphological and Molecular Characterization of SYT13i- and SYT13s- derived Tumor Cell 
Lines 
Tumors arising in syngeneic rats after subcutaneous transplantation of SYT13i and 
SYT13s cell lines were poorly differentiated carcinomas that were indistinguishable from 
tumors arising after transplantation of the parental GN6TF tumor cells or the CX4 MCH cell 
line (FIGURE 3.16.A).  Molecular characterization of tumor cell lines derived from SYT13i 
and SYT13s clones revealed that the neomycin resistance gene (located on the suppressive 
human chromosome 11) (40, 91) was not retained in any of the tumor forming cells (data not 
shown).  However, Alu-PCR of genomic DNA isolated from these tumor cell lines indicated 
the presence of human chromosomal DNA (FIGURE 3.16.B).  The Alu-PCR amplicon patterns 
generated for individual tumor cell lines suggested that portions of the human chromosome 
had been lost during tumorigenesis (FIGURE 3.16.B).  None of the tumor cell lines analyzed 
contain hSYT13, suggesting that loss of human 11p11.2 occurs coordinate with reexpression 
of tumorigenicity (FIGURE 3.16.B).  The psiRNA vector remained intact in all of the tumor 
revertant cell lines (data not shown).   
EXOGENOUS EXPRESSION OF HUMAN SYT13 IN THE GN6TF TUMOR CELL LINE  
Introduction of human chromosome 11 into the GN6TF tumor cell line resulted in the 
suppression of tumorigenicity in GN6TF-derived MCH cell lines, and mapping of the tumor 
suppressor locus identified SYT13 as a strong candidate for the 11p11.2 tumor suppressor 
gene.  Therefore, SYT13 was ectopically expressed in GN6TF tumor cells in order to directly 
investigate its tumor suppressive function in this model system. 
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Molecular Analysis of SYT13-Transfected Clones 
SYT13 expression:  FLAG-tagged-SYT13-transfected GN6TF clones B3, C1, C2, E2, 
F3, and J1, as well as the FLAG-tagged-GFP vector control were examined by western blot 
for SYT13 expression.  The SYT13 antibody recognized a 66 kDa protein monomer and the 
a 130 kDa SDS-resistant dimer, consistent with previous reports (80).  In addition, an 
intermediate species was identified that may represent a SYT13 degradation product or a 
non-specific binding reaction (FIGURE 3.17.A).  CX4, a positive control for SYT13, shows 
strong expression of the 66 kDA species compared to the other cell lines.  Relative to 
expression in the parental GN6TF tumor cell line, the SYT13 monomer is slightly increased 
in C1 and reduced in C2.  The other cell lines (GFP, B3, E2, F3, and J1) exhibit no real 
change in the expression of the SYT13 monomer compared to GN6TF.  The SYT13 dimer is 
absent in GN6TF, GFP, C1, and B3 and appears at low, but similar expression levels in the 
CX4, C2, E2, F3, and J1 cell lines.  (FIGURE 3.17.A). 
SYT13 mRNA was measured by real time RT-PCR with human specific probes 
(FIGURE 3.17.B).  Levels for GN6TF were essentially zero (10-5 times expression in the CX4 
MCH).  SYT13-transfected cell lines C2, F3, C1, and B3 expressed SYT13 similar to levels 
found in CX4.  Interestingly, SYT13 mRNA levels in E2 and J1 were found at the same level 
(essentially zero) seen in GN6TF cells (FIGURE 3.17.B).  These data, combined with 
protein/mRNA data from SYT13-silencing studies (FIGURES 3.11 AND 3.12), suggest that 
steady state levels of the protein (SYT13) do not necessarily correspond to steady state levels 
of the gene transcript (SYT13).  The implications of this finding are (i) although SYT13 is a 
strong candidate for the human 11p11.2 tumor suppressor gene, it may unlikely be identified 
by large-scale expression analysis in cancer research, and (ii) post-transcriptional and post-
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FIGURE 3.17. Molecular characterization of SYT13- and GFP-transfected GN6TF cell 
lines.  (A) Western analysis shows an induction of the expression of the SYT13 dimer in 
several (but not all) SYT13-transfected cell lines and slight alterations in the SYT13 
monomer which do not correlate with increases in the dimer.  Analysis with the α-FLAG 
antibody shows no immunoreactive monomeric species and increases in several (but not 
all) of the SYT13 dimer in SYT13-transfected cells.  Gapdh protein expression was 
utilized as a control to verify equal protein loading.  (B) Quantitative real-time RT-PCR 
analysis of SYT13 mRNA expression in GN6TF and SYT13-transfected cell lines 
expressed relative to CX4 cells (SYT13 mRNA was not measured in GFP-transfected 
cells).  *P<0.05 compared to GN6TF using the Student’s t-Test. 
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translational modifications may be very important in the regulation and function of SYT13.  
Exogenous protein expression:  The ectopically expressed SYT13 carries a FLAG tag 
which facilitates discrimination of the exogenous protein from the endogenous protein by 
western blot using an α-FLAG antibody.  The FLAG immunoreactive protein migrates at 130 
kDa and corresponds to the SDS-resistant dimer observed on the α-SYT13 immunoblot 
(FIGURE 3.17.A).  No FLAG-positive SYT13 monomer protein is observed in any of the 
transfected cell lines.  Likewise, it is found only in SYT13-transfected cell lines C2, E2, and 
F3 coordinate with expression of the SYT13 dimer, but it does not recognize the SYT13 
dimer in J1 (FIGURE 3.17.A).  The α-FLAG antibody also decorates the 30 kDa FLAG-tagged 
GFP protein expressed in the GFP vector control cell population (data not shown).  The lack 
of α-FLAG immunoreactivity with the 66 kDa SYT13 monomer suggests that either the 
antibody is unable to recognize the FLAG epitope on the monomeric species or that 
exogenously expressed SYT13 uniquely produces the SDS-resistant protein dimer.  If the 
latter is true, then only C2, E2, and F3 cells express exogenous SYT13, and the acquisition of 
the neomycin-resistance phenotype after transfection does not necessarily correspond to 
coordinate production of SYT13 (as in C1 and B3).   
Expression of rat Wt1 in transfected clones:  Transfected cell lines were analyzed by 
real-time RT-PCR for expression of the rat Wt1 tumor suppressor gene.  In our previous 
studies, Wt1 was implicated in the suppression of tumorigenicity in GN6TF-derived MCH 
cell lines as a potential effecter of 11p11.2-mediated tumor suppression (43).  Real-time RT-
PCR analysis revealed a significant increase in Wt1 mRNA in SYT13 dimer-positive cell 
lines C2, E2, F3, and J1 compared to GN6TF (FIGURE 3.18.).  Although CX4 displays the 
most robust expression of SYT13 (the monomeric species; FIGURE 3.18.A), expression of 
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Wt1 mRNA is greater (2-4-fold) in the SYT13-transfected cell lines C2, E2, F3, and J1 
(FIGURE 3.18.B).  Wt1 expression in neomycin-resistant, SYT13 dimer-negative cell lines 
(C1 and B3) was low and similar to the GN6TF cell line (FIGURE 3.18). Expression of Wt1 in 
the GFP-control cell line was similar to GN6TF (FIGURE 3.18).  This result (i) provides 
evidence that SYT13 may directly or indirectly regulate expression of Wt1, and (ii) suggests 
that the SYT13 dimer may be a more important downstream effecter than the monomeric 
species. 
Phenotypic and Growth Characteristics of SYT13-Transfected Clones In Vitro 
Cellular morphology of transfected clones:  GN6TF tumor cells display a spindly 
morphology with multiple cellular extensions (FIGURE 3.19), and after reaching confluency in 
culture, the cells continue to proliferate and exhibit multi-layered growth.  Microcell-
mediated introduction of human chromosome 11 into these cells resulted in MCHs (i.e. CX4, 
FIGURE 1.3) that grow in a contact-inhibited monolayer with an epithelioid, cobblestone 
morphology.  SYT13 dimer-positive (and Wt1-positive) GN6TF transfectants (C1, E2, F3 and 
J1; FIGURE 3.19) display a flattened, epithelioid, monolayer—similar to the suppressed MCH 
cell lines.  By contrast, the neomycin-resistant, SYT13 dimer-negative (and Wt1-negative) 
cell lines (C1 and B3, FIGURE 3.19) display a spindly morphology that is indistinguishable 
from the parental GN6TF tumor cells and the GFP-vector control (FIGURE 3.19). 
Contact-inhibition of SYT13-transfected cell lines:  Loss of contact inhibition is one 
measure of neoplastic growth in culture which can be visually observed in culture (FIGURE 
3.20.A) and can be assessed quantitatively by the saturation density assay.  SYT13 dimer- 
positive (and Wt1-positive) cell lines C2, E2, and J1 produced saturation densities that were 
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 FIGURE 3.18. Wt1 expression in SYT13- and GFP- transfected cell lines.  Quantitative 
real-time RT-PCR analysis of Wt1 mRNA expression in GN6TF, SYT13-, and GFP-
transfected cell lines expressed relative to CX4 cells.  *P<0.05 compared to GN6TF using 
the Student’s t-Test. 
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FIGURE 3.19. Phenotypic characterization of SYT13- and GFP-transfected cell lines.  
Phase contrast microscopy of GN6TF tumor cells, GFP-transfected cells (GFP), and 
SYT13-transfected cell lines (C1, B3, C2, E2, F3, and J1). 
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>50% reduced from that of the parental GN6TF tumor cell line (FIGURE 3.20.B). This result 
strongly suggests that establishment of contact inhibition accompanies the expression of the 
SYT13 dimer (and Wt1) in GN6TF transfectants.  Conversely SYT13 dimer-negative (and 
Wt1-negative) cell lines (GFP control and B3) displayed no change in contact inhibition 
compared to GN6TF (FIGURE 3.20.B) and maintained the ability to grow in multi-layered 
cultures.  These results suggest that the cell lines expressing the exogenous SYT13 dimer 
have acquired the ability to recognize and/or process extracellular stimuli for growth arrest, a 
pathway which appears to be disrupted in GN6TF tumor cells. 
Anchorage-dependent growth in SYT13-transfected cell lines:  Anchorage-
independent growth represents another measure of neoplastic growth in vitro.  Colony 
forming efficiencies relative to GN6TF are graphically represented in FIGURE 3.21.A and 
viable, MTT-stained colonies are displayed both macroscopically and microscopically in 
FIGURES 3.21.B. and C respectively.  SYT13-dimer positive cell lines C2, E2, and J1 have 
completely lost the ability to form colonies in soft agar.  Likewise, the CFE of SYT13 dimer-
positive cell line F3 was significantly attenuated, and the average size of the colonies formed 
was smaller than GN6TF colonies.  SYT13 dimer-negative cell lines C1 and B3 expressed 
reduced CFEs relative to GN6TF (63% and 43%, respectively), and the average colony size 
of C1 clones appeared to be smaller than GN6TF.  The CFE of the GFP vector control cell 
line did not significantly differ from that of GN6TF (FIGURE 3.21.B) and the average colony 
size appeared to be similar.  Although SYT13 dimer-negative (Wt1-negative) cell lines C1 
and B3 expressed reduced CFEs, they maintain a significant capacity for anchorage-
independent growth compared to the virtually ablated potential that accompanied SYT13 
expression in C2, E2, F3, and J1 cells.  This suggests that exogenous expression of SYT13, 
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FIGURE 3.20. Contact inhibition of SYT13- and GFP-transfected cell lines.  (A) Phase 
contrast microscopy of representative GFP-transfected and SYT13-transfected cells after 
14 days in culture. (B) Saturation densities of GN6TF tumor cells, GFP-transfected cells, 
and SYT13-transfected cell lines (expressed relative to GN6TF cells).  *P<0.05 and 
**P<0.001 compared to GN6TF using the Student’s t-Test. 
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FIGURE 3.21. Anchorage-independent growth of SYT13- and GFP-transfected cell lines.  
(A) Colony forming efficiency (CFE) of GN6TF, GFP-transfected cells, and SYT13-
transfected cell lines (expressed relative to GN6TF cells).  *P<0.05 and **P<0.001 
compared to GN6TF using the Student’s t-Test.  (B) and (C) Macroscopic and 
microscopic (obj. x20) views of MTT-stained colonies of GN6TF tumor cells, GFP-
transfected cells, and SYT13-trasfected cells in soft agar. 
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specifically the SYT13 dimeric species, is able to significantly attenuate the neoplastic 
growth of GN6TF cells in vitro.   
Tumorigenicity of SYT13-Transfected Cell Lines  In Vivo 
GN6TF tumor cells are highly aggressive in vivo and have been documented to form 
tumors in syngeneic hosts with an average latency of 21d (40).  SYT13-transfected GN6TF 
clones were transplanted into syngeneic neonatal rats to assess the ability of exogenously 
expressed SYT13 to alter tumorigenicity.  Ten days after transplantation, tumors were 
palpable and macroscopically visible in 100% of the animals transplanted with the SYT13 
dimer-negative cell lines GN6TF, GFP, C1, and B3.  At this time point after transplantation, 
there was no indication of tumor formation in animals transplanted with SYT13-positive cell 
lines C2, E2, F3, and J1 (FIGURE 3.22.A).  Tumor diameters in the remaining animals were 
measured (in vivo) 20 days post-transplantation, and at this time, there was still no palpable 
tumor formation in animals transplanted with the SYT13 dimer-positive cell lines C2, E2, 
and J1 (diameters of tumors that were harvested previous to 20 days post-transplantation 
were measured as 1 cm) (FIGURE 3.22.B).    By 30 days post-transplantation, 1 cm tumors 
had formed in 100% of the animals with each of the SYT13 dimer-negative cell lines 
GN6TF, GFP, C1, and B3 (TABLE 3.5 AND FIGURE 3.23).  There was no significant difference 
in average latency of tumor formation between these cell lines.  At the conclusion of the 
study (120 days), 20% (2/10) of the animals transplanted with the E2 cell line had formed 1 
cm tumors.  Of the animals remaining, 29% (2/7) transplanted with J1, 9% (1/11) 
transplanted with C2, and 50% (4/8) of the remaining animals transplanted with E2 had 
formed palpable tumors of less than 1 cm.  FIGURE 3.23 depicts a survival analysis among 
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FIGURE 3.22.  Early indications of tumorigenicity in vivo.  (A) Tumor formation in 
representative GFP and E2 syngeneic host animals of identical age 10 days after 
subcutaneous (on back) transplantation of GFP or E2 cells.  No tumor formation is noted 
at the transplantation site of animals injected with E2 cells.  (B) Average diameter of 
tumors formed in syngeneic host animals 20 days post- transplantation with parental 
GN6TF tumor cells, GFP-transfected, and SYT13-transfected cell lines.  *P<0.05 and 
**P<0.001 compared to GN6TF using the Student’s t-Test. 
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TABLE 3.4.  Tumorigenic potential of GN6TF cells and GFP-transfected and SYT13-
tranfected GN6TF cells 
Cell 
Line 
Tumorigenicity 
(%) 
Latency 
Range (d) 
Average 
Latency 
(d) 
Latency 
Significance 
(P)* 
Survival 
Significance 
(P)† 
GN6TF 5/5 (100%) 18 - 25 20 ± 1. -- -- 
GFP 7/7 (100%) 18 - 25 23 ± 1 0.13 (NS) 0.24 (NS) 
B3 7/7 (100%) 18 - 22 19 ± 1 0.58 (NS) 0.55 (NS) 
C1 9/9 (100%) 18 - 30 25 ± 1 0.06 (NS) 0.08 (NS) 
C2 0/11 (0%) -- -- N/A <0.0001 
E2 2/10 (20%) 107 - 109 108 ± 1 <0.0001 <0.0001 
J1 0/7 (0%) -- -- N/A 0.0003  
*Significance of average latency is compared to GN6TF cells using the Student’s t-Test 
†Significance of survival is compared to GN6TF cells using the Log-Rank test 
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animals transplanted with each individual cell line and indicates statistically powerful 
suppression of tumorigenicity in animals transplanted with SYT13 dimer-positive cell lines 
C2, E2, and J1.  The significant results of this study provide very strong evidence that 
SYT13, specifically as a protein dimer, is able to complement a molecular deficiency in 
GN6TF and suppress the tumorigenic phenotype of this cell line. 
LARGE-SCALE GENE EXPRESSION ANALYSIS OF SYT13-POSITIVE AND SYT13-NEGATIVE 
CELL LINES 
RNA isolated from several cell rat liver cell lines was subjected to large-scale gene 
expression analysis to identify specific genes and pathways that mediate SYT13-dependent 
tumor suppression.   
Affymetrix Microarray Analysis and Validation 
RNA from CX4, GN6TF, SYT13i5, SYT13i12, and SYT13s1 was isolated in duplicate 
and individually hybridized to gene arrays.  Expression analyses based on log signal values 
for duplicate hybridizations showed a Pearson correlation coefficient >0.995, demonstrating 
the reproducibility of data between duplicates.  FIGURES 3.24.A and B compare gene 
expression profiles between duplicate hybridizations of CX4 and GN6TF.  A log ratio plot 
showing gene expression in CX4 cells relative to expression in GN6TF cells is shown in 
(FIGURE 3.24.C).  Real-time RT-PCR was used to validate expression changes of Cdh1, 
Pawr, and Snail in the CX4 cell line relative to GN6TF cells (FIGURE 3.35).  Expression of 
these genes was also measured in SYT13-transfected cell lines to compare the gene 
expression patterns in 11p11.2-mediated (CX4) and SYT13-mediated (C2, E2, F3, and J1) 
tumor suppression (FIGURE 3.25).   
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FIGURE 3.24.  Scatterplot representation of microarray data.  (A) Scatterplot of log signal 
values for duplicate hybridizations of CX4 and (B) GN6TF cRNA.  Subscripts represent 
1st and 2nd hybridization experiments for CX4 (A) and GN6TF (B).  The Pearson 
correlation coefficient for replicate hybridizations of CX4 is 0.999 and is 0.997 for 
GN6TF.  (C) Scatterplot of the ratio of log signal values for CX4/GN6TF.  Each dot 
represents a transcript (gene) on the microarray.  Y values represent log2(CX4/GN6TF).  
Therefore, a point (transcript) that falls at 2 on the vertical axix is equal to a 4-fold (22) 
increase of expression in CX4 cells compared to expression in GN6TF. 
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FIGURE 3.25.  Validation of microarray results by quantitative RT-PCR.  Microarray 
results were validated by measuring mRNA levels of several genes (including Pawr/Par4, 
Cdh1, and Snail).  (A), (C), and (E) depictF microarray output on scatterplots of the ratio 
of log signal values for the CX4 cell line compared to GN6TF.  Y values of these data 
points (or genes, highlighted in red) correspond to fold change increases or decreases 
(designated by the negative signs) of the genes in CX4 compared to GN6TF cells.  (B), 
(D), and (F) demonstrate real-time RT-PCR analysis of these genes in GN6TF, CX4, and 
SYT13-transfected cell lines.  *P<0.05 and **P<0.001 compared to GN6TF using the 
Student’s t-Test.  (B) and (D) are depicted on log scale and (F), on linear scale. 
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Differentially Expressed Genes Revealed by Microarray Analysis 
The expression output was queried for genes with >2-fold increased expression in the 
CX4 cell line compared to GN6TF and a corresponding list of genes with decreased 
expression levels >2-fold in the CX4 cell line compared to GN6TF.  This analysis resulted in 
the identification of 2,742 transcripts with increased and 1,397 with reduced expression.  The 
2,742 transcripts expressed at least >2-fold higher in CX4 cells corresponded to a total of 
1,662 known or predicted genes in the R. norvegicus genome (APPENDIX A).  The 1,397 
unique Affymetrix Probe IDs that reflected >2-fold decreased expression in CX4 relative to 
GN6TF corresponded to 168 known or predicted genes in the R. norvegicus genome 
(APPENDIX B).   
To more closely examine the specific effects mediated by SYT13 expression,  a 
comparison was made between the expression profiles of three tumorigenic cell lines 
(GN6TF, SYT13i5 and SYT13i12) and two suppressed cell lines (CX4 and SYT13s1).  Genes 
identified using these stringent criteria must be expressed at >2-fold above or below  the 
expression levels in each of the tumorigenic cell lines (GN6TF, SYT13i5 and SYT13i12) 
compared to both of the suppressed (CX4 and SYT13s1) control cell lines (TABLE 3.5).  This 
analysis resulted in the identification of 22 transcripts (corresponding to 11 known or 
predicted genes) with >2-fold decreased expression in each of the aggressive cell lines 
compared to both of the suppressed cell lines (TABLE 3.5).  Only 3 genes were expressed at 
>2-fold greater in each of the suppressed cell lines (TABLE 3.5).  
Differentially Expressed Biological Themes Revealed by Microarray Analysis 
DAVID Bioinformatics 2006 [http://david.abcc.ncifcrf.gov, (67)] was utilized to 
identify enriched biological themes present in the gene lists generated by comparative 
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 TABLE 3.5.  Genes differentially expressed in aggressive SYT13-negative and 
suppressed SYT13-positive cell lines 
Affymetrix  ID Gene Name 
INCREASED  
APOE APOLIPOPROTEIN E 
AUTS2 AUTISM SUSCEPTIBILITY CANDIDATE 2 (PREDICTED)  
CD59 CD59 ANTIGEN 
EPHB6 EPH RECEPTOR B6 
FNDC1 FIBRONECTIN TYPE III DOMAIN CONTAINING 1 (PREDICTED)  
GOLPH4 GOLGI PHOSPHOPROTEIN 4 
SCIN SCINDERIN 
LOC263543 SIMILAR TO RIKEN CDNA 4930429H24 (PREDICTED)  
SLIT2 SLIT HOMOLOG 2 (DROSOPHILA)  
SULF2 SULFATASE 2 
TM4SF1 TRANSMEMBRANE 4 SUPERFAMILY MEMBER 1 (PREDICTED)  
DECREASED  
CA3 CARBONIC ANHYDRASE 3 
ESP8 EPIDERMAL GROWTH FACTOR RECEPTOR PATHWAY SUBSTRATE 8 
NRN1 NEURITIN 
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analysis of transcript expression in suppressed and non-suppressed cell lines.  The Functional 
Annotation Tool of DAVID converts gene lists to associated biological themes based on 
gene-annotation enrichment analysis using the Fisher’s Exact Test to determine P values.  
Gene ontology (GO) terms (or biological themes) associated with genes showing decreased 
expression following introduction of chromosome 11 into GN6TF cells (CX4 versus GN6TF, 
APPENDIX A) are shown in TABLE 3.6.  A complete list of statistically significant (P<0.05) 
biological themes can be found in APPENDIX C.  The most enriched theme in this list involves 
lipid metabolism/biosynthesis, and differentially expressed genes associated with this are 
listed in TABLE 3.7.  Expression values from the microarray analysis were extracted and 
uploaded into GenMapp software (66) to visualize the alterations of expression in genes 
associated with cholesterol biosynthesis.  The pathway generated by GenMapp is reproduced 
in FIGURE 3.25.  Expression of 8/10 genes in the cholesterol biosynthesis pathway is 
attenuated in the suppressed CX4 cell line compared to GN6TF cells.  This finding is 
consistent with the well documented observation that elevations in cholesterol/isoprenoid 
biosynthesis is commonly associated with a neoplastic phenotype (92, 93), and suggests a 
putative mechanism for SYT13-mediated tumor suppression.  Another statistically enriched 
biological theme that was decreased in CX4 cells compared to GN6TF cells is genes 
associated with the extracellular matrix.  A list of these matrix-associated genes is shown in 
TABLE 3.8.   
The same annotation tool was used to identify enriched biological themes in the list of 
genes up-regulated in the suppressed CX4 cell line relative to the tumorigenic GN6TF cell 
line (APPENDIX B).  A complete list of statistically significant biological themes is provided 
in APPENDIX D.  Several of the most significant themes are presented in TABLE 3.9.  
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TABLE 3.6.  Gene ontology  terms associated with genes down-regulated >2-fold in the 
CX4 cell line relative to GN6TF cells. 
Gene Ontology Term PValue 
cellular lipid metabolism 2.6 x10-6
lipid biosynthesis 8.7 x10-6
lipid synthesis 1.2 x10-5
cytoplasm 2.1 x10-5
nadp 2.6 x10-5
biosynthesis of steroids 3.2 x10-5
lipid metabolism 4.7 x10-5
Golgi-associated vesicle 9.0 x10-5
coenzyme metabolism 1.0 x10-4
extracellular matrix (sensu Metazoa) 1.1 x10-4
cholesterol biosynthesis 1.1 x10-4
organelle membrane 1.3 x10-4
cofactor metabolism 1.3 x10-4
extracellular matrix 1.4 x10-4
catalytic activity 1.6 x10-4
cholesterol metabolism 1.7 x10-4
isoprenoid biosynthesis 2.5 x10-4
sterol biosynthesis 2.5 x10-4
oxidoreductase activity, 2.6 x10-4
fatty acid metabolism 2.6 x10-4
Golgi apparatus 2.8 x10-4
oxidoreductase activity, acting on CH-OH group of donors 3.0 x10-4
integrin binding 3.1 x10-4
cell adhesion 3.1 x10-4
oxidoreductase activity 3.5 x10-4
organic acid metabolism 3.6 x10-4
Golgi membrane 3.7 x10-4
sterol metabolism 4.0 x10-4
cholesterol biosynthesis 4.5 x10-4
organ morphogenesis 4.7 x10-4
endoplasmic reticulum 5.7 x10-4
peroxisome 6. x10-4
collagen 7.0 x10-4
microbody 7.1 x10-4
peroxisome 7. x10-4
sterol biosynthesis 7.6 x10-4
carboxylic acid metabolism 7.9 x10-4
homophilic cell adhesion 7.9 x10-4
alcohol metabolism 8.0 x10-4
lipid metabolism 8.8 x10-4
endomembrane system 0.001
Golgi vesicle transport 0.001
steroid biosynthesis 0.001
isoprenoid metabolism 0.001
3 
1 
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TABLE 3.7.  Genes decreased >2-fold in CX4 cells compared to GN6TF cells 
associated with the cholesterol/steroid/mevalonate biosynthesis/metabolism 
24-dehydrocholesterol reductase DHCR24
3-hydroxy-3-methylglutaryl-coenzyme a reductase HMGCR
3-hydroxy-3-methylglutaryl-coenzyme a synthase 1 HMGCS1
acetyl-coenzyme a synthetase 2 (adp forming) (predicted) ACAS2
acyl-coa synthetase long-chain family member 1 ACSL1
acyl-coa synthetase long-chain family member 3 ACSL3
acyl-coa synthetase long-chain family member 4 ACSL4
acyl-coenzyme a dehydrogenase, short/branched chain ACADSB
acyl-coenzyme a dehydrogenase, very long chain ACADVL
acyl-coenzyme a oxidase 1, palmitoyl ACOX1
adiponectin receptor 2 ADIPOR2
adipose differentiation-related protein ADRP
alcohol dehydrogenase 1 ADH1
aldo-keto reductase family 1, member b8 AKR1B8
alkylglycerone phosphate synthase AGPS
alpha-fetoprotein AFP
atp citrate lyase ACLY
carnitine o-octanoyltransferase CROT
caveolin CAV
cd36 antigen CD36
crystallin, lamda 1 CRYL1
cytochrome p450, subfamily 51 CYP51
diacylglycerol o-acyltransferase homolog 2 (mouse) DGAT2
diazepam binding inhibitor DBI
dodecenoyl-coenzyme a delta isomerase DCI
dolichol-phosphate (beta-d) mannosyltransferase 1 (predicted) DPM1
electron-transfer-flavoprotein, beta polypeptide ETFB
elovl family member 6, elongation of long chain fatty acids (yeast) ELOVL6
enoyl coenzyme a hydratase 1, peroxisomal ECH1
farensyl diphosphate synthase FDPS
farnesyl diphosphate farnesyl transferase 1 FDFT1
fatty acid binding protein 5, epidermal FABP5
fatty acid desaturase 1 FADS1
fatty acid synthase FAS
ferredoxin reductase FDXR
glutathione peroxidase 4 GPX4
glyceronephosphate o-acyltransferase GNPAT
high density lipoprotein binding protein HDLBP
hydroxysteroid (17-beta) dehydrogenase 7 HSD17B7
hydroxysteroid 11-beta dehydrogenase 1 HSD11B1
isopentenyl-diphosphate delta isomerase IDI1
l-3-hydroxyacyl-coenzyme a dehydrogenase, short chain HADHSC
lanosterol synthase LSS
leukotriene b4 12-hydroxydehydrogenase LTB4DH
lipin 1 LPIN1
lipoprotein lipase LPL
low density lipoprotein receptor LDLR
low density lipoprotein receptor-related protein 1 LRP1
membrane-bound transcription factor protease, site 1 MBTPS1
mevalonate (diphospho) decarboxylase MVD
mevalonate kinase MVK
microsomal glutathione s-transferase 3 (predicted) MGST3
mitochondrial acyl-coa thioesterase 1 MTE1
nad(p) dependent steroid dehydrogenase-like NSDHL
notch1-induced protein LOC493574
nuclear receptor subfamily 0, group b, member 1 NR0B1
nuclear receptor subfamily 1, group h, member 3 NR1H3
nuclear receptor subfamily 2, group f, member 2 NR2F2
peroxisomal trans-2-enoyl-coa reductase PECR
peroxisome proliferator activated receptor, gamma PPARG
phosphatidylcholine transfer protein PCTP
phosphatidylinositol 3-kinase, c2 domain containing, alpha polypeptide PIK3C2A
phosphatidylinositol 3-kinase, regulatory subunit, polypeptide 1 PIK3R1
phosphatidylinositol-4-phosphate 5-kinase, type 1 alpha PIP5K1A
phosphatidylserine synthase 2 (predicted) PTDSS2
phospholipase a2, group iva (cytosolic, calcium-dependent) PLA2G4A
phospholipase c, beta 1 PLCB1
phospholipase c, delta 4 PLCD4
phosphorylase kinase alpha 1 PHKA1
phytanoyl-coa hydroxylase PHYH
prostaglandin-endoperoxide synthase 1 LOC497767
prostaglandin-endoperoxide synthase 2 PTGS1
protein kinase, camp dependent regulatory, type ii beta PTGS2
sialyltransferase 7f PRKAR2B
sialyltransferase 9 SIAT7F
similar to acetyl coa transferase-like SIAT9
cholinephosphotransferase 1 alpha MGC95138
similar to chromosome 20 open reading frame 155 RGD1311037
solute carrier family 27 (fatty acid transporter), member 3 (predicted) SLC27A3
sphingomyelin phosphodiesterase 1, acid lysosomal SMPD1
stearoyl-coenzyme a desaturase 1 SCD1
stearoyl-coenzyme a desaturase 2 SCD2
steroid sulfatase STS
steroidogenic acute regulatory protein STAR
sterol regulatory element binding factor 1 SREBF1
tumor necrosis factor receptor superfamily, member 1a TNFRSF1A  
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Idi1
Fdps
Fdps
Ebp
SqleLss
Fdft1
Mvd
Mvk
HMG-CoA
Mevalonate
Mevalonate-5-P Mevalonate-5-PP Isopentenyl-PP
Geranyl-PP
Farnesyl-PP
Squalene
Squalene-2,3-Epoxide
Lanosterol
Lathosterol
7-Dehydro-cholesterol
Cholesterol
-2.2
-2.3
-2.5
-4.6
-4.6
-3.0
-3.0
Not measured
Dhcr7
Hmgcr
Dimethylallyl-PP
-1.2
-1.4
+1.1
 
FIGURE 3.26.  Expression changes of genes involved in the cholesterol biosynthesis 
pathway in CX4 cells compared GN6TF cells.  Expression of genes in this pathway were 
measured by microarray analysis and loaded into GenMapp for visualization of the results.  
Genes in pink represent a >2-fold reduction of gene expression in suppressed CX4 
compared to GN6TF.  The adjacent numbers represent fold-change and the sign 
designates the direction of the change.  Hmgcr, Dhcr7 and Ebp were decreased, but did 
not meet the >2-fold criterion, and Lss was not measured. 
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TABLE 3.8.  Genes decreased >2-fold in CX4 cells compared to GN6TF cells 
associated with the extracellular matrix 
a disintegrin-like and metalloproteasewith thrombospondin type 1 ADAMTS1
biglycan BGN
chondroitin sulfate proteoglycan 2 CSPG2
collagen, type 1, alpha 1 COL1A1
collagen, type iii, alpha 1 COL3A1
collagen, type v, alpha 1 COL5A1
collagen, type v, alpha 2 COL5A2
collagen, type v, alpha 3 COL5A3
craniofacial development protein 1 CFDP1
egf-containing fibulin-like extracellular matrix protein 2 EFEMP2
fibrillin 1 FBN1
fibromodulin FMOD
glypican 1 GPC1
matrix extracellular phosphoglycoprotein with asarm motif (bone) MEPE
matrix metallopeptidase 13 MMP13
matrix metallopeptidase 3 MMP3
matrix metalloproteinase 14 (membrane-inserted) MMP14
nidogen 1 NID1
periostin, osteoblast specific factor (predicted) POSTN
pleiotrophin PTN
procollagen, type vi, alpha 3 (predicted) COL6A3
procollagen, type xii, alpha 1 COL7A1
procollagen, type xv COL15A1
procollagen, type xvi, alpha 1 COL16A1
procollagen, type xxvii, alpha 1 COL27A1
sarcoglycan, alpha (dystrophin-associated glycoprotein) (predicted) SGCA
sarcoglycan, beta (dystrophin-associated glycoprotein) (predicted) SGCB
sarcoglycan, epsilon SGCE
secreted acidic cysteine rich glycoprotein SPARC
secreted phosphoprotein 1 SPP1
sialophorin SPN
similar to glypican 4 LOC317322
spondin 1 SPON1
superoxide dismutase 3, extracellular SOD3
tenascin c TNC
transforming growth factor, beta induced TGFBI
vascular endothelial growth factor a VEGF1  
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Cluster analysis of these GO terms reveals enriched biological themes associated with 
nucleotide binding (specifically RNA-associated) and cell junction molecules (TABLE 3.10 
and TABLE 3.11 respectively).  These data suggest that introduction of a gene on 
chromosome 11 may be responsible for the transcriptional regulation of genes with RNA 
binding motifs (RRM, TABLE 3.10).  Consistent with the flattened cellular morphology and 
contact inhibition that accompanies suppression of the neoplastic phenotype in CX4 MCH 
cells, there is an up-regulation of cellular adhesion/junction genes (TABLE 3.11) that may 
account for the restored ability of these suppressed cells to recognize and/or process 
extracellular stimuli for growth arrest.   
These analyses provide a statistically relevant indication of groups of genes which 
may be directly or indirectly causative or affected by introduction of human chromosome 11 
into the tumorigenic rat liver tumor cell line GN6TF.  In order to understand more directly 
the effects of SYT13 in this system, the short list of genes that follows strict differential 
expression guidelines in suppressed and non-suppressed cell lines (TABLE 3.5) was submitted 
to the DAVID Functional Annotation Tool.  Several gene ontology terms were statistically 
associated with the short list of genes that were 2-fold down-regulated in all aggressive (i5, 
i12, and GN6TF) cell lines versus suppressed (CX4 and SYT13s1) (TABLE 3.12).  Enriched 
themes in this table include development and differentiation, specifically the regulation of 
neurogenesis. No GO terms were associated with the 4 genes up-regulated in the aggressive 
cell lines.  This analysis suggests novel information regarding both the biological 
relevance/function of SYT13 as well as an indication on the potential mechanism of SYT13-
mediated tumor suppression through a re-establishment of target cell differentiation. 
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TABLE 3.9.  Gene ontology terms associated with genes up-regulated in the 
CX4 cell line relative to GN6TF 
Gene Ontology Term PValue
nucleus 2.5 x10-8
intracellular 1.4 x10-7
nuclear protein 2.7 x10-7
cell 1.1 x10-6
cell junction 1.2 x10-6
cell organization and biogenesis 2.2 x10-6
intercellular junction 2.5 x10-6
rna-binding 3.8 x10-6
intracellular signaling cascade 6.6 x10-6
cellular localization 7.3 x10-6
establishment of cellular localization 7.8 x10-6
intracellular transport 8.9 x10-6
cytoskeleton 1.1 x10-5
protein binding 2.0 x10-5
phosphorylation 2.8 x10-5
RNA-binding region RNP-1 (RNA recognition motif) 7.5 x10-5
apical part of cell 9.3 x10-5
organelle 1.0 x10-4
intracellular organelle 1.1 x10-4
cytoskeletal protein binding 1.2 x10-4
adherens junction 1.2 x10-4
protein amino acid dephosphorylation 1.4 x10-4
non-membrane-bound organelle 1.5 x10-4
intracellular non-membrane-bound organelle 1.5 x10-4
Nucleotide-binding, alpha-beta plait 1.5 x10-4
actin binding 1.5 x10-4
RRM domain 1.8 x10-4
dephosphorylation 2.1 x10-4
cell-cell adherens junction 2.4 x10-4
regulation of cellular physiological process 2.4 x10-4
regulation of biological process 2.4 x10-4
adherens junction 2.6 x10-4
transforming protein 2.7 x10-4
positive regulation of apoptosis 3.8 x10-4
tight junction 4.4 x10-4
positive regulation of programmed cell death 4.9 x10-4
focal adhesion 5.1 x10-4
regulation of physiological process 5.2 x10-4
programmed cell death 5.2 x10-4
cell death 6.0 x10-4
regulation of cellular process 6.3 x10-4
zinc-finger 6.4 x10-4
apicolateral plasma membrane 6.4 x10-4
apical junction complex 6.4 x10-4
proto-oncogene 6.8 x10-4
biopolymer metabolism 6.9 x10-4
mRNA processing 7.0 x10-4
establishment of protein localization 7.1 x10-4
apoptosis 7.4 x10-4
nucleic acid binding 7.5 x10-4
DNA binding 7.7 x10-4
GTP binding 8.0 x10-4
guanyl nucleotide binding 8.5 x10-4
death 9.7 x10-4
Tyrosine specific protein phosphatase 0.001
chromosome 0.001
protein transport 0.001
phosphoprotein phosphatase activity 0.001
actin filament binding 0.001
regulation of programmed cell death 0.001
small GTPase mediated signal transduction 0.001
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TABLE 3.10.  Genes increased >2-fold in CX4 cells compared to GN6TF 
associated with RNA-binding 
atp-dependent, rna helicase DDX52
cell division cycle 5-like CDC5L
cleavage and polyadenylation specific factor 6, 68kda CPSF6
cold inducible rna binding protein CIRBP
cytochrome p450, family 2, subfamily s, polypeptide 1 CYP2S1
cytotoxic granule-associated rna binding protein 1 TIA1
ddx5 gene DDX5
down syndrome critical region homolog 1 (human) DSCR1
elav (embryonic lethal, abnormal vision, drosophila)-like 2 (hu antigen b) ELAVL2
eukaryotic translation initiation factor 2, subunit 1 alpha EIF2S1
eukaryotic translation initiation factor 4b EIF4B
exportin 1, crm1 homolog (yeast) XPO1
fibrillarin FBL
fus interacting protein (serine-arginine rich) 1 FUSIP1
fusion (involved in t(12;16) in malignant liposarcoma) FUS
heterogeneous nuclear ribonucleoprotein a/b HNRPAB
heterogeneous nuclear ribonucleoprotein a1 HNRPA1
heterogeneous nuclear ribonucleoprotein a3 HNRPA3
heterogeneous nuclear ribonucleoprotein d-like HNRPDL
heterogeneous nuclear ribonucleoprotein k HNRPK
heterogeneous nuclear ribonucleoprotein r HNRPR
high density lipoprotein binding protein HDLBP
hla-b-associated transcript 1a BAT1A
hnrnp-associated with lethal yellow RALY
hypothetical gene supported by nm_173309 LOC497806
hypothetical gene supported by y16641 RGD1564920
hypothetical rna binding protein rgd1359713 RGD1359713
iron responsive element binding protein 2 IREB2
matrin 3 MATR3
nucleophosmin 1 NPM1
pai-1 mrna-binding protein PAIRBP1
paraspeckle protein 1 PSPC1
protein phosphatase 1, regulatory subunit 10 PPP1R10
ras-gtpase-activating protein sh3-domain binding protein G3BP
ribosomal protein l22 RPL22
rna binding motif protein 16 RBM16
rna binding motif protein 24 (predicted) RBM24
rna binding motif protein 27 (predicted) RBM27
rna binding motif protein 8 (predicted) RBM8
rna helicase DDX46
rna-binding region (rnp1, rrm) containing 2 RNPC2
siah binding protein 1;ribonucleoprotein-binding protein 1 SIAHBP1
signal recognition particle 54 SRP54
similar to 2810036l13rik protein (predicted) RGD1305861
similar to chromosome 20 open reading frame 6 RGD1306067
similar to dj862k6.2.2 (splicing factor, arginine/serine-rich 6 (srp55-2)(isoform 2)) LOC362264
similar to heterogeneous nuclear ribonucleoprotein a0 RGD1563684
similar to heterogeneous nuclear ribonucleoprotein g - human LOC302855
similar to hnrpa3 protein RGD1563768
similar to hnrpa3 protein RGD1562688
similar to igf-ii mrna-binding protein 2 (predicted) RGD1305614
similar to msx-2 interacting nuclear target protein RGD1564662
similar to riken cdna 1700025b16 (predicted) RGD1308015
similar to riken cdna 3110010f15 RGD1308378
similar to riken cdna g430041m01 RGD1562563
similar to rna binding motif protein 25 RGD1565486
similar to rna binding protein gene with multiple splicing RGD1561067
similar to rna-binding protein isoform g3bp-2a RGD1309571
similar to rna-binding protein musashi2-s RGD156039
small nuclear ribonucleoprotein polypeptides b and b1 SNRPB
splicing factor proline/glutamine rich (polypyrimidine tract binding protein associated) SFPQ
splicing factor, arginine/serine-rich 10 (transformer 2 homolog, drosophila) SFRS10
splicing factor, arginine/serine-rich 12 SFRS12
splicing factor, arginine/serine-rich 3 (srp20) (predicted) SFRS3
splicing factor, arginine/serine-rich 5 SFRS5
src associated in mitosis, 68 kda KHDRBS1
synaptojanin 1 SYNJ1
synaptotagmin binding, cytoplasmic rna interacting protein SYNCRIP
tho complex 1 THOC1
tial1 cytotoxic granule-associated rna binding protein-like 1 (mapped) TIAL1
vascular endothelial zinc finger 1 (predicted) VEZF1
zinc responsive protein zd7 LOC474154  
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TABLE 3.11.  Genes increased >2-fold in CX4 cells compared to GN6TF 
cells associated with cell adhesion. 
a disintegrin and metalloproteinase domain 15 (metargidin) ADAM15
afadin AF6
ahnak nucleoprotein (desmoyokin) AHNAK
ajuba homolog (xenopus laevis) JUB
angiomotin like 2 AMOTL2
ash1 (absent, small, or homeotic)-like (drosophila) (predicted) ASH1L
cadherin 1 CDH1
catenin (cadherin-associated protein), alpha 1, 102kda CATNA1
coxsackie virus and adenovirus receptor CXADR
desmoplakin DSP
dipeptidylpeptidase 4 DPP4
discs, large homolog 5 (drosophila) (predicted) DLG5
envoplakin (predicted) EVPL
fat tumor suppressor homolog (drosophila) FATH
filamin, beta (predicted) FLNB
gap junction membrane channel protein alpha 4 GJA4
gap junction membrane channel protein beta 3 GJB3
gap junction membrane channel protein beta 5 GJB5
junction plakoglobin JUP
junctional adhesion molecule 1 F11R
laminin, alpha 3 LAMA3
lim domain only protein 7 LMO7
myosin, heavy polypeptide 9 MYH9
p21 (cdkn1a)-activated kinase 1 PAK1
par-6 (partitioning defective 6) homolog beta (c. elegans) (predicted) PAR6B
parvin, alpha PARVA
plakophilin 1 (predicted) PKP1
plakophilin 2 PKP2
plakophilin 3 (predicted) PKP3
plakophilin 4 (predicted) PKP4
poliovirus receptor-related 2 (herpesvirus entry mediator b) PVRL2
procollagen, type xvii, alpha 1 (predicted) COL17A1
protein kinase c, zeta PRKCZ
protein kinase, lysine deficient 4 PRKWNK4
protocadherin 1 (cadherin-like 1) (predicted) PCDH1
similar to claudin-18a1.2 LOC315953
similar to hypothetical protein mgc33926 MGC94782
thiopurine methyltransferase TPMT
tight junction protein 1 (predicted) TIP1
tight junction protein 2 TIP2
tight junction protein 3 (predicted) TIP3
transforming growth factor beta 1 induced transcript 1 TGFB1I1
transglutaminase 1 TGM1
vinculin (predicted) VCL
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TABLE 3.12.  Gene ontology terms associated with genes down-regulated 
in SYT13i5, SYT13i12, and GN6TF compared to CX4 and SYT13s1 
Gene Ontology Term   PValue 
regulation of development   0.002 
signal   
regulation of axonogenesis   0.009 
response to external stimulus   0.011 
regulation of neurogenesis   0.013 
extracellular space   0.014 
signal peptide   0.022 
extracellular region   0.023 
positive regulation of development  0.025 
axon guidance   0.025 
cell differentiation   0.029 
positive regulation of biological process  0.030 
phospholipid binding   0.037 
wound healing   0.040 
axonogenesis   
0.003 
0.046 
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DISCUSSION 
IDENTIFICATION OF SYT13 AS A CANDIDATE 11P11.2 TUMOR SUPPRESSOR GENE 
The studies presented herein were initiated January of 2001, approximately one year 
after the first version of the annotated genome by the International Human Genome 
Sequencing Consortium was published in Nature (94).  By April of 2003, 50 years after the 
description of the double helix structure of DNA (95), 99% of the gene-containing portion of 
the human genome had been sequenced with 99.99% accuracy (96).  The resources provided 
by the Human Genome Project, including the placement of genes and ESTs on human 
chromosome 11, facilitated a candidate gene approach to identification of putative liver 
tumor suppressor genes using our MCH model system.  Synaptotagmin XIII was identified as 
the strongest candidate for the 11p11.2 tumor suppressor gene based on its differential 
expression among a panel of several suppressed and MCH cell lines.  Additional evidence 
that suggested SYT13 as a novel tumor suppressor gene was its apparent methylation-
dependent attenuation in several human HCC cell lines.  However, as far as we know, SYT13 
has been implicated as a tumor suppressor only by its differential expression in two genome-
wide expression analyses of colorectal (97) and pancreatic (84) neoplasms, and its biological 
functions are unknown.   
CHARACTERIZATION OF SYT13 AS A CANDIDATE TUMOR SUPPRESSOR GENE 
Subsequent to the identification of SYT13 as a strong candidate tumor suppressor 
gene, it was essential to characterize its involvement and function in suppression of the 
neoplastic phenotype of rat liver tumor cell lines in our model system.  A complementary 
approach was utilized to silence SYT13 in a suppressed MCH cell line and to introduce 
SYT13 into a rat liver tumor cell line.  Specific silencing of the SYT13 protein in CX4 cells 
resulted in significant alterations of both the suppressed phenotype in vitro (FIGURE 3.15) and 
the average latency of tumor formation in vivo (TABLE 3.3), suggesting that SYT13 is 
necessary for 11p11.2-mediated tumor suppression in the CX4 MCH cell line.  SYT13 was 
exogenously expressed in GN6TF tumor cells to determine if SYT13 could independently 
effect the same level of tumor suppression seen in the MCH cell lines in response to human 
11p11.2.  Tumorigenicity was significantly reduced in transfected cell lines that expressed 
the dimeric form of SYT13 (TABLE 3.4).  The summation of these studies revealed that 
SYT13 is both necessary and sufficient for human chromosome 11p11.2-mediated 
suppression of tumorigenicity in GN6TF tumor cells.   
The current investigation has characterized several tumor-suppressive functions of 
SYT13, including (i) normalization of tumor cell morphology, (ii) restoration of contact 
inhibition, (iii) reestablishment of anchorage-dependent growth, and (iv) suppression of 
tumorigenic potential in vivo.  However, other functional characteristics ascribed to classic 
tumor suppressor genes have not been directly evaluated.  Thus, it remains to be determined 
if SYT13 possesses additional tumor suppressor functions.  Other measurable down-stream 
effects attributed to specific tumor suppressor genes (in culture and/or in vivo) include 
regulation of cellular proliferation/cell-cycle progression, inhibition of cell invasion and 
migration, reestablishment of tumor cell mortality, and restoration of sensitivity to pro-
apoptotic stimuli, among others (98).  Although not measured in the SYT13-transfected cells 
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described here, the potential effects of SYT13 on some of these characteristics can be 
extrapolated from previous studies and general observation.  Population doubling times for 
suppressed GN6TF-derived MCH cell lines were not significantly affected by introduction of 
human chromosome 11 (40).  Therefore, given that the suppressive effects of human 
chromosome 11 are SYT13-mediated, we can infer that SYT13 has minimal or no effect on 
the regulation of cellular proliferation or cell cycle control as they impact on the kinetics of 
cellular proliferation.  Likewise, neither the suppressed MCH cell lines nor the SYT13-
transfected cell lines senesce in culture.  Thus, SYT13-mediated tumor suppression des not 
simply reflect a reestablishment of cellular mortality.  Further, no appreciable level of 
apoptosis occurs in SYT13-expressing cells growing in culture at various densities, 
suggesting that direct induction of apoptosis is not a downstream effect of SYT13.  The 
abilities of SYT13-negative and SYT13-positive cells to invade and migrate in vitro were not 
measured.  Complete characterization of the tumor suppressor functions of SYT13 will 
require further investigation of these (and possibly other) tumor suppressive functions. 
THE SYNAPTOTAGMIN PROTEIN FAMILY 
Synaptotagmins are a family of membrane-associated synaptic vesicle transport 
proteins which largely serve as Ca2+ sensors in vesicular trafficking and exocytosis (78, 99).  
SYT1 was the first identified and most well characterized (100) and 14 other family members 
have been identified based on similar structural characteristics.  All synaptotagmins display 
type I membrane topology with a single transmembrane region (TMR) of varying lengths and 
two distinct tandem C2 domains (C2A and C2B) in the cytoplasmic C terminus (101).  The 
C2 domain forms an eight-stranded beta sandwich around a 4-stranded motif (101).  
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Common functions among synaptotagmin family members are calcium-dependent 
phospholipid binding in vesicle transport and calcium-independent binding to target SNARE 
(tSNARE) heterodimers during calcium-triggered membrane fusion (102).   
Synaptotagmin XIII is an atypical synaptotagmin (78, 79).  Perhaps the most 
conserved function across the protein family is calcium-independent binding to tSNARE 
heterodimers during membrane fusion, and SYT13 is one of the only two synaptotagmins 
(along with SYT12) that do not bind to this complex (102).  Additionally, SYT13 lacks the 
calcium-dependent phospholipid binding properties conserved in several of the family 
members.  The disparity between the functional roles of SYT13 and its family members most 
likely reflects the atypical characteristics of the SYT13 protein.  It displays less than 35% 
sequence similarity (at the amino acid level) with its closest relative among synaptotagmin 
family members, SYT1 (FIGURE 4.1).  SYT13 lacks an N-terminal intravesicular 
(extracellular) sequence that precedes the TMR, and the linker region between the TMR and 
first C2 domain is much longer in SYT13 than in any other synaptotagmin.  This proline-rich 
linker in SYT13 contains conserved PxxP motifs which von Poser et al. predict may be SH3-
domain binding regions (79).  In addition, the calcium-binding residues common in most 
synaptotagmins are not conserved in SYT13 (78, 79) which accounts for the absence of 
calcium-dependent functions.  Even the features that distinguish this synaptotagmin as such 
(the TMR, connecting sequence, C2A and C2B domains) are dissimilar from SYT1 (30%, 
0.0%, 22.7%, and 34.5% identity respectively) at the amino acid level (79). 
Possibly the most informative comparisons between SYT13 and typical 
synaptotagmin family members are the properties that are selectively conserved.  The C2B 
domains of synaptotagmins differ from C2A domains by a C-terminal sequence that 
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corresponds to an extra α-helix (FIGURE 4.1) (103).  Despite the lack of calcium binding sites 
and the absence of the calcium-dependent phospholipid binding properties of SYT13, it 
retains this differentiating α-helix at the end of the C2B domain (FIGURE 4.1) (79).  The 
function of this secondary structure is not fully understood, but is likely responsible for 
several of the calcium–independent functions of the C2B domain (103).  An additionally 
conserved feature among all synaptotagmins is the size of the linker sequence between the 
two C2 domains (6-7 amino acid residues) (FIGURE 4.1) (79), which suggests that the tertiary 
structure of the tandem C2 domains (C2A-linker-C2B) may be important for the conserved 
function of synaptotagmins.  SYT13 also retains the WHXL motif found at the C-terminus of 
all synaptotagmins (FIGURE 4.1).  This sequence is responsible for association with neurexins 
and the docking of vesicles to plasma membranes (104).  Neurexins are structural cell 
adhesion molecules and plasma membrane receptors that are responsible for cell recognition, 
axonal guidance, and epithelial cell polarity (105).  While describing SYT13 in mouse, 
Fukuda and Mikoshiba confirmed an association between SYT13 and neurexin 1α (78).  
Finally, a conserved cluster of cysteine residues reside at the cytoplasmic border between the 
TMR and the linker sequence of most synaptotagmins, including SYT13 (FIGURE 4.1).  
These cysteine residues are palmitoylated and are essential for SDS-resistant oligomerization 
of synaptotagmins (80).  This fatty acylation and subsequent oligomerization is critical for 
calcium-independent association with the plasma membrane which is necessary for several of 
the synaptotagmin functions (106). 
Temporal and spatial bio-availability of SYT13 has been, for the most part, 
determined by mRNA analysis.  A multiple tissue northern blot analysis performed by von 
Poser and Südhof found expression of a single species in rat brain (highest expression), 
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spleen, kidney, and testis (79).  Fukuda and Mikoshiba used RT-PCR to identify mRNA 
expression in mouse heart, brain, spleen, lung, skeletal muscle, kidney and testis (highest in 
brain, lung, and testis) (78).  Additionally, they found expression to peak on embryonic day 7  
of mouse development (78).  A genome wide expression analysis of normal human tissue 
provided by GeneNote (http://bioinfo2.weizmann.ac.il/cgi-bin/genenote/home_page.pl) 
found the highest expression of SYT13 in brain, spinal cord, heart, pancreas, prostate, and 
kidney (107).   However, several lines of evidence suggest that mRNA expression is an 
inappropriate measure of SYT13 protein expression, and that the expression of the protein 
may be regulated post-transcriptionally.  von Poser and Südhof used a polyclonal antibody 
raised to recombinant C2-domains from SYT13 in rat brain homogenates and subcellular 
fractions from rat brains and failed to detect a protein band of the appropriate size (79).  
Another indication of the inappropriate use of mRNA detection for measuring SYT13 protein 
production is the discrepancy of tissue-specific expression between human, mouse, and rat in 
these afore mentioned studies (78, 79, 107).  A study that compared a genomic and proteomic 
approach to identifying genes and proteins differentially secreted between cancerous and 
normal pancreatic cells showed a lack of correlation between SYT13 and the corresponding 
protein (84).  In fact, they found a correlation coefficient (r) of 0.28 between proteomic and 
transcriptomic studies (84).  Finally, the protein recognized by the polyclonal antibody 
utilized in these studies (for both silencing and transfection of SYT13) did not correlate with 
mRNA expression (FIGURES 3.11, 3.12 and 3.17), adding significantly to the argument that 
SYT13 protein expression is regulated at the posttranscriptional level.   
The human SYT13 gene is composed of 6 coding exons and 5 gt-ag introns distributed 
over 42 kb of genomic DNA [FIGURE 4.1; (79) and AceView 
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(http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly/index.html; (108)].  The complete 
coding sequence mRNA is 5,265 bp long.  The 3’ UTR contains 3,874 bp—among 5% of the 
longest 3’ UTRs recorded (AceView).  There appears to be no splice variants of the SYT13 
gene (AceView).  SYT13 homologs have been confirmed in P. troglodytes, C. familiaris, M. 
musculus, R. norvegicus, and G. gallus (NCBI).  The long 3’ UTR is conserved in each of 
these homologs, and is likely important for a conserved regulatory function which has not yet 
been elucidated.  
KNOWN AND INFERRED FUNCTIONS OF SYT13 
We are the first to functionally characterize SYT13 as a tumor suppressor gene.  The 
tumorigenic rat liver cell line GN6TF expresses both the endogenous Syt13 mRNA and 
protein (FIGURES 3.11 AND 3.12).  However, we have clearly shown that exogenous 
expression of human SYT13 is able to suppress the tumorigenic phenotype of this cell line.  
Specifically, suppression is rigorously associated with the expression of the SDS-resistant 
dimeric form of the protein.  Despite the presence of the endogenous protein and transcript, 
the suppressive dimeric species is not detected in GN6TF cells (FIGURES 3.11 and 3.17), nor 
is it detected in tumorigenic SYT13-transfected cell lines (FIGURE 3.17).  This strongly 
suggests that the suppressive function of SYT13 is restricted to the dimeric form of the 
protein.  It is known that the SDS-resistant, calcium-independent oligomerization of 
synaptotagmins is mediated by palmitoylation of the cysteine residues that cluster at the 
carboxyl-terminus of the TMR (80).  This fatty acylation and dimerization is critical for the 
calcium-independent membrane association of many synaptotagmins (80).  It is unclear if the 
structure of the dimeric form of the protein itself is critical for tumor suppressor function or if 
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its membrane localization is important for its downstream effects.  Nonetheless, these data 
provide strong evidence for a tumor suppressive function of the SYT13 dimer. 
Several additional studies have characterized functional properties of the SYT13 
protein.  These studies have identified calcium independent association of the C2B with 
phospholipids (78) and the absence of calcium-mediated association of the C2A domain with 
phospholipids (78).  Additionally, the role of vesicle trafficking has been attributed to SYT13 
based on its (i) multiple tissue expression, (ii) peri-nuclear compartmentalization 
(presumably in the Golgi), (iii) docking with the membrane receptor neurexin, and (iv) 
punctate cytosolic staining, apparently indicating transport from the Golgi to the plasma 
membrane (78).  Additional resources outline proposed or inferred biological functions of 
SYT13.  The GO biological process terms associated with SYT13 by the Gene Ontology 
Consortium [www.geneontology.org, (109)] are “transport” and “vesicle-mediated 
transport.”  However the evidence for these terms is “ISS” (inferred from sequence 
similarity) which is a code for predictions based on sequence alignment, structure 
comparison, or evaluation of sequence features such as composition 
(www.geneontology.org).   
Another potential source for information about the function of SYT13 is from 
deletion analyses in other diseases states.  Recent studies provide evidence that SYT13 may 
have other diseases implications.  Potocki-Shaffer syndrome (PSS) is a contiguous gene 
syndrome that results from haploinsufficiency of at least two genes on human chromosome 
11p11.2 (ALX4 and EXT2) and can manifest in multiple congenital anomalies and mental 
retardation (OMIM #601224; NCBI).  Wakui et al. constructed a panel of 11p11.2 deletions 
in several of these patients to identify 11p11.2 genes that are responsible for specific disease 
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traits (110).  They identified a 1.1 Mbp region (D11S554-D11S1385) that was necessarily 
deleted for the impaired cognitive function/mental retardation phenotype in the patients.  
These results were later confirmed by another group in a 3-generation patient subset lacking 
the mental retardation phenotype (111).  This region contains nine genes (including SYT13), 
and considering the implication for a neuronal development function of SYT13 in our 
microarray study (TABLE 3.9), it is a very likely candidate for the mental retardation 
phenotype seen in Potocki-Shaffer syndrome.   
Inferences of biological function may also be made by analyzing available microarray 
data which has identified differential expression of the SYT13 in various experimental 
settings (although it is important to recall that SYT13 mRNA and protein levels do not 
necessarily correlate).  TABLE 4.1 outlines several studies in which differential expression of 
SYT13 has been documented.  The studies presented in this table reiterate a potential function 
for SYT13 in neuronal development and differentiation (112-115), suggest different 
transcription factors and repressors that may be important in SYT13 regulation (116-118), and 
implicate loss of SYT13 in the progression of colorectal and pancreatic neoplasia (97, 119).   
Considering the variety of biological implications for SYT13 inferred from sequence 
similarity to other synaptotagmins, functional properties of the protein product, electronic 
annotation, and differential expression in various experimental settings, it will be essential to 
complete additional functional studies, similar to the ones presented here, to grasp a better 
understanding of the conserved biological functions of SYT13 in both disease and normal 
physiology.  The studies herein appear to be the first and only studies to experimentally 
describe a biological function for SYT13, the function of a tumor suppressor gene.   
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TABLE 4.1.  Differential expression of SYT13 in various experimental settings. 
Tissue SYT13 Context Implication Reference 
murine tissue  highly expressed in a pool of 10 
nervous tissues compared to a pool 
of 72 peripheral tissues 
representing 30 organs 
although SYT13 is expressed in various tissues, its 
expression may be enriched in the neural system 
(120) 
cultured murine airway 
smooth muscle cells 
decreased in cells with persistant 
β-adrenergic receptor signaling 
compared to wild type 
SYT13 may be regulated by receptor signaling (121) 
rat inner ear elevated in rat vestibular inner ear 
hair cells compared to adjacent 
supporting hair cells 
SYT13 may be involved in the differentiation of 
these cell types or contribute to the different 
functions 
(112) 
murine pancreas decreased in transcription factor 
Ngn3-deficient pancreatic tissue 
compared to wild type  
SYT13 may be directly or indirectly regulated by 
Ngn3—a transcription factor required for 
differentiation of pancreatic endocrine (vs. 
exocrine) cells  
(118) 
neuronally 
differentiated PC12 
cells 
elevated in ceramide-dependent 
apoptosis 
may be directly or indirectly be regulated by 
ceramide-dependent signaling and/or involved in 
apoptosis 
(122) 
murine primary visual 
cortex 
increased in dark rearing animals 
(DR) vs normal reared 
(i) may be important in aspects of activity-
dependent plasticity in the visual cortex (ii) may 
be regulated by enriched CREB pathway in DR 
(114) 
rat pancreas (i) decreased in fatty rat islets 
overexpressing SREBP-1c (ZDF) 
compared to lean controls (ii) 
increased in both ZDF and 
controls after treatment with 
dominant negative SREBP-1c 
SREBP may regulate SYT13 expression even 
under basal conditions 
(117) 
cultured human 
pancreatic ductal 
adenocarcinoma and 
non-neoplastic human 
pancreatic duct 
epithelial cell line 
(i) decreased in pancreatic cancer 
secretome compared to normal (ii) 
protein is down, but transcript is 
not detected on microarray (iii) 
correlation coefficient of 0.28 
between proteomic data and 
transcriptomic data 
(i) SYT13 may be directly or indirectly involved 
in tumor suppression (ii) SYT13 protein and 
transcript do not necessarily correlate (iii) 
genomic microarray data may not always identify 
important and relevant proteins 
(84) 
PC12 cells (i) SYT13 contains a cAMP 
response element that associates 
with the transcription factor CREB 
which regulates differentiation, 
survival, and synaptic plasticity 
(ii) elevated expression in 
response to forskolin stimulation 
(i) may be a CREB transcriptional target (ii) may 
be a cAMP-regulated gene  
(116) 
human colorectal 
carcinoma 
decreased in lyphatically 
metastasized compared to locally 
restricted colorectal carcinoma 
may be important for suppression of the invasive 
and metastatic progression of colorectal 
carcinoma 
(97) 
human brain increased in the brain of suicide 
victims and depressed suicide 
victims compared to 
psychiatrically normal controls 
SYT13 may be involved in the neurobiology and 
predisposition to suicide 
(123) 
rat lung elevated expression in adult rat 
lung tissue compared to both fetal 
and newborn lung 
may be important of normal lung function in 
adulthood 
(124) 
murine retinal ganglion 
cell 
down when the transcription factor 
Brn3b is deleted compared to wild 
type 
may be involved in establishment of axonal 
cytoskeletal network and axon guidance 
(113) 
human prostate cancer elevated in small-cell 
neuroendocrine carcinoma 
compared to prostate 
adenocarcinoma 
reflects the neuroendocrine origin of prostate 
small cell carcinoma 
(119) 
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POTENTIAL MECHANISMS OF SYT13-MEDIATEDTUMOR SUPPRESSION 
Our previous studies have implicated the induction of Wt1 in human chromosome 
11p11.2-mediated tumor suppression, and studies presented here further characterize the 
putative association between Wt1 expression and SYT13-mediated tumor suppression.  
Additional evidence used to delineate potential mechanisms of tumor suppression includes 
information generated by microarray analysis and comparisons between the phenotypic 
characteristics of aggressive SYT13-dimer-negative and suppressed SYT13-dimer-positive 
cell lines.  Coordinate with SYT13 expression in GN6TF tumor cells, we have observed:  an 
induction of Wt1 (FIGURE 3.18); the morphological organization of a polarized, contact-
inhibited epithelial sheet (FIGURE 3.19); the establishment of contact inhibition (FIGURE 
3.20); decreased expression of several genes associated with both the extracellular matrix and 
cholesterol/mevalonate biosynthesis (TABLE 3.7 AND TABLE 3.8); and elevated expression of 
genes associated both with development/differentiation and cellular adhesion (TABLE 3.5 AND 
TABLE 3.11).  A potential link between several or all of these observations is the phenotypic 
and functional differences between the mesenchymal and epithelial cell type, and the 
requirements and manifestations of a physiological switch (transdifferentiation) between the 
two.   
WT1 is a tumor suppressor gene implicated in hereditary and sporadic Wilms’ tumor 
and is required for normal renal development.  Based on several observations, including the 
temporal-spatial expression of Wt1 during renal development (125) and the correlation of 
Wt1 expression with the degree of epithelial differentiation of Wilm’s tumor (126), Wt1 has 
been implicated in mesenchymal-epithelial transition (MET, a process important in cellular 
differentiation and development) in both disease and normal states (127).  Luo et al. showed 
 118
that WT1 could slow the growth of both non-transformed and ras-transformed NIH3T3 
fibroblasts, and cells expressing WT1 were characterized by a flattened morphology (128).  
The group later demonstrated the ability of WT1 to induce features of epithelial 
differentiation in a mesenchymal cell line (127).  MET is characterized by changes in various 
markers including a flattened, contact inhibited cellular morphology; a decrease in 
extracellular matrix proteins; and an increase in cellular adhesion molecules.  Consistent with 
the WT1-associated induction of MET, our studies demonstrate a coordinate expression of 
Wt1 with the expression of an epithelioid cellular morphology (FIGURE 3.19), a reduction of 
several extracellular matrix proteins (TABLE 3.7), and an increase in cellular adhesion 
molecules (TABLE 3.11).  The adhesion molecule E-cadherin (CDH1) is an epithelial marker 
and tumor suppressor gene important in the maintenance of epithelial intracellular contact.  
Because CDH1 is absent in mesenchymal cells and consistently activated in MET events, 
CDH1 expression is commonly measured to identify the differentiation of cells from a 
mesenchymal to epithelial phenotype and signal MET.  WT1 directly transactivates CDH1 
through a WT1-response element in the promoter (129).  Consistent with this, our microarray 
data demonstrate an 84-fold increase in Cdh1 expression in CX4 cells compared to GN6TF 
cells (FIGURE 3.25.A).  Cdh1 levels were also measured in SYT13-transfected cell lines 
(FIGURE 3.25.B).  Expression levels of Cdh1 in the tumor suppressed and morphologically 
normal cell lines that express the SYT13 dimeric species (and Wt1) (C2, E2, F3, and J1) were 
greater than 100-fold elevated compared to GN6TF (FIGURE 3.25.B).  Furthermore, 
microarry data presented here (TABLE 3.12) and generated in additional studies [TABLE 4.1 
(112-115) and (110, 111)] suggest a role for SYT13 in development and cellular 
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differentiation, consistent with the idea that SYT13, directly or indirectly through induction 
of WT1, may be involved mesenchymal to epithelial differentiation.   
Another putative target of the WT1 transcription factor is the cholesterol/fatty acid 
synthetic pathways (130).  A study which analyzed complementary overlap of genes which 
were differentially expressed in WT1-transfected and WT1-silenced cells identified this 
pathway as a target.  Specifically, differential expression of IDI1, LSS, FDFT1, and FDPS 
was observed between WT1-positive and WT1-negative cells (130), and each of these genes 
(except LSS which was not measured) were similarly attenuated coordinate with increased 
Wt1 expression in CX4 cells (FIGURE 3.26). The group additionally provided evidence that 
the effects of WT1 were mediated by modifying (through protein-protein interaction) the 
transcriptional function of sterol responsive element-binding proteins (SREBPs), the proteins 
directly responsible for transcriptionally regulating the cholesterol biosynthesis pathway 
(130).  It is interesting to note that another group has found that SYT13 mRNA expression is 
affected by alterations in SREBP-1c function [TABLE 4.1, (117)]. 
Because our studies have provided supplementary evidence to suggest a role for WT1 
in the regulation of the cholesterol/mevalonate biosynthesis pathway, it is important to 
appreciate how this pathway may be important in both carcinogenesis and MET.  The 
mevalonate pathway generates prenyl intermediates that are essential for the biological 
activity of signal transducing proteins, especially those of the Ras superfamily.  These 
moieties covalently bind to ras and anchor it to the cell membrane where it is acted upon by 
surface receptors.  Ras then transduces signals inside the cell to affect cytoskeleton 
organization, cell proliferation, and apoptosis (92, 131).  Thus, aberrant expression of the 
mevalonate biosynthesis pathway corresponds to increased transforming activity of the ras 
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proto-oncogene.  Another specific function of ras activation that may be important in SYT13-
mediated effects is down-regulation of a prostate apoptosis response gene (Par4) through 
promoter hypermethylation (132).  Not only is Par4 a tumor suppressor gene via its pro-
apoptotic functions, but it also modulates both the transcriptional and growth suppression 
functions of WT1 (133).  Consistent with aberrant mevalonate synthesis inhibiting Par4 (and 
by extrapolation from our data, elevated in cells expressing SYT13), mRNA levels were 
increased 7-fold by microarray or 30-fold by real-time RT-PCR in CX4 cells compared to 
GN6TF (FIGURES 3.25.C and D ), and were also increased at least 10-fold in cells positive for 
the SYT13 dimer and Wt1 (FIGURE 3.25.D).  Another downstream effect of ras activation is 
induction of the powerful CDH1 repressor Snail (134).  Snail binds to E-boxes in the 
promoter of CDH1 and represses its transcription (135).  Thus, it is directly involved in 
epithelial to mesenchymal transition (EMT) which is essential for embryonic development 
and implicated in the progression of locally restricted cancers to metastatic disease (136).  
Snail mRNA expression was decreased >4-fold the suppressed CX4 cell line compared to 
GN6TF cells (FIGURE 3.25 E and F), and in each of the SYT13-transfected, dimer-positive 
cells (C2, E2, F3, and J1), Snail expression is decreased nearly 50% (FIGURE 3.25.F).  These 
studies combine to suggest a pathway through which Wt1 may be effecting MET and tumor 
suppression in this experimental system. 
The studies presented here suggest that the dimeric species of SYT13 is able to 
suppress the tumorigenic phenotype of GN6TF and induce differentiation of GN6TF cells to 
a normalized epithelial phenotype.  The mechanisms of SYT13-mediated tumor suppression 
have not been directly assessed.  However, several lines of evidence suggest different 
pathways/targets which may be directly or indirectly involved in this process.  FIGURE 4.2 
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SYT13
???
Tumorigenic
Wt1
Mevalonate Pathway
Ras
SnailPar4/Pawr
Wt1
Dysregulated apoptosis 
and  cell cycle 
progression: 
uncontrolled 
proliferation
prenylation
E-Cadherin
Suppressed  
FIGURE 4.2.  Potential mechanisms of SYT13-mediated tumor suppression.  Several genes 
implicated in SYT13-mediated tumor suppression are shown.  Genes in pink represent 
genes whose induction correspond to tumor suppression and epithelial differentiation, and in 
red are genes whose induction would promote a mesenchymal/tumorigenic phenotype.  
Question marks represent unknown pathways or mechanisms for regulation of expression. 
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illustrates several of the targets which have been implicated in SYT13-mediated tumor 
suppression. 
POTENTIAL MECHANISMS OF SYT13 INACTIVATION 
Several mechanisms of tumor suppressor gene inactivation have been recognized that 
contribute to neoplastic transformation of normal cells.  These include gene deletion, 
mutation, epigenetic silencing, post-transcriptional modification, or post-translational 
modifications of tumor suppressor proteins (98).  All of these mechanisms lead to loss of 
tumor suppressor function.  The mechanism(s) of SYT13 inactivation is (are) not known, but 
various lines of evidence suggest potential mechanisms which could be experimentally 
examined.  Mutation and/or deletion of a tumor suppressor gene represent potent 
mechanisms of inactivation.  Given that SYT13 has not been identified as a tumor suppressor 
gene through familial susceptibility segregation or otherwise detected in linkage and 
comparative genomic hybridization analyses, it is unlikely that SYT13 is inactivated by these 
mechanisms in a significant subset of cancers.  We have shown the potential for 5-aza-
mediated induction of SYT13 in HCC cell lines, suggesting that epigenetic regulation 
(specifically promoter hypermethylation) may directly or indirectly be responsible for gene 
inactivation in a subset of cancers.  But considering the powerful suppressive ability of 
SYT13 in GN6TF tumor cells and the variety of microarray-based expression analyses 
available for all tumor types, it is conspicuous that SYT13 has been implicated as a tumor 
suppressor-like gene in only two of these array-based experiments (84, 137).  Importantly, 
one of these studies identified SYT13 through a proteomic approach and failed to implicate 
SYT13 (mRNA) on their corresponding gene expression array (84).  This corroborates the 
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studies presented here that fail to find a correlation between SYT13 mRNA and the SYT13 
protein.  This observation is important because (i) it argues against the disqualification of 
SYT13 as a tumor suppressor gene based on its lack of differential mRNA expression in 
normal compared to neoplastic tissue, and (ii) it suggests that the inactivation of SYT13 
tumor suppressive function is regulated post-transcriptionally.   
A number of post-transcriptional mechanisms of gene inactivation might affect SYT13 
regulation and expression.  Interesting and perhaps relevant to SYT13 expression is the post-
transcriptional silencing mediated by microRNAs (miRNAs).  These non-coding mRNA 
transcripts form hairpin structures which hybridize to native mRNA (typically in the 3’ 
UTR).  Distinct from mechanisms of siRNA-mediated silencing, these molecules do not 
direct cleavage of target mRNA.  Rather miRNAs direct sequestration of mRNA away from 
translational machinery resulting in an inhibition of protein synthesis (82).  Several miRNAs 
have been implicated the progression of cancer (138, 139).  The evolutionarily conserved 3’ 
UTR of SYT13 is among the longest recognized in the human genome, strongly implicating 
this region in SYT13 regulation.  Additionally, temporal and spatial specificity of miRNA 
expression is important for gene regulation during differentiation and development (140).  
Since SYT13 has been implicated in development, miRNA expression may provide a 
mechanism by which SYT13 may be regulated during these events.  It is also been shown the 
viruses are capable of producing miRNAs that work in trans to manipulate expression of 
proteins in the host (141).  This is intriguing (i) because HCV and HBV are important 
etiologic factors for HCC and (ii) a BLAST search between SYT13 and the HCV genome 
reveals several instances of sequence homology (FIGURE 4.3).  A search for miRNA targets 
in SYT13 using the miRBASE Target Database (http://microrna.sanger.ac.uk) identified at 
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GGGAAGGTGAGCGGCTGCGGGACCCAGCCCCTCGCCGGGAGCGGGCACCATGGTGCTGTCGGTGCCTGTGATCGCGCTGGGCGCCACGCTGGGCACAGCCACCAGCATCCTCGCGTTGTGCGGGGTCACCTGCCTGTGTC 
GGCACATGCACCCCAAGAAGGGGCTGCTGCCGCGGGACCAGGACCCCGACCTGGAGAAGGCGAAGCCCAGCTTGCTCGGGTCTGCACAACAGTTCAATGTTAAAAAGTCCACGGAACCTGTTCAGCCCCGTGCCCTCCTC 
AAGTTCCCAGACATCTATGGACCCAGGCCAGCTGTGACGGCTCCAGAGGTCATCAACTATGCAGACTATTCACTGAGGTCTACGGAGGAGCCCACTGCACCTGCCAGCCCCCAACCCCCGAATGACAGTCGCCTCAAGAG 
GCAGGTCACAGAGGAGCTGTTCATCCTCCCTCAGAATGGTGTGGTGGAGGATGTCTGTGTCATGGAGACCTGGAACCCAGAGAAGGCTGCCAGTTGGAACCAGGCCCCCAAACTCCACTACTGCCTGGACTATGACTGTC 
AGAAGGCAGAATTGTTTGTGACTCGCCTGGAAGCTGTGACCAGCAACCACGACGGAGGCTGTGACTGCTACGTCCAAGGGAGTGTGGCCAATAGGACCGGCTCTGTGGAGGCTCAGACAGCCCTAAAGAAGCGGCAGCTG 
CACACCACCTGGGAGGAGGGCCTGGTGCTCCCCCTGGCGGAGGAGGAGCTCCCCACAGCCACCCTGACGCTGACCTTGAGGACCTGCGACCGCTTCTCCCGTCACAGCGTGGCCGGGGAGCTCCGCCTGGGCCTGGACGG 
GACATCTGTGCCTCTAGGGGCTGCCCAGTGGGGCGAGCTGAAGACTTCAGCGAAGGAGCCATCTGCAGGAGCTGGAGAGGTCCTACTATCCATCAGCTACCTCCCGGCTGCCAACCGCCTCCTGGTGGTGCTGATTAAAG 
CCAAGAACCTCCACTCTAACCAGTCCAAGGAGCTCCTGGGGAAGGATGTCTCTGTCAAGGTGACCTTGAAGCACCAGGCTCGGAAGCTGAAGAAGAAGCAGACTAAACGAGCTAAGCACAAGATCAACCCCGTGTGGAAC 
GAGATGATCATGTTTGAGCTGCCTGACGACCTGCTGCAGGCCTCCAGTGTGGAGCTGGAAGTGCTGGGCCAGGACGATTCAGGGCAGAGCTGTGCGCTTGGCCACTGCAGCCTGGGCCTGCACACCTCGGGCTCTGAGCG 
CAGCCACTGGGAGGAGATGCTCAAAAACCCTCGCCGGCAGATTGCCATGTGGCACCAGCTGCACCTGTAACCAGCTGCCCAGCTGCCTCCCTTCTTGGACAGCCCTGACCCGTCCTCTGCAACCTCCTTTCTGTGCCCCT 
TTCCTCATTCTGACACCCAGAAGACAGTGACAGATGTGTTTGCAAGGCTGGGATGGCTCTCTCATCATACTCTTGTTTCTTAGAAATAAGCAAGACAGAGCAGGAAATGGAATATGCGGGTCACACTGAGGAATGCATTT 
TGCTCATCTGTGTTATTGAAGGAGGTGCTTATTAAATACAGTTCCTATGCCTGTTTTATAGGTGGGGTTAGGCCAGATGCAGAGAAAGCTAAATGTGGGAATCATGGATGCAAAGAAGAATTTGGCTTTTTGAAAAACAA 
GCATTTCAAAAATGATGAAGGAAGTGAAAGTATCCTGGATCAACTCCTAGAGTTAGAGATTGCCCAGGTGGAAAGAAACCTTAGCCAGCGTTCAATCAAGCTCACCATGCAGGGCAGTCACCCGGCAGTTCTCAAACTTT 
AGCATGTGAAGAGTCACCAGCAGATTCCTGGGCTCGCCTGGAGACATTCCTAGTCGGTATTCCTGGTCGAAGCCCAGGAGCCTTCCTTTTTAACAAGCTGATGTAGAGGGTGGAGCACTGTATGTGGAGAAATTCCTTCT 
ACAATATTCCACACAGGTTTTTGGCCACAGTCCTTGATGGAGTCCCAAAACCATGGTGCAGCCAGTTCCAATGCTGGACACCTCAACCATCAGGGTGAAATCTGGGGCCTCAGCTTTTTAATTTAATTATTTTAATTCTT 
AATACTTTAATTTGTGCATTTCATAAGCCCCCTGCTCTTGGACTGAATTTTGTGCTTTTTATTGAAGAATTTTATTGTTTTTATCTTAAAATCAGTTTCTATTATCCTTGGGGAGACCATCCCTAACAAAGTACAGGTGG 
GATCTCCTGTGAGTCATTGGCTGGGTTCTGATTGCTAGATGTCACACCCACCAGCATCACCAAAGTGACTCTGAGATAGACCGGTCCCTTCTCAGCGTTCCAGTCACTTCAGGAGGAATTTAGTTATTGACTTAGTCTAT 
GACATCTGGCTACATGTAGGTAGAGAAGAAAGACAATTTTAAAAAGGAAATCAGGTCTTTTGCAACTGTGCCTCCCTCTGTCTGTTTTCACTTGAATGGGTAAATAACCAGCAGCTAGGTTTTGAATTCCTACCTTGTTA 
TTCTAAACAGATGTCCACATTGTTAATTAAATCTAAATTATGAGCCTTGCTGAGTGGATACGGTACTTACACCTGAACCAGGATTCCTGGGTTCTGTTGTTGACATTGCCCTTCAGCACCTGTTTGGCCAGCTGTATAAG 
ATAGGACTAATGACTAGGAAGCCTACCCCAATGAATGATATACTAGATGAAATAGTGTTCAAAACCTGTAGGCACTCTCTGGCTAAAAACAAACTCTGAGGCCACCAGCAGATCATCTTTAAGCTAAGTTACTATTTTTC 
ACCTTTTTTTTTAGACGGAGTTTTGCTCTTTGTTGCCCAGGCTGGAGTGCAGTGGCACGATCTCGGCTCACTGCAACCTCCGCCTCCCAAGTTCAAGCGATTCTCCTGTCTCAGCCTCCTGGGTAGCTGGGATTACAGGT 
GCCCACCAACATGCCTGGCTAATTTTTGTACTTTTAGTAGAGATGGGGTTTCACCATGTTGGCCAGGCTGGTCTTCAACTCCAGATCTCAGGTGATCTACCCTCCTCGGCCTCCCAAAGTACTGGGATTACAGGCCTGAG 
CCACCGCGCCCGGCCTATTTTTCACTTTAATTTGGCAGCTGAGAATGCCCAAAAAGTGCCAGAAGCATCGTGGCATTTCCAGAACCATGGATTCTGCCTTTGGACCCCTCTCTATTAATATTAAAACTCTGGGCCTTCAG 
ATGTCACCCTAATCCACTGCCCTAAGACAGAATTTCTGGACAAGATGGGTAAGGGCTTCATTCCTTCAACAAGTCAAGTCATACTTGGCCTCTCCCTGAGAATCTGAGCAGGAGCCTTATAACCTGTGGTCATTATTTTT 
TCTTTCTGTACAGAAATAGAAAAGCATTAGAAATAACTTCTAACCATCCTCTGAAAAAACAGAAAAAATATCGAATCCCTCTTTCATGAGAAGTCTTTTGGATAATTGGAAACCTTCATCACTGAGGTTGGCCAGCCCCT 
GCCAAGTGTTGTGTAGGCAAAGCACTTGTTAGTGGCTTCCTATGAAATGTTTTAGAGATCTCTTCACCATACTGGTTTCTTCTCTTTGGTTGGTGTGGGTAAAAGAAAACAAAACATTTCCTATAAGCTGAAAGCTGACC 
AGCATTCTCTTCTTGGTAACATCTACTACTCCAACCTAGAAAATTTGGATTCTAGACCAAAAATCAGGAAACATGGCTCCTTATAAATCTGTGCAGCTGCCTTATAGTACCATCAAAGGAATTTCAGGTGGGCTGGGCGG 
GGCCCCGATCCCAGAATTATCAACTCCACCCATCATCATTTGGTCATGAAGCATCCTTTCATTCTTCTTCTTCTTTTTTTTGGGGGGGGCGGGGCGGGGGAGGGATCTCAAAGTTTTAGTCTTCCAGAATCCAAATTAAA 
GGTTGCCCCTGATGGGGGCCAGGTTCCGCCACAGAACATCTTAGATGTCAGCCTTGACCTCACTTAGCAGGGATTACAGAAATGAGATACATTTTGAAGGAGAGTTGTCTGTTATGTTCACTGTATTCTAAGTGCCTGGG 
ATAAAGCTGTCTCATGGGTGCTCCATATATATTCATATATATTTGTTGAGTGAATTAATGAATTAAGAGTGGCTGGCAGAGTAGGCAGAAAAAGACACTGCAAATGGCATAAAAATTAAAGTCCTAGCTGAGTTCTCAAT 
GGTAAAGGCATCAGATGTCTTAGCAGTCAAGCTAGAAATTCATGACAATGAGTATTACTATTTGCCTAATGACAACTCATTGCTCTCCATGTAAATGTAATCAACAGATGAAGAGAATATAATTGCTCTGCTTTTCCACT 
AAAACTCCATCTTAGTGAATTTTAAATTATCCAGAGATGTCAAACTGCCAAATAAAAATATTTCAGTAGTCTTTGCATCAGCTTACCTTGTACCAGAAACATTTCCAATTTACTATCAAATTATAGTAACTGAGCCTGTG 
TGAAGTATCTCATCATTTTCGAAAGGAACACCTTGTGTGATGCCAGTGAGCATTTCTAAAAAGGGTGTGAGGTAGAGGTAAAAATAAGGTGAGAGACCATTTCAGAATGCACTGTTGCTCAAAAAGGTGATCTGGTTCTT 
TCTTCAGAGATTTCTACGGGGATAGAAAATCGGGAGTCTGCCCTCATTAATCTGTGACTCCACCTCTTGCATCAAATCAATATCTATTTGTTGAGCACTTATTGATTAAGACCTTGCATATGTCTGTCCATTTTGATTTG 
AGATACAACTTTTTGTGTGGGTTGAATGACAAATCACTCCAAACAAAACTGGGCACAGAGAATCAGCTAGGAGACCAGTTATTCAGGGTCCATTTCTCTTGGATGTAAAGGAGTCCTGGGTAAAATGTGGCTGTAACCTA 
AACCAACTAGTCCTTGTGATTTGTTTCTGCCCTCTGTGTTTCCTGTTGTCAAATGCTAAGTGTGTGTTTTGCAGTCATGAACTAAAGCACAAAAAGATGCATGAGACATTGTAGTCATATGTCTGGTGTGACACTTTGGA 
GCAAAAACCTTGCAGTGGTAAATAAAAAATTTCCAACAGGGAAAAAAAAAAAAAAAAAAAAAAAAAAA  
FIGURE 4.3.  Sequence similarity between the coding sequences for SYT13 and HCV.  
The coding sequence for SYT13 is shown.  Sequence similarities between SYT13 and 
HCV are highlighted in green. 
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least one potential miRNA target (and as many as 17) in each of the species (SYT13 
homologs) represented.  Although translational control of SYT13 via this mechanism would 
have to be experimentally confirmed, it is quite possible that miRNA-mediated  silencing is a 
potential post-transcriptional mode of SYT13 silencing.  However, this mechanism is not 
responsible for Syt13 inactivation in our model system.  Expression of both Syt13 and the 
monomeric form of the protein are detected, suggesting that endogenous transcription and 
translation machinery are functional.  The endogenous Syt13 gene found in GN6TF has not 
been sequenced.  Therefore, the simplest explanation of Syt13 inactivation in this cell line is 
a point mutation which inhibits the proper folding (thus function) of the protein.  Our data 
strongly suggests that tumor suppression of GN6TF cells requires the dimeric form of 
SYT13.  Since the native form of the protein is apparently unable to dimerize, this anomaly 
could provide evidence for alternative mechanisms of post-translational inactivation.  Protein 
palmitoylation on conserved cysteine residues is required for dimerization (80).  Therefore, if 
GN6TF cells lacked the capacity to execute this post-translational modification, the protein 
dimer would be absent.  However, this does not appear to be the case because exogenously 
expressed proteins properly form SYT13 dimers.  Another possibility is that a critical 
cysteine residue(s) has been mutated (80).  Importantly, it appears that loss of endogenous 
Syt13 function in GN6TF cells is related to aberrant post-translational modification.  
Potential mechanisms of inactivation of SYT13 are summarized in FIGURE 4.4.  This 
information and these cellular reagents provide an excellent background on which to further 
characterize and understand the biological function of Syt13.   
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FIGURE 4.4.  Potential mechanisms of SYT13 inactivation.  Potential mechanisms for loss 
of function are shown.  Initial insult to SYT13 (shown in blue) could be caused by gene 
mutation or deletion.  (A) SYT13 is not properly transcribed.  (B) Post-transcriptional 
silencing; the mRNA is not translated.  (C) Improper folding of the protein leads to loss of 
function.  (D) Deficient post-translational modification (such as palmitoylation) disables 
protein dimerization.  (E) Functional SYT13 dimer. 
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SUMMARY AND PERSPECTIVES 
The primary goals of this research project were (i) to identify the gene(s) responsible 
for suppression of the neoplastic phenotype of rat liver tumor cells, (ii) to characterize the 
involvement of this gene in tumor suppression, (iii) to determine the ability of this gene to 
individually express tumor suppressor activity in vivo, and (iv) to identify molecular targets 
and pathways in liver tumor cell lines that are subject to direct or indirect modification in 
response to the expression of the human chromosome 11p11.2 liver tumor suppressor gene.  
The results of the investigations described in this dissertation identified SYT13 as the human 
11p11.2 liver tumor suppressor gene and showed that this gene is required and sufficient for 
11p11.2-mediated suppression of tumorigenicity in GN6TF cells.  Furthermore, the results 
strongly suggest that the dimerized form of the SYT13 protein is necessary for tumor 
suppressor function and that tumor suppression may be affected through pathways implicated 
in epithelial to mesenchymal transition.  Our observations also suggest that the deficit in 
GN6TF that leads to the tumorigenic phenotype involves loss of the ability of the 
endogenous Syt13 to dimerize, perhaps through protein misfolding or loss of palmitoylation.  
This research has not only answered several questions about human chromosome 11p11.2-
mediated tumor suppression in rat liver tumor cells, but has raised new and intriguing 
questions regarding the biological function and regulation of SYT13 in tumor suppression, 
development, and the link between the two — epithelial to mesenchymal transition.  
Additional understanding of these phenomena may enable the development of effective 
strategies for prevention, detection, and/or molecular-based treatments of various 
developmental or neoplastic diseases. 
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APPENDIX A 
Transcripts >2-fold elevated in CX4 compared to GN6TF 
AFFY ID GENE SYMBOL GENE DESCRIPTION  
1383614_AT 1200013B22RIK SNF1/AMP-ACTIVATED PROTEIN KINASE 
1368081_AT ABCA2 ATP-BINDING CASSETTE, SUB-FAMILY A (ABC1), MEMBER 2 
1384603_AT ABCA4_PREDICTED ATP-BINDING CASSETTE, SUB-FAMILY A (ABC1), MEMBER 4 (PREDICTED) 
1383229_AT ABCA7 ATP-BINDING CASSETTE, SUB-FAMILY A, MEMBER 7 
1387030_AT ABCC5 ATP-BINDING CASSETTE, SUB-FAMILY C (CFTR/MRP), MEMBER 5 
1382137_AT ABHD3_PREDICTED ABHYDROLASE DOMAIN CONTAINING 3 (PREDICTED) 
1367958_AT ABI1 ABL-INTERACTOR 1  
1373215_AT ABR_PREDICTED ACTIVE BCR-RELATED GENE (PREDICTED) 
1371793_AT ACHE GLYCOLIPID-ANCHORED FORM OF ACETYLCHOLINESTERASE 
1397375_AT ACSL5 ACYL-COA SYNTHETASE LONG-CHAIN FAMILY MEMBER 5 
1373792_AT ACTR1B ARP1 ACTIN-RELATED PROTEIN 1 HOMOLOG B (YEAST) 
1387135_AT ADAM15 A DISINTEGRIN AND METALLOPROTEINASE DOMAIN 15 (METARGIDIN) 
1382481_A_AT ADAM33_PREDICTED A DISINTEGRIN AND METALLOPROTEASE DOMAIN 33 (PREDICTED) 
1375337_AT ADAM9_PREDICTED A DISINTEGRIN AND METALLOPROTEINASE DOMAIN 9 (MELTRIN GAMMA) (PREDICTED) 
1387128_AT ADCY3 ADENYLATE CYCLASE 3  
1379598_AT ADCY7 ADENYLATE CYCLASE 7  
1388487_AT ADD1 ADDUCIN 1 (ALPHA)  
1387219_AT ADM ADRENOMEDULLIN  
1372634_AT ADPRHL2_PREDICTED ADP-RIBOSYLHYDROLASE LIKE 2 (PREDICTED) 
1376810_AT ADPRTL1 ADP-RIBOSYLTRANSFERASE (NAD+; POLY (ADP-RIBOSE) POLYMERASE)-LIKE 1 
1369115_AT ADRB2 ADRENERGIC RECEPTOR, BETA 2  
1376091_AT ADSL_PREDICTED ADENYLOSUCCINATE LYASE (PREDICTED) 
1399050_AT ADSS2_PREDICTED ADENYLOSUCCINATE SYNTHETASE 2, NON MUSCLE (PREDICTED) 
1370302_AT AF348365 THYROID HORMONE-RESPONSE PROTEIN-1 
1370307_AT AGRN AGRIN  
1371703_AT AHNAK AHNAK NUCLEOPROTEIN (DESMOYOKIN) 
1368869_AT AKAP12 A KINASE (PRKA) ANCHOR PROTEIN (GRAVIN) 12 
1390229_AT AKAP14 A KINASE (PRKA) ANCHOR PROTEIN 14 
1389496_AT AKAP7 A KINASE (PRKA) ANCHOR PROTEIN 7 
1370911_AT AKAP8 A KINASE (PRKA) ANCHOR PROTEIN 8 
1368121_AT AKR7A3 ALDO-KETO REDUCTASE FAMILY 7, MEMBER A3 (AFLATOXIN ALDEHYDE REDUCTASE) 
1367720_AT ALAD AMINOLEVULINATE, DELTA-, DEHYDRATASE 
1367982_AT ALAS1 AMINOLEVULINIC ACID SYNTHASE 1  
1368130_AT ALDH3A1 ALDEHYDE DEHYDROGENASE FAMILY 3, MEMBER A1 
1368365_AT ALDH3A2 ALDEHYDE DEHYDROGENASE FAMILY 3, SUBFAMILY A2 
1382541_AT ALK ANAPLASTIC LYMPHOMA KINASE  
1392689_AT ALOXE3_PREDICTED ARACHIDONATE LIPOXYGENASE 3 (PREDICTED) 
1389363_AT ALP1 ACI-REDUCTONE DIOXYGENASE (ARD)-LIKE PROTEIN 1 
1377166_AT ALS2 AMYOTROPHIC LATERAL SCLEROSIS 2 (JUVENILE) 
1367933_AT AMD1 S-ADENOSYLMETHIONINE DECARBOXYLASE 1 
1389546_AT AMOTL2 ANGIOMOTIN LIKE 2  
1368342_AT AMPD3 ADENOSINE MONOPHOSPHATE DEAMINASE 3 
1367664_AT ANKRD1 ANKYRIN REPEAT DOMAIN 1 (CARDIAC MUSCLE) 
1373619_AT ANKRD10 ANKYRIN REPEAT DOMAIN 10  
1372069_AT ANKRD15 ANKYRIN REPEAT DOMAIN 15  
1371873_AT ANP32E ACIDIC (LEUCINE-RICH) NUCLEAR PHOSPHOPROTEIN 32 FAMILY, MEMBER E 
1388445_AT ANXA11 ANNEXIN A11  
1389305_AT ANXA4 ANNEXIN A4  
1386862_AT ANXA5 ANNEXIN A5  
1373654_AT ANXA8 ANNEXIN A8  
1371493_AT AP2A2 ADAPTOR PROTEIN COMPLEX AP-2, ALPHA 2 SUBUNIT 
1371614_AT APG12L AUTOPHAGY 12-LIKE (S. CEREVISIAE) 
1389273_AT APG4B APG4 (ATG4) AUTOPHAGY-RELATED HOMOLOG B (S. CEREVISIAE) 
1390436_AT APG7L AUTOPHAGY 7-LIKE (S. CEREVISIAE) 
1383193_AT APLP1 AMYLOID BETA (A4) PRECURSOR-LIKE PROTEIN 1 
1388121_AT APLP2 AMYLOID BETA (A4) PRECURSOR-LIKE PROTEIN 2 
1370862_AT APOE APOLIPOPROTEIN E  
1387055_AT APPBP1 AMYLOID BETA PRECURSOR PROTEIN BINDING PROTEIN 1 
1392891_AT APRIN ANDROGEN-INDUCED PROLIFERATION INHIBITOR 
1392891_AT APRIN_PREDICTED ANDROGEN-INDUCED PROLIFERATION INHIBITOR 
1368621_AT AQP9 AQUAPORIN 9  
1380794_AT AQR_PREDICTED AQUARIUS (PREDICTED)  
1388305_AT ARAF1 V-RAF ONCOGENE HOMOLOG 1 (MURINE SARCOMA 3611 VIRUS) 
1387068_AT ARC ACTIVITY REGULATED CYTOSKELETAL-ASSOCIATED PROTEIN 
1369871_AT AREG AMPHIREGULIN  
1388813_AT ARF2 ADP-RIBOSYLATION FACTOR 2  
1388997_AT ARF3 ADP-RIBOSYLATION FACTOR 3  
1368266_AT ARG1 ARGINASE 1  
1381296_AT ARG2 ARGINASE 2  
1377385_AT ARHGAP27 RHO GTPASE ACTIVATING PROTEIN 27 
1393666_AT ARHGAP5 RHO GTPASE ACTIVATING PROTEIN 5 
1376501_AT ARHGAP8 RHO GTPASE ACTIVATING PROTEIN 8 
1373881_AT ARHGDIB RHO, GDP DISSOCIATION INHIBITOR (GDI) BETA 
1381100_AT ARHGEF12 RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR (GEF) 12 
1383523_AT ARHGEF18_PREDICTED RHO/RAC GUANINE NUCLEOTIDE EXCHANGE FACTOR (GEF) 18 (PREDICTED) 
1377750_AT ARHGEF3_PREDICTED RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR (GEF) 3 (PREDICTED) 
1382389_AT ARHGEF5 RHO GUANINE NUCLEOTIDE EXCHANGE FACTOR (GEF) 5 
1374823_AT ARIH1 ARIADNE UBIQUITIN-CONJUGATING ENZYME E2 BINDING PROTEIN HOMOLOG 1 (DROSOPHILA) 
1373141_AT ARIH2_PREDICTED ARIADNE HOMOLOG 2 (DROSOPHILA) (PREDICTED) 
1389941_AT ARL2BP ADP-RIBOSYLATION FACTOR-LIKE 2 BINDING PROTEIN 
1367960_AT ARL4 ADP-RIBOSYLATION FACTOR-LIKE 4  
1372557_AT ARL6_PREDICTED ADP-RIBOSYLATION FACTOR-LIKE 6 (PREDICTED) 
1372470_AT ARVCF_PREDICTED ARMADILLO REPEAT GENE DELETED IN VELO-CARDIO-FACIAL SYNDROME (PREDICTED) 
1382847_AT ASH1L_PREDICTED ASH1 (ABSENT, SMALL, OR HOMEOTIC)-LIKE (DROSOPHILA) (PREDICTED) 
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1389719_AT ASH2L_PREDICTED ASH2 (ABSENT, SMALL, OR HOMEOTIC)-LIKE (DROSOPHILA) (PREDICTED) 
1370964_AT ASS ARGININOSUCCINATE SYNTHETASE  
1376599_AT ATAD2_PREDICTED ATPASE FAMILY, AAA DOMAIN CONTAINING 2 (PREDICTED) 
1389623_AT ATF1 ACTIVATING TRANSCRIPTION FACTOR 1 
1369268_AT ATF3 ACTIVATING TRANSCRIPTION FACTOR 3 
1376834_AT ATM_MAPPED ATAXIA TELANGIECTASIA MUTATED HOMOLOG (HUMAN) (MAPPED) 
1373546_AT ATP11A_PREDICTED ATPASE, CLASS VI, TYPE 11A (PREDICTED) 
1368108_AT ATP2A1 ATPASE, CA++ TRANSPORTING, CARDIAC MUSCLE, FAST TWITCH 1 
1372907_AT ATP6V0E2 ATPASE, H+ TRANSPORTING, V0 SUBUNIT E ISOFORM 2 
1371402_AT ATP6V1B2 ATPASE, H+ TRANSPORTING, V1 SUBUNIT B, ISOFORM 2 
1390429_AT AXIN2 AXIN2  
1398347_AT AXL_PREDICTED AXL RECEPTOR TYROSINE KINASE (PREDICTED) 
1371440_AT B2M BETA-2 MICROGLOBULIN  
1383689_AT B4GALT4 UDP-GAL:BETAGLCNAC BETA 1,4-GALACTOSYLTRANSFERASE, POLYPEPTIDE 4 
1374198_AT B7H3 B7 HOMLOG 3  
1377390_AT BACE2 BETA-SITE APP-CLEAVING ENZYME 2 
1392440_AT BARD1 BRCA1 ASSOCIATED RING DOMAIN 1 
1388158_AT BAT1A HLA-B-ASSOCIATED TRANSCRIPT 1A  
1388536_AT BAT2 HLA-B ASSOCIATED TRANSCRIPT 2  
1372709_AT BCAP29 B-CELL RECEPTOR-ASSOCIATED PROTEIN BAP29 
1374947_AT BCAR3_PREDICTED BREAST CANCER ANTI-ESTROGEN RESISTANCE 3 (PREDICTED) 
1368118_AT BCL10 B-CELL CLL/LYMPHOMA 10  
1398482_AT BCL3_PREDICTED B-CELL LEUKEMIA/LYMPHOMA 3 (PREDICTED) 
1392933_A_AT BCL7A_PREDICTED B-CELL CLL/LYMPHOMA 7A (PREDICTED) 
1373494_AT BCR_PREDICTED BREAKPOINT CLUSTER REGION (PREDICTED) 
1383822_AT BICD2 BICAUDAL D HOMOLOG 2 (DROSOPHILA) 
1382236_AT BIRC6_PREDICTED BACULOVIRAL IAP REPEAT-CONTAINING 6 (PREDICTED) 
1371808_AT BLMH BLEOMYCIN HYDROLASE  
1379659_AT BMP2K BMP-2 INDUCIBLE KINASE  
1390398_AT BMPR1A BONE MORPHOGENETIC PROTEIN RECEPTOR, TYPE 1A 
1383201_AT BMPR2 BONE MORPHOGENIC PROTEIN RECEPTOR, TYPE II (SERINE/THREONINE KINASE) 
1386978_AT BNIP3L BCL2/ADENOVIRUS E1B 19 KDA-INTERACTING PROTEIN 3-LIKE 
1392910_AT BOP1 BLOCK OF PROLIFERATION 1  
1374313_AT BPY2IP1_PREDICTED BPY2 INTERACTING PROTEIN 1 (PREDICTED) 
1389029_AT BRD3_PREDICTED BROMODOMAIN CONTAINING 3 (PREDICTED) 
1399055_AT BRD7_PREDICTED BROMODOMAIN CONTAINING 7 (PREDICTED) 
1373599_AT BRF2 BRF2, SUBUNIT OF RNA POLYMERASE III TRANSCRIPTION INITIATION FACTOR, BRF1-LIKE 
1388690_AT BRMS1L_PREDICTED BREAST CANCER METASTASIS-SUPPRESSOR 1-LIKE (PREDICTED) 
1372068_AT BS69 BS69 PROTEIN  
1367643_AT BSG BASIGIN  
1390738_AT BST2 BONE MARROW STROMAL CELL ANTIGEN 2 
1372720_AT BTBD1 BTB (POZ) DOMAIN CONTAINING 1  
1380459_AT BTBD14A BTB (POZ) DOMAIN CONTAINING 14A  
1387644_AT BTC BETACELLULIN  
1386773_AT BTD BIOTINIDASE  
1386994_AT BTG2 B-CELL TRANSLOCATION GENE 2, ANTI-PROLIFERATIVE 
1368072_AT BTG3 B-CELL TRANSLOCATION GENE 3  
1384050_AT BUB3 BUDDING UNINHIBITED BY BENZIMIDAZOLES 3 HOMOLOG (S. CEREVISIAE) 
1388554_AT BZW1 BASIC LEUCINE ZIPPER AND W2 DOMAINS 1 
1387043_AT C4.4A GPI-ANCHORED METASTASIS-ASSOCIATED PROTEIN HOMOLOG 
1372244_AT CAB39_PREDICTED CALCIUM BINDING PROTEIN 39 (PREDICTED) 
1370178_AT CACNB2 CALCIUM CHANNEL, VOLTAGE-DEPENDENT, BETA 2 SUBUNIT 
1393581_AT CALMBP1_PREDICTED CALMODULIN BINDING PROTEIN 1 (PREDICTED) 
1371686_AT CANX CALNEXIN  
1385851_AT CAPN5 CALPAIN 5  
1399091_AT CAPZB F-ACTIN CAPPING PROTEIN BETA SUBUNIT 
1388659_AT CARHSP1 CALCIUM REGULATED HEAT STABLE PROTEIN 1 
1385639_AT CASP8AP2_PREDICTED CASPASE 8 ASSOCIATED PROTEIN 2 (PREDICTED) 
1373466_AT CAST CALPASTATIN  
1371921_AT CATNA1 CATENIN (CADHERIN-ASSOCIATED PROTEIN), ALPHA 1, 102KDA 
1398354_AT CATNAL1_PREDICTED CATENIN ALPHA-LIKE 1 (PREDICTED) 
1376850_A_AT CCL27_PREDICTED CHEMOKINE (C-C MOTIF) LIGAND 27 (PREDICTED) 
1370346_AT CCNB1 CYCLIN B1  
1390343_AT CCNC CYCLIN C  
1367764_AT CCNG1 CYCLIN G1  
1368050_AT CCNL1 CYCLIN L1  
1385697_AT CCNT2_PREDICTED CYCLIN T2 (PREDICTED)  
1371784_AT CCRP CYTOPLASMIC CAR RETENTION PROTEIN 
1373784_AT CCT8_PREDICTED CHAPERONIN SUBUNIT 8 (THETA) (PREDICTED) 
1368593_AT CD1D1 CD1D1 ANTIGEN  
1372036_AT CD2BP2_PREDICTED CD2 ANTIGEN (CYTOPLASMIC TAIL) BINDING PROTEIN 2 (PREDICTED) 
1368518_AT CD53 CD53 ANTIGEN  
1367929_AT CD59 CD59 ANTIGEN  
1367716_AT CDA08 T-CELL IMMUNOMODULATORY PROTEIN 
1376782_AT CDC14A_PREDICTED CDC14 CELL DIVISION CYCLE 14 HOMOLOG A (S. CEREVISIAE) (PREDICTED) 
1389145_AT CDC42EP2 CDC42 EFFECTOR PROTEIN (RHO GTPASE BINDING) 2 
1375910_AT CDC42EP3_PREDICTED CDC42 EFFECTOR PROTEIN (RHO GTPASE BINDING) 3 (PREDICTED) 
1388730_AT CDC42EP4_PREDICTED CDC42 EFFECTOR PROTEIN (RHO GTPASE BINDING) 4 (PREDICTED) 
1389378_AT CDC42EP5_PREDICTED CDC42 EFFECTOR PROTEIN (RHO GTPASE BINDING) 5 (PREDICTED) 
1398793_AT CDC5L CELL DIVISION CYCLE 5-LIKE (S. POMBE) 
1371928_AT CDCA8 CELL DIVISION CYCLE ASSOCIATED 8 
1386947_AT CDH1 CADHERIN 1  
1369224_AT CDH17 CADHERIN 17  
1373089_AT CDH3 CADHERIN 3, TYPE 1, P-CADHERIN (PLACENTAL) 
1381316_AT CDKAL1_PREDICTED CDK5 REGULATORY SUBUNIT ASSOCIATED PROTEIN 1-LIKE 1 (PREDICTED) 
1368248_AT CDS1 CDP-DIACYLGLYCEROL SYNTHASE 1 
1398719_AT CDYL2_PREDICTED CHROMODOMAIN PROTEIN, Y CHROMOSOME-LIKE 2 (PREDICTED) 
1379538_AT CENPJ_PREDICTED CENTROMERE PROTEIN J (PREDICTED) 
1376030_AT CENTB1_PREDICTED CENTAURIN, BETA 1 (PREDICTED)  
1375699_AT CENTB2 CENTAURIN, BETA 2  
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1387871_AT CFL1 COFILIN 1  
1388928_AT CFL2_PREDICTED COFILIN 2, MUSCLE (PREDICTED)  
1368545_AT CFLAR CASP8 AND FADD-LIKE APOPTOSIS REGULATOR 
1371968_AT CGI119 CGI-119 PROTEIN  
1368692_A_AT CHKA CHOLINE KINASE ALPHA  
1387388_AT CHP CALCIUM BINDING PROTEIN P22  
1369091_AT CHRNB1 CHOLINERGIC RECEPTOR, NICOTINIC, BETA POLYPEPTIDE 1 (MUSCLE) 
1398726_AT CIAO1 WD40 PROTEIN CIAO1  
1367675_AT CIB1 CALCIUM AND INTEGRIN BINDING 1 (CALMYRIN) 
1382322_A_AT CIC_PREDICTED CAPICUA HOMOLOG (DROSOPHILA) (PREDICTED) 
1384068_AT CKAP2_PREDICTED CYTOSKELETON ASSOCIATED PROTEIN 2 (PREDICTED) 
1367740_AT CKB CREATINE KINASE, BRAIN  
1372056_AT CKLFSF6 CHEMOKINE-LIKE FACTOR SUPER FAMILY 6 
1390566_A_AT CKMT1 CREATINE KINASE, MITOCHONDRIAL 1, UBIQUITOUS 
1375685_AT CLASP1 CYTOPLASMIC LINKER ASSOCIATED PROTEIN 1 
1368219_AT CLCN2 CHLORIDE CHANNEL 2  
1381993_AT CLIC2 CHLORIDE INTRACELLULAR CHANNEL 2 
1374630_AT CLIC3 CHLORIDE INTRACELLULAR CHANNEL 3 
1383121_AT CLN2 CEROID-LIPOFUSCINOSIS, NEURONAL 2 
1389791_AT CLN8 CEROID-LIPOFUSCINOSIS, NEURONAL 8 
1374846_AT CLP1 CARDIAC LINEAGE PROTEIN 1  
1391077_AT CLSPN_PREDICTED CLASPIN HOMOLOG (XENOPUS LAEVIS) (PREDICTED) 
1371393_AT CLSTN1 CALSYNTENIN 1  
1367907_A_AT CLTB CLATHRIN, LIGHT POLYPEPTIDE (LCB) 
1367784_A_AT CLU CLUSTERIN  
1367940_AT CMKOR1 CHEMOKINE ORPHAN RECEPTOR 1  
1387856_AT CNN3 CALPONIN 3, ACIDIC  
1391270_AT CNNM3_PREDICTED CYCLIN M3 (PREDICTED)  
1393619_AT CNOT6L_PREDICTED CCR4-NOT TRANSCRIPTION COMPLEX, SUBUNIT 6-LIKE (PREDICTED) 
1368658_AT CNTF CILIARY NEUROTROPHIC FACTOR  
1384834_AT COBL_PREDICTED CORDON-BLEU (PREDICTED)  
1376868_AT COBLL1_PREDICTED COBL-LIKE 1 (PREDICTED)  
1382310_AT COG5_PREDICTED COMPONENT OF OLIGOMERIC GOLGI COMPLEX 5 (PREDICTED) 
1377254_A_AT COHH1_PREDICTED COHEN SYNDROME HOMOLOG 1 (PREDICTED) 
1376105_AT COL14A1_PREDICTED COLLAGEN, TYPE XIV, ALPHA 1 (UNDULIN) (PREDICTED) 
1383879_AT COL17A1_PREDICTED PROCOLLAGEN, TYPE XVII, ALPHA 1 (PREDICTED) 
1371893_AT COL4A3BP_PREDICTED PROCOLLAGEN, TYPE IV, ALPHA 3 (GOODPASTURE ANTIGEN) BINDING PROTEIN (PREDICTED) 
1393891_AT COL8A1_PREDICTED PROCOLLAGEN, TYPE VIII, ALPHA 1 (PREDICTED) 
1368826_AT COMT CATECHOL-O-METHYLTRANSFERASE 
1389271_AT CORO7 CORONIN 7  
1386921_AT CPE CARBOXYPEPTIDASE E  
1377746_AT CPNE1_PREDICTED COPINE I (PREDICTED)  
1374471_AT CPNE2_PREDICTED COPINE II (PREDICTED)  
1371993_AT CPNE3_PREDICTED COPINE III (PREDICTED)  
1377998_AT CPOX COPROPORPHYRINOGEN OXIDASE  
1389293_AT CPSF2_PREDICTED CLEAVAGE AND POLYADENYLATION SPECIFIC FACTOR 2 (PREDICTED) 
1398356_AT CPSF5 CLEAVAGE AND POLYADENYLATION SPECIFIC FACTOR 5 
1375033_AT CPT1C CARNITINE PALMITOYLTRANSFERASE 1C 
1386927_AT CPT2 CARNITINE PALMITOYLTRANSFERASE 2 
1369994_AT CRCP CALCITONIN GENE-RELATED PEPTIDE-RECEPTOR COMPONENT PROTEIN 
1393278_AT CREB3L4 CAMP RESPONSIVE ELEMENT BINDING PROTEIN 3-LIKE 4 
1381968_AT CREG_PREDICTED CELLULAR REPRESSOR OF E1A-STIMULATED GENES (PREDICTED) 
1370026_AT CRYAB CRYSTALLIN, ALPHA B  
1368685_AT CSPG4 CHONDROITIN SULFATE PROTEOGLYCAN 4 
1370057_AT CSRP1 CYSTEINE AND GLYCINE-RICH PROTEIN 1 
1376797_AT CSRP2BP_PREDICTED CYSTEINE AND GLYCINE-RICH PROTEIN 2 BINDING PROTEIN (PREDICTED) 
1370855_AT CST3 CYSTATIN C  
1368162_AT CST6 CYSTATIN E/M  
1367631_AT CTGF CONNECTIVE TISSUE GROWTH FACTOR 
1378127_AT CUL2_PREDICTED CULLIN 2 (PREDICTED)  
1393343_AT CUL3_PREDICTED CULLIN 3 (PREDICTED)  
1368200_AT CX3CL1 CHEMOKINE (C-X3-C MOTIF) LIGAND 1 
1372064_AT CXCL16 SIMILAR TO CHEMOKINE (C-X-C MOTIF) LIGAND 16 
1368192_AT CXCR3 CHEMOKINE (C-X-C MOTIF) RECEPTOR 3 
1386904_A_AT CYB5 CYTOCHROME B-5  
1398383_AT CYB561_PREDICTED CYTOCHROME B-561 (PREDICTED)  
1368990_AT CYP1B1 CYTOCHROME P450, FAMILY 1, SUBFAMILY B, POLYPEPTIDE 1 
1390282_AT CYP2S1 CYTOCHROME P450, FAMILY 2, SUBFAMILY S, POLYPEPTIDE 1 
1370387_AT CYP3A13 CYTOCHROME P450, FAMILY 3, SUBFAMILY A, POLYPEPTIDE 13 
1368290_AT CYR61 CYSTEINE RICH PROTEIN 61  
1388159_AT CYTB CYTOCHROME B  
1370990_AT CYTOR4 SIMILAR TO CYTOKINE RECEPTOR RELATED PROTEIN 4 
1368274_AT DBNL DREBRIN-LIKE  
1398600_AT DCBLD2 DISCOIDIN, CUB AND LCCL DOMAIN CONTAINING 2 
1384041_AT DCK DEOXYCYTIDINE KINASE  
1388904_AT DD25 HYPOTHETICAL PROTEIN DD25  
1394597_AT DDHD1 DDHD DOMAIN CONTAINING 1  
1375901_AT DDX21B DEAD (ASP-GLU-ALA-ASP) BOX POLYPEPTIDE 21B 
1387912_AT DDX46 RNA HELICASE  
1372484_AT DDX5 DDX5 GENE  
1368588_AT DDX52 ATP-DEPENDENT, RNA HELICASE  
1398945_AT DDX6_MAPPED DEAD (ASP-GLU-ALA-ASP/HIS) BOX POLYPEPTIDE 6 (MAPPED) 
1376914_AT DEPDC1_PREDICTED DEP DOMAIN CONTAINING 1 (PREDICTED) 
1371806_AT DGCR8_PREDICTED DIGEORGE SYNDROME CRITICAL REGION GENE 8 (PREDICTED) 
1395579_AT DHX32_PREDICTED DEAH (ASP-GLU-ALA-HIS) BOX POLYPEPTIDE 32 (PREDICTED) 
1377763_AT DHX33_PREDICTED DEAH (ASP-GLU-ALA-HIS) BOX POLYPEPTIDE 33 (PREDICTED) 
1393432_A_AT DHX36_PREDICTED DEAH (ASP-GLU-ALA-HIS) BOX POLYPEPTIDE 36 (PREDICTED) 
1374299_AT DHX9_PREDICTED DEAH (ASP-GLU-ALA-HIS) BOX POLYPEPTIDE 9 (PREDICTED) 
1373221_AT DIAP1_PREDICTED DIAPHANOUS HOMOLOG 1 (DROSOPHILA) (PREDICTED) 
1388194_AT DLAT DIHYDROLIPOAMIDE S-ACETYLTRANSFERASE (E2 COMPONENT OF PYRUVATE 
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DEHYDROGENASE COMPLEX) 
1377121_AT DLG5_PREDICTED DISCS, LARGE HOMOLOG 5 (DROSOPHILA) (PREDICTED) 
1380558_AT DLX3_PREDICTED DISTAL-LESS HOMEOBOX 3 (PREDICTED) 
1368852_AT DNAJA1 DNAJ-LIKE PROTEIN  
1389308_AT DNAJB11 DNAJ (HSP40) HOMOLOG, SUBFAMILY B, MEMBER 11 
1372722_AT DNAJB4 DNAJ (HSP40) HOMOLOG, SUBFAMILY B, MEMBER 4 
1392598_AT DNAJB6 DNAJ (HSP40) HOMOLOG, SUBFAMILY B, MEMBER 6 
1387116_AT DNAJB9 DNAJ (HSP40) HOMOLOG, SUBFAMILY B, MEMBER 9 
1384305_AT DNB5 PROTON-ASSOCIATED SUGAR TRANSPORTER A 
1368402_AT DNCLI2 DYNEIN, CYTOPLASMIC, LIGHT INTERMEDIATE POLYPEPTIDE 2 
1373772_AT DNMT1 DNA (CYTOSINE-5-)-METHYLTRANSFERASE 1 
1384525_AT DOCK11 DEDICATOR OF CYTOKINESIS 11  
1372300_AT DOK4_PREDICTED DOCKING PROTEIN 4 (PREDICTED)  
1376026_AT DONSON DOWNSTREAM NEIGHBOR OF SON  
1388589_AT DOT1L_PREDICTED DOT1-LIKE, HISTONE H3 METHYLTRANSFERASE (S. CEREVISIAE) (PREDICTED) 
1384400_AT DPDE1 PHOSPHODIESTERASE 4C, CAMP-SPECIFIC 
1388486_AT DPP8_PREDICTED DIPEPTIDYLPEPTIDASE 8 (PREDICTED) 
1372453_AT DR1 DOWN-REGULATOR OF TRANSCRIPTION 1 
1388686_AT DSCR1 DOWN SYNDROME CRITICAL REGION HOMOLOG 1 (HUMAN) 
1388506_AT DSP DESMOPLAKIN  
1376130_A_AT DTNB DYSTROBREVIN, BETA  
1368983_AT DTR DIPHTHERIA TOXIN RECEPTOR  
1394028_AT DUSP10_PREDICTED DUAL SPECIFICITY PHOSPHATASE 10 (PREDICTED) 
1373324_AT DUSP14_PREDICTED DUAL SPECIFICITY PHOSPHATASE 14 (PREDICTED) 
1372385_AT DUSP8_PREDICTED DUAL SPECIFICITY PHOSPHATASE 8 (PREDICTED) 
1377424_AT DUTP DEOXYURIDINE TRIPHOSPHATASE  
1388698_AT ECM1 EXTRACELLULAR MATRIX PROTEIN 1  
1383747_AT ECT2_PREDICTED ECT2 ONCOGENE (PREDICTED)  
1369519_AT EDN1 ENDOTHELIN 1  
1369536_AT EDN2 ENDOTHELIN 2  
1373462_AT EED_PREDICTED EMBRYONIC ECTODERM DEVELOPMENT (PREDICTED) 
1389328_AT EEF1A1 EUKARYOTIC TRANSLATION ELONGATION FACTOR 1 ALPHA 1 
1374388_AT EFHD2 EF HAND DOMAIN CONTAINING 2  
1387306_A_AT EGR2 EARLY GROWTH RESPONSE 2  
1387442_AT EGR4 EARLY GROWTH RESPONSE 4  
1376145_AT EIF2B5 EUKARYOTIC TRANSLATION INITIATION FACTOR 2B, SUBUNIT 5 EPSILON 
1385118_AT EIF2S1 EUKARYOTIC TRANSLATION INITIATION FACTOR 2, SUBUNIT 1 ALPHA 
1374721_AT EIF2S2 EUKARYOTIC TRANSLATION INITIATION FACTOR 2, SUBUNIT 2 (BETA) 
1371404_AT EIF4B EUKARYOTIC TRANSLATION INITIATION FACTOR 4B 
1373364_AT EIF4G3_PREDICTED EUKARYOTIC TRANSLATION INITIATION FACTOR 4 GAMMA, 3 (PREDICTED) 
1398845_AT EIF5 EUKARYOTIC TRANSLATION INITIATION FACTOR 5 
1396191_AT EIF5B EUKARYOTIC TRANSLATION INITIATION FACTOR 5B 
1383736_AT ELAVL2 ELAV (EMBRYONIC LETHAL, ABNORMAL VISION, DROSOPHILA)-LIKE 2 (HU ANTIGEN B) 
1374119_AT ELF3 E74-LIKE FACTOR 3  
1388714_AT ELL_PREDICTED ELONGATION FACTOR RNA POLYMERASE II (PREDICTED) 
1388111_AT ELN ELASTIN  
1368541_AT EMB EMBIGIN  
1368513_AT ENPEP GLUTAMYL AMINOPEPTIDASE  
1388926_AT ENPP5 ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 5 
1370845_AT ENTPD2 ECTONUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 2 
1374300_AT ENTPD4_PREDICTED ECTONUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 4 (PREDICTED) 
1374984_AT EPB4.1L5 ERYTHROCYTE PROTEIN BAND 4.1-LIKE 5 
1378997_AT EPHB6 EPH RECEPTOR B6  
1373019_AT EPS15 EPIDERMAL GROWTH FACTOR RECEPTOR PATHWAY SUBSTRATE 15 
1372654_AT EPS8L2_PREDICTED EPS8-LIKE 2 (PREDICTED)  
1387813_AT ERBB2 V-ERB-B2 ERYTHROBLASTIC LEUKEMIA VIRAL ONCOGENE HOMOLOG 2,  
1377821_AT ERBB3 V-ERB-B2 ERYTHROBLASTIC LEUKEMIA VIRAL ONCOGENE HOMOLOG 3 (AVIAN) 
1376866_AT ERCC1_PREDICTED EXCISION REPAIR CROSS-COMPLEMENTING RODENT REPAIR DEFICIENCY,  
1391723_AT ERCC3 EXCISION REPAIR CROSS-COMPLEMENTING RODENT REPAIR DEFICIENCY,  
1374687_AT ESPL1_PREDICTED EXTRA SPINDLE POLES LIKE 1 (S. CEREVISIAE) (PREDICTED) 
1372306_AT ETHE1_PREDICTED ETHYLMALONIC ENCEPHALOPATHY 1 (PREDICTED) 
1371710_AT ETNK1_PREDICTED ETHANOLAMINE KINASE 1 (PREDICTED) 
1368851_AT ETS1 V-ETS ERYTHROBLASTOSIS VIRUS E26 ONCOGENE HOMOLOG 1 (AVIAN) 
1375908_AT EVA_PREDICTED EPITHELIAL V-LIKE ANTIGEN (PREDICTED) 
1376082_AT EVI1_PREDICTED ECOTROPIC VIRAL INTEGRATION SITE 1 (PREDICTED) 
1389115_AT EVPL_PREDICTED ENVOPLAKIN (PREDICTED)  
1387279_AT F11R JUNCTIONAL ADHESION MOLECULE 1 
1367899_AT F2R COAGULATION FACTOR II (THROMBIN) RECEPTOR 
1387596_AT F2RL1 COAGULATION FACTOR II (THROMBIN) RECEPTOR-LIKE 1 
1369182_AT F3 COAGULATION FACTOR III  
1391199_AT FADD FAS (TNFRSF6)-ASSOCIATED VIA DEATH DOMAIN 
1368453_AT FADS2 FATTY ACID DESATURASE 2  
1389568_AT FAM26B FAMILY WITH SEQUENCE SIMILARITY 26, MEMBER B 
1367654_AT FATH FAT TUMOR SUPPRESSOR HOMOLOG (DROSOPHILA) 
1388528_AT FBL FIBRILLARIN  
1389533_AT FBLN2 FIBULIN 2  
1368622_AT FBP2 FRUCTOSE-1,6-BISPHOSPHATASE 2  
1373147_AT FBXL3A F-BOX AND LEUCINE-RICH REPEAT PROTEIN 3A 
1389333_AT FBXO3_PREDICTED F-BOX ONLY PROTEIN 3 (PREDICTED) 
1392469_AT FBXW2_PREDICTED F-BOX AND WD-40 DOMAIN PROTEIN 2 (PREDICTED) 
1367983_AT FEN1 FLAP STRUCTURE-SPECIFIC ENDONUCLEASE 1 
1388137_A_AT FEZ2 FASCICULATION AND ELONGATION PROTEIN ZETA 2 (ZYGIN II) 
1376042_AT FGD1 FYVE, RHOGEF AND PH DOMAIN CONTAINING 1 
1368114_AT FGF13 FIBROBLAST GROWTH FACTOR 13  
1387640_AT FGF15 FIBROBLAST GROWTH FACTOR 15  
1370106_AT FGF18 FIBROBLAST GROWTH FACTOR 18  
1392479_AT FKBP1A FK506 BINDING PROTEIN 1A  
1390576_AT FLI1 FRIEND LEUKEMIA INTEGRATION 1  
1388401_AT FLNB_PREDICTED FILAMIN, BETA (PREDICTED)  
1370234_AT FN1 FIBRONECTIN 1  
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1382540_AT FNBP3_PREDICTED FORMIN BINDING PROTEIN 3 (PREDICTED) 
1374726_AT FNDC1 FIBRONECTIN TYPE III DOMAIN CONTAINING 1 (PREDICTED) 
1370795_AT FOXC2 FORKHEAD BOX C2  
1377347_AT FOXJ3_PREDICTED FORKHEAD BOX J3 (PREDICTED)  
1368550_AT FOXQ1 FORKHEAD BOX Q1  
1376249_AT FUCA2 FUCOSIDASE, ALPHA-L- 2, PLASMA  
1373195_AT FUS FUSION (INVOLVED IN T(12;16) IN MALIGNANT LIPOSARCOMA) 
1388889_AT FXNA PUTATIVE AMINOPEPTIDASE FXNA  
1378054_AT FXR1H FRAGILE X MENTAL RETARDATION GENE 1, AUTOSOMAL HOMOLOG 
1368207_AT FXYD5 FXYD DOMAIN-CONTAINING ION TRANSPORT REGULATOR 5 
1373937_AT FYCO1_PREDICTED FYVE AND COILED-COIL DOMAIN CONTAINING 1 (PREDICTED) 
1374530_AT FZD7_PREDICTED FRIZZLED HOMOLOG 7 (DROSOPHILA) (PREDICTED) 
1382314_AT G1P2_PREDICTED INTERFERON, ALPHA-INDUCIBLE PROTEIN (CLONE IFI-15K) (PREDICTED) 
1370976_AT G3BP RAS-GTPASE-ACTIVATING PROTEIN SH3-DOMAIN BINDING PROTEIN 
1383377_AT GABPA_PREDICTED GA REPEAT BINDING PROTEIN, ALPHA (PREDICTED) 
1372016_AT GADD45B GROWTH ARREST AND DNA-DAMAGE-INDUCIBLE 45 BETA 
1388792_AT GADD45G GROWTH ARREST AND DNA-DAMAGE-INDUCIBLE 45 GAMMA 
1376790_AT GALC GALACTOSYLCERAMIDASE  
1378214_AT GALNAC4S6ST N-ACETYLGALACTOSAMINE 4-SULFATE 6-O-SULFOTRANSFERASE 
1393651_AT GALNT10 UDP-N-ACETYL-ALPHA-D-GALACTOSAMINE: 
1384667_X_AT GALR2 GALANIN RECEPTOR 2  
1370963_AT GAS7 GROWTH ARREST SPECIFIC 7  
1387894_AT GATA4 GATA BINDING PROTEIN 4  
1368332_AT GBP2 GUANYLATE NUCLEOTIDE BINDING PROTEIN 2 
1368085_AT GCHFR GTP CYCLOHYDROLASE I FEEDBACK REGULATOR 
1390517_AT GCN1L1_PREDICTED GCN1 GENERAL CONTROL OF AMINO-ACID SYNTHESIS 1-LIKE 1 (YEAST) (PREDICTED) 
1368770_AT GCNT1 GLUCOSAMINYL (N-ACETYL) TRANSFERASE 1, CORE 2 
1382203_AT GDF1_PREDICTED GROWTH DIFFERENTIATION FACTOR 1 (PREDICTED) 
1368307_AT GGTL3 GAMMA-GLUTAMYLTRANSFERASE-LIKE 3 
1369898_A_AT GIP GLUCOSE-DEPENDENT INSULINOTROPIC PEPTIDE 
1370023_AT GJA4 GAP JUNCTION MEMBRANE CHANNEL PROTEIN ALPHA 4 
1368689_AT GJB5 GAP JUNCTION MEMBRANE CHANNEL PROTEIN BETA 5 
1376781_AT GLB1_MAPPED GALACTOSIDASE, BETA 1 (MAPPED) 
1376427_A_AT GLDC_PREDICTED GLYCINE DEHYDROGENASE (DECARBOXYLATING; GLYCINE DECARBOXYLASE 
1374690_AT GLE1L GLE1 RNA EXPORT MEDIATOR-LIKE (YEAST 
1382077_AT GLI3 GLI-KRUPPEL FAMILY MEMBER GLI3  
1390121_AT GLIS2_PREDICTED GLIS FAMILY ZINC FINGER 2 (PREDICTED) 
1373490_AT GMFG GLIA MATURATION FACTOR, GAMMA 
1370423_AT GNA15 GUANINE NUCLEOTIDE BINDING PROTEIN, ALPHA 15 
1392471_AT GNG12 GUANINE NUCLEOTIDE BINDING PROTEIN (G PROTEIN), GAMMA 12 
1368117_AT GPHN GEPHYRIN  
1387383_AT GPR51 G PROTEIN-COUPLED RECEPTOR 51  
1373693_AT GPRC5C G PROTEIN-COUPLED RECEPTOR, FAMILY C, GROUP 5, MEMBER C 
1368408_AT GPRK5 G PROTEIN-COUPLED RECEPTOR KINASE 5 
1382232_AT GPT2_PREDICTED GLUTAMIC PYRUVATE TRANSAMINASE (ALANINE AMINOTRANSFERASE) 2 (PREDICTED) 
1368386_AT GRB2 GROWTH FACTOR RECEPTOR BOUND PROTEIN 2 
1368334_AT GRB7 GROWTH FACTOR RECEPTOR BOUND PROTEIN 7 
1369128_AT GRIK5 GLUTAMATE RECEPTOR, IONOTROPIC, KAINATE 5 
1368690_A_AT GRM4 GLUTAMATE RECEPTOR, METABOTROPIC 4 
1385001_AT GSDMDC1_PREDICTED GASDERMIN DOMAIN CONTAINING 1 (PREDICTED) 
1389714_AT GSK3A GLYCOGEN SYNTHASE KINASE 3 ALPHA 
1371524_AT GTL3 GENE TRAP LOCUS 3  
1378166_AT GTL7_PREDICTED GENE TRAP LOCUS 7 (PREDICTED)  
1398985_AT GTPBP1_PREDICTED GTP BINDING PROTEIN 1 (PREDICTED) 
1376285_AT GULP1 GULP, ENGULFMENT ADAPTOR PTB DOMAIN CONTAINING 1 
1395652_AT GYLTL1B GLYCOSYLTRANSFERASE-LIKE 1B  
1391280_AT H13_PREDICTED HISTOCOMPATIBILITY 13 (PREDICTED) 
1371765_AT H2A HISTONE 2A  
1370004_AT H2AFY H2A HISTONE FAMILY, MEMBER Y  
1388428_AT HARS2_PREDICTED HISTIDYL TRNA SYNTHETASE 2 (PREDICTED) 
1391731_AT HBP1 HIGH MOBILITY GROUP BOX TRANSCRIPTION FACTOR 1 
1395570_AT HDH HUNTINGTON DISEASE GENE HOMOLOG 
1388918_AT HDLBP HIGH DENSITY LIPOPROTEIN BINDING PROTEIN 
1383912_AT HECA_PREDICTED HEADCASE HOMOLOG (DROSOPHILA) (PREDICTED) 
1374599_AT HERC1_PREDICTED HECT (HOMOLOGOUS TO THE E6-AP (UBE3A) CARBOXYL TERMINUS) DOMAIN AND RCC1 
1367741_AT HERPUD1 HOMOCYSTEINE-INDUCIBLE, ENDOPLASMIC RETICULUM STRESS-INDUCIBLE 
1387036_AT HES1 HAIRY AND ENHANCER OF SPLIT 1 (DROSOPHILA) 
1372706_AT HEXB HEXOSAMINIDASE B  
1399067_AT HFE HEMOCHROMATOSIS  
1381006_AT HGFAC HEPATOCYTE GROWTH FACTOR ACTIVATOR 
1374105_AT HIG1 HYPOXIA INDUCED GENE 1  
1389132_AT HIP1 HUNTINGTIN INTERACTING PROTEIN 1 
1370994_AT HIP1R HUNTINGTIN INTERACTING PROTEIN 1 RELATED 
1385259_AT HIP2_PREDICTED HUNTINGTIN INTERACTING PROTEIN 2 (PREDICTED) 
1392476_AT HIST1H4B GERMINAL HISTONE H4 GENE  
1392476_AT HIST1H4M_PREDICTED GERMINAL HISTONE H4 GENE  
1371959_AT HIST2H2AA_PREDICTED HISTONE 2, H2AA (PREDICTED)  
1392476_AT HIST2H4_PREDICTED GERMINAL HISTONE H4 GENE  
1392512_AT HIST3H2BA_PREDICTED HISTONE 3, H2BA (PREDICTED)  
1383087_AT HMG20B_PREDICTED HIGH MOBILITY GROUP 20 B (PREDICTED) 
1388309_AT HMGA1 HIGH MOBILITY GROUP AT-HOOK 1  
1367676_AT HMGB2 HIGH MOBILITY GROUP BOX 2  
1373927_AT HMGB2L1_PREDICTED HIGH MOBILITY GROUP BOX 2-LIKE 1 (PREDICTED) 
1371352_AT HMGN2 HIGH MOBILITY GROUP NUCLEOSOMAL BINDING DOMAIN 2 
1388581_AT HN1 HEMATOLOGICAL AND NEUROLOGICAL EXPRESSED SEQUENCE 1 
1371333_AT HNRPDL HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN D-LIKE 
1398797_AT HNRPK HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K 
1373905_AT HNRPR HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN R 
1370171_AT HNRPU HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN U 
1380824_AT HOOK3 HOOK HOMOLOG 3  
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1368873_AT HOXA2 HOMEO BOX A2  
1392183_AT HOXC8_MAPPED HOMEO BOX C8 (MAPPED)  
1382182_AT HOXC9_PREDICTED HOMEO BOX C9 (PREDICTED)  
1371012_AT HPCL2 2-HYDROXYPHYTANOYL-COENZYME A LYASE 
1368407_AT HPSE HEPARANASE  
1371490_AT HSBP1 HEAT SHOCK FACTOR BINDING PROTEIN 1 
1370433_AT HSD3B7 CCA2 PROTEIN  
1370344_AT HSPA4 HEAT SHOCK PROTEIN 4  
1383680_AT HSPA5BP1 HEAT SHOCK 70KDA PROTEIN 5 BINDING PROTEIN 1 
1368195_AT HSPBAP1 HSPB ASSOCIATED PROTEIN 1  
1387741_AT HTR1B 5-HYDROXYTRYPTAMINE (SEROTONIN) RECEPTOR 1B 
1367787_AT ICA1 ISLET CELL AUTOANTIGEN 1  
1387202_AT ICAM1 INTERCELLULAR ADHESION MOLECULE 1 
1387028_A_AT ID1 INHIBITOR OF DNA BINDING 1, HELIX-LOOP-HELIX PROTEIN (SPLICE VARIATION) 
1389355_AT IER5 IMMEDIATE EARLY RESPONSE 5  
1372070_AT IFI30 INTERFERON GAMMA INDUCIBLE PROTEIN 30 
1371357_AT IGFBP7 INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 7 
1378396_AT IGSF10 IMMUNOGLOBULIN SUPERFAMILY, MEMBER 10 
1376733_AT IGSF11 IMMUNOGLOBULIN SUPERFAMILY, MEMBER 11 
1368424_AT IKBKB INHIBITOR OF KAPPAB KINASE BETA 
1370331_AT IL11RA1 INTERLEUKIN 11 RECEPTOR, ALPHA CHAIN 1 
1368210_AT IL24 INTERLEUKIN 24  
1386987_AT IL6R INTERLEUKIN 6 RECEPTOR  
1372193_AT IMPACT IMPRINTED AND ANCIENT  
1377163_AT INHBB INHIBIN BETA-B  
1388697_AT INPP5A_PREDICTED INOSITOL POLYPHOSPHATE-5-PHOSPHATASE A (PREDICTED) 
1368073_AT IRF1 INTERFERON REGULATORY FACTOR 1 
1387770_AT ISG12(A) PUTATIVE ISG12(A) PROTEIN  
1389282_AT ITGA3_PREDICTED INTEGRIN ALPHA 3 (PREDICTED)  
1383240_AT ITGA6 INTEGRIN, ALPHA 6  
1383398_AT ITGA8 INTEGRIN ALPHA 8  
1368612_AT ITGB4 INTEGRIN BETA 4  
1388507_AT ITGB4BP INTEGRIN BETA 4 BINDING PROTEIN  
1371320_AT ITM2B INTEGRAL MEMBRANE PROTEIN 2B  
1373623_AT ITPKC INOSITOL 1,4,5-TRISPHOSPHATE 3-KINASE C 
1397161_A_AT ITSN INTERSECTIN 1  
1368725_AT JAG1 JAGGED 1  
1387905_AT JDP1 JUN DIMERIZATION PROTEIN 1  
1387788_AT JUNB JUN-B ONCOGENE  
1387762_S_AT JUND JUN D PROTO-ONCOGENE  
1387061_AT JUP JUNCTION PLAKOGLOBIN  
1397645_AT KA17 TYPE I KERATIN KA17  
1377246_AT KB40 TYPE II KERATIN KB40  
1379276_AT KCMF1 POTASSIUM CHANNEL MODULATORY FACTOR 1 
1398290_AT KCNK13 POTASSIUM CHANNEL, SUBFAMILY K, MEMBER 13 
1387264_AT KCNK6 POTASSIUM CHANNEL, SUBFAMILY K, MEMBER 6 
1368930_AT KCNN4 
POTASSIUM INTERMEDIATE/SMALL CONDUCTANCE CALCIUM-ACTIVATED CHANNEL, 
SUBFAMILY N, MEMBER 4 
1385226_AT KCTD11_PREDICTED POTASSIUM CHANNEL TETRAMERISATION DOMAIN CONTAINING 11 (PREDICTED) 
1373119_AT KCTD3 POTASSIUM CHANNEL TETRAMERISATION DOMAIN CONTAINING 3 
1374582_AT KCTD9_PREDICTED POTASSIUM CHANNEL TETRAMERISATION DOMAIN CONTAINING 9 (PREDICTED) 
1398773_AT KHDRBS1 SRC ASSOCIATED IN MITOSIS, 68 KDA 
1387327_AT KHDRBS2 KH DOMAIN CONTAINING, RNA BINDING, SIGNAL TRANSDUCTION ASSOCIATED 2 
1387196_AT KHDRBS3 ETOILE, SAM68-LIKE PROTEIN SLM-2 
1370930_AT KIF1C KINESIN FAMILY MEMBER 1C  
1389593_AT KIF2 KINESIN HEAVY CHAIN FAMILY, MEMBER 2 
1384828_AT KIF7_PREDICTED KINESIN FAMILY MEMBER 7 (PREDICTED) 
1389374_AT KIFC3 KINESIN FAMILY MEMBER C3  
1388068_AT KLC3 KINESIN LIGHT CHAIN 3  
1387260_AT KLF4 KRUPPEL-LIKE FACTOR 4 (GUT)  
1383173_AT KLRC1 KILLER CELL LECTIN-LIKE RECEPTOR SUBFAMILY C, MEMBER 1 
1374794_AT KNSL7 KINESIN-LIKE 7  
1367683_AT KPNA2 KARYOPHERIN (IMPORTIN) ALPHA 2  
1373858_AT KPNB1 KARYOPHERIN (IMPORTIN) BETA 1  
1372355_AT KRAS2 KIRSTEN RAT SARCOMA VIRAL ONCOGENE HOMOLOGUE 2 (ACTIVE) 
1371895_AT KRT1-14 KERATIN COMPLEX 1, ACIDIC, GENE 14 
1388433_AT KRT1-19 KERATIN COMPLEX 1, ACIDIC, GENE 19 
1373900_AT KRT2-7 KERATIN COMPLEX 2, BASIC, GENE 7 (PREDICTED) 
1371530_AT KRT2-8 KERATIN COMPLEX 2, BASIC, GENE 8 
1374195_AT LAD1_PREDICTED LADININ (PREDICTED)  
1370538_AT LAMA3 LAMININ, ALPHA 3  
1388932_AT LAMA5 LAMININ, ALPHA 5  
1367880_AT LAMB2 LAMININ, BETA 2  
1383080_AT LAMP2 LYSOSOMAL MEMBRANE GLYCOPROTEIN 2 
1376579_AT LAP3 LEUCINE AMINOPEPTIDASE 3  
1388728_AT LAPTM4B LYSOSOMAL-ASSOCIATED PROTEIN TRANSMEMBRANE 4B 
1367650_AT LCN7 LIPOCALIN 7  
1388725_AT LEPROT LEPTIN RECEPTOR OVERLAPPING TRANSCRIPT 
1388587_AT LER3 IMMEDIATE EARLY RESPONSE 3  
1389157_AT LGALS2 LECTIN, GALACTOSIDE-BINDING, SOLUBLE 2 
1369716_S_AT LGALS5 LECTIN, GALACTOSE BINDING, SOLUBLE 5 
1369716_S_AT LGALS9 LECTIN, GALACTOSE BINDING, SOLUBLE 9 
1368804_AT LIF LEUKEMIA INHIBITORY FACTOR  
1387090_A_AT LIMK2 LIM MOTIF-CONTAINING PROTEIN KINASE 2 
1368368_A_AT LISCH7 LIVER-SPECIFIC BHLH-ZIP TRANSCRIPTION FACTOR 7 
1389500_AT LOC191574 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE 
1370696_AT LOC207121 MEMBRANE AND MICROFILAMENT-ASSOCIATED PROTEIN P58 
1371091_AT LOC207125 UNKNOWN PROTEIN  
1383222_AT LOC257646 FERM-DOMAIN-CONTAINING PROTEIN 163SCII 
1397362_AT LOC257650 HIPPYRAGRANIN  
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1391059_AT LOC259224 PREPRO-NEUROPEPTIDE W POLYPEPTIDE 
1370565_AT LOC286991 PUTATIVE RETROVIRUS-RELATED GAG PROTEIN 
1374991_AT LOC287938 HYPOTHETICAL LOC287938  
1389040_AT LOC288165 SIMILAR TO PEST-CONTAINING NUCLEAR PROTEIN 
1372809_AT LOC290595 HYPOTHETICAL GENE SUPPORTED BY AF152002 
1371817_AT LOC290651 SIMILAR TO MYO-INOSITOL 1-PHOSPHATE SYNTHASE A1 
1389918_AT LOC290704 SIMILAR TO PALLADIN  
1370925_AT LOC291411 SIMILAR TO POTENTIAL PHOSPHOLIPID-TRANSPORTING ATPASE IIB 
1393066_AT LOC292666 SIMILAR TO PREGNANCY-SPECIFIC BETA 1-GLYCOPROTEIN 
1374116_AT LOC295241 SIMILAR TO METAXIN 1, ISOFORM 2  
1398726_AT LOC296126 SIMILAR TO U5 SNRNP-SPECIFIC PROTEIN, 200 KDA 
1391491_A_AT LOC298012 SIMILAR TO MHR23B  
1388773_AT LOC299339 SIMILAR TO [MOUSE PRIMARY RESPONSE GENE B94 MRNA, 3END.], GENE PRODUCT 
1373393_AT LOC299907 SIMILAR TO EXT1  
1379422_AT LOC300284 SIMILAR TO RIKEN CDNA 4833435D08 
1398756_AT LOC300303 SIMILAR TO NUCLEOPHOSMIN (NPM) (NUCLEOLAR PHOSPHOPROTEIN B23) (NUMATRIN)  
1372629_AT LOC300768 SIMILAR TO KIAA0925 PROTEIN  
1389600_AT LOC301748 SIMILAR TO RIKEN CDNA 1700001E04 
1382146_AT LOC302313 SIMILAR TO TRANSMEMBRANE 4 SUPERFAMILY MEMBER 6 
1373335_AT LOC302808 MEMBRANE-ASSOCIATED DHHC9 ZINC FINGER PROTEIN 
1374181_AT LOC302855 SIMILAR TO HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN G - HUMAN 
1372740_AT LOC303259 SIMILAR TO MAP4K6-PENDING PROTEIN 
1391022_AT LOC305078 LAMININ CHAIN  
1398988_AT LOC307347 HYPOTHETICAL PROTEIN LOC307347  
1383888_AT LOC307495 SIMILAR TO BLVRB PROTEIN  
1372989_AT LOC308081 SIMILAR TO ZINC FINGER, DHHC DOMAIN CONTAINING 14 
1386013_AT LOC308348 SIMILAR TO CG17669-PA  
1377869_AT LOC310395 SIMILAR TO CARBON CATABOLITE REPRESSION 4 PROTEIN HOMOLOG 
1374725_AT LOC310756 SIMILAR TO MKIAA1631 PROTEIN  
1388985_AT LOC310926 HYPOTHETICAL PROTEIN LOC310926  
1379748_AT LOC310968 SIMILAR TO MINOR HISTOCOMPATIBILITY ANTIGEN PRECURSOR 
1371468_AT LOC312502 SIMILAR TO MKIAA0857 PROTEIN  
1379244_AT LOC312777 SIMILAR TO TEL PROTEIN  
1381326_AT LOC313744 SIMILAR TO RIKEN CDNA 4632412I24  
1377903_AT LOC313934 SIMILAR TO INTERSECTIN 2 (SH3 DOMAIN-CONTAINING PROTEIN 1B) (SH3P18) 
1375862_AT LOC314016 SIMILAR TO MKIAA0230 PROTEIN  
1383932_AT LOC314964 SIMILAR TO PHD FINGER PROTEIN 20-LIKE 1 ISOFORM 1 
1391604_AT LOC315508 SIMILAR TO MKIAA0056 PROTEIN  
1390145_AT LOC315676 SIMILAR TO DMX-LIKE 2  
1372725_AT LOC315883 SIMILAR TO PHOSPHOLIPID SCRAMBLASE 2 
1389600_AT LOC316186 SIMILAR TO RIKEN CDNA 1700001E04 
1383906_AT LOC316326 SIMILAR TO LUNG INDUCIBLE NEURALIZED-RELATED C3HC4 RING FINGER PROTEIN 
1389911_AT LOC316842 SIMILAR TO CDNA SEQUENCE BC019776 
1373232_AT LOC317070 SIMILAR TO NIDOGEN 2 PROTEIN  
1382331_AT LOC317214 SIMILAR TO RIKEN CDNA 0610038L10 GENE 
1376861_AT LOC317312 SIMILAR TO RIKEN CDNA 1810018L05  
1398939_AT LOC360618 SIMILAR TO ORM1-LIKE 3  
1389600_AT LOC360998 SIMILAR TO RIKEN CDNA 1700001E04 
1396292_AT LOC361014 SIMILAR TO PEPTIDE N-GLYCANASE  
1390029_AT LOC361110 HYPOTHETICAL PROTEIN  
1389180_AT LOC361377 SIMILAR TO PHOSPHORYLASE KINASE (EC 2.7.1.38) BETA CHAIN, NON-MUSCLE - RABBIT 
1390058_AT LOC361990 SIMILAR TO DKFZP547E1010 PROTEIN 
1372448_AT LOC362156 MEMBRANE-ASSOCIATED DHHC5 ZINC FINGER PROTEIN 
1384565_AT LOC362557 HYPOTHETICAL PROTEIN LOC362557  
1371940_AT LOC362587 SIMILAR TO MICROFILAMENT AND ACTIN FILAMENT CROSS-LINKER PROTEIN ISOFORM A 
1399092_AT LOC362608 SIMILAR TO HYPOTHETICAL PROTEIN FLJ10315 
1389636_AT LOC362665 SIMILAR TO KIAA0833 PROTEIN  
1388709_AT LOC362703 SIMILAR TO WD-REPEAT PROTEIN 43 
1392655_AT LOC363269 SIMILAR TO NUCLEAR AUTOANTIGEN SP-100 (SPECKLED 100 KDA) 
1389600_AT LOC363306 HYPOTHETICAL PROTEIN LOC363306  
1389600_AT LOC363320 SIMILAR TO RIKEN CDNA 1700001E04 
1373489_AT LOC363333 SIMILAR TO CHROMATIN ASSEMBLY FACTOR-I P150 SUBUNIT 
1373232_AT LOC363405 SIMILAR TO NIDOGEN 2 PROTEIN  
1389600_AT LOC363433 SIMILAR TO RIKEN CDNA 1700001E04 
1397537_AT LOC363433 SIMILAR TO RIKEN CDNA 1700001E04 
1397537_AT LOC363434 SIMILAR TO CDNA SEQUENCE AY358078 
1382316_AT LOC363849 SIMILAR TO HISTONE CELL CYCLE REGULATION DEFECTIVE HOMOLOG A ISOFORM 1 
1384253_AT LOC364558 SIMILAR TO PALLADIN; CGI-151 PROTEIN 
1376160_AT LOC365510 SIMILAR TO AVIAN RETICULOENDOTHELIOSIS VIRAL (V-REL) ONCOGENE RELATED B 
1383287_AT LOC365960 SIMILAR TO SEMAF CYTOPLASMIC DOMAIN ASSOCIATED PROTEIN 2 
1372474_AT LOC366595 SIMILAR TO SYNAPTOPHYSIN-LIKE PROTEIN; PANTOPHYSIN; PAN I; DNA SEGMENT, 
1377653_AT LOC366669 SIMILAR TO MKIAA1011 PROTEIN  
1392901_AT LOC367113 SIMILAR TO RIKEN CDNA A430093J20 GENE 
1397537_AT LOC367381 SIMILAR TO RIKEN CDNA 4930555G01 
1373232_AT LOC367653 SIMILAR TO NIDOGEN 2 PROTEIN  
1379422_AT LOC367759 SIMILAR TO GLYCOSYLTRANSFERASE 28 DOMAIN CONTAINING 1 
1372406_AT LOC367976 SIMILAR TO DNA REPLICATION LICENSING FACTOR MCM3  
1389080_AT LOC474154 ZINC RESPONSIVE PROTEIN ZD7  
1387071_A_AT LOC497674 HYPOTHETICAL GENE SUPPORTED BY NM_017212 
1370517_AT LOC497675 NEURONAL PENTRAXIN 1  
1368550_AT LOC497713 HYPOTHETICAL GENE SUPPORTED BY NM_022858 
1368151_AT LOC497720 MATRIN 3  
1368812_AT LOC497722 HYPOTHETICAL GENE SUPPORTED BY NM_053905 
1367853_AT LOC497723 HYPOTHETICAL GENE SUPPORTED BY NM_031798 
1387264_AT LOC497732 HYPOTHETICAL GENE SUPPORTED BY NM_053806 
1383736_AT LOC497806 HYPOTHETICAL GENE SUPPORTED BY NM_173309 
1368174_AT LOC497816 HYPOTHETICAL GENE SUPPORTED BY NM_019371 
1373705_AT LOC497876 SIMILAR TO MRPL28 PROTEIN  
1378611_AT LOC498289 SIMILAR TO ENCEPHALOPSIN  
1374812_AT LOC498331 PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 13 
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1389054_AT LOC498368 SIMILAR TO RIKEN CDNA 0610040J01  
1389600_AT LOC498374 SIMILAR TO RIKEN CDNA 1700001E04 
1389488_AT LOC498544 HYPOTHETICAL PROTEIN LOC498544  
1392644_S_AT LOC498662 SIMILAR TO RIKEN CDNA 2610019F03 
1377141_AT LOC498685 SIMILAR TO RIKEN CDNA 1110018J18  
1374170_AT LOC498749 SIMILAR TO PUTATIVE TRAF AND TNF RECEPTOR ASSOCIATED PROTEIN 
1393094_AT LOC498883 SIMILAR TO METHYL-CPG BINDING PROTEIN MBD2 
1388570_AT LOC498909 SIMILAR TO RIKEN CDNA 2310005O14 
1386823_AT LOC498918 IROQUOIS HOMEOBOX PROTEIN 5  
1374322_AT LOC499087 SIMILAR TO MKIAA1064 PROTEIN  
1382629_AT LOC499247 SIMILAR TO MALE STERILITY DOMAIN CONTAINING 2 
1382331_AT LOC499328 SIMILAR TO RIKEN CDNA 0610038L10 GENE 
1392494_AT LOC499331 SIMILAR TO HYPOTHETICAL PROTEIN D030056L22 
1398691_AT LOC499624 SIMILAR TO KIAA0669 GENE PRODUCT 
1371248_AT LOC499660 SIMILAR TO CORNIFIN ALPHA (SMALL PROLINE-RICH PROTEIN 1) (SPRR1) 
1373324_AT LOC499736 SIMILAR TO DUAL SPECIFICITY PHOSPHATASE 14 
1390602_A_AT LOC499749 SIMILAR TO RIKEN CDNA C430004E15 
1373100_AT LOC499779 SIMILAR TO RIKEN CDNA 2900010J23  
1372250_AT LOC499941 SCF APOPTOSIS RESPONSE PROTEIN 1 
1397537_AT LOC500070 SIMILAR TO RIKEN CDNA 4930555G01 
1372213_AT LOC500300 SIMILAR TO HYPOTHETICAL PROTEIN MGC6835 
1388838_AT LOC500373 SIMILAR TO 2010012F05RIK PROTEIN  
1393866_AT LOC500592 SIMILAR TO WSL-1-LIKE PROTEIN  
1377673_AT LOC500715 SIMILAR TO CYCLIN K  
1373819_AT LOC500855 HYPOTHETICAL PROTEIN LOC500855  
1374746_AT LOC500877 AB1-152  
1371479_AT LOC500939 LOC500939  
1389640_AT LOC501026 SIMILAR TO SH3 DOMAIN BINDING GLUTAMIC ACID-RICH PROTEIN LIKE 2 
1398342_AT LOC501052 SIMILAR TO FUS1 PROTEIN  
1389600_AT LOC501091 SIMILAR TO RIKEN CDNA 1700001E04 
1397537_AT LOC501091 SIMILAR TO RIKEN CDNA 1700001E04 
1389600_AT LOC501092 SIMILAR TO RIKEN CDNA 4930555G01 
1397537_AT LOC501092 SIMILAR TO RIKEN CDNA 4930555G01 
1389600_AT LOC501093 SIMILAR TO RIKEN CDNA 2610042L04  
1388985_AT LOC501211 LOC501211  
1389600_AT LOC501221 SIMILAR TO CDNA SEQUENCE AY358078 
1397537_AT LOC501221 SIMILAR TO CDNA SEQUENCE AY358078 
1397537_AT LOC501222 SIMILAR TO RIKEN CDNA 4930555G01 
1389600_AT LOC501225 SIMILAR TO CDNA SEQUENCE AY358078 
1389600_AT LOC501226 SIMILAR TO RIKEN CDNA 1700001E04 
1389600_AT LOC501245 SIMILAR TO CDNA SEQUENCE AY358078 
1389600_AT LOC501250 SIMILAR TO RETICULOCALBIN 1 PRECURSOR 
1389600_AT LOC501253 SIMILAR TO RIKEN CDNA 4930555G01 
1373232_AT LOC501271 SIMILAR TO NIDOGEN 2 PROTEIN  
1389600_AT LOC501393 SIMILAR TO CDNA SEQUENCE AY358078 
1389600_AT LOC501396 HYPOTHETICAL PROTEIN LOC501396  
1389600_AT LOC501399 SIMILAR TO RIKEN CDNA 1700001E04 
1397537_AT LOC501399 SIMILAR TO RIKEN CDNA 1700001E04 
1370684_S_AT LOC501546 HYPOTHETICAL PROTEIN LOC501546  
1376861_AT LOC501648 SIMILAR TO RIKEN CDNA 1810018L05  
1392257_AT LOC501706 HYPOTHETICAL PROTEIN LOC501706  
1391125_AT LOC501937 SIMILAR TO CDNA SEQUENCE BC061212 
1393177_AT LOC502020 SIMILAR TO MKIAA1016 PROTEIN  
1371816_AT LOC502684 HYPOTHETICAL PROTEIN LOC502684  
1374777_AT LOC502894 HYPOTHETICAL PROTEIN LOC502894  
1394889_AT LOC503215 SIMILAR TO DEATH-ASSOCIATED PROTEIN KINASE 3 (DAP KINASE 3) (DAP-LIKE KINASE)  
1387905_AT LOC619393 JUN DIMERIZATION PROTEIN 1  
1373830_AT LOC619574 HYPOTHETICAL PROTEIN LOC619574  
1375527_AT LOC65027 BETA-CATENIN BINDING PROTEIN  
1367952_AT LRP2 LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 2 
1371683_AT LSM4_PREDICTED LSM4 HOMOLOG, U6 SMALL NUCLEAR RNA ASSOCIATED (S. CEREVISIAE) (PREDICTED) 
1367912_AT LTBP1 LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN 1 
1371500_AT LTBP4 LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN 4 
1369949_AT LU LUTHERAN BLOOD GROUP (AUBERGER B ANTIGEN INCLUDED) 
1387003_AT LUZP1 LEUCINE ZIPPER PROTEIN 1  
1367768_AT LXN LATEXIN  
1368679_A_AT LYN YAMAGUCHI SARCOMA VIRAL (V-YES-1) ONCOGENE HOMOLOG 
1376184_AT LYNX1_PREDICTED LY6/NEUROTOXIN 1 (PREDICTED)  
1376951_AT MAD2L1_PREDICTED MAD2 (MITOTIC ARREST DEFICIENT, HOMOLOG)-LIKE 1 (YEAST) (PREDICTED) 
1387040_AT MAL MYELIN AND LYMPHOCYTE PROTEIN 
1393053_AT MAN1C1_PREDICTED MANNOSIDASE, ALPHA, CLASS 1C, MEMBER 1 (PREDICTED) 
1377621_AT MAP2K4 MITOGEN ACTIVATED PROTEIN KINASE KINASE 4 
1390372_AT MAP3K12 MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 12 
1399075_AT MAP3K7_PREDICTED MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 7 (PREDICTED) 
1373719_AT MAP4K3 MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 3 
1376568_AT MAP4K4_PREDICTED MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 (PREDICTED) 
1398297_AT MAPK12 MITOGEN-ACTIVATED PROTEIN KINASE 12 
1377007_AT MAPKAP1 MITOGEN-ACTIVATED PROTEIN KINASE ASSOCIATED PROTEIN 1 
1371446_AT MAPKAPK2 MAP KINASE-ACTIVATED PROTEIN KINASE 2 
1375525_AT MAPRE1 MICROTUBULE-ASSOCIATED PROTEIN, RP/EB FAMILY, MEMBER 1 
1387071_A_AT MAPT MICROTUBULE-ASSOCIATED PROTEIN TAU 
1371031_AT MAT1A METHIONINE ADENOSYLTRANSFERASE I, ALPHA 
1368151_AT MATR3 MATRIN 3  
1372406_AT MCM3_PREDICTED MINICHROMOSOME MAINTENANCE DEFICIENT 3 (S. CEREVISIAE) (PREDICTED) 
1373557_AT MCM4 MINICHROMOSOME MAINTENANCE DEFICIENT 4 HOMOLOG (S. CEREVISIAE) 
1375382_AT MDC1 MEDIATOR OF DNA DAMAGE CHECKPOINT 1 
1398427_AT MEF2D MYOCYTE ENHANCER FACTOR 2D  
1384308_AT MEIS1_PREDICTED MEIS1, MYELOID ECOTROPIC VIRAL INTEGRATION SITE 1 HOMOLOG (PREDICTED) 
1399137_AT METAP1_PREDICTED METHIONYL AMINOPEPTIDASE 1 (PREDICTED) 
1375035_AT MFN1 MITOFUSIN 1  
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1367796_AT MGAT1 ALPHA-1,3-MANNOSYL-GLYCOPROTEIN 2-BETA-N-ACETYLGLUCOSAMINYLTRANSFERASE 
1369201_AT MGAT3 MANNOSIDE ACETYL GLUCOSAMINYLTRANSFERASE 3 
1392547_AT MGC105649 HYPOTHETICAL LOC302884  
1390944_AT MGC108776 SNF7 HOMOLOGUE ASSOCIATED WITH ALIX 3 
1398924_AT MGC109145 SIMILAR TO MANNOSIDASE, BETA A, LYSOSOMAL-LIKE 
1382113_AT MGC72612 SIMILAR TO EXPRESSED SEQUENCE AI449175 
1383623_AT MGC72984 THYMOCYTE PROTEIN THY28  
1383635_AT MGC93714 SIMILAR TO RIKEN CDNA 1210002B07 
1394491_AT MGC93975 SIMILAR TO 2310044H10RIK PROTEIN  
1371919_AT MGC94056 SIMILAR TO RP2 PROTEIN, TESTOSTERONE-REGULATED - RICEFIELD MOUSE (MUS CAROLI) 
1381591_AT MGC94145 SIMILAR TO CDNA SEQUENCE BC026682 
1371705_AT MGC94168 SIMILAR TO VACUOLAR PROTEIN SORTING 26; VACUOLE PROTEIN SORTING 26; H BETA 58 
1374509_AT MGC94226 SIMILAR TO RIKEN CDNA 1110018O08 
1390419_A_AT MGC94243 SIMILAR TO N33 PROTEIN  
1389407_AT MGC94370 DEHYDROGENASE/REDUCTASE (SDR FAMILY) MEMBER 1 
1390407_AT MGC94479 SIMILAR TO PROTEIN C3ORF4 HOMOLOG 
1374644_AT MGC94555 INTIMAL THICKNESS-RELATED RECEPTOR 
1372498_AT MGC94686 SIMILAR TO RIKEN CDNA 2810413N20 
1376106_AT MGC94782 SIMILAR TO HYPOTHETICAL PROTEIN MGC33926 
1373070_AT MGC94941 SIMILAR TO MKRN1 PROTEIN  
1397758_AT MGC95241 SIMILAR TO CHOLINE PHOSPHOTRANSFERASE 1;  
1398969_AT MGEA5 MENINGIOMA EXPRESSED ANTIGEN 5 (HYALURONIDASE) 
1368311_AT MGMT O-6-METHYLGUANINE-DNA METHYLTRANSFERASE 
1386075_AT MINA MYC INDUCED NUCLEAR ANTIGEN  
1398296_AT MIR16 MEMBRANE INTERACTING PROTEIN OF RGS16 
1374775_AT MKI67_PREDICTED ANTIGEN IDENTIFIED BY MONOCLONAL ANTIBODY KI-67 (PREDICTED) 
1374618_AT MLLT2_PREDICTED MYELOID/LYMPHOID OR MIXED-LINEAGE LEUKEMIA 
1385953_AT MLLT3 MYELOID/LYMPHOID OR MIXED-LINEAGE LEUKEMIA,TRANSLOCATED TO, 3 
1368595_AT MMP24 MATRIX METALLOPEPTIDASE 24  
1375966_AT MMRN2_PREDICTED MULTIMERIN 2 (PREDICTED)  
1395604_AT MMS19L MMS19-LIKE (MET18 HOMOLOG, S. CEREVISIAE) 
1385702_AT MNDA MYELOID CELL NUCLEAR DIFFERENTIATION ANTIGEN 
1375929_AT MNT_PREDICTED MAX BINDING PROTEIN (PREDICTED)  
1397949_AT MPP6_PREDICTED MEMBRANE PROTEIN, PALMITOYLATED 6 (MAGUK P55 SUBFAMILY MEMBER 6) (PREDICTED) 
1382659_AT MRC2_PREDICTED MANNOSE RECEPTOR, C TYPE 2 (PREDICTED) 
1369980_S_AT MRIP MYOSIN PHOSPHATASE-RHO INTERACTING PROTEIN 
1386996_AT MRLCB MYOSIN LIGHT CHAIN, REGULATORY B 
1382811_AT MRPL16 MITOCHONDRIAL RIBOSOMAL PROTEIN L16 
1371604_AT MRPL34 MITOCHONDRIAL RIBOSOMAL PROTEIN L34 
1371553_AT MRPL36_PREDICTED MITOCHONDRIAL RIBOSOMAL PROTEIN L36 (PREDICTED) 
1388654_AT MRPL52_PREDICTED MITOCHONDRIAL RIBOSOMAL PROTEIN L52 (PREDICTED) 
1377937_AT MRPS14_PREDICTED MITOCHONDRIAL RIBOSOMAL PROTEIN S14 (PREDICTED) 
1396227_AT MRRF MITOCHONDRIAL RIBOSOME RECYCLING FACTOR 
1381201_AT MRVLDC2_PREDICTED MARVEL (MEMBRANE-ASSOCIATING) DOMAIN CONTAINING 2 (PREDICTED) 
1368441_AT MSLN MESOTHELIN  
1388549_AT MSMB BETA-MICROSEMINOPROTEIN  
1371237_A_AT MT1A METALLOTHIONEIN 1A  
1368345_AT MTAP6 MICROTUBULE-ASSOCIATED PROTEIN 6 
1392916_AT MTAP7_PREDICTED MICROTUBULE-ASSOCIATED PROTEIN 7 (PREDICTED) 
1372566_AT MTCH2_PREDICTED MITOCHONDRIAL CARRIER HOMOLOG 2 (C. ELEGANS) (PREDICTED) 
1374214_AT MTDH METADHERIN  
1368181_AT MTHFD1 
METHYLENETETRAHYDROFOLATE DEHYDROGENASE (NADP+ DEPENDENT), 
METHENYLTETRAHYDROFOLATE CYCLOHYDROLASE, FORMYLTETRAHYDROFOLATE 
SYNTHASE 
1390878_AT MUC1 MUCIN 1, TRANSMEMBRANE  
1372580_AT MYBPC3_PREDICTED MYOSIN BINDING PROTEIN C, CARDIAC (PREDICTED) 
1368308_AT MYC MYELOCYTOMATOSIS VIRAL ONCOGENE HOMOLOG (AVIAN) 
1384264_AT MYH14 MYOSIN, HEAVY POLYPEPTIDE 14  
1371508_AT MYH4_PREDICTED CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (88KD) 
1370933_AT MYO1E MYOSIN IE  
1368355_AT MYO5B MYOSIN 5B  
1391701_AT MYST3 MYST HISTONE ACETYLTRANSFERASE (MONOCYTIC LEUKEMIA) 3 
1374925_AT NAB2 NGFI-A BINDING PROTEIN 2  
1371872_AT NAP1L1 NUCLEOSOME ASSEMBLY PROTEIN 1-LIKE 1 
1374075_AT NAPG N-ETHYLMALEIMIDE-SENSITIVE FACTOR ATTACHMENT PROTEIN, GAMMA 
1378264_AT NASP NUCLEAR AUTOANTIGENIC SPERM PROTEIN 
1378175_AT NAT5_PREDICTED N-ACETYLTRANSFERASE 5 (ARD1 HOMOLOG, S. CEREVISIAE) (PREDICTED) 
1381986_AT NAV1_PREDICTED NEURON NAVIGATOR 1 (PREDICTED) 
1387004_AT NBL1 NEUROBLASTOMA, SUPPRESSION OF TUMORIGENICITY 1 
1387977_AT NBN NIBRIN  
1378191_AT NCBP1 NUCLEAR CAP BINDING PROTEIN SUBUNIT 1, 80KDA 
1367956_AT NCDN NEUROCHONDRIN  
1371407_AT NCKAP1 NCK-ASSOCIATED PROTEIN 1  
1382126_AT NCOR1 NUCLEAR RECEPTOR CO-REPRESSOR 1 
1370229_AT NDR4 N-MYC DOWNSTREAM REGULATED 4 
1376590_AT NDUFA5 NADH DEHYDROGENASE (UBIQUINONE) 1 ALPHA SUBCOMPLEX 5 
1395045_AT NDUFA7_PREDICTED NADH DEHYDROGENASE (UBIQUINONE) 1 ALPHA SUBCOMPLEX, 7 (B14.5A) (PREDICTED) 
1389507_AT NEDD4L NEURAL PRECURSOR CELL EXPRESSED, DEVELOPMENTALLY DOWN-REGULATED 4-LIKE 
1370815_AT NEFH NEUROFILAMENT, HEAVY POLYPEPTIDE 
1372000_AT NET1 NEUROEPITHELIAL CELL TRANSFORMING GENE 1 
1378543_AT NFE2L3_PREDICTED NUCLEAR FACTOR, ERYTHROID DERIVED 2, LIKE 3 (PREDICTED) 
1368488_AT NFIL3 NUCLEAR FACTOR, INTERLEUKIN 3 REGULATED 
1389538_AT NFKBIA NUCLEAR FACTOR OF KAPPA LIGHT CHAIN GENE ENHANCER IN B-CELLS INHIBITOR, ALPHA 
1378637_AT NFX1 NUCLEAR TRANSCRIPTION FACTOR, X-BOX BINDING 1 
1382082_AT NFYB NUCLEAR TRANSCRIPTION FACTOR-Y BETA 
1374098_AT NG3 NG3 PROTEIN  
1377091_AT NG5 NG5 PROTEIN  
1382214_AT NHLRC2_PREDICTED NHL REPEAT CONTAINING 2 (PREDICTED) 
1388618_AT NID2 NIDOGEN 2  
1370408_AT NID67 PUTATIVE SMALL MEMBRANE PROTEIN NID67 
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1384242_AT NLN NEUROLYSIN (METALLOPEPTIDASE M3 FAMILY) 
1392473_AT NMT2 N-MYRISTOYLTRANSFERASE 2  
1368031_AT NOLC1 NUCLEOLAR AND COILED-BODY PHOSPHOPROTEIN 1 
1387311_AT NOX1 NADPH OXIDASE 1  
1396192_AT NPAT_PREDICTED NUCLEAR PROTEIN IN THE AT REGION (PREDICTED) 
1398756_AT NPM1 NUCLEOPHOSMIN 1  
1367616_AT NPPB NATRIURETIC PEPTIDE PRECURSOR TYPE B 
1370517_AT NPTX1 NEURONAL PENTRAXIN 1  
1370816_AT NR1D1 NUCLEAR RECEPTOR SUBFAMILY 1, GROUP D, MEMBER 1 
1398826_S_AT NR2F6 NUCLEAR RECEPTOR SUBFAMILY 2, GROUP F, MEMBER 6 
1372032_AT NRAS NEUROBLASTOMA RAS ONCOGENE  
1371069_AT NRITP ION TRANSPORTER PROTEIN  
1391413_AT NT5C2_PREDICTED 5'-NUCLEOTIDASE, CYTOSOLIC II (PREDICTED) 
1376112_A_AT NTF2 NUCLEAR TRANSPORT FACTOR 2  
1370180_AT NUDT4 NUDIX (NUCLEOSIDE DIPHOSPHATE LINKED MOIETY X)-TYPE MOTIF 4 
1375536_AT NUMB NUMB GENE HOMOLOG (DROSOPHILA) 
1370934_AT NUP153 NUCLEOPORIN 153KD  
1393277_AT NUP155 NUCLEOPORIN 155  
1372519_AT NUP93 NUCLEOPORIN 93  
1367847_AT NUPR1 NUCLEAR PROTEIN 1  
1371908_AT NXT1_PREDICTED NTF2-RELATED EXPORT PROTEIN 1 (PREDICTED) 
1370191_AT OAZIN ORNITHINE DECARBOXYLASE ANTIZYME INHIBITOR 
1370163_AT ODC1 ORNITHINE DECARBOXYLASE 1  
1368496_AT ODF1 OUTER DENSE FIBER OF SPERM TAILS 1 
1397492_AT OLR1733_PREDICTED OLFACTORY RECEPTOR 1733 (PREDICTED) 
1388432_AT OPTN OPTINEURIN  
1385522_AT ORC1L ORIGIN RECOGNITION COMPLEX, SUBUNIT 1-LIKE (S.CEREVIAIAE) 
1378010_AT ORC4 ORIGIN RECOGNITION COMPLEX, SUBUNIT 4 
1367519_AT OSBPL2 OXYSTEROL BINDING PROTEIN-LIKE 2 
1393368_AT OSBPL5 OXYSTEROL BINDING PROTEIN-LIKE 5 
1378002_AT OSP94_PREDICTED OSMOTIC STRESS PROTEIN 94 KDA (PREDICTED) 
1380133_AT OSR2 ODD-SKIPPED RELATED 2 (DROSOPHILA) 
1370606_AT P2RY1 PURINERGIC RECEPTOR P2Y, G-PROTEIN COUPLED 1 
1372610_AT P4HA2_PREDICTED PROCOLLAGEN-PROLINE, 2-OXOGLUTARATE 4-DIOXYGENASE (PROLINE 4-HYDROXYLASE), 
1372857_AT PACSIN2 PROTEIN KINASE C AND CASEIN KINASE SUBSTRATE IN NEURONS 2 
1379335_AT PAIP1_PREDICTED POLYADENYLATE BINDING PROTEIN-INTERACTING PROTEIN 1 (PREDICTED) 
1389153_AT PAIRBP1 PAI-1 MRNA-BINDING PROTEIN  
1393184_AT PAK2 P21 (CDKN1A)-ACTIVATED KINASE 2  
1378380_AT PAK4_PREDICTED P21 (CDKN1A)-ACTIVATED KINASE 4 (PREDICTED) 
1367687_A_AT PAM PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE 
1387581_AT PAMCI PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE COOH-TERMINAL INTERACTOR 
1374753_AT PAPD4 PAP ASSOCIATED DOMAIN CONTAINING 4 
1374612_AT PAPD5_PREDICTED PAP ASSOCIATED DOMAIN CONTAINING 5 (PREDICTED) 
1380101_AT PAPOLG_PREDICTED POLY(A) POLYMERASE GAMMA (PREDICTED) 
1392927_AT PAQR4 PROGESTIN AND ADIPOQ RECEPTOR FAMILY MEMBER IV 
1373642_AT PAQR6_PREDICTED PROGESTIN AND ADIPOQ RECEPTOR FAMILY MEMBER VI (PREDICTED) 
1383224_AT PARD6B_PREDICTED PAR-6 (PARTITIONING DEFECTIVE 6) HOMOLOG BETA (C. ELEGANS) (PREDICTED) 
1370354_AT PARG POLY (ADP-RIBOSE) GLYCOHYDROLASE 
1368702_AT PAWR PRKC, APOPTOSIS, WT1, REGULATOR 
1374503_AT PBX3_PREDICTED PRE B-CELL LEUKEMIA TRANSCRIPTION FACTOR 3 (PREDICTED) 
1374266_AT PCDH1_PREDICTED PROTOCADHERIN 1 (CADHERIN-LIKE 1) (PREDICTED) 
1367888_AT PCDH21 MT-PROTOCADHERIN  
1371966_AT PCMT1 PROTEIN-L-ISOASPARTATE (D-ASPARTATE) O-METHYLTRANSFERASE 1 
1390650_AT PCNT1 PERICENTRIN 1  
1379047_AT PDAP1 PDGFA ASSOCIATED PROTEIN 1  
1375367_AT PDLIM2 PDZ AND LIM DOMAIN 2  
1380045_AT PDP2 PYRUVATE DEHYDROGENASE PHOSPHATASE ISOENZYME 2 
1373748_AT PDZRN3_PREDICTED PDZ DOMAIN CONTAINING RING FINGER 3 (PREDICTED) 
1390814_AT PELI1 PELLINO HOMOLOG 1 (DROSOPHILA) 
1368303_AT PER2 PERIOD HOMOLOG 2 (DROSOPHILA)  
1372294_AT PERC64 PE RESPONSIVE PROTEIN C64  
1368526_AT PEX3 PEROXISOMAL BIOGENESIS FACTOR 3 
1389654_AT PGEA1 PKD2 INTERACTOR, GOLGI AND ENDOPLASMIC RETICULUM ASSOCIATED 1 
1373769_AT PGM1_PREDICTED PHOSPHOGLUCOMUTASE 1 (PREDICTED) 
1388180_AT PHAX PHOSPHORYLATED ADAPTOR FOR RNA EXPORT 
1389201_AT PHF10 PHD FINGER PROTEIN 10  
1386974_AT PHLDB1 PLECKSTRIN HOMOLOGY-LIKE DOMAIN, FAMILY B, MEMBER 1 
1372863_AT PHR1_PREDICTED PAM, HIGHWIRE, RPM 1 (PREDICTED) 
1369042_AT PIGM PHOSPHATIDYLINOSITOL GLYCAN, CLASS M 
1387847_AT PIK3CB PHOSPHATIDYLINOSITOL 3-KINASE, CATALYTIC, BETA POLYPEPTIDE 
1373528_AT PIK3CD_PREDICTED PHOSPHATIDYLINOSITOL 3-KINASE CATALYTIC DELTA POLYPEPTIDE (PREDICTED) 
1370318_AT PIK4CA PHOSPHATIDYLINOSITOL 4-KINASE, CATALYTIC, ALPHA POLYPEPTIDE 
1374429_AT PIM1 PROVIRAL INTEGRATION SITE 1  
1392560_AT PIP5K1B_PREDICTED PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE, TYPE 1 BETA (PREDICTED) 
1372861_AT PIP5K1C PHOSPHATIDYLINOSITOL-4-PHOSPHATE 5-KINASE, TYPE I, GAMMA 
1373082_AT PKIA PROTEIN KINASE INHIBITOR, ALPHA  
1385182_AT PKP1_PREDICTED PLAKOPHILIN 1 (PREDICTED)  
1388539_AT PKP2 PLAKOPHILIN 2  
1381056_AT PKP3_PREDICTED PLAKOPHILIN 3 (PREDICTED)  
1373091_AT PLAGL2_PREDICTED PLEIOMORPHIC ADENOMA GENE-LIKE 2 (PREDICTED) 
1367800_AT PLAT PLASMINOGEN ACTIVATOR, TISSUE  
1389628_AT PLCD3_PREDICTED PHOSPHOLIPASE C, DELTA 3 (PREDICTED) 
1368700_AT PLCL1 PHOSPHOLIPASE C-LIKE 1  
1383286_AT PLEK2_PREDICTED PLECKSTRIN 2 (PREDICTED)  
1398327_AT PLEKHC1 PLECKSTRIN HOMOLOGY DOMAIN CONTAINING, FAMILY C (WITH FERM DOMAIN) MEMBER 1 
1372824_AT PLEKHF2_PREDICTED PLECKSTRIN HOMOLOGY DOMAIN CONTAINING, FAMILY F (WITH FYVE DOMAIN) MEMBER 2  
1368106_AT PLK2 POLO-LIKE KINASE 2 (DROSOPHILA)  
1369029_AT PLSCR1 PHOSPHOLIPID SCRAMBLASE 1  
1371411_AT PLXNB2 PLEXIN B2  
1376312_A_AT PNAS-4 CGI-146 PROTEIN  
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1370381_AT PNRC1 PROLINE RICH 2  
1387795_AT POLA2 POLYMERASE (DNA DIRECTED), ALPHA 2 
1387142_AT POLB POLYMERASE (DNA DIRECTED), BETA 
1388808_AT POLR2A_MAPPED POLYMERASE (RNA) II (DNA DIRECTED) POLYPEPTIDE A (MAPPED) 
1398899_AT POLR2C POLYMERASE (RNA) II (DNA DIRECTED) POLYPEPTIDE C 
POLR2D_PREDICTED POLYMERASE (RNA) II (DNA DIRECTED) POLYPEPTIDE D (PREDICTED) 1379832_AT 
POLR2E_PREDICTED POLYMERASE (RNA) II (DNA DIRECTED) POLYPEPTIDE E (PREDICTED) 1367471_AT 
POM210 NUCLEAR PORE MEMBRANE GLYCOPROTEIN 210 1367919_AT 
PON2 PARAOXONASE 2  1375848_AT 
PPAPDC2 PHOSPHATIDIC ACID PHOSPHATASE TYPE 2 DOMAIN CONTAINING 2 1373083_AT 
PPAT PHOSPHORIBOSYL PYROPHOSPHATE AMIDOTRANSFERASE 1369785_AT 
1373444_AT PPFIA1_PREDICTED PROTEIN TYROSINE PHOSPHATASE, RECEPTOR TYPE, F POLYPEPTIDE (PTPRF) 
1372531_AT PPFIBP2 PROTEIN TYROSINE PHOSPHATASE, RECEPTOR-TYPE, F INTERACTING PROTEIN 
1370319_AT PPIF PEPTIDYLPROLYL ISOMERASE F (CYCLOPHILIN F) 
1387229_AT PPIG PEPTIDYLPROLYL ISOMERASE G  
1372517_AT PPIL1 PEPTIDYLPROLYL ISOMERASE (CYCLOPHILIN)-LIKE 1 
1391187_AT PPL_PREDICTED PERIPLAKIN (PREDICTED)  
1383475_AT PPM1A PROTEIN PHOSPHATASE 1A, MAGNESIUM DEPENDENT, ALPHA ISOFORM 
1371136_AT PPM1B PROTEIN PHOSPHATASE 1B, MAGNESIUM DEPENDENT, BETA ISOFORM 
1374884_AT PPM1D_PREDICTED PROTEIN PHOSPHATASE 1D MAGNESIUM-DEPENDENT, DELTA ISOFORM (PREDICTED) 
1376060_AT PPM1H PROTEIN PHOSPHATASE 1H (PP2C DOMAIN CONTAINING) 
1390990_AT PPP1CB PROTEIN PHOSPHATASE 1, CATALYTIC SUBUNIT, BETA ISOFORM 
1386971_AT PPP1R10 PROTEIN PHOSPHATASE 1, REGULATORY SUBUNIT 10 
1376662_AT PPP1R12A PROTEIN PHOSPHATASE 1, REGULATORY (INHIBITOR) SUBUNIT 12A 
1373301_AT PPP1R13B_PREDICTED PROTEIN PHOSPHATASE 1, REGULATORY (INHIBITOR) SUBUNIT 13B (PREDICTED) 
1372446_AT PPP1R2 PROTEIN PHOSPHATASE 1, REGULATORY (INHIBITOR) SUBUNIT 2 
1376728_AT PPP1R8_PREDICTED PROTEIN PHOSPHATASE 1, REGULATORY (INHIBITOR) SUBUNIT 8 (PREDICTED) 
PPP2CB PROTEIN PHOSPHATASE 2A, CATALYTIC SUBUNIT, BETA ISOFORM 1367827_AT 
PPP2R2C PROTEIN PHOSPHATASE 2 (FORMERLY 2A), REGULATORY SUBUNIT B (PR 52), GAMMA ISOFORM 1369297_AT 
PPP2R5C_PREDICTED PROTEIN PHOSPHATASE 2, REGULATORY SUBUNIT B (B56), GAMMA ISOFORM (PREDICTED) 1373384_AT 
PPP3CB PROTEIN PHOSPHATASE 3, CATALYTIC SUBUNIT, BETA ISOFORM 1379314_AT 
PR1 PROTEIN DISTANTLY RELATED TO TO THE GAMMA SUBUNIT FAMILY 1388103_AT 
1392899_AT PRC1_PREDICTED PROTEIN REGULATOR OF CYTOKINESIS 1 (PREDICTED) 
1390202_AT PRDM2_MAPPED PR DOMAIN CONTAINING 2, WITH ZNF DOMAIN (MAPPED) 
1388182_AT PRIM1 DNA PRIMASE, P49 SUBUNIT  
1386945_A_AT PRKAB1 PROTEIN KINASE, AMP-ACTIVATED, BETA 1 NON-CATALYTIC SUBUNIT 
1389463_AT PRKAR1B PROTEIN KINASE, CAMP DEPENDENT REGULATORY, TYPE I, BETA 
1372176_AT PRKCA PROTEIN KINASE C, ALPHA  
1368169_AT PRKCABP PROTEIN KINASE C, ALPHA BINDING PROTEIN 
1374466_AT PRKCE PROTEIN KINASE C, EPSILON  
1379912_AT PRKCM PROTEIN KINASE C, MU  
1370197_A_AT PRKCZ PROTEIN KINASE C, ZETA  
1389662_AT PRKWNK4 PROTEIN KINASE, LYSINE DEFICIENT 4 
1398867_AT PRP19 NEURONAL DIFFERENTIATION-RELATED GENE 
1384329_AT PRSS22_PREDICTED PROTEASE, SERINE, 22 (PREDICTED) 
1373152_AT PRSS23 PROTEASE, SERINE, 23  
1370064_AT PSEN2 PRESENILIN 2  
1394047_AT PSG4 PREGNANCY SPECIFIC BETA-1-GLYCOPROTEIN 4 
1373350_AT PSIP1 PC4 AND SFRS1 INTERACTING PROTEIN 1 
1368508_AT PSMA3 PROTEASOME (PROSOME, MACROPAIN) SUBUNIT, ALPHA TYPE 3 
1368508_AT PSMA3L PROTEASOME (PROSOME, MACROPAIN) SUBUNIT, ALPHA TYPE 3 
1376069_AT PSMD11_PREDICTED PROTEASOME (PROSOME, MACROPAIN) 26S SUBUNIT, NON-ATPASE, 11 (PREDICTED) 
1392983_AT PSMD12 PROTEASOME 26S NON-ATPASE SUBUNIT 12 
1367663_AT PSME1 PROTEASE (PROSOME, MACROPAIN) 28 SUBUNIT, ALPHA 
1368818_AT PSME4 PROTEASOME (PROSOME, MACROPAIN) ACTIVATOR SUBUNIT 4 
1384465_AT PSPC1 PARASPECKLE PROTEIN 1  
1370445_AT PSPLA1 PHOSPHATIDYLSERINE-SPECIFIC PHOSPHOLIPASE A1 
1393638_AT PTGER4 PROSTAGLANDIN E RECEPTOR 4 (SUBTYPE EP4) 
1367986_AT PTGFRN PROSTAGLANDIN F2 RECEPTOR NEGATIVE REGULATOR 
1369688_S_AT PTK2B PROTEIN TYROSINE KINASE 2 BETA  
1369496_AT PTPN12 PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 12 
1373065_AT PTPN18 PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 18 
1371261_AT PTPN2 PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 2 
1368087_A_AT PTPN21 PROTEIN TYROSINE PHOSPHATASE 2E 
1368010_AT PTPN6 PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 6 
1391669_AT PTPRB_PREDICTED PROTEIN TYROSINE PHOSPHATASE, RECEPTOR TYPE, B (PREDICTED) 
1373419_AT PTPRG PROTEIN TYROSINE PHOSPHATASE, RECEPTOR TYPE, G 
1383017_AT PTPRM PROTEIN TYROSINE PHOSPHATASE, RECEPTOR TYPE, M 
1368358_A_AT PTPRR PROTEIN TYROSINE PHOSPHATASE, RECEPTOR TYPE, R 
1370177_AT PVR POLIOVIRUS RECEPTOR  
1368674_AT PYGL LIVER GLYCOGEN PHOSPHORYLASE 
1373022_AT RAB1 RAB1, MEMBER RAS ONCOGENE FAMILY 
1375338_AT RAB10 RAB10, MEMBER RAS ONCOGENE FAMILY 
1374069_AT RAB11A RAB11A, MEMBER RAS ONCOGENE FAMILY 
1398825_AT RAB11B RAB11B, MEMBER RAS ONCOGENE FAMILY 
1373646_AT RAB15 RAB15, MEMBER RAS ONOCOGENE FAMILY 
1392681_AT RAB2 RAB2, MEMBER RAS ONCOGENE FAMILY 
1389331_AT RAB21 RAB21, MEMBER RAS ONCOGENE FAMILY 
1376029_AT RAB2L RAB2, MEMBER RAS ONCOGENE FAMILY-LIKE 
1387821_AT RAB3IP RAB3A INTERACTING PROTEIN  
1370001_AT RAB8A RAB8A, MEMBER RAS ONCOGENE FAMILY 
1373658_AT RACGAP1_PREDICTED RAC GTPASE-ACTIVATING PROTEIN 1 (PREDICTED) 
1397642_AT RAD50 RAD50 HOMOLOG (S. CEREVISIAE)  
1376828_AT RAI3 RETINOIC ACID INDUCED 3  
1387001_AT RALB V-RAL SIMIAN LEUKEMIA VIRAL ONCOGENE HOMOLOG B 
1368217_AT RALBP1 RALA BINDING PROTEIN 1  
1388363_AT RALY HNRNP-ASSOCIATED WITH LETHAL YELLOW 
1367701_AT RAMP2 RECEPTOR (CALCITONIN) ACTIVITY MODIFYING PROTEIN 2 
1389279_AT RAN RAN, MEMBER RAS ONCOGENE FAMILY 
1373933_AT RAPGEF2_PREDICTED RAP GUANINE NUCLEOTIDE EXCHANGE FACTOR (GEF) 2 (PREDICTED) 
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1389181_AT RAPGEF6_PREDICTED RAP GUANINE NUCLEOTIDE EXCHANGE FACTOR (GEF) 6 (PREDICTED) 
1370415_AT RASSF5 RAS ASSOCIATION (RALGDS/AF-6) DOMAIN FAMILY 5 
1379449_AT RB1CC1_PREDICTED RB1-INDUCIBLE COILED-COIL 1 (PREDICTED) 
1369896_S_AT RBM16 RNA BINDING MOTIF PROTEIN 16  
1388751_AT RBM24_PREDICTED RNA BINDING MOTIF PROTEIN 24 (PREDICTED) 
1388886_AT RBM25_PREDICTED RNA BINDING MOTIF PROTEIN 25 (PREDICTED) 
1389981_AT RBM27_PREDICTED RNA BINDING MOTIF PROTEIN 27 (PREDICTED) 
1384751_AT RBM8_PREDICTED RNA BINDING MOTIF PROTEIN 8 (PREDICTED) 
1388538_AT RBX1 RING-BOX 1  
1384391_AT RDH10 RETINOL DEHYDROGENASE 10 (ALL-TRANS) 
1389304_AT REST RE1-SILENCING TRANSCRIPTION FACTOR 
1385504_AT RFFL FRING  
1374936_AT RGD1304601 SIMILAR TO RIKEN CDNA 5730457F11 
1389107_AT RGD1304623_PREDICTED SIMILAR TO KIAA1749 PROTEIN (PREDICTED) 
1380243_AT RGD1304693_PREDICTED SIMILAR TO CG14803-PA (PREDICTED) 
1367510_AT RGD1304696 SIMILAR TO HYPOTHETICAL PROTEIN FLJ22625 
1373903_AT RGD1304715_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN MGC32399 (PREDICTED) 
1382945_AT RGD1304748 SIMILAR TO CDNA SEQUENCE BC006662 
1390403_AT RGD1304790 SIMILAR TO CG8312-PA  
1394468_AT RGD1304792_PREDICTED SIMILAR TO CHROMOSOME 2 OPEN READING FRAME 3; TRANSCRIPTION FACTOR 9  
1390526_AT RGD1304814_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN KIAA1354 (PREDICTED) 
1376260_AT RGD1304822_PREDICTED SIMILAR TO KIAA1627 PROTEIN (PREDICTED) 
1390387_AT RGD1304885_PREDICTED SIMILAR TO SH3 DOMAIN PROTEIN D19 (PREDICTED) 
1377899_AT RGD1304982_PREDICTED SIMILAR TO RIKEN CDNA 2810025M15 (PREDICTED) 
1373447_AT RGD1305117 SIMILAR TO HN1-LIKE PROTEIN  
1367518_AT RGD1305121_PREDICTED SIMILAR TO FATSO (PREDICTED)  
1374159_AT RGD1305208_PREDICTED SIMILAR TO RN49018 (PREDICTED)  
1388987_AT RGD1305215 SIMILAR TO EXPRESSED SEQUENCE AA960436 
1393394_AT RGD1305240_PREDICTED SIMILAR TO PM5 PROTEIN; DNA SEGMENT, CHR 7, ERATO DOI 156, EXPRESSED (PREDICTED) 
1383308_A_AT RGD1305243_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN FLJ34389 (PREDICTED) 
1371730_AT RGD1305466 SIMILAR TO RIKEN CDNA 1300002A08 
1398385_AT RGD1305475_PREDICTED SIMILAR TO RIKEN CDNA 1500006O09 (PREDICTED) 
1373870_AT RGD1305486 SIMILAR TO RIKEN CDNA 2810405J04  
1375563_AT RGD1305506_PREDICTED SIMILAR TO DENDRITIC CELL-DERIVED UBIQUITIN-LIKE PROTEIN (PREDICTED) 
1389782_AT RGD1305587_PREDICTED SIMILAR TO RIKEN CDNA 2010107G23 (PREDICTED) 
1374438_AT RGD1305606 SIMILAR TO MKIAA1046 PROTEIN  
1382220_AT RGD1305614_PREDICTED SIMILAR TO IGF-II MRNA-BINDING PROTEIN 2 (PREDICTED) 
1388930_AT RGD1305625 SIMILAR TO RIKEN CDNA 2310075C12 
1372136_AT RGD1305714_PREDICTED SIMILAR TO TETRASPANIN SIMILAR TO TM4SF9 (PREDICTED) 
1374699_AT RGD1305779_PREDICTED SIMILAR TO NSE1 (PREDICTED)  
1372164_AT RGD1305793 SIMILAR TO HYPOTHETICAL PROTEIN FLJ20154 
1372957_AT RGD1305846_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN A730008H23 (PREDICTED) 
1391475_AT RGD1305861_PREDICTED SIMILAR TO 2810036L13RIK PROTEIN (PREDICTED) 
1382178_AT RGD1305866_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN FLJ20200 (PREDICTED) 
1376100_AT RGD1305887 SIMILAR TO RIKEN CDNA 2310057H16 
1383841_AT RGD1305891_PREDICTED SIMILAR TO DNA (CYTOSINE-5)-METHYLTRANSFERASE 3A (DNMT3A)  
1377737_AT RGD1306051_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN MGC5466 (PREDICTED) 
1399150_AT RGD1306064_PREDICTED SIMILAR TO RIKEN CDNA A630054L15; HYPOTHETICAL PROTEIN MGC38041 (PREDICTED) 
1378007_AT RGD1306148_PREDICTED SIMILAR TO KIAA0368 (PREDICTED)  
1377877_AT RGD1306152_PREDICTED SIMILAR TO KIAA0980 PROTEIN (PREDICTED) 
1398397_AT RGD1306185 SIMILAR TO PARG1-PENDING PROTEIN 
1376263_AT RGD1306222 SIMILAR TO 1810034B16RIK PROTEIN  
1379315_AT RGD1306244_PREDICTED SIMILAR TO RIKEN CDNA 2400009B11 GENE (PREDICTED) 
1389197_AT RGD1306248 SIMILAR TO RIKEN CDNA 9630046K23 
1373924_AT RGD1306568 SIMILAR TO C530044N13RIK PROTEIN 
1383267_AT RGD1306577 SIMILAR TO RIKEN CDNA 2210404D11 
1388648_AT RGD1306614 SIMILAR TO D7WSU128E PROTEIN  
1391157_AT RGD1306651_PREDICTED SIMILAR TO CG7744-PA (PREDICTED) 
1392579_AT RGD1306658 SIMILAR TO 5830411E10RIK PROTEIN  
1393832_AT RGD1306676 SIMILAR TO RIKEN CDNA 0610033I05 (PREDICTED) 
1388579_AT RGD1306691_PREDICTED SIMILAR TO HYPOTHETICAL GENE MGC19595 (PREDICTED) 
1373060_AT RGD1306781_PREDICTED SIMILAR TO CGI-84 PROTEIN (PREDICTED) 
1381091_AT RGD1306802 SIMILAR TO HYPOTHETICAL PROTEIN BC008207 
1372917_AT RGD1306819 SIMILAR TO A230072I16RIK PROTEIN  
1388321_AT RGD1306825_PREDICTED SIMILAR TO RIKEN CDNA 1190002L16 (PREDICTED) 
1377190_AT RGD1306939 SIMILAR TO MKIAA0386 PROTEIN  
1377011_AT RGD1307034_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN CG003 (PREDICTED) 
1372922_AT RGD1307036_PREDICTED HYPOTHETICAL LOC287306 (PREDICTED) 
1388408_AT RGD1307129 SIMILAR TO RIKEN CDNA 1110020C13 
1375037_AT RGD1307145_PREDICTED SIMILAR TO SPORULATION-INDUCED TRANSCRIPT 4-ASSOCIATED PROTEIN (PREDICTED) 
1372192_AT RGD1307374_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN MGC36325 (PREDICTED) 
1374124_AT RGD1307381 SIMILAR TO RIKEN CDNA 2610003J06  
1372913_AT RGD1307433 SIMILAR TO RIKEN CDNA 2310065K24 
1372748_AT RGD1307436 SIMILAR TO KIAA1055 PROTEIN  
1378104_AT RGD1307465 SIMILAR TO RIKEN CDNA 8430406I07  
1388471_AT RGD1307494 SIMILAR TO RIKEN CDNA E430026E19 
1389007_AT RGD1307524_PREDICTED SIMILAR TO FRIEDREICH ATAXIA REGION GENE X123 (PREDICTED) 
1376144_AT RGD1307534_PREDICTED SIMILAR TO B AGGRESSIVE LYMPHOMA (PREDICTED) 
1371347_AT RGD1307561 SIMILAR TO RIKEN CDNA B230114J08 
1390336_AT RGD1307569_PREDICTED SIMILAR TO PROTEIN C21ORF63 HOMOLOG PRECURSOR (PREDICTED) 
1373093_AT RGD1307599 SIMILAR TO MITOGEN-INDUCIBLE GENE 6 PROTEIN HOMOLOG (MIG-6) (GENE 33 POLYPEPTIDE) 
1384388_AT RGD1307627 SIMILAR TO GP25L2 PROTEIN  
1393085_AT RGD1307700 SIMILAR TO HYPOTHETICAL PROTEIN BC018453 
1384185_AT RGD1307704_PREDICTED SIMILAR TO RIKEN CDNA 2410016O06 (PREDICTED) 
1385481_AT RGD1307724_PREDICTED SIMILAR TO NCAG1 (PREDICTED)  
1383186_AT RGD1307749_PREDICTED SIMILAR TO RIKEN CDNA 1600013K19 (PREDICTED) 
1388881_AT RGD1307773_PREDICTED SIMILAR TO RIKEN CDNA 1700012G19 GENE (PREDICTED) 
1398517_AT RGD1307854 SIMILAR TO HSPC182 PROTEIN  
1372763_AT RGD1307879_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN D10ERTD438E (PREDICTED) 
1389171_AT RGD1307901_PREDICTED SIMILAR TO RIKEN CDNA 1110001E17 (PREDICTED) 
 154
1379682_AT RGD1307927_PREDICTED SIMILAR TO RIKEN CDNA 6030446I19 GENE (PREDICTED) 
1379778_AT RGD1307983_PREDICTED SIMILAR TO HSPC043 PROTEIN (PREDICTED) 
1398951_AT RGD1308009 SIMILAR TO KIAA1007 PROTEIN; ADRENAL GLAND PROTEIN AD-005 
1391166_AT RGD1308015_PREDICTED SIMILAR TO RIKEN CDNA 1700025B16 (PREDICTED) 
1372420_AT RGD1308064_PREDICTED SIMILAR TO FKSG24 (PREDICTED)  
1375767_AT RGD1308089_PREDICTED SIMILAR TO COMMON-SITE LYMPHOMA LEUKEMIA GUANINE NUCLEOTIDE EXCHANGE FACTOR  
1372563_AT RGD1308143 SIMILAR TO D330021B20 PROTEIN  
1389393_AT RGD1308210 SIMILAR TO RIKEN CDNA 2210412D01 
1395796_AT RGD1308257 SIMILAR TO INTERMEDIATE FILAMENT-LIKE PROTEIN MGC:2625 ISOFORM 2; 
1393898_AT RGD1308268_PREDICTED SIMILAR TO KIAA0460 PROTEIN (PREDICTED) 
1379027_AT RGD1308329_PREDICTED SIMILAR TO KIAA0869 PROTEIN (PREDICTED) 
1393775_AT RGD1308356 SIMILAR TO HYPOTHETICAL PROTEIN KIAA0341 
1392508_AT RGD1308378 SIMILAR TO RIKEN CDNA 3110010F15 
1391595_AT RGD1308414_PREDICTED SIMILAR TO ACHERON; DEATH-ASSOCIATED LA MOTIF PROTEIN (PREDICTED) 
1388577_AT RGD1308433 SIMILAR TO STEROID DEHYDROGENASE-LIKE 
1375941_AT RGD1308452 SIMILAR TO RIKEN CDNA 1300006M19 
1379407_AT RGD1308463 SIMILAR TO IMP4  
1382428_AT RGD1308591_PREDICTED SIMILAR TO 4930485D02RIK PROTEIN (PREDICTED) 
1373493_AT RGD1308768_PREDICTED SIMILAR TO ARS COMPONENT B PRECURSOR (PREDICTED) 
1374418_AT RGD1308816_PREDICTED SIMILAR TO CG8009-PA (PREDICTED) 
1373852_AT RGD1308828 SIMILAR TO SRD5A2L  
1377021_AT RGD1308877_PREDICTED SIMILAR TO CGI-09 PROTEIN (PREDICTED) 
1376376_AT RGD1308984 SIMILAR TO RIKEN CDNA 6030404E16 
1372488_AT RGD1309016 SIMILAR TO RIKEN CDNA 2310057D15 
1373521_AT RGD1309038 SIMILAR TO RIKEN CDNA D430044G18 
1371697_AT RGD1309044_PREDICTED SIMILAR TO RIKEN CDNA 0610039C21 (PREDICTED) 
1383738_AT RGD1309101_PREDICTED SIMILAR TO KIAA0582 PROTEIN (PREDICTED) 
1372781_AT RGD1309181 SIMILAR TO RIKEN CDNA 1810073M12 
1374408_AT RGD1309199 SIMILAR TO CBF1 INTERACTING COREPRESSOR 
1372288_AT RGD1309256 SIMILAR TO D11BWG0280E PROTEIN  
1376680_AT RGD1309258_PREDICTED SIMILAR TO RIKEN CDNA 5730409F24 (PREDICTED) 
1372554_AT RGD1309266_PREDICTED SIMILAR TO RW1 PROTEIN (PREDICTED) 
1393009_AT RGD1309326 SIMILAR TO RIKEN CDNA 2410002F23 
1383975_AT RGD1309383 SIMILAR TO RIKEN CDNA G630055P03 GENE 
1372003_AT RGD1309417_PREDICTED SIMILAR TO CG17660-PA (PREDICTED) 
1372059_AT RGD1309437 SIMILAR TO RIKEN CDNA 2610528E23 
1380309_AT RGD1309443_PREDICTED SIMILAR TO MKIAA0804 PROTEIN (PREDICTED) 
1374568_AT RGD1309492_PREDICTED SIMILAR TO MKIAA1737 PROTEIN (PREDICTED) 
1375974_AT RGD1309571 SIMILAR TO RNA-BINDING PROTEIN ISOFORM G3BP-2A 
1390392_AT RGD1309602_PREDICTED SIMILAR TO RIKEN CDNA 2500001K11 (PREDICTED) 
1372641_AT RGD1309860_PREDICTED SIMILAR TO MYOCYTIC INDUCTION/DIFFERENTIATION ORIGINATOR (PREDICTED) 
1395973_AT RGD1309871_PREDICTED SIMILAR TO RIKEN CDNA 5730596K20 (PREDICTED) 
1377829_AT RGD1309884 SIMILAR TO TRANSLOKIN  
1393043_AT RGD1309957_PREDICTED SIMILAR TO HYPOTHETICAL WD-REPEAT PROTEIN CGI-48 (PREDICTED) 
1373407_AT RGD1309983_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN 9930016O13 (PREDICTED) 
1389708_AT RGD1310006 SIMILAR TO RIKEN CDNA 5730421E18 
1376780_AT RGD1310022 SIMILAR TO RIKEN CDNA 2610204K14 
1391419_AT RGD1310031_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN MGC29331 (PREDICTED) 
1373035_AT RGD1310127 SIMILAR TO CDNA SEQUENCE BC017158 
1375182_AT RGD1310143 SIMILAR TO RIKEN CDNA D030028O16 
1384219_AT RGD1310144 SIMILAR TO EAP30 SUBUNIT OF ELL COMPLEX 
1384788_AT RGD1310193_PREDICTED SIMILAR TO KCCR13L (PREDICTED)  
1372433_AT RGD1310211_PREDICTED SIMILAR TO CG11030-PA (PREDICTED) 
1375060_AT RGD1310244_PREDICTED SIMILAR TO CC2-27 (PREDICTED)  
1393701_AT RGD1310265_PREDICTED SIMILAR TO ALPHA-1,4-N-ACETYLGLUCOSAMINYLTRANSFERASE (ALPHA4GNT) (PREDICTED) 
1373588_AT RGD1310323 SIMILAR TO RIKEN CDNA 1200004M23 
1372903_AT RGD1310360 SIMILAR TO 3000004C01RIK PROTEIN  
1378947_AT RGD1310402 SIMILAR TO C-TERMINAL TENSIN-LIKE 
1390218_AT RGD1310440_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN (PREDICTED) 
1372805_AT RGD1310444_PREDICTED LOC363015 (PREDICTED)  
1374042_AT RGD1310453_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN FLJ23451 (PREDICTED) 
1392556_AT RGD1310470 SIMILAR TO PDZ DOMAIN ACTIN BINDING PROTEIN SHROOM 
1382765_AT RGD1310493_PREDICTED SIMILAR TO RIKEN CDNA 2410007P03 (PREDICTED) 
1375943_AT RGD1310509_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN KIAA0419 (PREDICTED) 
1372202_AT RGD1310553 SIMILAR TO EXPRESSED SEQUENCE AI597479 
1372851_AT RGD1310570_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN (PREDICTED) 
1393015_AT RGD1310587 SIMILAR TO HYPOTHETICAL PROTEIN FLJ14146 
1374359_AT RGD1310592_PREDICTED SIMILAR TO RIKEN CDNA 2810013E07 (PREDICTED) 
1389793_AT RGD1310596 SIMILAR TO P66 ALPHA HOMOLOG  
1386266_AT RGD1310606 SIMILAR TO RIKEN CDNA 1200009B18; EST AA408438 
1377016_AT RGD1310614 SIMILAR TO RIKEN CDNA 5730592L21  
1372814_AT RGD1310623 SIMILAR TO RIKEN CDNA 2010005O13 
1371747_AT RGD1310660 SIMILAR TO RIKEN CDNA 2700038C09 
1394612_AT RGD1310781_PREDICTED SIMILAR TO RIKEN CDNA 1810020G14 (PREDICTED) 
1373576_AT RGD1310783 SIMILAR TO CCR4  
1376328_AT RGD1310819_PREDICTED SIMILAR TO PUTATIVE PROTEIN (5S487) (PREDICTED) 
1378032_AT RGD1310834_PREDICTED SIMILAR TO MOLECULE POSSESSING ANKYRIN-REPEATS INDUCED BY LIPOPOLYSACCHARIDE 
1383531_AT RGD1310862_PREDICTED SIMILAR TO ADULT RETINA PROTEIN (PREDICTED) 
1373965_AT RGD1310931_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN BC013949 (PREDICTED) 
1395856_AT RGD1311021_PREDICTED HYPOTHETICAL LOC308765 (PREDICTED) 
1383794_AT RGD1311080_PREDICTED SIMILAR TO RIKEN CDNA A930038C07 (PREDICTED) 
1398442_AT RGD1311091_PREDICTED SIMILAR TO CHROMOSOME 14 OPEN READING FRAME 80 (PREDICTED) 
1378288_AT RGD1311100_PREDICTED SIMILAR TO RIKEN CDNA D630035O19 (PREDICTED) 
1374265_AT RGD1311104_PREDICTED SIMILAR TO ARYLACETAMIDE DEACETYLASE (ESTERASE) (PREDICTED) 
1373971_AT RGD1311177_PREDICTED SIMILAR TO PCPD PROTEIN (PREDICTED) 
1377210_AT RGD1311203 SIMILAR TO HGFL PROTEIN  
1380134_AT RGD1311204 SIMILAR TO B7S1  
1371740_AT RGD1311316 SIMILAR TO RIKEN CDNA 5730470L24  
1397346_AT RGD1311320_PREDICTED SIMILAR TO MGC31683 PROTEIN (PREDICTED) 
1383461_AT RGD1311362 SIMILAR TO HYPOTHETICAL PROTEIN FLJ10204 
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1392337_AT RGD1311424_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN FLJ38348 (PREDICTED) 
1374562_AT RGD1311429_PREDICTED SIMILAR TO KIAA1267 PROTEIN (PREDICTED) 
1385369_AT RGD1311430 SIMILAR TO HYPOTHETICAL PROTEIN FLJ32844 
1391126_AT RGD1311462_PREDICTED SIMILAR TO RIKEN CDNA 2410011G03 (PREDICTED) 
1398380_AT RGD1311476 SIMILAR TO VON WILLEBRAND FACTOR A-DOMAIN CONTAINING 1 
1380981_AT RGD1311502_PREDICTED SIMILAR TO STONIN 2; HOMOLOG OF STONED B (DROSOPHILA) (PREDICTED) 
1373171_AT RGD1311520 SIMILAR TO HYPOTHETICAL PROTEIN DKFZP434L0117 
1377287_AT RGD1311527_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN BC009115 (PREDICTED) 
1388909_AT RGD1311534_PREDICTED SIMILAR TO CDNA SEQUENCE BC019806 (PREDICTED) 
1390876_AT RGD1311552_PREDICTED SIMILAR TO KIAA0377-LIKE PROTEIN (PREDICTED) 
1382630_AT RGD1311558_PREDICTED SIMILAR TO 4930506M07RIK PROTEIN (PREDICTED) 
1374142_AT RGD1311589_PREDICTED SIMILAR TO RIKEN CDNA E130201N16 (PREDICTED) 
1373186_AT RGD1311593_PREDICTED SIMILAR TO RIKEN CDNA 5033405K12 (PREDICTED) 
1371923_AT RGD1311599_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN FLJ20481 (PREDICTED) 
1393718_AT RGD1311704_PREDICTED SIMILAR TO DKFZP564P1916 PROTEIN (PREDICTED) 
1378120_AT RGD1311709_PREDICTED SIMILAR TO RIBOSOMAL PROTEIN P0-LIKE PROTEIN 
1383548_AT RGD1311759_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN FLJ20189 (PREDICTED) 
1381390_AT RGD1311768_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN FLJ32001 (PREDICTED) 
1391121_AT RGD1311793_PREDICTED SIMILAR TO DNA SEGMENT, CHR 8, ERATO DOI 82, EXPRESSED (PREDICTED) 
1374609_AT RGD1311857_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN FLJ10326 (PREDICTED) 
1384296_AT RGD1311909_PREDICTED HYPOTHETICAL LOC312654 (PREDICTED) 
1389656_AT RGD1312037 SIMILAR TO RIKEN CDNA 1700023M09 
1397579_X_AT RGD1359127 SIMILAR TO RIKEN CDNA 2310011J03  
1373866_AT RGD1359509 SIMILAR TO HYPOTHETICAL PROTEIN FLJ13448 
1380334_AT RGD1359713 HYPOTHETICAL RNA BINDING PROTEIN RGD1359713 
1385783_AT RGD1559427_PREDICTED SIMILAR TO BH3-ONLY MEMBER B PROTEIN 
1390865_AT RGD1559440_PREDICTED SIMILAR TO CA2+-DEPENDENT ACTIVATOR FOR SECRETION PROTEIN 2 
1373584_AT RGD1559643_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN A430031N04 
1378906_AT RGD1559690_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN FLJ25416 
1388842_AT RGD1559787_PREDICTED SIMILAR TO SERUM RESPONSE FACTOR 
1391443_AT RGD1559923_PREDICTED SIMILAR TO CHROMOSOME 14 OPEN READING FRAME 35 
1398432_AT RGD1559931_PREDICTED SIMILAR TO ANKYRIN REPEAT DOMAIN PROTEIN 28 
1367676_AT RGD1559962_PREDICTED SIMILAR TO HIGH MOBILITY GROUP PROTEIN 2 (HMG-2) 
1379108_AT RGD1559968_PREDICTED SIMILAR TO ADP-RIBOSYLATION FACTOR GUANINE NUCLEOTIDE FACTOR 6 ISOFORM A 
1372403_AT RGD1560011_PREDICTED SIMILAR TO NUCLEAR MEMBRANE BINDING PROTEIN NUCLING 
1389050_AT RGD1560049_PREDICTED SIMILAR TO DUAL SPECIFICITY PROTEIN PHOSPHATASE 3 (T-DSP11) 
1389425_AT RGD1560091_PREDICTED SIMILAR TO 5(3)-DEOXYRIBONUCLEOTIDASE 
1372840_AT RGD1560093_PREDICTED SIMILAR TO ZBED4 PROTEIN  
1388957_AT RGD1560152_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN D10ERTD641E 
1384886_AT RGD1560157_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN LOC168850 
1391474_AT RGD1560170_PREDICTED SIMILAR TO COFACTOR REQUIRED FOR SP1 TRANSCRIPTIONAL ACTIVATION, SUBUNIT 2, 150KDA 
1379029_AT RGD1560191_PREDICTED SIMILAR TO ZINC FINGER PROTEIN 62 HOMOLOG (ZFP-62) (ZT3) 
1377961_AT RGD1560268_PREDICTED SIMILAR TO AT MOTIF-BINDING FACTOR 
1373321_AT RGD1560328_PREDICTED SIMILAR TO UPF0197 PROTEIN C11ORF10 HOMOLOG 
1383616_AT RGD1560373_PREDICTED SIMILAR TO CLASS II CYTOKINE RECEPTOR 4 
1392930_AT RGD1560393_PREDICTED SIMILAR TO ARMADILLO REPEAT-CONTAINING PROTEIN 
1377675_AT RGD1560441_PREDICTED LOC498261  
1390586_AT RGD1560601_PREDICTED SIMILAR TO JUMONJI/ARID DOMAIN-CONTAINING PROTEIN 1C (SMCX PROTEIN) (XE169 PROTEIN) 
1371382_AT RGD1560614_PREDICTED SIMILAR TO FILAMIN A (ALPHA-FILAMIN) (FILAMIN 1) (ENDOTHELIAL ACTIN-BINDING PROTEIN)  
1373906_AT RGD1560629_PREDICTED SIMILAR TO RIKEN CDNA A930016P21 
1375859_A_AT RGD1560682_PREDICTED SIMILAR TO ZINC FINGER PROTEIN 565 
1391269_AT RGD1560759_PREDICTED SIMILAR TO SERINE-THREONINE PROTEIN KINASE PIM-2 ISOFORM 1 
1374003_AT RGD1560835_PREDICTED LOC498007  
1389440_AT RGD1560863_PREDICTED SIMILAR TO CELL DIVISION CYCLE ASSOCIATED 5 
1383095_AT RGD1560873_PREDICTED SIMILAR TO RIKEN CDNA E230015L20 GENE 
1380449_AT RGD1560924_PREDICTED SIMILAR TO C230080I20RIK PROTEIN  
1374375_AT RGD1560925_PREDICTED SIMILAR TO 2610034M16RIK PROTEIN 
1382331_AT RGD1560961_PREDICTED SIMILAR TO RIKEN CDNA 0610038L10 GENE 
1380318_AT RGD1560976_PREDICTED LOC499196  
1372373_AT RGD1560982_PREDICTED SIMILAR TO PUTATIVE WD-REPEAT PROTEIN 
1372460_AT RGD1561000_PREDICTED LOC499767  
1376177_AT RGD1561062_PREDICTED SIMILAR TO RIKEN CDNA 5730593F17 
1377819_AT RGD1561065_PREDICTED SIMILAR TO MKIAA1111 PROTEIN  
1399041_AT RGD1561117_PREDICTED SIMILAR TO OPA3 PROTEIN  
1396379_AT RGD1561121_PREDICTED SIMILAR TO PLECKSTRIN HOMOLOGY-LIKE DOMAIN, FAMILY B, MEMBER 3 
1375873_AT RGD1561149_PREDICTED SIMILAR TO MKIAA1522 PROTEIN  
1376087_AT RGD1561189_PREDICTED SIMILAR TO RIKEN CDNA 1300010M03 
1389307_AT RGD1561211_PREDICTED SIMILAR TO AMYLOID BETA (A4) PRECURSOR-LIKE PROTEIN 1 
1385558_AT RGD1561304_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN D930024E11 
1379603_AT RGD1561386_PREDICTED SIMILAR TO CBL E3 UBIQUITIN PROTEIN LIGASE (SIGNAL TRANSDUCTION PROTEIN CBL)  
1393170_AT RGD1561431_PREDICTED SIMILAR TO HOMEOBOX-CONTAINING TRANSCRIPTION FACTOR 
1392128_AT RGD1561464_PREDICTED SIMILAR TO NOVEL PROTEIN  
1383312_AT RGD1561596_PREDICTED SIMILAR TO JM11 PROTEIN  
1392987_AT RGD1561605_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN 
1383743_AT RGD1561607_PREDICTED SIMILAR TO RP23-462P2.7  
1384457_AT RGD1561663_PREDICTED SIMILAR TO FBXW17 PROTEIN  
1393346_AT RGD1561673_PREDICTED SIMILAR TO RIKEN CDNA 5830436D01 
1367676_AT RGD1561694_PREDICTED SIMILAR TO HIGH MOBILITY GROUP PROTEIN 2 (HMG-2) 
1389580_AT RGD1561695_PREDICTED LOC499580  
1372292_AT RGD1561742_PREDICTED SIMILAR TO SERINE/THREONINE PROTEIN KINASE 24 
1389242_AT RGD1561784_PREDICTED SIMILAR TO LRRGT00194  
1380100_AT RGD1561817_PREDICTED SIMILAR TO TRAF2 AND NCK INTERACTING KINASE, SPLICE VARIANT 4 
1379085_AT RGD1561878_PREDICTED SIMILAR TO MKIAA0978 PROTEIN  
1373616_AT RGD1561936_PREDICTED LOC499369  
1371544_AT RGD1561971_PREDICTED SIMILAR TO ENHANCER OF RUDIMENTARY HOMOLOG 
1373183_AT RGD1561982_PREDICTED LOC500713  
1380619_AT RGD1561986_PREDICTED SIMILAR TO RIKEN CDNA 3110001I22  
1393713_AT RGD1561989_PREDICTED SIMILAR TO GDP-MANNOSE 4, 6-DEHYDRATASE 
1371823_AT RGD1562042_PREDICTED SIMILAR TO STROMAL ANTIGEN 2  
1373761_AT RGD1562072_PREDICTED SIMILAR TO IMMUNOGLOBULIN LIGHT CHAIN 
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1382406_AT RGD1562149_PREDICTED SIMILAR TO MIXED-LINEAGE PROTEIN KINASE 1 
1391603_AT RGD1562161_PREDICTED SIMILAR TO CHROMOSOME X OPEN READING FRAME 23 
1390808_AT RGD1562232_PREDICTED SIMILAR TO MICROFIBRILLAR-ASSOCIATED PROTEIN 1 
1389907_AT RGD1562249_PREDICTED SIMILAR TO ARCHEASE  
1380118_AT RGD1562252_PREDICTED SIMILAR TO HYPOTHETICAL GENE SUPPORTED BY AK085276 
1382750_AT RGD1562274_PREDICTED LOC500687  
1399025_AT RGD1562337_PREDICTED SIMILAR TO MESODERM INDUCTION EARLY RESPONSE 1 (MI-ER1) 
1392476_AT RGD1562378_PREDICTED GERMINAL HISTONE H4 GENE  
1381937_AT RGD1562446_PREDICTED SIMILAR TO 60S RIBOSOMAL PROTEIN L7A 
1398943_AT RGD1562476_PREDICTED SIMILAR TO ESO3 PROTEIN  
1391595_AT RGD1562514_PREDICTED SIMILAR TO RIBOSOMAL PROTEIN L21 
1392109_AT RGD1562529_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN FLJ21439 
1390226_AT RGD1562552_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN LOC340061 
1392758_AT RGD1562563_PREDICTED SIMILAR TO RIKEN CDNA G430041M01 
1374536_AT RGD1562568_PREDICTED LOC499569  
1383146_AT RGD1562629_PREDICTED SIMILAR TO NEUROBEACHIN  
1385551_AT RGD1562652_PREDICTED SIMILAR TO CLASS I HISTOCOMPATIBILITY ANTIGEN ALPHA CHAIN - COTTON-TOP TAMARIN 
1385592_AT RGD1562735_PREDICTED SIMILAR TO BCOR PROTEIN (BCL-6 COREPRESSOR) 
1383991_AT RGD1562754_PREDICTED SIMILAR TO 1810049O03RIK PROTEIN 
1375429_AT RGD1562784_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN 
1379104_AT RGD1562845_PREDICTED SIMILAR TO ZINC FINGER PROTEIN 120 ISOFORM 1 
1378860_AT RGD1562973_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN D930020E02 
1382084_AT RGD1562988_PREDICTED SIMILAR TO EHM2  
1375362_AT RGD1563001_PREDICTED SIMILAR TO RIKEN CDNA 2010106G01 
1385876_AT RGD1563063_PREDICTED SIMILAR TO GPC6 PROTEIN  
1372262_AT RGD1563087_PREDICTED LOC500344  
1379475_AT RGD1563120_PREDICTED SIMILAR TO RIKEN CDNA 2210009G21 
1394789_AT RGD1563160_PREDICTED LOC499812  
1380226_AT RGD1563203_PREDICTED SIMILAR TO STERILE ALPHA MOTIF DOMAIN CONTAINING 10 
1382331_AT RGD1563242_PREDICTED SIMILAR TO RIKEN CDNA 0610038L10 GENE 
1391518_AT RGD1563264_PREDICTED SIMILAR TO 60S RIBOSOMAL PROTEIN L7A 
1370802_AT RGD1563276_PREDICTED SIMILAR TO INTEGRIN BETA-5  
1385687_AT RGD1563327_PREDICTED SIMILAR TO RIKEN CDNA 2200001I15  
1384254_AT RGD1563344_PREDICTED SIMILAR TO OTU DOMAIN CONTAINING 1 
1377670_AT RGD1563397_PREDICTED SIMILAR TO MKIAA0824 PROTEIN  
1378003_AT RGD1563429_PREDICTED SIMILAR TO T-CELL ACTIVATION LEUCINE REPEAT-RICH PROTEIN 
1377818_AT RGD1563506_PREDICTED SIMILAR TO JUNCTION-MEDIATING AND REGULATORY PROTEIN 
1377155_AT RGD1563507_PREDICTED SIMILAR TO RIKEN CDNA 1700019G17 
1372830_AT RGD1563508_PREDICTED SIMILAR TO PI-3-KINASE-RELATED KINASE SMG-1 ISOFORM 2 
1395428_AT RGD1563533_PREDICTED SIMILAR TO NOVEL PROTEIN  
1373088_AT RGD1563661_PREDICTED HYPOTHETICAL LOC291665  
1388446_AT RGD1563684_PREDICTED SIMILAR TO HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A0 
1372545_AT RGD1563727_PREDICTED SIMILAR TO GENE MODEL 609  
1391296_AT RGD1563762_PREDICTED SIMILAR TO COX11 HOMOLOG, CYTOCHROME C OXIDASE ASSEMBLY PROTEIN 
1376018_AT RGD1563803_PREDICTED SIMILAR TO LMNB2 PROTEIN  
1372530_AT RGD1563804_PREDICTED SIMILAR TO HCF  
1374433_AT RGD1563902_PREDICTED SIMILAR TO FERRITIN LIGHT CHAIN (FERRITIN L SUBUNIT) 
1389412_AT RGD1563919_PREDICTED LOC499414  
1373557_AT RGD1563943_PREDICTED SIMILAR TO MCDC21 PROTEIN  
1375041_AT RGD1563982_PREDICTED SIMILAR TO F-BOX ONLY PROTEIN 27 
1388720_AT RGD1564045_PREDICTED HYPOTHETICAL LOC361225  
1390808_AT RGD1564148_PREDICTED SIMILAR TO MICROFIBRILLAR-ASSOCIATED PROTEIN 1 
1375857_AT RGD1564216_PREDICTED SIMILAR TO MYOFERLIN (FER-1 LIKE PROTEIN 3) 
1374586_AT RGD1564269_PREDICTED SIMILAR TO ADP-RIBOSYLATION FACTOR RELATED PROTEIN 2 
1390474_AT RGD1564315_PREDICTED SIMILAR TO RIKEN CDNA 9330161F08 
1372626_AT RGD1564417_PREDICTED SIMILAR TO TUMOR PROTEIN D53  
1382940_AT RGD1564436_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN MGC47419 
1393186_AT RGD1564454_PREDICTED SIMILAR TO RIKEN CDNA 2010200O16 
1367676_AT RGD1564519_PREDICTED HIGH MOBILITY GROUP BOX 2  
1367479_AT RGD1564529_PREDICTED SIMILAR TO NUCLEAR PROTEIN IN TESTIS 
1380185_AT RGD1564541_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN FLJ22965 
1396219_AT RGD1564559_PREDICTED SIMILAR TO MIC2L1  
1399081_AT RGD1564594_PREDICTED SIMILAR TO PELLINO PROTEIN  
1389400_AT RGD1564662_PREDICTED SIMILAR TO MSX-2 INTERACTING NUCLEAR TARGET PROTEIN 
1374766_AT RGD1564703_PREDICTED SIMILAR TO MKIAA0493 PROTEIN  
1384956_AT RGD1564714_PREDICTED SIMILAR TO BC021442 PROTEIN  
1383012_AT RGD1564719_PREDICTED SIMILAR TO RIKEN CDNA C230052I12  
1383299_AT RGD1564793_PREDICTED SIMILAR TO KIAA0965 PROTEIN  
1374775_AT RGD1564824_PREDICTED SIMILAR TO MKI67 PROTEIN  
1379310_AT RGD1564862_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN MGC51082 
1383428_AT RGD1564871_PREDICTED SIMILAR TO THIOREDOXIN DOMAIN CONTAINING PROTEIN 6 (THIOREDOXIN-LIKE PROTEIN 2)  
1371984_AT RGD1564875_PREDICTED SIMILAR TO MKIAA0613 PROTEIN  
1371771_AT RGD1564888_PREDICTED SIMILAR TO NOVEL PROTEIN  
1374175_AT RGD1564947_PREDICTED SIMILAR TO PORCUPINE-D  
1387388_AT RGD1564956_PREDICTED SIMILAR TO CALCIUM BINDING PROTEIN P22 
1392476_AT RGD1565073_PREDICTED SIMILAR TO GERMINAL HISTONE H4 GENE 
1376885_AT RGD1565098_PREDICTED SIMILAR TO CHEMOKINE-LIKE FACTOR SUPER FAMILY 4 
1374718_AT RGD1565144_PREDICTED SIMILAR TO DELTEX 3-LIKE  
1397855_AT RGD1565145_PREDICTED SIMILAR TO CYSTEINE SULFINIC ACID DECARBOXYLASE 
1390122_AT RGD1565175_PREDICTED SIMILAR TO TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS-LIKE 1 
1383056_A_AT RGD1565210_PREDICTED LOC499072  
1383538_AT RGD1565257_PREDICTED SIMILAR TO ZINC FINGER PROTEIN 650 
1390891_AT RGD1565333_PREDICTED SIMILAR TO KINESIN FAMILY MEMBER 11 
1389639_AT RGD1565350_PREDICTED SIMILAR TO SHB PROTEIN  
1382130_AT RGD1565392_PREDICTED SIMILAR TO PROTOCADHERIN 19 PRECURSOR 
1391537_AT RGD1565408_PREDICTED SIMILAR TO SERTA DOMAIN CONTAINING 4 
1372767_AT RGD1565461_PREDICTED SIMILAR TO CDNA SEQUENCE BC043098 
1392936_AT RGD1565486_PREDICTED SIMILAR TO RNA BINDING MOTIF PROTEIN 25 
1383581_AT RGD1565520_PREDICTED SIMILAR TO 60S RIBOSOMAL PROTEIN L7A 
1382776_AT RGD1565561_PREDICTED SIMILAR TO O-ACYLTRANSFERASE (MEMBRANE BOUND) DOMAIN CONTAINING 1 
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1384070_AT RGD1565577_PREDICTED SIMILAR TO GEM-INTERACTING PROTEIN 
1387388_AT RGD1565588_PREDICTED SIMILAR TO CALCIUM BINDING PROTEIN P22 
1374294_AT RGD1565594_PREDICTED HYPOTHETICAL LOC293513  
1397196_AT RGD1565595_PREDICTED LOC498009  
1372604_AT RGD1565597_PREDICTED SIMILAR TO RIKEN CDNA 2210421G13 
1378390_AT RGD1565635_PREDICTED SIMILAR TO ZINC FINGER PROTEIN 124 
1380619_AT RGD1565661_PREDICTED SIMILAR TO RIKEN CDNA 3110001I22  
1373639_AT RGD1565675_PREDICTED SIMILAR TO RIKEN CDNA 2410022L05  
1372395_AT RGD1565757_PREDICTED SIMILAR TO KIAA0597 PROTEIN  
1373248_AT RGD1565800_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN FLJ20674 
1393247_AT RGD1565847_PREDICTED SIMILAR TO ZINC FINGER PROTEIN 560 
1376937_AT RGD1565927_PREDICTED SIMILAR TO 4631422O05RIK PROTEIN 
1381759_AT RGD1565975_PREDICTED HYPOTHETICAL LOC291903  
1376013_AT RGD1565985_PREDICTED SIMILAR TO MKIAA0227 PROTEIN  
1383361_AT RGD1565996_PREDICTED SIMILAR TO DNAJ HOMOLOG SUBFAMILY B MEMBER 6 (HEAT SHOCK PROTEIN J2) (HSJ-2) (MRJ)  
1367527_AT RGD1565998_PREDICTED SIMILAR TO RIBOSOMAL PROTEIN L34 
1391062_AT RGD1566052_PREDICTED SIMILAR TO ELONGATION PROTEIN 4 HOMOLOG 
1378155_AT RGD1566064_PREDICTED SIMILAR TO KIAA1096 PROTEIN  
1389102_AT RGD1566072_PREDICTED SIMILAR TO DOCK1 PROTEIN  
1373232_AT RGD1566091_PREDICTED SIMILAR TO NIDOGEN 2  
1393214_AT RGD1566144_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN A230042K10 
1388903_AT RGD1566162_PREDICTED T-COMPLEX ASSOCIATED-TESTIS-EXPRESSED 1-LIKE (PROTEIN 91/23) 
1374775_AT RGD1566252_PREDICTED SIMILAR TO KI-67  
1372585_AT RGD1566254_PREDICTED LOC499318  
1371755_AT RGD1566359_PREDICTED SIMILAR TO RIKEN CDNA B230219D22 
1371959_AT RGD1566374_PREDICTED SIMILAR TO HIST2H2AA1 PROTEIN  
1374328_AT RGD1566393_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN 
1392754_AT RGD1566394_PREDICTED SIMILAR TO CYSTEINE-RICH GLYCOPROTEIN 
1389794_AT RGD1566403_PREDICTED SIMILAR TO OTTHUMP00000040081  
1368226_AT RGD620382 NUCLEOSIDE 2-DEOXYRIBOSYLTRANSFERASE DOMAIN CONTAINING PROTEIN RGD620382 
1395960_AT RHBDL7_PREDICTED RHOMBOID, VEINLET-LIKE 7 (DROSOPHILA) (PREDICTED) 
1369958_AT RHOB RHOB GENE  
1371659_AT RHOC_PREDICTED RAS HOMOLOG GENE FAMILY, MEMBER C (PREDICTED) 
1382197_AT RHOD_PREDICTED RAS HOMOLOG GENE FAMILY, MEMBER D (PREDICTED) 
1374534_AT RHOT2 MIRO2 PROTEIN  
1387153_AT RIL REVERSION INDUCED LIM GENE  
1375020_AT RIN3_PREDICTED RAS AND RAB INTERACTOR 3 (PREDICTED) 
1370422_AT RIPK3 RECEPTOR-INTERACTING SERINE-THREONINE KINASE 3 
1374545_AT RKHD2_PREDICTED RING FINGER AND KH DOMAIN CONTAINING 2 (PREDICTED) 
1381386_AT RNF10 RING FINGER PROTEIN 10  
1383139_AT RNF141 RING FINGER PROTEIN 141  
1395820_AT RNF150_PREDICTED RING FINGER PROTEIN 150 (PREDICTED) 
1388937_AT RNF19_PREDICTED RING FINGER PROTEIN (C3HC4 TYPE) 19 (PREDICTED) 
1376805_AT RNF2 RING FINGER PROTEIN 2  
1368662_AT RNF39 RING FINGER PROTEIN 39  
1371489_AT RNF4 RING FINGER PROTEIN 4  
1372867_AT RNMT RNA (GUANINE-7-) METHYLTRANSFERASE 
1399101_AT RNPC2 RNA-BINDING REGION (RNP1, RRM) CONTAINING 2 
1372181_AT RPA1 REPLICATION PROTEIN A1  
1388135_AT RPA2 REPLICATION PROTEIN A2  
1389202_AT RPE_PREDICTED RIBULOSE-5-PHOSPHATE-3-EPIMERASE (PREDICTED) 
1387176_AT RPH3AL RABPHILIN 3A-LIKE (WITHOUT C2 DOMAINS) 
1374990_AT RPL22 RIBOSOMAL PROTEIN L22  
1376110_AT RPP25 RIBONUCLEASE P 25 SUBUNIT (HUMAN) 
1392473_AT RPP38 RIBONUCLEASE P/MRP 38KDA SUBUNIT 
1398617_AT RPS27A RIBOSOMAL PROTEIN S27A  
1391211_AT RPS6KA4_PREDICTED RIBOSOMAL PROTEIN S6 KINASE, POLYPEPTIDE 4 (PREDICTED) 
1374331_AT RQCD1 RCD1 (REQUIRED FOR CELL DIFFERENTIATION) HOMOLOG 1 (S. POMBE) 
1371862_AT RRM1_MAPPED RIBONUCLEOTIDE REDUCTASE M1 (MAPPED) 
1376065_AT RRS1_PREDICTED RRS1 RIBOSOME BIOGENESIS REGULATOR HOMOLOG (S. CEREVISIAE) (PREDICTED) 
1370400_AT RT1-N1 RT1 CLASS IB GENE, H2-TL-LIKE, GRC REGION (N1) 
1370400_AT RT1-N2 RT1 CLASS IB GENE, H2-TL-LIKE, GRC REGION(N2) 
1370400_AT RT1-N3 RT1 CLASS IB GENE, H2-TL-LIKE, GRC REGION (N3) 
1385551_AT RT1-O RT1 CLASS IB, LOCUS H2-Q-LIKE, GRC REGION 
1373571_AT RTN3 RETICULON 3  
1389480_AT RWDD4A RWD DOMAIN CONTAINING 4A  
1374077_AT RXRA RETINOID X RECEPTOR ALPHA  
1375170_AT S100A11_PREDICTED S100 CALCIUM BINDING PROTEIN A11 (CALIZZARIN) (PREDICTED) 
1388356_AT S100A16_PREDICTED S100 CALCIUM BINDING PROTEIN A16 (PREDICTED) 
1371774_AT SAT_MAPPED SPERMIDINE/SPERMINE N1-ACETYL TRANSFERASE (MAPPED) 
1372968_AT SBF1_PREDICTED SET BINDING FACTOR 1 (PREDICTED) 
1388819_AT SCAMP1 SECRETORY CARRIER MEMBRANE PROTEIN 1 
1367688_AT SCAMP4 SECRETORY CARRIER MEMBRANE PROTEIN 4 
1377198_AT SCAP2 SRC FAMILY ASSOCIATED PHOSPHOPROTEIN 2 
1391279_AT SCIN SCINDERIN  
1377647_AT SCMH1_PREDICTED SEX COMB ON MIDLEG HOMOLOG 1 (PREDICTED) 
1387896_AT SCP2 STEROL CARRIER PROTEIN 2  
1367721_AT SDC4 SYNDECAN 4  
1376973_AT SDCBP2 SYNDECAN BINDING PROTEIN (SYNTENIN) 2 
1372874_AT SDCCAG8 SLINKY  
1373043_AT SDF2L1 STROMAL CELL-DERIVED FACTOR 2-LIKE 1 
1378160_AT SDFR2_PREDICTED STROMAL CELL DERIVED FACTOR RECEPTOR 2 (PREDICTED) 
1381981_AT SEC10L1 SEC10-LIKE 1 (S. CEREVISIAE)  
1387369_AT SEC15L1 SEC15-LIKE 1 (S. CEREVISIAE)  
1388857_AT SEC23B_PREDICTED SEC23B (S. CEREVISIAE) (PREDICTED) 
1397765_AT SEC61A2_PREDICTED SEC61, ALPHA SUBUNIT 2 (S. CEREVISIAE) (PREDICTED) 
1390115_AT SEC63_PREDICTED SEC63-LIKE (S. CEREVISIAE) (PREDICTED) 
1377336_AT SEMA3B_PREDICTED  (SEMAPHORIN) 3B (PREDICTED) 
1374678_AT SEMA4B SEMA DOMAIN, IMMUNOGLOBULIN DOMAIN (IG),  
1368926_AT SEMA4F SEMAPHORIN 4F  
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1372594_AT SENP5_PREDICTED SUMO/SENTRIN SPECIFIC PROTEASE 5 (PREDICTED) 
SERTAD1 1372417_AT SERTA DOMAIN CONTAINING 1  
1388132_AT SFPQ SPLICING FACTOR PROLINE/GLUTAMINE RICH 
SFRS10 1370189_AT SPLICING FACTOR, ARGININE/SERINE-RICH 10 (TRANSFORMER 2 HOMOLOG, DROSOPHILA) 
1383520_AT SFRS12 SPLICING FACTOR, ARGININE/SERINE-RICH 12 
1368992_A_AT SFRS5 SPLICING FACTOR, ARGININE/SERINE-RICH 5 
SFXN3 1387008_AT SIDEROFLEXIN 3  
1367802_AT SGK SERUM/GLUCOCORTICOID REGULATED KINASE 
SGPP1 1373874_AT SPHINGOSINE-1-PHOSPHATE PHOSPHATASE 1 
SH3BP4 SH3-DOMAIN BINDING PROTEIN 4 1387106_AT  
SH3BP5 1387294_AT SH3-DOMAIN BINDING PROTEIN 5 (BTK-ASSOCIATED) 
1371485_AT SH3MD1_PREDICTED SH3 MULTIPLE DOMAINS 1 (PREDICTED) 
1393617_AT SH3RF2 SH3 DOMAIN CONTAINING RING FINGER 2 
SH3TC1_PREDICTED 1392301_AT SH3 DOMAIN AND TETRATRICOPEPTIDE REPEATS 1 (PREDICTED) 
SIAH1A SEVEN IN ABSENTIA 1A 1387266_AT  
SIAHBP1 1392012_AT SIAH BINDING PROTEIN 1; FBP INTERACTING REPRESSOR 
1379390_AT SIAT7B ALPHA-N-ACETYLGALACTOSAMINIDE ALPHA-2,6-SIALYLTRANSFERASE II () 
1377690_AT SIPA1L3 SIGNAL-INDUCED PROLIFERATION-ASSOCIATED 1 LIKE 3 
SIVA_PREDICTED 1383962_AT CD27 BINDING PROTEIN (HINDU GOD OF DESTRUCTION) 
1381253_AT SLC12A2 SOLUTE CARRIER FAMILY 12, MEMBER 2 
1371525_AT SLC12A7 SOLUTE CARRIER FAMILY 12 (POTASSIUM/CHLORIDE TRANSPORTERS), MEMBER 7 
SLC16A3 1368965_AT MONOCARBOXYLATE TRANSPORTER 
1368564_AT SLC17A6 SOLUTE CARRIER FAMILY 17, MEMBER 6 
1371040_AT SLC1A5 SOLUTE CARRIER FAMILY 1, MEMBER 7 
SLC25A26_PREDICTED 1374652_AT SOLUTE CARRIER FAMILY 25, MEMBER 26 (PREDICTED) 
1368193_AT SLC26A4 SOLUTE CARRIER FAMILY 26, MEMBER 4 
1367789_AT SLC27A1 SOLUTE CARRIER FAMILY 27 (FATTY ACID TRANSPORTER), MEMBER 1 
SLC29A1 1398295_AT SOLUTE CARRIER FAMILY 29 (NUCLEOSIDE TRANSPORTERS), MEMBER 1 
1388534_AT SLC31A1 SOLUTE CARRIER FAMILY 31 (COPPER TRANSPORTERS), MEMBER 1 
1383996_AT SLC35E1_PREDICTED SOLUTE CARRIER FAMILY 35, MEMBER E1 (PREDICTED) 
SLC35E4 1387942_AT SOLUTE CARRIER FAMILY 35, MEMBER E4 
1398531_AT SLC36A4_PREDICTED SOLUTE CARRIER FAMILY 36 (PROTON/AMINO ACID SYMPORTER), MEMBER 4 (PREDICTED) 
1376709_AT SLC39A8 SOLUTE CARRIER FAMILY 39 (METAL ION TRANSPORTER), MEMBER 8 
SLC40A1 1390412_AT SOLUTE CARRIER FAMILY 39 (IRON-REGULATED TRANSPORTER), MEMBER 1 
1391613_AT SLC8A3 SOLUTE CARRIER FAMILY 8 (SODIUM/CALCIUM EXCHANGER), MEMBER 3 
1387793_AT SLC9A3R1 ERM-BINDING PHOSPHOPROTEIN  
SLIT2 SLIT HOMOLOG 2 (DROSOPHILA) 1395986_AT  
SLMAP_PREDICTED 1372489_AT SARCOLEMMA ASSOCIATED PROTEIN (PREDICTED) 
1390534_AT SMC5L1_PREDICTED SMC5 STRUCTURAL MAINTENANCE OF CHROMOSOMES 5-LIKE 1 (YEAST) (PREDICTED) 
1377202_AT SMC6L1_PREDICTED SMC6 STRUCTURAL MAINTENANCE OF CHROMOSOMES 6-LIKE 1 (YEAST) (PREDICTED) 
SMPD3 1368991_AT SPHINGOMYELIN PHOSPHODIESTERASE 3, NEUTRAL 
1373850_AT SMPDL3B SPHINGOMYELIN PHOSPHODIESTERASE, ACID-LIKE 3B 
1373213_AT SNAP29 SYNAPTOSOMAL-ASSOCIATED PROTEIN 29 
SNRPB 1397294_AT SMALL NUCLEAR RIBONUCLEOPROTEIN POLYPEPTIDES B AND B1 
SNX5_PREDICTED SORTING NEXIN 5 (PREDICTED) 1372743_AT  
SOCS2 1372727_AT SUPPRESSOR OF CYTOKINE SIGNALING 2 
1370173_AT SOD2 SUPEROXIDE DISMUTASE 2, MITOCHONDRIAL 
1391557_AT SOX15_PREDICTED SRY-BOX CONTAINING GENE 15 (PREDICTED) 
SOX17_PREDICTED 1392990_AT SRY-BOX CONTAINING GENE 17 (PREDICTED) 
SP1 SP1 TRANSCRIPTION FACTOR 1392180_AT  
SP3 1397734_AT SP3 TRANSCRIPTION FACTOR  
1388520_AT SPAG9_PREDICTED SPERM ASSOCIATED ANTIGEN 9 (PREDICTED) 
SPATA9_PREDICTED 1391885_AT SPERMATOGENESIS ASSOCIATED 9 (PREDICTED) 
1383192_AT SPG4_PREDICTED SPASTIC PARAPLEGIA 4 (AUTOSOMAL DOMINANT; SPASTIN) (PREDICTED) 
1368254_A_AT SPHK1 SPHINGOSINE KINASE 1  
1383290_AT SPINT1 HEPATOCYTE GROWTH FACTOR ACTIVATOR INHIBITOR 1 
1388320_AT SPINT2 SERINE PROTEASE INHIBITOR, KUNITZ TYPE 2 
SPNA2 1370838_S_AT ALPHA-SPECTRIN 2  
1389008_AT SPRED2 SPROUTY-RELATED, EVH1 DOMAIN CONTAINING 2 
SRD5A1 1370420_AT STEROID 5 ALPHA-REDUCTASE 1  
1391773_AT SRP54 SIGNAL RECOGNITION PARTICLE 54  
1371714_AT SRPK1 SERINE/ARGININE-RICH PROTEIN SPECIFIC KINASE 1 
1370228_AT SRPRB SIGNAL RECOGNITION PARTICLE RECEPTOR, B SUBUNIT 
SRR 1375895_AT SERINE RACEMASE  
1371425_AT SRRM1_PREDICTED SERINE/ARGININE REPETITIVE MATRIX 1 (PREDICTED) 
SSH3 1383138_AT SLINGSHOT HOMOLOG 3 (DROSOPHILA) 
1398409_AT ST13 SUPPRESSION OF TUMORIGENICITY 13 
1387195_AT ST14 SUPPRESSION OF TUMORIGENICITY 14 
ST5_PREDICTED 1373288_AT SUPPRESSION OF TUMORIGENICITY 5 (PREDICTED) 
STAG1_PREDICTED STROMAL ANTIGEN 1 (PREDICTED) 1389226_AT  
STAP2 1389420_AT SIGNAL-TRANSDUCING ADAPTOR PROTEIN-2 
STFA3_PREDICTED STEFIN A3 (PREDICTED) 1398063_X_AT  
STIM1_PREDICTED 1376024_AT STROMAL INTERACTION MOLECULE 1 (PREDICTED) 
1379279_AT STIM2_PREDICTED STROMAL INTERACTION MOLECULE 2 (PREDICTED) 
1369712_AT STK3 SERINE/THREONINE KINASE 3 (STE20 HOMOLOG, YEAST) 
STK4_PREDICTED 1392231_AT SERINE/THREONINE KINASE 4 (PREDICTED) 
1372078_AT STRAP SERINE/THREONINE KINASE RECEPTOR ASSOCIATED PROTEIN 
1379732_AT STX11 SYNTAXIN 11  
STX3 SYNTAXIN 3 1390447_AT  
SULF2 1388753_AT SULFATASE 2  
1370019_AT SULT1A1 SULFOTRANSFERASE FAMILY 1A, PHENOL-PREFERRING, MEMBER 1 
SUPT16H_PREDICTED 1377281_AT SUPPRESSOR OF TY 16 HOMOLOG (S. CEREVISIAE) (PREDICTED) 
1384849_AT SUSD1_PREDICTED SUSHI DOMAIN CONTAINING 1 (PREDICTED) 
1388586_AT SYNJ1 SYNAPTOJANIN 1  
1395678_AT SYT15 SYNAPTOTAGMIN 15  
1388199_AT TACSTD1 TUMOR-ASSOCIATED CALCIUM SIGNAL TRANSDUCER 1 
1391509_AT TACSTD2 TUMOR-ASSOCIATED CALCIUM SIGNAL TRANSDUCER 2 
1367570_AT TAGLN TRANSGELIN  
1373922_AT TANC TPR DOMAIN, ANKYRIN-REPEAT AND COILED-COIL-CONTAINING 
1388392_AT TAX1BP3 TAX1 (HUMAN T-CELL LEUKEMIA VIRUS TYPE I) BINDING PROTEIN 3 
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1374972_AT TBC1D2_PREDICTED TBC1 DOMAIN FAMILY, MEMBER 2 (PREDICTED) 
1373242_AT TBPL1_PREDICTED TATA BOX BINDING PROTEIN-LIKE 1 (PREDICTED) 
1371787_AT TCEB3 TRANSCRIPTION ELONGATION FACTOR B (SIII), POLYPEPTIDE 3 
1379914_AT TCFCP2L2 TRANSCRIPTION FACTOR CP2-LIKE 2 
1388903_AT TCTE1L T-COMPLEX ASSOCIATED-TESTIS-EXPRESSED 1-LIKE (PROTEIN 91/23) 
1374697_AT TECH NEURONAL RHOA GEF PROTEIN  
1393681_AT TESSP5 TESTIS-SPECIFIC SERINE PROTEASE-5 
1370453_AT TEX101 TESTIS EXPRESSED GENE 101  
1382487_AT TEX14_PREDICTED TESTIS EXPRESSED GENE 14 (PREDICTED) 
1370228_AT TF TRANSFERRIN  
1383171_AT TFB2M TRANSCRIPTION FACTOR B2, MITOCHONDRIAL 
1387450_AT TGFA TRANSFORMING GROWTH FACTOR ALPHA 
1370887_AT TGFB1I1 TRANSFORMING GROWTH FACTOR BETA 1 INDUCED TRANSCRIPT 1 
1398759_AT TGFB1I4 TRANSFORMING GROWTH FACTOR BETA 1 INDUCED TRANSCRIPT 4 
1373421_AT TGIF TG INTERACTING FACTOR  
1370051_AT TGM1 TRANSGLUTAMINASE 1  
1378447_AT THRAP1_PREDICTED THYROID HORMONE RECEPTOR ASSOCIATED PROTEIN 1 (PREDICTED) 
1382536_AT THRAP2_PREDICTED THYROID HORMONE RECEPTOR ASSOCIATED PROTEIN 2 (PREDICTED) 
1367525_AT THRAP3 THYROID HORMONE RECEPTOR ASSOCIATED PROTEIN 3 
1370474_AT THRB THYROID HORMONE RECEPTOR BETA 
1388567_AT THUMPD1 THUMP DOMAIN CONTAINING 1  
1381985_AT TIA1 CYTOTOXIC GRANULE-ASSOCIATED RNA BINDING PROTEIN 1 
1368650_AT TIEG TGFB INDUCIBLE EARLY GROWTH RESPONSE 
1368522_AT TIMELESS TIMELESS HOMOLOG (DROSOPHILA) 
1390237_AT TIMM8A TRANSLOCASE OF INNER MITOCHONDRIAL MEMBRANE 8 HOMOLOG A (YEAST) 
1372473_AT TJP1_PREDICTED TIGHT JUNCTION PROTEIN 1 (PREDICTED) 
1370940_AT TJP2 TIGHT JUNCTION PROTEIN 2  
1378567_AT TJP3_PREDICTED TIGHT JUNCTION PROTEIN 3 (PREDICTED) 
1376635_AT TKT TRANSKETOLASE  
1374425_AT TLE1_PREDICTED TRANSDUCIN-LIKE ENHANCER OF SPLIT 1, HOMOLOG OF DROSOPHILA E(SPL) (PREDICTED) 
1387169_AT TLE3 TRANSDUCIN-LIKE ENHANCER OF SPLIT 3, E(SPL) HOMOLOG (DROSOPHILA) 
1392280_AT TLR2 TOLL-LIKE RECEPTOR 2  
1386943_AT TM4SF11 TRANSMEMBRANE 4 SUPERFAMILY MEMBER 11 
1391684_AT TMEM14A_PREDICTED TRANSMEMBRANE PROTEIN 14A (PREDICTED) 
1382387_AT TMEM16A_PREDICTED TRANSMEMBRANE PROTEIN 16A (PREDICTED) 
1372624_AT TMEM16F_PREDICTED TRANSMEMBRANE PROTEIN 16F (PREDICTED) 
1394160_AT TMEM2_PREDICTED TRANSMEMBRANE PROTEIN 2 (PREDICTED) 
1392534_AT TMEPAI_PREDICTED TRANSMEMBRANE, PROSTATE ANDROGEN INDUCED RNA (PREDICTED) 
1399015_AT TMP21 TRANSMEMBRANE TRAFFICKING PROTEIN 21 
1371796_AT TMX2 THIOREDOXIN-RELATED TRANSMEMBRANE PROTEIN 2 
1371911_AT TNFAIP1 TUMOR NECROSIS FACTOR, ALPHA-INDUCED PROTEIN 1 (ENDOTHELIAL) 
1371785_AT TNFRSF12A TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 12A 
1388492_AT TNIP1_PREDICTED TNFAIP3 INTERACTING PROTEIN 1 (PREDICTED) 
1371610_AT TNKS_PREDICTED TANKYRASE, TRF1-INTERACTING ANKYRIN-RELATED ADP-RIBOSE POLYMERASE (PREDICTED) 
1393095_AT TNKS1BP1_PREDICTED TANKYRASE 1 BINDING PROTEIN 1 (PREDICTED) 
1388145_AT TNXA TENASCIN XA  
1373039_AT TOMM70A TRANSLOCASE OF OUTER MITOCHONDRIAL MEMBRANE 70 HOMOLOG A 
1399046_AT TOP1 TOPOISOMERASE (DNA) I  
1368540_AT TPBG TROPHOBLAST GLYCOPROTEIN  
1387617_AT TPM3 TROPOMYOSIN 3, GAMMA  
1386979_AT TPO1 DEVELOPMENTALLY REGULATED PROTEIN TPO1 
1367976_AT TPP2 TRIPEPTIDYL PEPTIDASE II  
1382939_AT TPR TRANSLOCATED PROMOTER REGION 
1377052_AT TRIM26 TRIPARTITE MOTIF PROTEIN 26  
1377234_AT TRIM27_PREDICTED TRIPARTITE MOTIF PROTEIN 27 (PREDICTED) 
1389058_AT TRIM29_PREDICTED TRIPARTITE MOTIF PROTEIN 29 (PREDICTED) 
1373398_AT TRIM37_PREDICTED TRIPARTITE MOTIF PROTEIN 37 (PREDICTED) 
1390415_AT TRIP13 THYROID HORMONE RECEPTOR INTERACTOR 13 
1398521_AT TRPV6 TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY V, MEMBER 6 
1398953_AT TSTA3_PREDICTED TISSUE SPECIFIC TRANSPLANTATION ANTIGEN P35B (PREDICTED) 
1376974_AT TTC7 TETRATRICOPEPTIDE REPEAT DOMAIN 7 
1376035_AT TTC7B_PREDICTED TETRATRICOPEPTIDE REPEAT DOMAIN 7B (PREDICTED) 
1371542_AT TUBA4 TUBULIN, ALPHA 4  
1371390_AT TUBB2 TUBULIN, BETA, 2  
1371618_S_AT TUBB3 TUBULIN, BETA 3  
1398624_X_AT TUBB4 TUBULIN, BETA 4  
1384143_AT TUFT1_PREDICTED TUFTELIN 1 (PREDICTED)  
1376712_AT TXNDC4 THIOREDOXIN DOMAIN CONTAINING 4 (ENDOPLASMIC RETICULUM) 
1371131_A_AT TXNIP UPREGULATED BY 1,25-DIHYDROXYVITAMIN D-3 
1388862_AT TXNL1 THIOREDOXIN-LIKE (32KD)  
1388656_AT UBC2E UBIQUITIN-CONJUGATING ENZYME E2D 2 
1388656_AT UBE2D2 UBIQUITIN-CONJUGATING ENZYME E2D 2 
1398802_AT UBE2D3 UBIQUITIN-CONJUGATING ENZYME E2D 3 (UBC4/5 HOMOLOG, YEAST) 
1383408_AT UBE2G1 UBIQUITIN-CONJUGATING ENZYME E2G 1 (UBC7 HOMOLOG, C. ELEGANS) 
1388474_AT UBE2I UBIQUITIN-CONJUGATING ENZYME E2I 
1371945_AT UBE2L3_PREDICTED UBIQUITIN-CONJUGATING ENZYME E2L 3 (PREDICTED) 
1398897_AT UBE2V1_PREDICTED UBIQUITIN-CONJUGATING ENZYME E2 VARIANT 1 (PREDICTED) 
1381878_AT UBN1_PREDICTED UBINUCLEIN 1 (PREDICTED)  
1388719_AT UBQLN1 UBIQUILIN 1  
1383477_AT UCHL5 UBIQUITIN CARBOXYL-TERMINAL HYDROLASE L5 
1368669_AT UCP2 UNCOUPLING PROTEIN 2  
1388696_AT UFD1L UBIQUITIN FUSION DEGRADATION 1-LIKE 
1387975_AT UGCG UDP-GLUCOSE CERAMIDE GLUCOSYLTRANSFERASE 
1389218_AT UGCGL1 UDP-GLUCOSE CERAMIDE GLUCOSYLTRANSFERASE-LIKE 1 
1389587_AT UMPS URIDINE MONOPHOSPHATE SYNTHETASE 
1383875_AT UPK1B UROPLAKIN 1B  
1377004_AT USP15 UBIQUITIN SPECIFIC PROTEASE 15  
1389427_AT USP3 UBIQUITIN SPECIFIC PROTEASE 3  
1374940_AT USP36_PREDICTED UBIQUITIN SPECIFIC PROTEASE 36 (PREDICTED) 
1399029_AT USP48 UBIQUITIN SPECIFIC PROTEASE 48  
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1379341_AT USP6NL_PREDICTED USP6 N-TERMINAL LIKE (PREDICTED) 
1394435_AT VANGL1_PREDICTED VANG, VAN GOGH-LIKE 1 (DROSOPHILA) (PREDICTED) 
1386745_AT VCIP135 VALOSIN-CONTAINING PROTEIN (P97)/P47 COMPLEX-INTERACTING PROTEIN 135 
1368463_AT VEGFC VASCULAR ENDOTHELIAL GROWTH FACTOR C 
1374072_AT VEZF1_PREDICTED VASCULAR ENDOTHELIAL ZINC FINGER 1 (PREDICTED) 
1375533_AT VGLL4 VESTIGIAL LIKE 4 (DROSOPHILA)  
1370875_AT VIL2 VILLIN 2  
1389253_AT VNN1 VANIN 1  
1389560_AT VPS24 VACUOLAR PROTEIN SORTING 24 (YEAST) 
1372806_AT VPS35_MAPPED VACUOLAR PROTEIN SORTING 35 (MAPPED) 
1389369_AT VPS52 VACUOLAR PROTEIN SORTING 52 (YEAST) 
1380009_AT VRK1 VACCINIA RELATED KINASE 1  
1368854_AT VSNL1 VISININ-LIKE 1  
1379980_AT VTI1A VESICLE TRANSPORT THROUGH INTERACTION WITH T-SNARES HOMOLOG 1A (YEAST) 
1376448_AT WDFY1 WD REPEAT AND FYVE DOMAIN CONTAINING 1 
1389128_AT WDFY3_PREDICTED WD REPEAT AND FYVE DOMAIN CONTAINING 3 (PREDICTED) 
1391201_AT WDHD1_PREDICTED WD REPEAT AND HMG-BOX DNA BINDING PROTEIN 1 (PREDICTED) 
1389993_AT WDR33_PREDICTED WD REPEAT DOMAIN 33 (PREDICTED) 
1380499_AT WDR9_PREDICTED WD REPEAT DOMAIN 9 (PREDICTED)  
1380148_AT WHSC1_PREDICTED WOLF-HIRSCHHORN SYNDROME CANDIDATE 1 (PREDICTED) 
1392806_AT WHSC1L1_PREDICTED WOLF-HIRSCHHORN SYNDROME CANDIDATE 1-LIKE 1 (PREDICTED) 
1387021_AT WIG1 WILD-TYPE P53-INDUCED GENE 1  
1381034_AT WNT10A_PREDICTED WINGLESS RELATED MMTV INTEGRATION SITE 10A (PREDICTED) 
1389090_AT WRNIP1 WERNER HELICASE INTERACTING PROTEIN 1 
1374204_AT WSB1 WD REPEAT AND SOCS BOX-CONTAINING 1 
1369695_AT WT1 WILMS TUMOR 1  
1374395_AT XPO1 EXPORTIN 1, CRM1 HOMOLOG (YEAST) 
1383296_A_AT XPO4_PREDICTED EXPORTIN 4 (PREDICTED)  
1367498_AT YTHDF1 YTH DOMAIN FAMILY 1  
1389524_AT YTHDF3_PREDICTED YTH DOMAIN FAMILY 3 (PREDICTED)  
1398800_AT YWHAB TYROSINE 3-MONOOXYGENASE/TRYPTOPHAN 5-MONOOXYGENASE ACTIVATION PROTEIN 
1395901_AT YY1 YY1 TRANSCRIPTION FACTOR  
1393652_AT ZBTB1 ZINC FINGER AND BTB DOMAIN CONTAINING 1 
1376125_AT ZBTB10 ZINC FINGER AND BTB DOMAIN CONTAINING 10 
1390142_AT ZCWCC3_PREDICTED ZINC FINGER, CW-TYPE WITH COILED-COIL DOMAIN 3 (PREDICTED) 
1370828_AT ZDHHC2 ZINC FINGER, DHHC DOMAIN CONTAINING 2 
1393388_AT ZDHHC3 ZINC FINGER, DHHC DOMAIN CONTAINING 3 (PREDICTED) 
1398339_AT ZFP162 ZINC FINGER PROTEIN 162  
1394591_AT ZFP207 ZINC FINGER PROTEIN 207  
1389252_AT ZFP238 ZINC FINGER PROTEIN 238  
1382223_AT ZFP262_PREDICTED ZINC FINGER PROTEIN 262 (PREDICTED) 
1368228_AT ZFP265 ZINC FINGER PROTEIN 265  
1379441_AT ZFP294 ZINC FINGER PROTEIN 294  
1373763_AT ZFP297B ZINC FINGER PROTEIN 297B  
1372865_AT ZFP364_PREDICTED ZINC FINGER PROTEIN 364 (PREDICTED) 
1379967_AT ZFP367 ZINC FINGER PROTEIN 367  
1387105_AT ZFP422 ZINC FINGER PROTEIN 422  
1387105_AT ZFP422_PREDICTED ZINC FINGER PROTEIN 422 (PREDICTED) 
1375148_AT ZFPM1_PREDICTED ZINC FINGER PROTEIN, MULTITYPE 1 (PREDICTED) 
1372319_AT ZHX3 ZINC FINGERS AND HOMEOBOXES 3  
1379264_AT ZNRF1_PREDICTED ZINC AND RING FINGER 1 (PREDICTED) 
1376113_AT ZSWIM1_PREDICTED ZINC FINGER, SWIM DOMAIN CONTAINING 1 (PREDICTED) 
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APPENDIX B 
Transcripts >2-fold decreased in CX4 compared to GN6TF 
AFFY ID GENE SYMBOL GENE DESCRIPTION 
1373660_AT AFG3L1_PREDICTED AFG3(ATPASE FAMILY GENE 3)-LIKE 1 (YEAST) (PREDICTED) 
1370137_AT AGPS ALKYLGLYCERONE PHOSPHATE SYNTHASE 
1380746_AT AHRR ARYL-HYDROCARBON RECEPTOR REPRESSOR 
1371493_AT AP2A2 ADAPTOR PROTEIN COMPLEX AP-2, ALPHA 2 SUBUNIT 
1371497_AT ASB6 ANKYRIN REPEAT AND SOCS BOX-CONTAINING PROTEIN 6 
1379741_AT ATP6V0A4_PREDICTED ATPASE, H+ TRANSPORTING, LYSOSOMAL V0 SUBUNIT A ISOFORM 4 (PREDICTED) 
1369248_A_AT BIRC4 BACULOVIRAL IAP REPEAT-CONTAINING 4 
1390873_AT BTBD11_PREDICTED BTB (POZ) DOMAIN CONTAINING 11 (PREDICTED) 
1387446_AT C1GALT1 CORE 1 UDP-GALACTOSE:N-ACETYLGALACTOSAMINE-ALPHA-R  
1387893_AT C1S COMPLEMENT COMPONENT 1, S SUBCOMPONENT 
1387726_AT CDX2 CAUDAL TYPE HOMEO BOX 2 
1385827_AT CLC CARDIOTROPHIN-LIKE CYTOKINE 
1374190_AT CLYBL CITRATE LYASE BETA LIKE 
1390846_AT COL16A1 PROCOLLAGEN, TYPE XVI, ALPHA 1 
1368347_AT COL5A3 COLLAGEN, TYPE V, ALPHA 3 
1389340_AT CRIP3_PREDICTED CYSTEINE-RICH PROTEIN 3 (PREDICTED) 
1371847_AT CRTAP_PREDICTED CARTILAGE ASSOCIATED PROTEIN (PREDICTED) 
1376051_AT CRYL1 CRYSTALLIN, LAMDA 1 
1378377_AT DAPP1_PREDICTED DUAL ADAPTOR FOR PHOSPHOTYROSINE AND 3-PHOSPHOINOSITIDES 1 (PREDICTED) 
1395316_AT DDX21A DEAD (ASP-GLU-ALA-ASP) BOX POLYPEPTIDE 21A 
1382024_AT DNAJB6 DNAJ (HSP40) HOMOLOG, SUBFAMILY B, MEMBER 6 
1385210_AT DOCK5_PREDICTED DEDICATOR OF CYTOKINESIS 5 (PREDICTED) 
1368315_AT ENTPD6 ECTONUCLEOSIDE TRIPHOSPHATE DIPHOSPHOHYDROLASE 6 
1398466_AT EPS15 EPIDERMAL GROWTH FACTOR RECEPTOR PATHWAY SUBSTRATE 15 
1383213_AT EPS8_PREDICTED EPIDERMAL GROWTH FACTOR RECEPTOR PATHWAY SUBSTRATE 8 (PREDICTED) 
1369587_AT EREG EPIREGULIN 
1393808_AT FA2H_PREDICTED FATTY ACID 2-HYDROXYLASE (PREDICTED) 
1381193_AT FAM34A_PREDICTED FAMILY WITH SEQUENCE SIMILARITY 34, MEMBER A (PREDICTED) 
1389106_AT FBXW9 F-BOX AND WD-40 DOMAIN PROTEIN 9 
1378046_AT FUK_PREDICTED FUCOKINASE (PREDICTED) 
1382325_AT GCAT GLYCINE C-ACETYLTRANSFERASE (2-AMINO-3-KETOBUTYRATE-COENZYME A LIGASE) 
1382351_AT GEM_PREDICTED GTP BINDING PROTEIN (GENE OVEREXPRESSED IN SKELETAL MUSCLE) (PREDICTED) 
1378079_AT GOLGA3_PREDICTED GOLGI AUTOANTIGEN, GOLGIN SUBFAMILY A, 3 (PREDICTED) 
1376650_AT GOLGA5 GOLGI AUTOANTIGEN, GOLGIN SUBFAMILY A, 5 
1369571_AT GOLPH3 GOLGI PHOSPHOPROTEIN 3 
1387182_AT GPR37 G PROTEIN-COUPLED RECEPTOR 37 
RC_AI235747_AT GSTA2 GLUTATHIONE-S-TRANSFERASE, ALPHA TYPE2 
1382779_AT HACE1_PREDICTED HECT DOMAIN AND ANKYRIN REPEAT CONTAINING, E3 UBIQUITIN PROTEIN LIGASE 1  
1392089_AT HCFC2 HOST CELL FACTOR C2 
1393629_AT HLX1_PREDICTED H2.0-LIKE HOMEO BOX 1 (DROSOPHILA) (PREDICTED) 
1392616_AT IAG2 IMPLANTATION-ASSOCIATED PROTEIN 
AF008554_AT IAG2 IMPLANTATION-ASSOCIATED PROTEIN 
1391133_AT IL17RC_PREDICTED INTERLEUKIN 17 RECEPTOR C (PREDICTED) 
1387642_AT IL23A INTERLEUKIN 23, ALPHA SUBUNIT P19 
1385649_AT ITGA5_MAPPED INTEGRIN ALPHA 5 (MAPPED) 
1369038_AT ITGAD INTEGRIN, ALPHA D 
1388329_AT KA13 TYPE I KERATIN KA13 
1372153_AT KA15 TYPE I KERATIN KA15 
RC_AA859966_I_AT KCTD13 POTASSIUM CHANNEL TETRAMERISATION DOMAIN CONTAINING 13 
1395966_AT KCTD14_PREDICTED POTASSIUM CHANNEL TETRAMERISATION DOMAIN CONTAINING 14 (PREDICTED) 
1392292_AT KCTD5_PREDICTED POTASSIUM CHANNEL TETRAMERISATION DOMAIN CONTAINING 5 (PREDICTED) 
1369253_AT KREMEN KRINGLE CONTAINING TRANSMEMBRANE PROTEIN 
1388747_AT LCMT1 LEUCINE CARBOXYL METHYLTRANSFERASE 1 
1372469_AT LOC292322 SIMILAR TO STRESS-INDUCED-PHOSPHOPROTEIN 1  
1396034_AT LOC307660 CARBOXYLESTERASE 615 
1381162_AT LOC309891 SIMILAR TO SEPTIN 10 ISOFORM 1 
1383673_AT LOC317247 SIMILAR TO NAP1L2 
1394537_AT LOC317380 SIMILAR TO LMO6 PROTEIN 
1378985_AT LOC362681 SIMILAR TO PSEUDOURIDYLATE SYNTHASE-LIKE 1 
1383213_AT LOC365516 SIMILAR TO EPS8 
1386282_X_AT LOC367880 HYPOTHETICAL GENE SUPPORTED BY NM_138833 
RC_AI235747_AT LOC494499 LOC494499 PROTEIN 
AF008554_AT LOC497846 HYPOTHETICAL GENE SUPPORTED BY NM_053946 
1392839_AT LOC498176 SIMILAR TO BRI3-BINDING PROTEIN 
1375552_AT LOC498351 SIMILAR TO SIGNAL RECOGNITION PARTICLE,72 KDA SUBUNIT 
1372291_AT LOC498512 SIMILAR TO OXA1L PROTEIN 
1376011_AT LOC501789 SIMILAR TO MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 13 
RC_AI102539_AT LOC502605 SIMILAR TO LIPOPROTEIN RECEPTOR-RELATED PROTEIN 
1369866_AT LOC56825 PROCHYMOSIN 
RC_AI102539_AT LRP1 LOW DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 1 
1382277_AT LY96 LYMPHOCYTE ANTIGEN 96 
1395316_AT MAGEH1 MELANOMA ANTIGEN, FAMILY H, 1 
1397556_AT MAK3_PREDICTED MAK3 HOMOLOG (S. CEREVISIAE) (PREDICTED) 
RC_AI235753_AT MAPK3 MITOGEN ACTIVATED PROTEIN KINASE 3 
1387330_AT MEPE MATRIX EXTRACELLULAR PHOSPHOGLYCOPROTEIN WITH ASARM MOTIF (BONE) 
1381388_AT MGC116217 SIMILAR TO NASOPHARYNGEAL EPITHELIUM SPECIFIC PROTEIN 1 
1387500_AT MID1 MIDLINE 1 
1391095_AT MMP19_PREDICTED MATRIX METALLOPROTEINASE 19 (PREDICTED) 
1397372_AT MOBK1B_PREDICTED SIMILAR TO MOB4B PROTEIN 
1387745_AT MOX2R ANTIGEN IDENTIFIED BY MONOCLONAL ANTIBODY MRC OX-2 RECEPTOR 
1387732_AT MTERF MITOCHONDRIAL TRANSCRIPTION TERMINATION FACTOR 1 
RC_AI011922_AT NAP1L1 NUCLEOSOME ASSEMBLY PROTEIN 1-LIKE 1 
1393689_AT NDUFAF1_PREDICTED NADH DEHYDROGENASE (UBIQUINONE) 1 ALPHA SUBCOMPLEX, ASSEMBLY FACTOR 1  
1387454_AT NIBAN NIBAN PROTEIN 
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1394851_AT NKX2-3_PREDICTED NK2 TRANSCRIPTION FACTOR RELATED, LOCUS 3 (DROSOPHILA) (PREDICTED) 
RC_AA850885_S_AT NOL3 NUCLEOLAR PROTEIN 3 (APOPTOSIS REPRESSOR WITH CARD DOMAIN) 
1396173_AT NRIP3_PREDICTED NUCLEAR RECEPTOR INTERACTING PROTEIN 3 (PREDICTED) 
1379560_AT NSD1_PREDICTED NUCLEAR RECEPTOR BINDING SET DOMAIN PROTEIN 1 (PREDICTED) 
1370000_AT NUCB2 NUCLEOBINDIN 2 
1396909_AT PANK2_PREDICTED PANTOTHENATE KINASE 2 (HALLERVORDEN-SPATZ SYNDROME) (PREDICTED) 
1385974_AT PARD6G_PREDICTED PAR-6 PARTITIONING DEFECTIVE 6 HOMOLOG GAMMA (C. ELEGANS) (PREDICTED) 
1384824_AT PCDH18_PREDICTED PROTOCADHERIN 18 (PREDICTED) 
RC_AI232135_AT PFKL PHOSPHOFRUCTOKINASE, LIVER, B-TYPE 
1367841_A_AT PRLPC2 PROLACTIN-LIKE PROTEIN C 2 
1397686_AT PSMD9 PROTEASOME (PROSOME, MACROPAIN) 26S SUBUNIT, NON-ATPASE, 9 
1394486_AT RAB43 RAS-RELATED PROTEIN RAB43 
1377338_AT RAD1_PREDICTED RAD1 HOMOLOG (S. POMBE) (PREDICTED) 
1378740_AT RASAL2_PREDICTED RAS PROTEIN ACTIVATOR LIKE 2 (PREDICTED) 
1391776_AT RGD1305283_PREDICTED SIMILAR TO RIKEN CDNA 2010110K16 (PREDICTED) 
1378948_AT RGD1306164_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN FLJ90798 (PREDICTED) 
1377872_AT RGD1306936_PREDICTED SIMILAR TO CHROMOSOME 7 OPEN READING FRAME 30 (PREDICTED) 
1394392_AT RGD1307696_PREDICTED SIMILAR TO DJ881L22.2 (NOVEL PROTEIN) (PREDICTED) 
1379059_AT RGD1307875_PREDICTED SIMILAR TO FLJ23471 PROTEIN (PREDICTED) 
1383118_AT RGD1309682 SIMILAR TO HYPOTHETICAL PROTEIN FLJ14803 
1374120_AT RGD1309971_PREDICTED SIMILAR TO KIAA1126 PROTEIN (PREDICTED) 
1385801_AT RGD1310237 SIMILAR TO RIKEN CDNA 2700075B01 
1378587_AT RGD1310602_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN MGC15396 (PREDICTED) 
1373230_AT RGD1311802 SIMILAR TO CDNA SEQUENCE BC036718 
1375080_AT RGD1311842_PREDICTED SIMILAR TO EXPRESSED SEQUENCE AW491445 (PREDICTED) 
1389720_AT RGD1559577_PREDICTED SIMILAR TO RIKEN CDNA 1700020L24 
1389037_AT RGD1559874_PREDICTED SIMILAR TO RIT 
1376897_AT RGD1560022_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN 4832420M10 
1382552_AT RGD1560155_PREDICTED SIMILAR TO MKIAA0934 PROTEIN 
1393547_AT RGD1560399_PREDICTED SIMILAR TO HYPOTHETICAL PROTEIN C630023L15 
RC_AI011922_AT RGD1560617_PREDICTED HYPOTHETICAL GENE SUPPORTED BY NM_053561; AF062594 
1393653_AT RGD1560766_PREDICTED SIMILAR TO PUTATIVE PROTEIN PRODUCT OF HMFN2073 
RC_AI171982_AT RGD1560916_PREDICTED SIMILAR TO FUN14 DOMAIN CONTAINING 2 
1374643_AT RGD1560944_PREDICTED SIMILAR TO 6030410K14RIK PROTEIN 
1384437_AT RGD1561046_PREDICTED SIMILAR TO SMARCA1 PROTEIN 
1377718_AT RGD1561555_PREDICTED SIMILAR TO CDNA SEQUENCE BC022692 
1387893_AT RGD1561715_PREDICTED SIMILAR TO COMPLEMENT COMPONENT 1, S SUBCOMPONENT 
1375928_AT RGD1561853_PREDICTED SIMILAR TO SET DOMAIN-CONTAINING PROTEIN 
1372236_AT RGD1562269_PREDICTED SIMILAR TO CASPASE RECRUITMENT DOMAIN PROTEIN 4 
1373000_AT RGD1562444_PREDICTED SIMILAR TO SUSHI-REPEAT CONTAINING PROTEIN 
1397372_AT RGD1562445_PREDICTED SIMILAR TO MOB4B PROTEIN 
1382024_AT RGD1562684_PREDICTED SIMILAR TO MDJ4 
1385912_AT RGD1562711_PREDICTED SIMILAR TO INTERFERON REGULATORY FACTOR 10 
1384752_AT RGD1563033_PREDICTED SIMILAR TO OSTEOCLAST INHIBITORY LECTIN 
AF036761_G_AT RGD1563648_PREDICTED SIMILAR TO STEAROYL-COA DESATURASE-4 
1390652_AT RGD1563662_PREDICTED SIMILAR TO LOC283514 PROTEIN 
1378587_AT RGD1563810_PREDICTED SIMILAR TO RIKEN CDNA 5530600A18 
1383528_AT RGD1563945_PREDICTED SIMILAR TO MKIAA0215 PROTEIN 
1391262_AT RGD1564247_PREDICTED SIMILAR TO SUMO/SENTRIN SPECIFIC PROTEASE 5 
1373020_AT RGD1564452_PREDICTED MITOCHONDRIA-ASSOCIATED GRANULOCYTE MACROPHAGE  
1392856_AT RGD1565105_PREDICTED SIMILAR TO SMALL EDRK-RICH FACTOR 1 
1371847_AT RGD1565180_PREDICTED SIMILAR TO CARTILAGE-ASSOCIATED PROTEIN PRECURSOR 
1382024_AT RGD1565241_PREDICTED SIMILAR TO DNAJ HOMOLOG SUBFAMILY B MEMBER 6 
1378079_AT RGD1565361_PREDICTED SIMILAR TO MALE-ENHANCED ANTIGEN-2 
RC_AI235753_AT RGD1565506_PREDICTED SIMILAR TO EXTRACELLULAR SIGNAL-RELATED KINASE 1C 
1389504_AT RGD1566181_PREDICTED SIMILAR TO DELTEX3 
1380682_AT RKHD3_PREDICTED RING FINGER AND KH DOMAIN CONTAINING 3 (PREDICTED) 
1390524_AT RNF12 RING FINGER PROTEIN 12 
1395571_AT RNF3_PREDICTED RING FINGER PROTEIN 3 (PREDICTED) 
AF036761_G_AT SCD1 STEAROYL-COENZYME A DESATURASE 1 
RC_AA963858_AT SCD1 STEAROYL-COENZYME A DESATURASE 1 
AF036761_G_AT SCD2 STEAROYL-COENZYME A DESATURASE 2 
1391262_AT SENP5_PREDICTED SUMO/SENTRIN SPECIFIC PROTEASE 5 (PREDICTED) 
1397866_AT SERPINB6B SERINE (OR CYSTEINE) PROTEINASE INHIBITOR, CLADE B, MEMBER 6B 
1369547_AT SERPINB7 SERINE (OR CYSTEINE) PROTEINASE INHIBITOR, CLADE B, MEMBER 7 
1398435_AT SLC22A15_PREDICTED SOLUTE CARRIER FAMILY 22 (ORGANIC CATION TRANSPORTER), MEMBER 15 () 
1379805_AT SLC41A2_PREDICTED SOLUTE CARRIER FAMILY 41, MEMBER 2 (PREDICTED) 
1369160_A_AT SLC4A7 SOLUTE CARRIER FAMILY 4, SODIUM BICARBONATE COTRANSPORTER, MEMBER 7 
1387134_AT SLFN3 SCHLAFEN 3 
1386282_X_AT SNRK SNF RELATED KINASE 
1395405_AT SNX26_PREDICTED SORTING NEXIN 26 (PREDICTED) 
1368620_AT SPAG4 SPERM ASSOCIATED ANTIGEN 4 
1393706_AT STEAP_PREDICTED SIX TRANSMEMBRANE EPITHELIAL ANTIGEN OF THE PROSTATE (PREDICTED) 
1375084_AT TDE2L TUMOR DIFFERENTIALLY EXPRESSED 2-LIKE 
1381196_AT TM6SF2_PREDICTED TRANSMEMBRANE 6 SUPERFAMILY MEMBER 2 (PREDICTED) 
1376450_AT TMEM5 TRANSMEMBRANE PROTEIN 5 
RC_AI010612_AT TNC TENASCIN C 
1395635_AT TNFRSF26_PREDICTED TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 26 (PREDICTED) 
1385227_AT TRPS1_PREDICTED TRICHORHINOPHALANGEAL SYNDROME I (PREDICTED) 
1373274_AT TXNRD3_PREDICTED THIOREDOXIN REDUCTASE 3 (PREDICTED) 
1388938_AT USP5_PREDICTED UBIQUITIN SPECIFIC PROTEASE 5 (ISOPEPTIDASE T) (PREDICTED) 
1372837_AT WDFY2_PREDICTED WD REPEAT AND FYVE DOMAIN CONTAINING 2 (PREDICTED) 
1385275_AT WNT16 WINGLESS-RELATED MMTV INTEGRATION SITE 16 
1389340_AT ZNF318_PREDICTED ZINC FINGER PROTEIN 318 (PREDICTED) 
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APPENDIX C 
Significant biological themes associated with genes decreased in CX4 compared to GN6TF 
Gene Ontology Term PValue 
cellular lipid metabolism 2.6E-06 
lipid biosynthesis 8.7E-06 
lipid synthesis 1.2E-05 
cytoplasm 2.1E-05 
nadp 2.6E-05 
biosynthesis of steroids 3.2E-05 
lipid metabolism 4.7E-05 
Golgi-associated vesicle 9.0E-05 
coenzyme metabolism 1.0E-04 
extracellular matrix (sensu Metazoa) 1.1E-04 
cholesterol biosynthesis 1.1E-04 
organelle membrane 1.3E-04 
cofactor metabolism 1.3E-04 
extracellular matrix 1.4E-04 
catalytic activity 1.6E-04 
cholesterol metabolism 1.7E-04 
isoprenoid biosynthesis 2.5E-04 
sterol biosynthesis 2.5E-04 
oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor 2.6E-04 
fatty acid metabolism 2.6E-04 
Golgi apparatus 2.8E-04 
oxidoreductase activity, acting on CH-OH group of donors 3.0E-04 
integrin binding 3.1E-04 
cell adhesion 3.1E-04 
oxidoreductase activity 3.5E-04 
organic acid metabolism 3.6E-04 
Golgi membrane 3.7E-04 
sterol metabolism 4.0E-04 
cholesterol biosynthesis 4.5E-04 
organ morphogenesis 4.7E-04 
endoplasmic reticulum 5.7E-04 
peroxisome 6.3E-04 
collagen 7.0E-04 
microbody 7.1E-04 
peroxisome 7.1E-04 
sterol biosynthesis 7.6E-04 
carboxylic acid metabolism 7.9E-04 
homophilic cell adhesion 7.9E-04 
alcohol metabolism 8.0E-04 
lipid metabolism 8.8E-04 
endomembrane system 0.001 
Golgi vesicle transport 0.001 
steroid biosynthesis 0.001 
isoprenoid metabolism 0.001 
coated membrane 0.002 
membrane coat 0.002 
coenzyme A metabolism 0.002 
vesicle-mediated transport 0.002 
antioxidant activity 0.002 
vesicle coat 0.002 
intracellular transport 0.002 
glutathione transferase activity 0.003 
Fibrillar collagen, C-terminal 0.003 
oxidoreductase 0.003 
coated vesicle membrane 0.003 
cellular localization 0.003 
cellular carbohydrate metabolism 0.003 
Golgi stack 0.003 
oxidoreductase activity, acting on the CH-CH group of donors 0.004 
establishment of cellular localization 0.004 
calcium ion binding 0.004 
transferase activity, transferring alkyl or aryl (other than methyl) groups 0.004 
COPI vesicle coat 0.004 
COPI coated vesicle membrane 0.004 
extracellular matrix 0.004 
RAB protein domain 0.004 
calcium 0.004 
COLFI protein domain 0.005 
steroid biosynthesis 0.005 
carbohydrate metabolism 0.005 
coenzyme A biosynthesis 0.006 
oxidoreductase activity, acting on the CH-CH group of donors, NAD or NADP as acceptor 0.006 
antigen 0.006 
membrane 0.006 
thiolester hydrolase activity 0.007 
blood vessel morphogenesis 0.007 
intracellular protein transport 0.007 
vacuole 0.007 
peroxidase activity 0.007 
oxidoreductase activity, acting on peroxide as acceptor 0.007 
protein localization 0.008 
Endoplasmic reticulum 0.008 
organ development 0.008 
cytoplasmic vesicle membrane 0.009 
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ER-Golgi intermediate compartment 0.010 
steroid metabolism 0.011 
skeletal development 0.011 
prenylation 0.012 
vesicle membrane 0.012 
ADP-ribosylation factor 0.012 
reproductive organismal physiological process 0.012 
protein transport 0.013 
vasculogenesis 0.014 
dimer 0.014 
reproductive physiological process 0.014 
vasculature development 0.014 
coated vesicle 0.014 
Collagen helix repeat 0.015 
ECM-RECEPTOR INTERACTION 0.015 
NICOTINATE AND NICOTINAMIDE METABOLISM 0.015 
glycosaminoglycan binding 0.015 
GLUTATHIONE METABOLISM 0.016 
ER to Golgi vesicle-mediated transport 0.016 
cytosol 0.017 
polysaccharide binding 0.017 
coenzyme biosynthesis 0.017 
fibrillar collagen 0.018 
COPI-coated vesicle 0.018 
microtubule 0.018 
protein amino acid O-linked glycosylation 0.019 
Peptidylprolyl isomerase, FKBP-type 0.019 
fatty acid metabolism 0.019 
transport vesicle 0.019 
Ras small GTPase, Rab type 0.020 
blood vessel development 0.021 
lysosome 0.021 
alternative promoter usage 0.021 
heparin-binding 0.022 
establishment of protein localization 0.022 
coenzyme A 0.022 
Nucleotide transport and metabolism 0.022 
collagen 0.022 
cell-cell adhesion 0.023 
lytic vacuole 0.023 
peroxidase 0.023 
Rotamase 0.024 
pattern binding 0.024 
transit peptide 0.024 
Ras GTPase 0.025 
endoplasmic reticulum 0.027 
electron transporter activity 0.027 
female sex differentiation 0.028 
female gonad development 0.028 
development of primary female sexual characteristics 0.028 
acetyl-CoA metabolism 0.029 
signal sequence binding 0.029 
heparin binding 0.029 
IB protein domain 0.029 
BRLZ protein domain 0.029 
transcription cofactor activity 0.030 
Small GTP-binding protein domain 0.030 
vesicle 0.030 
homotetramer 0.030 
hydroxylation 0.030 
Collagen triple helix repeat 0.031 
golgi stack 0.031 
cytoplasmic vesicle 0.031 
localization 0.032 
HUNTINGTON'S DISEASE 0.033 
carbohydrate binding 0.034 
collagen type V 0.034 
membrane-bound vesicle 0.035 
transcription corepressor activity 0.035 
glutathione transferase 0.035 
secretory pathway 0.037 
GTP-binding nuclear protein Ran 0.037 
protein transporter activity 0.037 
isoprene biosynthesis 0.037 
cytoplasmic membrane-bound vesicle 0.039 
Basic-leucine zipper (bZIP) transcription factor 0.039 
menstrual cycle 0.040 
coated pit 0.041 
establishment of localization 0.042 
ABC transporter, transmembrane region 0.043 
cell-substrate adhesion 0.043 
cell-matrix adhesion 0.043 
ubiquitin thiolesterase activity 0.044 
nucleotide phosphate-binding region:NADP 0.047 
angiogenesis 0.049 
embryonic pattern specification 0.050 
 165
APPENDIX D 
Significant biological themes associated with genes elevated in CX4 compared to GN6TF 
Gene Ontology Term PValue 
nucleus 2.5E-08 
intracellular 1.4E-07 
nuclear protein 2.7E-07 
cell 1.1E-06 
cell junction 1.2E-06 
cell organization and biogenesis 2.2E-06 
intercellular jnction 2.5E-06 
rna-binding 3.8E-06 
intracellular signaling cascade 6.6E-06 
cellular localization 7.3E-06 
establishment of cellular localization 7.8E-06 
intracellular transport 8.9E-06 
cytoskeleton 1.1E-05 
protein binding 2.0E-05 
phosphorylation 2.8E-05 
RNA-binding region RNP-1 (RNA recognition motif) 7.5E-05 
apical part of cell 9.3E-05 
organelle 1.0E-04 
intracellular organelle 1.1E-04 
cytoskeletal protein binding 1.2E-04 
adherens junction 1.2E-04 
protein amino acid dephosphorylation 1.4E-04 
non-membrane-bound organelle 1.5E-04 
intracellular non-membrane-bound organelle 1.5E-04 
Nucleotide-binding, alpha-beta plait 1.5E-04 
actin binding 1.5E-04 
RRM domain 1.8E-04 
dephosphorylation 2.1E-04 
cell-cell adherens junction 2.4E-04 
regulation of cellular physiological process 2.4E-04 
regulation of biological process 2.4E-04 
adherens junction 2.6E-04 
transforming protein 2.7E-04 
positive regulation of apoptosis 3.8E-04 
tight junction 4.4E-04 
positive regulation of programmed cell death 4.9E-04 
focal adhesion 5.1E-04 
regulation of physiological process 5.2E-04 
programmed cell death 5.2E-04 
cell death 6.0E-04 
regulation of cellular process 6.3E-04 
zinc-finger 6.4E-04 
apicolateral plasma membrane 6.4E-04 
apical junction complex 6.4E-04 
proto-oncogene 6.8E-04 
biopolymer metabolism 6.9E-04 
mRNA processing 7.0E-04 
establishment of protein localization 7.1E-04 
apoptosis 7.4E-04 
nucleic acid binding 7.5E-04 
DNA binding 7.7E-04 
GTP binding 8.0E-04 
guanyl nucleotide binding 8.5E-04 
death 9.7E-04 
Tyrosine specific protein phosphatase 0.001 
chromosome 0.001 
protein transport 0.001 
phosphoprotein phosphatase activity 0.001 
actin filament binding 0.001 
regulation of programmed cell death 0.001 
small GTPase mediated signal transduction 0.001 
induction of programmed cell death 0.002 
induction of apoptosis 0.002 
mRNA metabolism 0.002 
RNA transport 0.002 
establishment of RNA localization 0.002 
nucleic acid transport 0.002 
basolateral plasma membrane 0.002 
FERM 0.002 
protein localization 0.002 
prenylation 0.002 
sh3 domain 0.002 
zinc 0.002 
regulation of apoptosis 0.002 
zinc finger region:C2H2-type 2 0.002 
cytoskeleton organization and biogenesis 0.002 
nucleocytoplasmic transport 0.003 
regulation of actin cytoskeleton 0.003 
cytoskeleton 0.003 
RNA localization 0.003 
protein transport 0.003 
zinc finger region:C2H2-type 1 0.003 
RNA splicing 0.003 
basement membrane 0.004 
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protein tyrosine phosphatase activity 0.004 
glycosphingolipid metabolism 0.004 
transition metal ion homeostasis 0.004 
GTPase activity 0.004 
tyrosine-specific phosphatase 0.005 
antigen presentation, endogenous antigen 0.005 
microtubule-based process 0.005 
enzyme binding 0.005 
cytoskeleton-dependent intracellular transport 0.005 
Rho protein signal transduction 0.005 
membrane-bound organelle 0.005 
intracellular membrane-bound organelle 0.005 
dna-binding 0.006 
nucleobase, nucleoside, nucleotide and nucleic acid transport 0.006 
RNA processing 0.006 
protein kinase cascade 0.006 
Heat shock protein DnaJ 0.006 
cell cycle 0.007 
mRNA transport 0.007 
phosphoric monoester hydrolase activity 0.007 
Tyrosine specific protein phosphatase and dual specificity protein phosphatase 0.007 
protein ubiquitination 0.007 
EGF_Lam 0.007 
organelle organization and biogenesis 0.007 
glucuronosyltransferase 0.007 
nucleotide binding 0.007 
nucleotide phosphate-binding region:GTP 0.007 
PTPc 0.007 
protein metabolism 0.008 
microtubule-based movement 0.008 
IPR001452:Src homology-3 0.008 
negative regulation of biological process 0.008 
zinc finger region:C2H2-type 3 0.008 
biopolymer modification 0.008 
DNA replication 0.008 
protein phosphatase 0.009 
gtp-binding 0.009 
nuclear transport 0.009 
RNA splicing, via transesterification reactions with bulged adenosine as nucleophile 0.009 
RNA splicing, via transesterification reactions 0.009 
nuclear mRNA splicing, via spliceosome 0.009 
PTPc_motif 0.009 
prenylated cysteine 0.009 
cross-link:Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin) 0.009 
regulation of metabolism 0.009 
Heat shock protein DnaJ, N-terminal 0.009 
manganese ion binding 0.010 
iron ion homeostasis 0.010 
cell communication 0.010 
Band 4.1 0.010 
GTP binding 0.010 
mhc i 0.010 
epidermis development 0.011 
cellular morphogenesis 0.012 
calcium-dependent phospholipid binding 0.012 
cellular process 0.012 
regulation of progression through cell cycle 0.012 
protein modification 0.013 
transcription regulation 0.013 
regulation of cell cycle 0.013 
Protein tyrosine phosphatase, catalytic region 0.013 
regulation of DNA replication 0.014 
regulation of protein metabolism 0.014 
coated pit 0.014 
transcription 0.014 
IPR001464:Annexin 0.014 
IPR006212:Furin-like repeat 0.014 
intracellular protein transport 0.014 
IPR002213:UDP-glucuronosyl/UDP-glucosyltransferase 0.014 
MHC class I receptor activity 0.015 
RNA helicase activity 0.015 
RNO04512:ECM-RECEPTOR INTERACTION 0.015 
phosphoric monoester hydrolase 0.015 
nucleobase, nucleoside, nucleotide and nucleic acid metabolism 0.015 
pyrophosphatase activity 0.015 
signal transduction 0.015 
negative regulation of cellular physiological process 0.016 
RNA metabolism 0.016 
domain:J 0.016 
metal ion-binding site:Manganese 2 0.016 
metal ion-binding site:Manganese 1 0.016 
SF002359:annexin I 0.016 
SF001710:Rab protein 0.016 
IPR003577:Ras small GTPase, Ras type 0.017 
regulation of cellular metabolism 0.017 
IPR002041:GTP-binding nuclear protein Ran 0.017 
hydrolase activity, acting on acid anhydrides, in phosphorus-containing anhydrides 0.017 
IPR003579:Ras small GTPase, Rab type 0.017 
cellular physiological process 0.017 
ubiquitin-protein ligase activity 0.018 
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manganese 0.018 
morphogenesis 0.018 
hydrolase activity, acting on acid anhydrides 0.018 
annexin 0.018 
negative regulation of cellular process 0.019 
tight junction 0.019 
apical plasma membrane 0.019 
ectoderm development 0.019 
DNA replication, recombination, and repair 0.020 
negative regulation of physiological process 0.020 
kinase binding 0.021 
RNO04320:DORSO-VENTRAL AXIS FORMATION 0.022 
SM00261:FU 0.022 
IPR003578:Ras small GTPase, Rho type 0.022 
Rac GTPase activator activity 0.023 
structural constituent of cytoskeleton 0.023 
antigen processing, endogenous antigen via MHC class I 0.024 
protein phosphatase type 2A activity 0.024 
regulation of mRNA processing 0.024 
response to DNA damage stimulus 0.024 
IPR003118:Sterile alpha motif/pointed 0.024 
transcription 0.024 
IPR004088:KH, type 1 0.024 
IPR004087:KH 0.024 
RNO04662:B CELL RECEPTOR SIGNALING PATHWAY 0.025 
ligase activity, forming carbon-nitrogen bonds 0.025 
IPR001806:Ras GTPase 0.025 
primary metabolism 0.025 
RNO00220:UREA CYCLE AND METABOLISM OF AMINO GROUPS 0.026 
regulation of axonogenesis 0.026 
methylation 0.026 
cellular protein metabolism 0.027 
cell cycle 0.028 
magnesium-dependent protein serine/threonine phosphatase activity 0.028 
nucleotide binding 0.028 
SM00251:SAM_PNT 0.028 
phosphoric ester hydrolase activity 0.029 
nuclear chromosome 0.029 
positive regulation of axonogenesis 0.029 
cellular macromolecule metabolism 0.030 
phosphoprotein 0.030 
RNA export from nucleus 0.030 
protein kinase CK2 activity 0.031 
metal-binding 0.031 
endocytic vesicle 0.032 
basal lamina 0.032 
regulation of transcription 0.032 
SH3 domain binding 0.033 
protein polymerization 0.033 
SM00335:ANX 0.033 
regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolism 0.034 
RNO04010:MAPK SIGNALING PATHWAY 0.034 
domain:SH3 0.035 
DNA-dependent DNA replication 0.035 
enzyme regulator activity 0.035 
negative regulation of metabolism 0.035 
protein targeting 0.035 
transferase activity, transferring hexosyl groups 0.036 
P-loop 0.036 
protein serine/threonine kinase activity 0.037 
lamellipodium 0.038 
repeat:Annexin 4 0.039 
repeat:Annexin 3 0.039 
repeat:Annexin 2 0.039 
repeat:Annexin 1 0.039 
site:Stutter 0.039 
induction of apoptosis by intracellular signals 0.040 
nuclear export 0.040 
desmosome 0.040 
regulation of transcription, DNA-dependent 0.040 
T CELL RECEPTOR SIGNALING PATHWAY 0.041 
RNA recognition, region 1 0.041 
urea cycle 0.042 
macromolecule metabolism 0.043 
Chaperone DnaJ, C-terminal 0.044 
jun transforming protein 0.044 
CTD phosphatase activity 0.044 
myosin phosphatase activity 0.044 
cell adhesion 0.044 
Ets 0.045 
protein domain specific binding 0.045 
enzyme linked receptor protein signaling pathway 0.046 
translation initiation factor activity 0.047 
kinase activity 0.047 
Neutrophil cytosol factor 2 0.047 
negative regulation of progression through cell cycle 0.047 
CIRCADIAN RHYTHM 0.049 
transcription from RNA polymerase II promoter 0.049 
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